
/* screensaver_user */

INSERT INTO screensaver_user VALUES (1, 0, '2006-11-09 00:00:00', 'Chris', 'Dimitri', 'chris_dimitri@hms.harvard.edu', '617-432-1281', '', '11/9/06 Chris is piloting an assay for a small molecule screen.', NULL, NULL, NULL, '30555120');
INSERT INTO screensaver_user VALUES (3, 0, '2006-08-07 00:00:00', 'Jennifer', 'Baltz', 'jbaltz@hms.harvard.edu', '617-432-3839', '', '8/7/06 Jen is continuing this project (screen #299). At this point, she intends only to screen compounds provided by collaborators and not screen ICCB-L libraries. ', NULL, NULL, NULL, '60607389');
INSERT INTO screensaver_user VALUES (6, 0, '2006-03-01 00:00:00', 'Hong', 'Zhu', 'hong_zhu@hms.harvard.edu', '617-432-4171', NULL, NULL, NULL, NULL, NULL, '50464814');
INSERT INTO screensaver_user VALUES (8, 0, '2006-05-04 00:00:00', 'Grace', 'Gao', 'sizhen_gao@hms.harvard.edu', '617-432-3971', '', '', NULL, NULL, NULL, '90567896');
INSERT INTO screensaver_user VALUES (14, 0, '2006-10-04 00:00:00', 'Derek', 'Elli', 'delli@bsd.uchicago.edu', '773-834-7734', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (18, 0, '2006-01-18 00:00:00', 'Nadire', 'Ramadan', 'nramadan@genetics.med.harvard.edu', '617-432-6546', NULL, 'replacing work done by Susan Armkenecht in Perrimon Lab. Also, Namrata Chandhok is working with Nadire in the Perrimon lab temporarily, she is from the Pellman lab at DFCI. ', NULL, NULL, NULL, '90580043');
INSERT INTO screensaver_user VALUES (20, 0, '2002-02-06 00:00:00', 'Melissa', 'Nicholson', 'Melissa.Nicholson@has.missing.email', '617-632-6937', 'D-1410', 'Robot use only.
7-1-04 Screened only at LDDN.', NULL, NULL, NULL, '40568751');
INSERT INTO screensaver_user VALUES (22, 0, '2004-08-05 00:00:00', 'Mike', 'Malecki', 'malecki@fas.harvard.edu', NULL, NULL, 'RNAi screen in collaboration with Harper lab.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (25, 0, '2006-05-04 00:00:00', 'Fuxin', 'Shi', 'fuxin_shi@meei.harvard.edu', '617-573-3251', '', '', NULL, NULL, NULL, '20633239');
INSERT INTO screensaver_user VALUES (27, 0, '2006-01-13 00:00:00', 'Timmy', 'Ho', 'tho@mit.edu', NULL, NULL, '01-13-06 Timmy is a Med Student working with Janet in the King lab.  He will be using the Wallac plate reader. ', NULL, NULL, NULL, '70644150');
INSERT INTO screensaver_user VALUES (33, 0, '2004-02-22 00:00:00', 'Gary', 'Wessel', 'Gary.Wessel@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (34, 0, '2002-01-30 00:00:00', 'Steve', 'Haggarty', 'haggarty@fas.harvard.edu', NULL, NULL, '2/22/02: Proposed to screen Jason Wong''s deacetylase inhibitor bias library for inhibitors of tubulin and histone deacetylation (Jason Wong= lead screener).', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (37, 0, '2003-01-03 00:00:00', 'Adam', 'Friedman', 'adamf@MIT.EDU', NULL, NULL, 'Using SR plate readers to pilot a FRET assay.
12-04: Using Vario to transfer dsRNA constructs.', NULL, NULL, NULL, '40555536');
INSERT INTO screensaver_user VALUES (38, 0, '2004-08-05 00:00:00', 'Vishal', 'Soni', 'vsoni@rics.bwh.harvard.edu', NULL, NULL, 'Doing fluorescence assay to measure cholesterol. ', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (41, 0, '2006-02-22 00:00:00', 'Amy', 'Hall', 'amy_hall@hms.harvard.edu', '617-432-3971', '', 'Will be using the M5.
Sept. 15, 2006: Will start screen of an an assay related to Yoko''s (same assay, different cell line); will screen Sanofi-Aventis libraries at least initially.  ', NULL, NULL, NULL, '50570452');
INSERT INTO screensaver_user VALUES (43, 0, '2003-04-17 00:00:00', 'Kent', 'Nybakken', 'knybakke@genetics.med.harvard.edu', '617-432-7571', NULL, 'An RNAi screen at this point only. Kent is looking for inhibitors of hedgehog signalling from the "stimulated" state. He is using Drosophila cells and his readout is a patch transcription -dependent firefly luciferase reporter gene. As a control using a renilla luciferase. Promega kit. ', NULL, NULL, NULL, '905338270605');
INSERT INTO screensaver_user VALUES (48, 0, '2002-01-30 00:00:00', 'Min', 'Wu', 'min_wu@dfci.harvard.edu', '632-4693', 'Dana Bldg. D-630B', 'uses G. McGill server account', NULL, NULL, NULL, '20547006');
INSERT INTO screensaver_user VALUES (50, 0, '2002-04-05 00:00:00', 'Aimee', 'Dudley', 'dudley@genetics.med.harvard.edu', '(617) 432-7670', 'Alpert', 'Using multidrop only.', NULL, NULL, NULL, '60400598');
INSERT INTO screensaver_user VALUES (53, 0, '2003-01-31 00:00:00', 'Bob', 'Lake', 'rlake@partners.org', '617-724-2282', NULL, 'Using Brian DeDecker''s server account.', NULL, NULL, NULL, '40514678');
INSERT INTO screensaver_user VALUES (55, 0, '2004-12-03 00:00:00', 'Kazuo', 'Oshima', 'kazuo_oshima@meei.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '206087490');
INSERT INTO screensaver_user VALUES (57, 0, '2004-11-04 00:00:00', 'Julie', 'Su', 'su@wi.mit.edu', '617-258-6517', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (62, 0, '2006-11-08 00:00:00', 'Jian', 'You', 'jian.you@childrens.harvard.edu', '617-919-2650', '', '', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (64, 0, '2005-10-28 00:00:00', 'Jonathan', 'Swoboda', 'swoboda@fas.harvard.edu', '432-5498', 'Armenise Room 633
200 Longwood St.
Boston, MA 02115', '', NULL, NULL, NULL, '20608730');
INSERT INTO screensaver_user VALUES (67, 0, '2006-01-18 00:00:00', 'Jens', 'Kuhn', 'jens_kuhn@hms.harvard.edu', '508-786-3326', 'New England Primate Research Center
1 Pine Hill Drive
Southborough, MA 01772-9102
USA
Phone: (508) 786-3326
Fax: (508) 786-3317', 'NSRB screener', NULL, NULL, NULL, '10602645');
INSERT INTO screensaver_user VALUES (79, 0, '2004-02-22 00:00:00', 'Ellis', 'Reinherz', 'Ellis.Reinherz@has.missing.email', NULL, NULL, '8-23-04 Not sure this guy is in Wagner lab.
This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '40023925');
INSERT INTO screensaver_user VALUES (81, 0, '2006-05-15 00:00:00', 'Clayton', 'Knight', 'clayk09@gmail.com', '(214)458-6098', 'Texas A&M University
LF Peterson Building
Mailstop 2132
College Station, TX
77840', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (86, 0, '2004-02-22 00:00:00', 'Bill', 'Sellers', 'Bill.Sellers@has.missing.email', NULL, NULL, 'This user''s date created was changed from 2003-11-21 to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (87, 0, '2003-09-03 00:00:00', 'Kittichoat (Pum)', 'Tiyanont', 'tiyanont@fas.harvard.edu', '617-432-5498', NULL, NULL, NULL, NULL, NULL, '50616312');
INSERT INTO screensaver_user VALUES (88, 0, '2006-08-23 00:00:00', 'Steven', 'Barthel', 'sbarthel@rics.bwh.harvard.edu', '617-525-5698', 'HIM Building, Room 650', '', NULL, NULL, NULL, '40674209');
INSERT INTO screensaver_user VALUES (90, 0, '2002-04-05 00:00:00', 'Jesse', 'Boehm', 'jboehm@fas.harvard.edu', '617-632-5670', 'D-630', 'BBS rotation student, spring''02.Using Scott Lokey  ICCB server account unitl 4/02 then switched to G. McGill''s account. ', NULL, NULL, NULL, '30555066');
INSERT INTO screensaver_user VALUES (100, 0, '2002-01-02 00:00:00', 'Jeremy', 'Wilbur', 'wilbur@helix.mgh.harvard.edu', '617-726-5729', 'MGH Charlestown', 'Uses Cris Bragg''s server account.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (102, 0, '2003-10-09 00:00:00', 'Susumu', 'Kobayashi', 'skobayas@bidmc.harvard.edu', '617-667-4272', NULL, NULL, NULL, NULL, NULL, '105823691');
INSERT INTO screensaver_user VALUES (106, 0, '2005-08-02 00:00:00', 'Justin', 'Kern', 'jkern@uchicago.edu', '773-834-8151', 'University of Chicago', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (109, 0, '2005-05-10 00:00:00', 'Sonia', 'Cantel Paille', 'Sonia_CantelPaille@hms.harvard.edu', '617-621-6104', NULL, '4/13/05 I am a post-doc in the Laboratory of Translational Research (Tosteson/Halperin lab.) at HMS. I have a collaborative project with Nathan Moerke in Prof. Gerhard Wagner''s group and need to have an access to the analyst plate reader, so would it be possible to use the ICCB''s one and get my ID coded?
7/26/05: ecommons user name = SC95', NULL, NULL, NULL, '80631235');
INSERT INTO screensaver_user VALUES (112, 0, '2005-05-23 00:00:00', 'Shawn', 'Hakim', 'shawn_hakim@hms.harvard.edu', NULL, NULL, '5/23/05 - Stewart asked me to get Shawn a Matterhorn account. I assume Shawn is an RNAi user. I am unsure of his classification. - Dara
07/05- Working with Yoko', NULL, NULL, NULL, '10634849');
INSERT INTO screensaver_user VALUES (118, 0, '2002-04-15 00:00:00', 'Michael', 'Boutros', 'mboutros@hms.harvard.edu', '432-7548', 'WAB 4th floor', 'Data folder in data6.Using Precision 2000 and plate readers to read luciferase assays for Drosophila RNAi screens. He is assaying  the function of signalling pathways (at least 2) required for innate immunity.', NULL, NULL, NULL, '20522364');
INSERT INTO screensaver_user VALUES (119, 0, '2004-07-13 00:00:00', 'Maria', 'Chmura', 'maria_chmura@hms.harvard.edu', '617-432-1927', NULL, 'NSRB screener', NULL, NULL, NULL, '30605977');
INSERT INTO screensaver_user VALUES (122, 0, '2006-06-22 00:00:00', 'Yongmun', 'Choi', 'yongmun_choi@dfci.harvard.edu', '617-582-8589', '', '', NULL, NULL, NULL, '40682031');
INSERT INTO screensaver_user VALUES (124, 0, '2006-01-20 00:00:00', 'Sue', 'Shoesmith', 'sshoesmith@comcast.net', '508-999-8588', 'Department of Chemistry and Biochemistry, University of Massachusetts
285 Old Westport Rd. 
Dartmouth, MA 02747 USA 
Phone: 508-999-8588 
Fax: 508-999-8451', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (128, 0, '2004-02-22 00:00:00', 'Meg', 'Philipps', 'Meg.Philipps@has.missing.email', NULL, NULL, 'This user''s date created was changed from 2003-11-21 to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (129, 0, '2006-02-10 00:00:00', 'Anton', 'Agarkov', 'anagarko@UTMB.EDU', NULL, NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (135, 0, '2002-04-10 00:00:00', 'Seth', 'Field', 'sfield@alum.mit.edu', '617-667-0946', 'HIM 1007', 'Not carrying out a screen. Using Cartesian robot.', NULL, NULL, NULL, '20316691');
INSERT INTO screensaver_user VALUES (139, 0, '2003-02-27 00:00:00', 'Marion', 'Shonn', 'marion.shonn@tufts.edu', '617-636-4092', NULL, 'Plate reader use only (Wallac).Using Russell Dorer''s NTONE account.', NULL, NULL, NULL, '10543312');
INSERT INTO screensaver_user VALUES (141, 0, '2004-02-22 00:00:00', 'Yanan', 'Hu', 'Yanan.Hu@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (142, 0, '2006-06-19 00:00:00', 'Roy', 'Kishony', 'roy_kishony@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '40600035');
INSERT INTO screensaver_user VALUES (143, 0, '2005-05-13 00:00:00', 'Justin', 'Robbins', 'jrobbins@wadsworth.org', NULL, NULL, 'NSRB Screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (146, 0, '2004-11-29 00:00:00', 'Ru', 'Gunawardane', 'ru_gunawardane@hms.harvard.edu', '617-432-3971', '', '9/30/06 - email is either not correct or no longer active - removing from active screening users list', NULL, NULL, NULL, '905 6930 9');
INSERT INTO screensaver_user VALUES (140, 1, '2004-02-12 00:00:00', 'Ralph', 'Isberg', 'ralph.isberg@tufts.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (152, 0, '2003-03-04 00:00:00', 'Kevin', 'Bryant', 'kevin_bryant@student.hms.harvard.edu', '617-432-1789', NULL, 'Wallac plate reader use only.', NULL, NULL, NULL, '50536572');
INSERT INTO screensaver_user VALUES (156, 0, '2005-02-11 00:00:00', 'Nghia (James)', 'Bui', 'sbui@hms.harvard.edu', '617-432-3972', NULL, NULL, NULL, NULL, NULL, '30566580');
INSERT INTO screensaver_user VALUES (162, 0, '2003-06-10 00:00:00', 'Dodzie', 'Sogah', 'sogah@fas.harvard.edu', '432-4172', '4th floor SGM', 'Using plate reader only.', NULL, NULL, NULL, '704868650');
INSERT INTO screensaver_user VALUES (163, 0, '2004-05-17 00:00:00', 'Ute', 'Osmers', 'osmers@cbr.med.harvard.edu', '617-432-3194', NULL, NULL, NULL, NULL, NULL, '012046790 ');
INSERT INTO screensaver_user VALUES (168, 0, '2005-10-26 00:00:00', 'Terese', 'Frazier', 'terese_frazier@hms.harvard.edu', ' 617-432-4964', NULL, 'ecommons tmf2', NULL, NULL, NULL, '50619095');
INSERT INTO screensaver_user VALUES (171, 0, '2005-09-28 00:00:00', 'James', 'Orth', 'james_orth@hms.harvard.edu', '617-432-3728', '', '5-3-06 SPR - removed from screening users list due to bounceback emails saying unrecognized', NULL, NULL, NULL, '50634663');
INSERT INTO screensaver_user VALUES (172, 0, '2006-05-24 00:00:00', 'Jody', 'Matewish', 'jody_matewish@hms.harvard.edu', '617-432-5092', '', 'NSRB screener', NULL, NULL, NULL, '906284020');
INSERT INTO screensaver_user VALUES (177, 0, '2003-02-19 00:00:00', 'Charles', 'Kim', 'charles_kim@hms.harvard.edu', '617-432-4957', NULL, 'For plate reader use only right now.', NULL, NULL, NULL, '50584496');
INSERT INTO screensaver_user VALUES (178, 0, '2002-06-07 00:00:00', 'Ked', 'Matchacheep', 'matchach@fas.harvard.edu', '617-496-7039', NULL, 'data file on data6', NULL, NULL, NULL, '905552940');
INSERT INTO screensaver_user VALUES (179, 0, '2004-09-30 00:00:00', 'Nikos', 'Reppas', 'nreppas@fas.harvard.edu', '617-432-6516', NULL, NULL, NULL, NULL, NULL, '50500942');
INSERT INTO screensaver_user VALUES (180, 0, '2004-10-06 00:00:00', 'Jonathan', 'Abraham', 'abraham2@fas.harvard.edu', '', '', '', NULL, NULL, NULL, '60557713');
INSERT INTO screensaver_user VALUES (185, 0, '2004-02-22 00:00:00', 'Stuart', 'Calderwood', 'Stuart.Calderwood@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '80291574');
INSERT INTO screensaver_user VALUES (186, 0, '2006-12-11 00:00:00', 'Dan', 'Aiello', 'daiello@microbiotix.com', '508-757-2800, x109', 'Microbiotix, Inc.
One Innovation Dr.
Worcester, MA  01605-4306', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (188, 0, '2006-06-12 00:00:00', 'Ian', 'White', 'ian_white@hms.harvard.edu', '617-432-6340', '', 'uses plate centrifuge', NULL, NULL, NULL, '70614375');
INSERT INTO screensaver_user VALUES (190, 0, '2006-06-14 00:00:00', 'Dana', 'Harmon', 'dana.harmon@tufts.edu', '', '', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (198, 0, '2004-04-08 00:00:00', 'Thomas ', 'Kuper', 'Thomas.Kueper@ruhr-uni-bochum.de', NULL, NULL, '4/04 Visiting student working with GaroToby.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (201, 0, '2005-07-14 00:00:00', 'Michelle', 'De La Vega', '<Michelle_DeLaVega@dfci.harvard.edu', '617-632-2083', NULL, '7/05 Maria Stotsky is leaving D''Andrea lab and Michelle is taking over her role on the screen.', NULL, NULL, NULL, '1205451');
INSERT INTO screensaver_user VALUES (205, 0, '2003-02-12 00:00:00', 'Eunis', 'Choi', 'echoi2@caregroup.harvard.edu', NULL, NULL, 'Will use Steve Balk server account.
7/6/04 email from Eunis (Eunis no longer working for Steve Balk, Robert Borgesi likely to continue screen): 
Hi Jim,
I actually have no Harvard ID.  I have no affiliation with Harvard
except through BIDMC.  Also, I left my job last week so I won''t be coming in
anymore.  One of the other technicians in my lab will be taking over.
Hisname is Robert Borgesi, but he probably won''t be coming in for awhile.
Thanks for everything,
Eunis
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (206, 0, '2004-02-22 00:00:00', 'Eva', 'Gordon', 'Eva.Gordon@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '60513392');
INSERT INTO screensaver_user VALUES (208, 0, '2006-06-12 00:00:00', 'Peter', 'Yoon', 'sangsun_yoon@hms.harvard.edu', '617-432-0767', '', 'using Wallac for Luminescence readout', NULL, NULL, NULL, '20361115');
INSERT INTO screensaver_user VALUES (211, 0, '2002-01-24 00:00:00', 'Jeremy', 'Jenkins', 'jeremy_jenkins@hms.harvard.edu', '617.432-1154', NULL, NULL, NULL, NULL, NULL, '60541760');
INSERT INTO screensaver_user VALUES (214, 0, '2006-06-15 00:00:00', 'Alison', 'Stewart', 'astewie@gmail.com', '', '', '6/15/06  Alison is a rotation student in the Gray lab. ', NULL, NULL, NULL, '40646787');
INSERT INTO screensaver_user VALUES (221, 0, '2006-02-17 00:00:00', 'Boriana', 'Marintcheva', 'boriana_marintcheva@hms.harvard.edu', '617-432-3129', NULL, 'using the Analyst for FP assay', NULL, NULL, NULL, '70587262');
INSERT INTO screensaver_user VALUES (223, 0, '2006-12-13 00:00:00', 'Chandrasekhar', 'Miduturu', 'chandra_miduturu@dfci.harvard.edu', '617-582-8589', '', 'using Envision 2 for Coumarin FI readout', NULL, NULL, NULL, '30684192');
INSERT INTO screensaver_user VALUES (228, 0, '2004-02-25 00:00:00', 'Sarah', 'Takacs', 'stakacs@childhooddiseases.org', NULL, NULL, '   she is leaving the Rothberg
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (229, 0, '2006-12-11 00:00:00', 'Hsiao-Chun (Lino)', 'Huang', 'hsiao-chun_huang@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '80562217');
INSERT INTO screensaver_user VALUES (230, 0, '2004-02-22 00:00:00', 'Amy', 'Cheung', 'Amy.Cheung@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '30508548');
INSERT INTO screensaver_user VALUES (232, 0, '2006-02-13 00:00:00', 'Mathew', 'Sowa', 'mathew_sowa@hms.harvard.edu', '617-432-6594', NULL, '2-13-06: He will be using the M5 plate reader.', NULL, NULL, NULL, '50610993');
INSERT INTO screensaver_user VALUES (236, 0, '2006-10-19 00:00:00', 'Benedicte', 'Py', 'benedicte_py@hms.harvard.edu', '617-432-4173', '', 'collaborating with Marta Lipinski', NULL, NULL, NULL, '80619219');
INSERT INTO screensaver_user VALUES (240, 0, '2006-01-09 00:00:00', 'Gabriele', 'Casadei', 'G.Casadei@neu.edu', NULL, 'Department of Biology
Northeastern University
360 Huntington Avenue
Mugar 405
Boston, MA 02115', 'NSRB screener
Ecommons ID: GC46 created 1/19/2006  DG
reactivated 3/13/2006  expires 6/12/2006  SJ
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (244, 0, '2006-03-10 00:00:00', 'Rhonda', 'Feinbaum', 'feinbaum@molbio.mgh.harvard.edu', '617-281-9373', NULL, NULL, NULL, NULL, NULL, '50242854');
INSERT INTO screensaver_user VALUES (245, 0, '2004-02-25 00:00:00', 'Caroline', 'Burns', 'cburns@enders.tch.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '20548967');
INSERT INTO screensaver_user VALUES (247, 0, '2002-01-02 00:00:00', 'Katharine', 'Beach', 'kate_beach@hms.harvard.edu', '617-432-4964', 'HMS C2-666', NULL, NULL, NULL, NULL, '10567505');
INSERT INTO screensaver_user VALUES (255, 0, '2006-06-30 00:00:00', 'Anders', 'Berg', 'ahberg@partners.org', '646-483-1456', '', 'user of M5 and plate washer', NULL, NULL, NULL, '70613565');
INSERT INTO screensaver_user VALUES (256, 0, '2004-02-25 00:00:00', 'Suzanne', 'Sobel', 'ssobel@childhooddiseases.org', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (257, 0, '2004-09-08 00:00:00', 'Xiao', 'Tang', 'xrtang@bu.edu', '617-638-4441', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (259, 0, '2005-01-14 00:00:00', 'Timothy ', 'Sikorski', 'Timothy .Sikorski@has.missing.email', NULL, NULL, 'Rotation student in the King Lab.  Working with Nate Hathaway. May be piloting a small screen in the near future.
', NULL, NULL, NULL, '206081960');
INSERT INTO screensaver_user VALUES (263, 0, '2006-01-04 00:00:00', 'Lynn', 'Wartschow', 'lynn.wartschow@childrens.harvard.edu', '617-919-2851', '', '', NULL, NULL, NULL, '01260245');
INSERT INTO screensaver_user VALUES (266, 0, '2003-07-08 00:00:00', 'Tiffany', 'DeSimone', 'tdesimon@fas.harvard.edu', 'cell 617-312-6511', NULL, 'Rotation student with Dyann Wirth summer 2003.Dr. Wirth''s COMS #: R92-120(Transfection of Malaria Parasites)tiffanydesimone@alum.barnard.edu ', NULL, NULL, NULL, '20592427');
INSERT INTO screensaver_user VALUES (270, 0, '2006-04-05 00:00:00', 'Rui', 'Zhou', 'rzhou@genetics.med.harvard.edu', '617-432-7673', '', 'using Ananlyst b/c Perrimon lab''s reader is broken.', NULL, NULL, NULL, '10488753');
INSERT INTO screensaver_user VALUES (271, 0, '2004-06-16 00:00:00', 'Hanna (Yoko)', 'Irie', 'hirie@partners.org', NULL, NULL, '6/16/04 Not sure whether ID access to screening room was ever activated.', NULL, NULL, NULL, '203294670');
INSERT INTO screensaver_user VALUES (272, 0, '2002-10-22 00:00:00', 'Cheryl', 'Wojciechowski', 'cheryl_wojciechowski@dfci.harvard.edu', '617-632-5106', 'Smith 922', 'Will provide ID# when she gets it. Will use Tweeny''s NTONE account for the time being.
2003-CW left Silver lab for another job.', NULL, NULL, NULL, '90586378');
INSERT INTO screensaver_user VALUES (273, 0, '2002-03-01 00:00:00', 'Eileen', 'Boye', 'eboye@hms.harvard.edu', '432-1762', 'LHRRB 108', 'Not doing a screen. Will be using Wallac with 24-well plates.', NULL, NULL, NULL, '40491929');
INSERT INTO screensaver_user VALUES (275, 0, '2003-04-01 00:00:00', 'Alina', 'Vrabioiu', 'alina_vrabioiu@student.hms.harvard.edu', '2-3728', 'SGM 529', NULL, NULL, NULL, NULL, ' 705182870');
INSERT INTO screensaver_user VALUES (277, 0, '2005-02-22 00:00:00', 'Cynthia', 'Castillo', 'Cynthia.Castillo@tufts.edu', '617-636-2743', '', 'NSRB screener
9/30/06 - email is either not correct or no longer active - removing from active screening users list', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (280, 0, '2002-04-05 00:00:00', 'Angie', 'Martinez', 'maria_martinez@hms.harvard.edu', '432-3972', 'LHRRB ', 'Not carrying out a screen.  Using plate readers and possibly autoscope to quantitate staining of mammalian  cells.', NULL, NULL, NULL, '20466790');
INSERT INTO screensaver_user VALUES (281, 0, '2004-02-13 00:00:00', 'Gita', 'Singh', 'gitanjali_singh@student.hms.harvard.edu', NULL, NULL, 'rotation student 2-11-04. will use guest acc''t. Will suggest that she use Derek''s public NTONE acc''t.for data deposition.', NULL, NULL, NULL, '60591989');
INSERT INTO screensaver_user VALUES (283, 0, '2003-07-29 00:00:00', 'May', 'Han', 'mhan@mpi.com and also may.han@verizon.net', '617-470-4733', NULL, 'May currently  works at Millenium and is consulting on her own time for this project with Michael and Gerhard. 8/4/03 Spoke with Gerhard Wagner to confirm the situation.  Michael R. is finishing up and May is continuing the screen.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (287, 0, '2006-07-14 00:00:00', 'Guang2', 'Hu', 'ghu@bidmc.harvard.edu', '617-667-1605', '', '', NULL, NULL, NULL, '40552960');
INSERT INTO screensaver_user VALUES (289, 0, '2004-08-24 00:00:00', 'Yousang', 'Gwack', 'gwack@cbr.med.harvard.edu', '617-278-3263', NULL, 'Carrying out an RNAi screen.  Will use plate filler and plate reader for a few plates only.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (290, 0, '2002-02-06 00:00:00', 'Roberto', 'Sanchez-Olea', 'roberto_olea@hms.harvard.edu', '617-432-4188', 'SGM-419', 'Plate reader only.', NULL, NULL, NULL, '20449365');
INSERT INTO screensaver_user VALUES (292, 0, '2004-05-24 00:00:00', 'Robert (HongXiang)', 'Lu', 'hlu@rics.bwh.harvard.edu', '617-525-4269', 'Channing Laboratories', NULL, NULL, NULL, NULL, '20599979');
INSERT INTO screensaver_user VALUES (293, 0, '2006-07-19 00:00:00', 'Viswanathan', 'Srinivasan', 'vishi@rics.bwh.harvard.edu', '617-525-4236', '', 'NSRB screener', NULL, NULL, NULL, '40587047');
INSERT INTO screensaver_user VALUES (297, 0, '2006-04-19 00:00:00', 'Mary', 'Packard', 'mpackard@genetics.med.harvard.edu', '617-432-7673', '', 'Envision user (luminescence 96)', NULL, NULL, NULL, '80607350');
INSERT INTO screensaver_user VALUES (298, 0, '2004-02-27 00:00:00', 'James', 'Cha', 'cha@fas.harvard.edu', '617-432-4188', NULL, 'Working with Mike Boyce on an RNAi screen in collaboration with the Perrimon Lab to find Drosophila genes that, when knocked down, will protect from ER stress-induced cell death. Cell Titre Glo kit is used for live-dead readout. Using our liquid handling (plate fillers) but will probably use Juan lab plate reader. ', NULL, NULL, NULL, '20485574');
INSERT INTO screensaver_user VALUES (299, 0, '2003-05-06 00:00:00', 'Shane', 'Woods', 'shane_woods@hms.harvard.edu', '617-432-4961', NULL, 'Shane is an undergrad/co-op student from Queens University, Canada, and will be at ICCB from 05/03 to 012/03.  He will be working on screens 151 and 221 (annotation screen).', NULL, NULL, NULL, '205-9185-40');
INSERT INTO screensaver_user VALUES (301, 0, '2002-02-06 00:00:00', 'Roger', 'Greenberg', 'roger_greenberg@hotmail.com', '617-432-4173', 'SGM-419', 'Plate reader use only.', NULL, NULL, NULL, '70544717');
INSERT INTO screensaver_user VALUES (305, 0, '2002-10-22 00:00:00', 'Lifang (Lillian)', 'Lu', 'lflu@hsph.harvard.edu', '617-432-2065', NULL, 'Using ICCB plate readers only; not carrying out a screen. Is setting up FP assay to measure binding of p27 to Skp1/2 complex.  Would like to do screen in the future.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (307, 0, '2003-05-02 00:00:00', 'Jeff', 'Gross', 'jmgross@fas.harvard.edu', '617-495-2599', NULL, NULL, NULL, NULL, NULL, '60583986');
INSERT INTO screensaver_user VALUES (308, 0, '2002-01-02 00:00:00', 'Michael', 'Roehrl', 'michael_roehrl@hms.harvard.edu', '617-432-3212', NULL, NULL, NULL, NULL, NULL, '80493835');
INSERT INTO screensaver_user VALUES (310, 0, '2005-09-22 00:00:00', 'Alice', 'Robson', 'a.robson@bristol.ac.uk', '617-432-1611', NULL, 'Alice is a visiting postdoc in the Rapoport lab. She will be at HMS for a couple of months (starting 9/05). Her HMS email (not often used) is alice_robson@hms.harvard.edu.', NULL, NULL, NULL, '30653351');
INSERT INTO screensaver_user VALUES (312, 0, '2006-02-07 00:00:00', 'Ghassan', 'Mouneimne', 'gmouneim@aecom.yu.edu', '617-432-3972', NULL, 'new postdoc in the process of getting harvard ID will update info and submit for activation once received, also will update with harvard email.  2/7/06', NULL, NULL, NULL, '40662162');
INSERT INTO screensaver_user VALUES (315, 0, '2004-02-22 00:00:00', 'Konrad', 'Howitz', 'Konrad.Howitz@has.missing.email', NULL, NULL, 'This user''s date created was changed from 2003-11-21 to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (120, 1, '2004-02-22 00:00:00', 'Rob', 'Zipkin', 'zipkinre@biomol.com', NULL, NULL, 'This user''s date created was changed from 2003-11-21 to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (317, 0, '2002-01-02 00:00:00', 'David', 'Chalmers', 'david_chalmers@hms.harvard.edu', NULL, 'SGM 610', NULL, NULL, NULL, NULL, '70561255');
INSERT INTO screensaver_user VALUES (319, 0, '2006-06-21 00:00:00', 'Nen', 'Cao', 'nencao@fas.harvard.edu', '908-398-7720', '', 'Nen is an undergrad working possibly until Jan. 2007.', NULL, NULL, NULL, '205770450');
INSERT INTO screensaver_user VALUES (321, 0, '2004-02-22 00:00:00', 'Oliver', 'Muehlemann', 'Oliver.Muehlemann@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (324, 0, '2004-02-25 00:00:00', 'Emily', 'Humphrey', 'humphrey@fas.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (325, 0, '2002-07-10 00:00:00', 'Change', 'Tan', 'ctan@genetics.med.harvard.edu', '617-432-7548', '200 Longwood Ave.', 'Using liq. handling + plate readers only for dsRNA screen. Data folder is on Data 3.', NULL, NULL, NULL, '805524160605');
INSERT INTO screensaver_user VALUES (327, 0, '2005-11-07 00:00:00', 'Bob', 'Freeman', 'bob_freeman@hms.harvard.edu', '617-432-2293', NULL, 'ecommons, rmf1.  Bob will be using our facility to transfer from his source plate to a destination plate with the pin transfer robot.  ', NULL, NULL, NULL, '40346880');
INSERT INTO screensaver_user VALUES (328, 0, '2006-02-09 00:00:00', 'Neil', 'Kubica', 'neil_kubica@hms.harvard.edu', '617-432-4849', NULL, NULL, NULL, NULL, NULL, '206573320');
INSERT INTO screensaver_user VALUES (329, 0, '2006-01-12 00:00:00', 'karolina', 'mizeracka', 'Karolina_Mizeracka@hms.harvard.edu', NULL, NULL, 'Karolina is a rotation student working with Kaylene Simpson through April 2006. ', NULL, NULL, NULL, '80636482');
INSERT INTO screensaver_user VALUES (332, 0, '2006-10-25 00:00:00', 'Alexander', 'Loewer', 'alexander_loewer@hms.harvard.edu', '617-432-5952', '', 'using the IX Micro', NULL, NULL, NULL, '50656268');
INSERT INTO screensaver_user VALUES (333, 0, '2002-07-12 00:00:00', 'Jim (Zhen-Yu)', 'Sun', 'jsun@wagnerlab.med.harvard.edu', '617-432-3211', 'C1-103', 'Only using plate reader.Has NTONE account via BCMP. Rich Ryder moved Jim to ICCB users group on NTONE (presumably so Jim can log onto ICCB equipment). ', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (334, 0, '2005-02-08 00:00:00', 'Shenghua', 'Zhou', 'Shenghua.Zhou@umassmed.edu', '508-856-3626', 'Department of Medicine
University of Mass.Medical School
364 Plantation St, Worcester, MA 01545', 'NSRB screener
11/2/05- EcommonsID SZ25 expired. IT extended it through Feb 20, 2006.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (336, 0, '2006-04-12 00:00:00', 'Curtis', 'Thorne', 'curtis.thorne@vanderbilt.edu', '615-322-1412', 'Curtis A. Thorne
Ethan Lee Lab
Cell & Developmental Biology
Vanderbilt University
U-4200 Learned Lab
1161 21st Ave. S.
Nashville, TN 37232-2175
Tel: 615-322-1412
Fax: 615-343-453', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (338, 0, '2005-10-13 00:00:00', 'Frederic', 'Sigoillot', 'Frederic_Sigoillot@hms.harvard.edu', '617-432-4964', '', '', NULL, NULL, NULL, '40648623');
INSERT INTO screensaver_user VALUES (341, 0, '2005-03-16 00:00:00', 'Kristi', 'Piehl', 'piehlk@ohsu.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (344, 0, '2004-02-22 00:00:00', 'Diane', 'Turcotte', 'Diane.Turcotte@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '60597553');
INSERT INTO screensaver_user VALUES (346, 0, '2002-01-02 00:00:00', 'Benjamin', 'Myers', 'myers@slsiris.harvard.edu', '617-495-8394', NULL, NULL, NULL, NULL, NULL, '20502762');
INSERT INTO screensaver_user VALUES (348, 0, '2002-06-18 00:00:00', 'Bernadette', 'Lord', 'blord@rics.bwh.harvard.edu', '617-768-8281', NULL, 'Will use Tomo''s server account.Left the Rich  Lee lab 5/2/03.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (353, 0, '2003-05-29 00:00:00', 'Michael', 'Pacold', 'michael_pacold@student.hms.harvard.edu', '617-432-4788', NULL, NULL, NULL, NULL, NULL, '80573650');
INSERT INTO screensaver_user VALUES (355, 0, '2006-09-20 00:00:00', 'Wooyoung', 'Hur', 'wooyoung_hur@dfci.harvard.edu', '617-582-8589', '', 'receiving pin transfers of own library on Epson
future training on Analyst', NULL, NULL, NULL, '012648040');
INSERT INTO screensaver_user VALUES (357, 0, '2005-11-22 00:00:00', 'James', 'Dilks', 'jdilks@caregroup.harvard.edu', NULL, NULL, 'From Rob 11-05: We will just be using a few plates at a time.  (We are still working on a project derived from the initial screen.) ', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (358, 0, '2004-05-27 00:00:00', 'Xulin', 'Chen', 'x_chen@fccc.edu', '215-728-3030 ', 'Philadelphia, PA', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (360, 0, '2004-03-22 00:00:00', 'Yangqing (Jason) ', 'Xu', 'yangqing_xu@hms.harvard.edu', '617-432-3724', NULL, 'Jason is continuing the profiling project started by Yan Feng in collaboration with Tim Mitchison.  He will be using the screening microscopes but not the screening room.
7/05 Collaborating with Greg Hoffman (Blenis lab) on RNAi screen.', NULL, NULL, NULL, '70604582');
INSERT INTO screensaver_user VALUES (108, 1, '2004-03-22 00:00:00', 'Jeremy', 'Gunawardena', 'jeremy_gunawardena@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '70569833');
INSERT INTO screensaver_user VALUES (364, 0, '2002-03-19 00:00:00', 'Katie', 'Koeller', 'koeller@slsiris.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (365, 0, '2006-09-06 00:00:00', 'Zachary', 'Schafer', 'zachary_schafer@hms.harvard.edu', '617-432-3972', '', '', NULL, NULL, NULL, '10680107');
INSERT INTO screensaver_user VALUES (366, 0, '2004-09-30 00:00:00', 'Xiaoxia (Nina)', 'Lin', 'xiaoxia@genetics.med.harvard.edu', '617-432-6510', NULL, NULL, NULL, NULL, NULL, '80588275');
INSERT INTO screensaver_user VALUES (368, 0, '2006-09-11 00:00:00', 'Tiao', 'Xie', 'tiao_xie@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '80683286');
INSERT INTO screensaver_user VALUES (372, 0, '2004-07-06 00:00:00', 'Hong', 'Fang', 'hong.fang@vanderbilt.edu', NULL, NULL, 'NSRB screener
No need to add to screening users email list; Neil Green is already on it.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (374, 0, '2006-10-10 00:00:00', 'Brian', 'Quinlan', 'quinlan@fas.harvard.edu', '203-858-4582', '', '', NULL, NULL, NULL, '30664442');
INSERT INTO screensaver_user VALUES (376, 0, '2004-10-22 00:00:00', 'Dong', 'Lee', 'donglee@salk.edu', NULL, NULL, NULL, NULL, NULL, NULL, '80518579');
INSERT INTO screensaver_user VALUES (377, 0, '2003-02-12 00:00:00', 'Shinta', 'Cheng', 'scheng@caregroup.harvard.edu', NULL, NULL, 'Will use Steve Balk server account.', NULL, NULL, NULL, '30453956');
INSERT INTO screensaver_user VALUES (379, 0, '2006-10-05 00:00:00', 'Marco', 'Mazzone', 'marco_mazzone@hms.harvard.edu', '617-432-3971', '', 'using the SpectraMax M5 plate reader', NULL, NULL, NULL, '306616640');
INSERT INTO screensaver_user VALUES (380, 0, '2005-11-17 00:00:00', 'Jennifer', 'Wang', 'Jennifer_Wang@hms.harvard.edu', '617-432-1927', '', 'NSRB screener
ecommons JTW6', NULL, NULL, NULL, '10643775');
INSERT INTO screensaver_user VALUES (386, 0, '2005-10-28 00:00:00', 'Kerry', 'Love', 'kerry_love@hms.harvard.edu', '617-432-5498', 'Armenise Room 633
200 Longwood Ave.
Boston, MA 02115', NULL, NULL, NULL, NULL, '20604352');
INSERT INTO screensaver_user VALUES (387, 0, '2004-07-09 00:00:00', 'Lucy', 'Park', 'lucy_park@hms.harvard.edu', '617-432-1874', 'LHRRB 111', 'Wallac user with Aileen Boyd.', NULL, NULL, NULL, '20549084');
INSERT INTO screensaver_user VALUES (389, 0, '2003-09-09 00:00:00', 'Huiming', 'Li', 'li@cbr.med.harvard.edu', '617-278-3265', NULL, 'Not screening; just doing follow-up exp''ts with Patrick. Using Hogan server acc''t.', NULL, NULL, NULL, '805856591606');
INSERT INTO screensaver_user VALUES (390, 0, '2002-01-24 00:00:00', 'Shidong', 'Jia', 'sjia@hms.harvard.edu', '617.432-3948', 'SGM 408', 'Using F. McKeon server account', NULL, NULL, NULL, '40548866');
INSERT INTO screensaver_user VALUES (391, 0, '2006-10-05 00:00:00', 'Ji', 'Luo', 'jluo@rics.bwh.harvard.edu', '617-525-4514', '', 'using Analyst plate reader', NULL, NULL, NULL, '10500605');
INSERT INTO screensaver_user VALUES (392, 0, '2006-10-02 00:00:00', 'Marnie', 'Gelbart', 'mgelbart@rics.bwh.harvard.edu', '617-525-4523', '', 'Working with Erica Larschan using IXMicro in C607', NULL, NULL, NULL, '70424126');
INSERT INTO screensaver_user VALUES (395, 0, '2006-03-06 00:00:00', 'Luke', 'Jasenosky', 'ldjasenosky@students.wisc.edu', '608-263-9486', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (401, 0, '2002-12-17 00:00:00', 'Amy', 'Kiger', 'Amy.Kiger@has.missing.email', NULL, NULL, 'Using Analyst only. RNAi screen.', NULL, NULL, NULL, '70548658');
INSERT INTO screensaver_user VALUES (403, 0, '2004-02-22 00:00:00', 'Isabel', 'Bise', 'Isabel.Bise@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (408, 0, '2005-05-10 00:00:00', 'Ning', 'Pan', 'ning.pan@umassmed.edu', '508-856-6037', 'Ning Pan Ph.D.
Department of Molecular Genetics and Microbiology
University of Massachusetts Medical School
55 Lake Avenue North
Worcester, MA 01655', 'NSRB Screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (189, 1, '2004-02-22 00:00:00', 'Adrian', 'Salic', 'adrian_salic@hms.harvard.edu', '', '', '4/12/06 Adrian was a grad student with Marc Kirshner at the time he carried out screen # 135. He is now a PI in Cell Biology at HMS. Today this record was updated to reflect this. 
This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '90414488');
INSERT INTO screensaver_user VALUES (410, 0, '2005-12-01 00:00:00', 'Ushma', 'Kriplani', 'ushma@anl.gov', '203-449-7846', '9700 South Cass Ave. Bldg -202
Argonne, IL 60439', 'alternate email: ushma_kriplani@yahoo.com', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (415, 0, '2004-06-03 00:00:00', 'Arun', 'Ranganathan', 'arun_ranganathan@hms.harvard.edu', '617-432-5815', NULL, 'Visiting graduate student for summer 2004, collaborating with Derek Martyn.', NULL, NULL, NULL, '506130700');
INSERT INTO screensaver_user VALUES (417, 0, '2005-05-09 00:00:00', 'Justine', 'Melo', 'jmelo@molbio.mgh.harvard.edu', '617-726-5973', 'Department of Genetics
Harvard Medical School
Department of Molecular Biology
Massachusetts General Hospital
Wellman 8, room 827
50 Blossom Street
Boston, MA 02114', 'Justine Melo, PhD', NULL, NULL, NULL, '50614085');
INSERT INTO screensaver_user VALUES (422, 0, '2004-09-17 00:00:00', 'Kurt', 'Toenjes', 'Kurt.Toenjes@uvm.edu', '802-656-0720', NULL, ' Kurt Toenjes  Ph.D.
Microbiology and Molecular Genetics
University of Vermont
117 Stafford Hall
95 Carigan Dr.
Burlington, VT 05405
phone 802-656-0720
FAX 802-656-8749', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (424, 0, '2004-11-19 00:00:00', 'Nwakaso', 'Umejiego', 'nwak@brandeis.edu', '781-736-2334', 'Hedstrom Lab
Brandeis University/Biochemistry
415 South St
Waltham, MA 02453', 'NSRB screener
Ecommons ID: NNU1', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (428, 0, '2005-10-28 00:00:00', 'Mihai', 'Ciustea', 'mihai@biochem.dental.upenn.edu', '215-898-3908', 'Levy Research Building, Room 251
4010 Locust Street
Philadelphia, PA 19104
fax: 215-898-8385', 'NSRB screener
mc022001@aol.com was listed as his email but according to Mihai this must be someone else in the lab
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (431, 0, '2004-06-16 00:00:00', 'Julie', 'Wilsbacher', 'julie_wilsbacher@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '20533935');
INSERT INTO screensaver_user VALUES (435, 0, '2002-02-06 00:00:00', 'Andreas', 'Luch', 'andreas_luch@hms.harvard.edu', NULL, 'C-666', '2/02:Not starting screen yet. Access to robots only', NULL, NULL, NULL, '80568649');
INSERT INTO screensaver_user VALUES (23, 1, '2004-08-05 00:00:00', 'Steve', 'Blacklow', 'sblacklow@rics.bwh.harvard.edu', '617-525-4413', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (436, 0, '2006-01-20 00:00:00', 'Shuowei', 'Cai', 'scai@umassd.edu', '508-999-8807', 'Department of Chemistry and Biochemistry, University of Massachusetts 
285 Old Westport Rd. 
Dartmouth, MA 02747 USA 
Phone: 508-999-8588 
Fax: 508-999-8451', 'NSRB screener
Ecommons ID: SC113 (invited user)', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (437, 0, '2006-07-28 00:00:00', 'Brian', 'Quattrochi', 'brian_quattrochi@hms.harvard.edu', '617-432-4964', '', 'New employee as of June 19, 2006; working with Frederic Sigoillot in King lab.', NULL, NULL, NULL, '906757610');
INSERT INTO screensaver_user VALUES (438, 0, '2006-05-04 00:00:00', 'Jeff', 'Forrester', 'jeff_forrester@meei.harvard.edu', '617-573-3162', '', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (442, 0, '2005-09-14 00:00:00', 'Hakryul', 'Jo', 'hakryul.jo@childrens.harvard.edu', '617-919-2687', NULL, 'Ecommons ID: HJ11', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (447, 0, '2004-02-22 00:00:00', 'Debu', 'RayChaudhuri', 'debu.raychaudhuri@tufts.edu', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (448, 0, '2002-02-06 00:00:00', 'Qing', 'Li', 'qli@hms.harvard.edu', '617-432-1762', 'LHRRB 108', 'Plate reader use only.
7-1-04: May not need access any longer.', NULL, NULL, NULL, '90514687');
INSERT INTO screensaver_user VALUES (450, 0, '2006-02-17 00:00:00', 'Yao', 'Yu', 'yaoyu@fas.harvard.edu', '480-459-8060', NULL, 'using Analyst for FP assay', NULL, NULL, NULL, '80595336');
INSERT INTO screensaver_user VALUES (452, 0, '2006-10-05 00:00:00', 'Yu-chen', 'Hwang', 'yhwan003@ucr.edu', '', '', 'Visiting student from UC, Riverside; will be working in Priscilla Yang''s lab.  Using SpectraMax M5 plate reader.', NULL, NULL, NULL, '20686529');
INSERT INTO screensaver_user VALUES (454, 0, '2003-06-20 00:00:00', 'Scott', 'Jones', 'sljones@fas.harvard.edu', '617-632-5109', NULL, 'Undergrad starting work summer ''03 with Tweeny.', NULL, NULL, NULL, '40558489');
INSERT INTO screensaver_user VALUES (455, 0, '2004-02-22 00:00:00', 'Ari', 'Helenius', 'Ari.Helenius@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (457, 0, '2006-06-13 00:00:00', 'Cecilia', 'Cotta-Ramusino', 'ccotta@rics.bwh.harvard.edu', '617-525-4517', '', 'Brigham and Women''s ID with a white harvard access card, working with Rob McDonald from the Elledge lab on their RNAi screen. ', NULL, NULL, NULL, '906590650');
INSERT INTO screensaver_user VALUES (461, 0, '2006-11-09 00:00:00', 'Nate', 'Price', 'nprice@fas.harvard.edu', '617-432-1281', '', '11/9/06 Nate is rotating in the Blenis lab and is working with Chris Dimitri piloting a small molecule screening assay.', NULL, NULL, NULL, '706680920');
INSERT INTO screensaver_user VALUES (462, 0, '2004-04-08 00:00:00', 'Greg ', 'Korbel', 'greg_korbel@hms.harvard.edu', '617-432-4779', ' ', NULL, NULL, NULL, NULL, '70500620');
INSERT INTO screensaver_user VALUES (464, 0, '2004-07-22 00:00:00', 'Adriana', 'Donovan', 'donovan@enders.tch.harvard.edu', '617-919-2122', NULL, NULL, NULL, NULL, NULL, '20415150');
INSERT INTO screensaver_user VALUES (465, 0, '2006-05-02 00:00:00', 'Jessica', 'Hurt', 'jessica_hurt@hms.harvard.edu', '617-432-6404', '', 'Collaborating with Natalie Gilks on her RNAi screen. Primarily using ImagXpress Micro.', NULL, NULL, NULL, '90573160');
INSERT INTO screensaver_user VALUES (466, 0, '2006-11-09 00:00:00', 'Michael', 'Springer', 'michael_springer@hms.harvard.edu', '617-861-7281 (cell)', '', 'Rearraying protocol - FX user', NULL, NULL, NULL, '306038691');
INSERT INTO screensaver_user VALUES (467, 0, '2006-02-28 00:00:00', 'Manoj', 'Krishnan', 'mnk8@email.med.yale.edu', '203-737-5635', 'Department of Internal Medicine
Yale University School of Medicine
1 Gilbert street
TAC Building, Room #S410
New Haven, CT 06510', 'NSRB screener
ecommons MNK3 - Extended until May 2007 on 11/20/2006 SMJ
FEDEX Account #: 006500196', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (471, 0, '2005-08-19 00:00:00', 'Michael', 'Scholle', 'mscholle@anl.gov', '630-252-3799', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (472, 0, '2004-02-22 00:00:00', 'Jonathan', 'Matsui', 'Jonathan.Matsui@has.missing.email', NULL, NULL, 'This user''s date created was changed from 2003-11-21 to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (474, 0, '2006-06-15 00:00:00', 'Seema', 'Sehrawat', 'ssehrawat@rics.bwh.harvard.edu', '', '', '', NULL, NULL, NULL, '60604541');
INSERT INTO screensaver_user VALUES (66, 1, '2006-06-15 00:00:00', 'Tanya', 'Mayadas', 'tmayadas@rics.bwh.harvard.edu', '617-525-4336', '', '', NULL, NULL, NULL, '60412324');
INSERT INTO screensaver_user VALUES (475, 0, '2003-02-06 00:00:00', 'Scott', 'Rodig', 'scott_rodig@hms.harvard.edu', NULL, NULL, '9/4/03 Frank says screen will be taken over by Arminja. Scott no longer likely to screen.', NULL, NULL, NULL, '60506515');
INSERT INTO screensaver_user VALUES (477, 0, '2006-05-04 00:00:00', 'Maura', 'Porto', 'mporto@genetics.med.harvard.edu', '617-432-7673', '', '', NULL, NULL, NULL, '60667926');
INSERT INTO screensaver_user VALUES (484, 0, '2005-05-10 00:00:00', 'Shinji', 'Watanabe', 'watanabs@svm.vetmed.wisc.edu', '608-263-9486', '4325a Veterinary Medicine Building
2015 Linden Dr
Madison, WI 53706', 'NSRB screener; SW69 invited user ID', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (485, 0, '2005-10-31 00:00:00', 'Nina', 'Renlund', 'nina.renlund@ki.se', '617-726-8865', '', 'nrenlund@partners.org', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (487, 0, '2002-04-05 00:00:00', 'Kurt', 'Cannon', 'kurt_cannon@hms.harvard.edu', '432-1612', 'LHRRB 607', 'Not carrying out a screen.  Using plate reader only.
9/30/06 - email is either not correct or no longer active - removing from active screening users list', NULL, NULL, NULL, '10571030');
INSERT INTO screensaver_user VALUES (488, 0, '2004-07-13 00:00:00', 'Travis', 'Taylor', 'travis_taylor@hms.harvard.edu', '617-432-1927', NULL, 'NSRB screener', NULL, NULL, NULL, '90432753');
INSERT INTO screensaver_user VALUES (489, 0, '2006-01-18 00:00:00', 'Sheli', 'Radoshitzky', 'sheli_radoshitzky@student.hms.harvard.edu', NULL, 'New England Primate Research Center
1 Pine Hill Drive
Southborough, MA 01772-9102
USA
Phone: (508) 786-3326
Fax: (508) 786-3317', 'NSRB screener', NULL, NULL, NULL, '30592069');
INSERT INTO screensaver_user VALUES (490, 0, '2003-01-31 00:00:00', 'Philippos', 'Mourikis', 'mourikis@helix.mgh.harvard.edu', '617-726-1551', NULL, 'Using Brian DeDecker''s server account.', NULL, NULL, NULL, '20529784');
INSERT INTO screensaver_user VALUES (491, 0, '2005-08-02 00:00:00', 'Anthony', 'Maresso', 'amaresso@bsd.uchicago.edu', '773-834-8151', 'Microbiology, CLSC 601
University of Chicago', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (110, 1, '2005-05-10 00:00:00', 'Magdelena', 'Tosteson', 'Magdelena.Tosteson@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (493, 0, '2003-08-13 00:00:00', 'Lisa', 'Corcoran', 'lisa_corcoran@hms.harvard.edu', '617-432-4961', 'SGM 610', 'Lisa is working with Qing Liu on the aggregation screen (#140)', NULL, NULL, NULL, '80588186');
INSERT INTO screensaver_user VALUES (495, 0, '2004-02-12 00:00:00', 'Su', 'Chiang', 'su_chiang@hms.harvard.edu', '617-432-5237', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (496, 0, '2006-05-02 00:00:00', 'Tara', 'Love', 'tara_love@dfci.harvard.edu', '617-582-7963', '', '5-2-06 SPR - She is working for Carl Novina at DFCI and they are reformatting a siRNA library here using the Vario.  They want to reformat 356 (4 individuals for each siRNA x 89 96-well plates).  This will produce 89 384-well plates x3 copies and 356 intermediate 96-well plates x2 leftover copies.   The details of their reformat are below:

-Transfer from 1 master plate (Nunc 96-well V-bottom PS containing ~7ul of siRNA) 2uL into each of 3 intermediate daughter plates (Costar 96-well U-bottom PS containing 98uL of DEPC water) and mixing.
-Transfer from the first intermediate plate into 3 final plates (Costar 384-well clear sterile PS flat bottom plates) 30uL, 30uL and 40uL(remainder).  
-Repeat above steps for each of the four quadrants for the final 384-well plates.', NULL, NULL, NULL, '60638438');
INSERT INTO screensaver_user VALUES (498, 0, '2002-04-05 00:00:00', 'Dan', 'Janse', 'djanse@arep.med.harvard.edu', '(617) 432-7670', 'Alpert', NULL, NULL, NULL, NULL, '20500727');
INSERT INTO screensaver_user VALUES (499, 0, '2006-07-26 00:00:00', 'Casey', 'Gifford', 'casey_gifford@hms.harvard.edu', '617-432-0832', '', 'WIll be working with Joseph Mougous on piloting a luminescence-based screen.', NULL, NULL, NULL, '10648599');
INSERT INTO screensaver_user VALUES (510, 0, '2004-02-22 00:00:00', 'Steve', 'Miller', 'stephen_miller@hms.harvard.edu', NULL, NULL, 'This user''s date created was changed from 2003-11-21 to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (512, 0, '2003-06-03 00:00:00', 'Maria', 'Wasserman', 'Maria_Stotsky@dfci.harvard.edu', '617-632-2083', NULL, 'maiden name is Stotsky. 5-27-04 Changed last name spelling to Wasserman from Vasserman', NULL, NULL, NULL, '012045530');
INSERT INTO screensaver_user VALUES (515, 0, '2006-11-03 00:00:00', 'Carolyn', 'McGuinness', 'cmcguinn@wadsworth.org', '518-402-4081', 'Carolyn McGuinness
 Wadsworth Center
 120 New Scotland Ave
 DAI Room 4005
 Albany, NY 12208 
', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (518, 0, '2004-02-20 00:00:00', 'Han', 'Chen', 'han_chen@hms.harvard.edu', '617-621-6104', NULL, 'Plate reader use only. Collaborating with  Nate  Moerke.', NULL, NULL, NULL, '80552157');
INSERT INTO screensaver_user VALUES (524, 0, '2004-02-22 00:00:00', 'Michael', 'Glotzer', 'Michael.Glotzer@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (526, 0, '2005-12-12 00:00:00', 'Vishal', 'Patel', 'vpatel@fas.harvard.edu', '847-471-4464', NULL, 'ecommons: vpp2', NULL, NULL, NULL, '60592098');
INSERT INTO screensaver_user VALUES (527, 0, '2004-07-07 00:00:00', 'Nick', 'Kwiatkowski', 'nicholas_kwiatkowski@student.hms.harvard.edu', '617-432-3801', NULL, 'Working with Masaka Fujita, a (chemist) postdoc in the Clardy lab.  This is a collaboration with the Fink Lab (MIT) to identify the factors secreted by Candida albicans that promote ', NULL, NULL, NULL, '105922240');
INSERT INTO screensaver_user VALUES (528, 0, '2005-02-09 00:00:00', 'Guillaume', 'Normand', 'Guillaume_Normand@hms.harvard.edu', '617-432-4964', NULL, 'Working with Susan Lyman on her RNAi screen.', NULL, NULL, NULL, '20630892');
INSERT INTO screensaver_user VALUES (530, 0, '2003-02-20 00:00:00', 'Anan', 'Yu', 'yu@cbr.med.harvard.edu', '617-278-3224', 'WA 128', 'For plate reader use only.', NULL, NULL, NULL, '905863350');
INSERT INTO screensaver_user VALUES (531, 0, '2006-01-24 00:00:00', 'Paul', 'Lindo', 'plindo@umassd.edu', '508-999-8588', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (532, 0, '2004-02-22 00:00:00', 'Lan', 'Chen', 'Lan.Chen@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '80615604');
INSERT INTO screensaver_user VALUES (534, 0, '2005-05-18 00:00:00', 'Luciano', 'Marraffini', 'lmarraff@uchicago.edu', NULL, NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (539, 0, '2006-02-07 00:00:00', 'Sang Tae', 'Park', 'sangtae.park@childrens.harvard.edu', '617-919-2882', NULL, 'NSRB screener', NULL, NULL, NULL, '806187000');
INSERT INTO screensaver_user VALUES (540, 0, '2006-06-12 00:00:00', 'Shantanu', 'Gaur', 'gaur@fas.harvard.edu', '', '', 'undergraduate working in King lab summer 2006
using Wallac with Timmy Ho', NULL, NULL, NULL, '30609549');
INSERT INTO screensaver_user VALUES (541, 0, '2002-02-06 00:00:00', 'Anthony', 'Griffiths', 'anthony_griffiths@hms.harvard.edu', NULL, NULL, 'Plate reader use only.', NULL, NULL, NULL, '60488746');
INSERT INTO screensaver_user VALUES (544, 0, '2005-10-27 00:00:00', 'Xing', 'Zeng', 'xing_zeng@hms.harvard.edu', '617-777-0244(cell)', NULL, 'ecommons xz42', NULL, NULL, NULL, '80636954');
INSERT INTO screensaver_user VALUES (546, 0, '2005-07-05 00:00:00', 'Anastasia', 'Kazimirova', 'anastasia_kazimirova@hms.harvard.edu', '617-432-5092', NULL, NULL, NULL, NULL, NULL, '80647093');
INSERT INTO screensaver_user VALUES (549, 0, '2006-05-22 00:00:00', 'Stanley', 'Tabor', 'tabor@hms.harvard.edu', '617-432-3128', '', 'using M5', NULL, NULL, NULL, '70117886');
INSERT INTO screensaver_user VALUES (552, 0, '2004-09-02 00:00:00', 'Gary', 'Zhai', 'gzhai@rics.bwh.harvard.edu', '617-278-0182 ', NULL, 'Gary Zhai

Instructor & Assistant Director

Laboratory of Molecular Neuro-Radiation Oncology

Dept. of Radiation Oncology and Neurosurgery 

Harvard Medical School

221 Longwood Avenue, Room LM-035, 

Boston, MA 02115

(617) 278 0182 (Ph)

(617) 278 0143 (Ph & Fax)

gzhai@rics.bwh.harvard.edu
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (553, 0, '2006-06-27 00:00:00', 'Hieu Minh Thi', 'Vu', 'hieu_vu@hms.harvard.edu', '', '', 'Working with Greg Hoffman', NULL, NULL, NULL, '20608773');
INSERT INTO screensaver_user VALUES (130, 1, '2006-02-03 00:00:00', 'Vladimir', 'Motin', 'vlmotin@utmb.edu', '409-772-3158', 'Departments of Pathology and Microbiology & Immunology
University of Texas Medical Branch
3.148 Keiller Building, Route 0609
301 University Boulevard
Galveston, TX 77555-0609', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (519, 1, '2004-02-20 00:00:00', 'Jose', 'Halperin', 'jose_halperin@hms.harvard.edu', '617-621-6136', NULL, NULL, NULL, NULL, NULL, '70270226');
INSERT INTO screensaver_user VALUES (556, 0, '2005-07-25 00:00:00', 'Mijung', 'Kwon', 'mijung_kwon@dfci.harvard.edu', '617-632-2090', NULL, 'Potential future drsc RNAi screen testing liquid handling here 7/25/05', NULL, NULL, NULL, '10608627');
INSERT INTO screensaver_user VALUES (181, 1, '2005-07-25 00:00:00', 'David', 'Pellman', 'David.Pellman@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, '40299963');
INSERT INTO screensaver_user VALUES (558, 0, '2004-03-26 00:00:00', 'Jeff', 'MacKeigan', 'to be determined@hms.harvard.edu', NULL, NULL, 'Collaborating with Leon Murphy', NULL, NULL, NULL, '80587465');
INSERT INTO screensaver_user VALUES (563, 0, '2003-12-19 00:00:00', 'Wenyu', 'Lin', 'wlin1@partners.org', '617-726-2061', NULL, NULL, NULL, NULL, NULL, '80412568');
INSERT INTO screensaver_user VALUES (564, 0, '2006-11-22 00:00:00', 'Heinrich', 'Hoffmann', 'heinrich.hoffmann@mssm.edu', '', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (566, 0, '2006-06-19 00:00:00', 'Alex', 'Guth', 'alexguth@gmail.com', '', '', 'Rotation student in Lee Gehrke''s lab; NSRB screener if thus affiliated.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (567, 0, '2004-12-03 00:00:00', 'Sang jun', 'Jeon', 'sangjun_jeon@meei.harvard.edu', '617-413-0014', NULL, NULL, NULL, NULL, NULL, '406224700');
INSERT INTO screensaver_user VALUES (68, 2, '2006-01-18 00:00:00', 'Michael', 'Farzan', 'Michael_Farzan@hms.harvard.edu', '508-624-8019', 'New England Primate Research Center
1 Pine Hill Drive
Southborough, MA 01772
Tel: (508) 624-8019
Fax: (508) 786-3317', 'NSRB screener', NULL, NULL, NULL, '80042655');
INSERT INTO screensaver_user VALUES (569, 0, '2006-12-12 00:00:00', 'Alicia', 'Chung', 'achung@hsph.harvard.edu', '617-432-2065', '', 'working with Elizabeth Rico-Bautista on her screen', NULL, NULL, NULL, '50646289');
INSERT INTO screensaver_user VALUES (575, 0, '2004-02-02 00:00:00', 'Susan', 'Lyman', 'susan_lyman@hms.harvard.edu', '617.432.4964', NULL, 'RNAi using Qiagen library (collab with Aventis).  5000 targets x 2 seqs per target. Essentially the taxol override screen (HeLa cells) carried out originally by Katrina Schulberg /Jon Hoyt/Nicky Tolliday (#221). Readout on imaging scope.', NULL, NULL, NULL, '30600134');
INSERT INTO screensaver_user VALUES (576, 0, '2002-06-06 00:00:00', 'Tim', 'Sprigings', 'tsprigings@hms.harvard.edu', '617-432-4956', 'SGM 620', NULL, NULL, NULL, NULL, '90515896');
INSERT INTO screensaver_user VALUES (56, 1, '2004-12-03 00:00:00', 'Stefan', 'Heller', 'stefan_heller@meei.harvard.edu', '617-573-6393', NULL, NULL, NULL, NULL, NULL, '10547636');
INSERT INTO screensaver_user VALUES (578, 0, '2003-02-13 00:00:00', 'Henry', 'Pelish', 'pelish@fas.harvard.edu', '617-872-5700', 'ICCB', 'Also workin gwith Tomas Kirchhausen, Yan Feng, Jeff Peterson, and Marc Kirschner.', NULL, NULL, NULL, '705005820');
INSERT INTO screensaver_user VALUES (580, 0, '2006-02-15 00:00:00', 'Christine', 'Kiely', 'ckiely@hms.harvard.edu', '410-493-4573', NULL, NULL, NULL, NULL, NULL, '60636354');
INSERT INTO screensaver_user VALUES (583, 0, '2006-02-13 00:00:00', 'Douglas (Ewen)', 'Cameron', 'douglas_cameron@student.hms.harvard.edu', '617-432-0832', NULL, '2-13-06: He is preparing bacterial libraries - sequence defined transposon insertion library production using the Beckman FX', NULL, NULL, NULL, '60592470');
INSERT INTO screensaver_user VALUES (584, 0, '2004-10-01 00:00:00', 'Max', 'Hsia', 'mhsia@hms.harvard.edu', '', '', 'Max is a Harvard Employee but is involved in a close collaboration with Aventis.  He is carrying out an siRNA screen looking at phospho-S6 (immunostain, scoring on autoscope). 
12/22/05 Max is the Technician for Jessie Hanrahan
Ecommons ID: MEH25
9/30/06 - email is either not correct or no longer active - removing from active screening users list', NULL, NULL, NULL, '30603443');
INSERT INTO screensaver_user VALUES (588, 0, '2003-03-19 00:00:00', 'Lin', 'Xu', 'lin_xu@hms.harvard.edu', '617-432-1764', 'LHRRB 108', 'plate reader use  only; not screening.', NULL, NULL, NULL, '304118111');
INSERT INTO screensaver_user VALUES (274, 4, '2004-02-12 00:00:00', 'Bjorn', 'Olsen', 'bjorn_olsen@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '80270313');
INSERT INTO screensaver_user VALUES (590, 0, '2004-02-22 00:00:00', 'Scott', 'Lokey', 'Scott.Lokey@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '70498898');
INSERT INTO screensaver_user VALUES (592, 0, '2003-07-10 00:00:00', 'Janet', 'Lorang', 'janet_lorang@student.hms.harvard.edu', NULL, NULL, '7-10-03 Janet is a rotation student with Randy and will  not be doing a screen, just using the plate readers.', NULL, NULL, NULL, '30573234');
INSERT INTO screensaver_user VALUES (593, 0, '2002-11-12 00:00:00', 'Mikhail (Misha)', 'Reibarkh', 'misha@rage.med.harvard.edu', '617-432-3211', NULL, 'Will use Alexei Degterev''s ICCB server account.', NULL, NULL, NULL, '10578639');
INSERT INTO screensaver_user VALUES (595, 0, '2005-01-14 00:00:00', 'Alice', 'Tommasi di Vignano', 'alice.tommasidivignano@cbrc2.mgh.harvard.edu', '617-724-9537', 'Massachusetts General Hospital
Cutaneous Biology Research Center
Blg 149 - 13th Street
Charlestown, MA 02129', NULL, NULL, NULL, NULL, '90585819');
INSERT INTO screensaver_user VALUES (597, 0, '2005-11-07 00:00:00', 'Laurent', 'Ruel', 'ruel@unice.fr', '617-432-6546', NULL, 'Member of Therond''s lab at the NRB DRSC.  Nadire will be coordinating this and other RNAi screens from the DRSC. ', NULL, NULL, NULL, '01262438');
INSERT INTO screensaver_user VALUES (599, 0, '2005-03-04 00:00:00', 'Niklaus', 'Mueller', 'nhm3@georgetown.edu', '202-687-6546', '', 'ECommons extended until March 2007 - 11/30/2006 SJ

NSRB screener

05-17-05 Stewart,

  I am not planning on any trips in the near future.  I think Pad will want to get another grant based on our data thus far betfore he makes another trip to Boston.

Nik', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (602, 0, '2006-06-08 00:00:00', 'Jianming', 'Zhang', 'jianming_zhang@dfci.harvard.edu', '617-582-8589', '', 'screening own compounds using all forms of equipment', NULL, NULL, NULL, '10673585');
INSERT INTO screensaver_user VALUES (123, 5, '2006-06-08 00:00:00', 'Nathaneal', 'Gray', 'nathanael_gray@dfci.harvard.edu', '', '', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (603, 0, '2004-12-23 00:00:00', 'Natalie', 'Gilks', 'natalie_gilks@student.hms.harvard.edu', NULL, NULL, '12/04-Getting help from Garo, need to confirm whether is starting new screen.
6/05-Starting RNAi screen.', NULL, NULL, NULL, '60592322');
INSERT INTO screensaver_user VALUES (605, 0, '2002-06-14 00:00:00', 'Philippe', 'Roux', 'philippe_roux@hms.harvard.edu', '617-432-1281', 'LHRRB 606', 'will  share ICCB server account with Leon.', NULL, NULL, NULL, '90569872');
INSERT INTO screensaver_user VALUES (606, 0, '2004-06-16 00:00:00', 'Melodie', 'Knowlton', 'melodie_knowlton@student.hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '70573199');
INSERT INTO screensaver_user VALUES (607, 0, '2005-11-02 00:00:00', 'Jennifer', 'Svendsen', 'jennifer_svendsen@hms.harvard.edu', '617-432-6594', NULL, 'She is a tech working on the Beckman FX in 610 for the Harper lab', NULL, NULL, NULL, '40591982');
INSERT INTO screensaver_user VALUES (610, 0, '2006-12-13 00:00:00', 'Jessica', 'Pinkham', 'jessica_pinkham@hms.harvard.edu', '6174325509', '', '', NULL, NULL, NULL, '30675460');
INSERT INTO screensaver_user VALUES (611, 0, '2003-11-13 00:00:00', 'Julie', 'Gorenstein', 'julie_gorenstein@hms.harvard.edu', '617-432-3949', NULL, NULL, NULL, NULL, NULL, '80578776');
INSERT INTO screensaver_user VALUES (612, 0, '2002-01-02 00:00:00', 'Susan', 'Armknecht', 'sarmkne1@GENETICS.MED.HARVARD.EDU', '617-432-7571', 'Susan Armknecht
HMS NRB, Rm 085
Department of Genetics
Drosophila RNAi Screening Center
77 Avenue Louis Pasteur
Boston, MA  02115
(617)432-6546
(617)432-6238 (fax)', 'Working with Sara Cherry.  Using Sara Cherry''s server account', NULL, NULL, NULL, '50533794');
INSERT INTO screensaver_user VALUES (613, 0, '2006-03-29 00:00:00', 'Hiba', 'Tannoury', 'htannoury@partners.org', '617-378-5352', 'MGH', E'Using Cellworx
Ecommons:  HHT1
Using PI (Vineet Gupta) ID:  50591875
Access to matterhorn\\screening\\current', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (617, 0, '2004-02-22 00:00:00', 'Ulrik', 'Nielsen', 'unielsen@merrimackpharma.com', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (618, 0, '2004-11-02 00:00:00', 'Brian', 'Kraybill', 'brian_kraybill@hms.harvard.edu', '617-432-5965', '', '11-2-04 Working with Ben Gross to pilot a screen for inhibitors of O-GlcNAc transferase using a fluorescence polarization assay similar to the one  used very successfully last year with the bacterial transglycosylase MurG.  Will submit an application soon.', NULL, NULL, NULL, '70615347');
INSERT INTO screensaver_user VALUES (621, 0, '2004-07-06 00:00:00', 'Manfred', 'Neuberg', 'mneuberg@bidmc.harvard.edu', NULL, NULL, 'Probably left the lab shortly after filing the application, and never initiated a screen.  Towia A. Libermann, Ph.D., Director of BIDMC Genomics Center, will assign a new investigator who will continue with the screen and follow up on the leads (most likely Luiz Zerbini, Ph.D., since he is already collaborating on the project). ', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (291, 1, '2004-07-06 00:00:00', 'Towia', 'Liberman', 'tliberma@bidmc.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (622, 0, '2005-11-10 00:00:00', 'Dana', 'Christofferson', 'Dana.Christofferson@has.missing.email', NULL, NULL, '11-05 BBS rotation student using plate reader occasionally while working in Yuan lab. Helped by Dodzie Sogah.', NULL, NULL, NULL, '20636408');
INSERT INTO screensaver_user VALUES (623, 0, '2005-07-28 00:00:00', 'Margaret', 'Andrews', 'andrews@fas.harvard.edu', '919-605-5739', NULL, 'Also affiliated with the Wirth lab', NULL, NULL, NULL, '30607406');
INSERT INTO screensaver_user VALUES (624, 0, '2006-04-20 00:00:00', 'Jason', 'Harris', 'JBHARRIS@PARTNERS.ORG', '617-519-6706', 'Jason B. Harris, M.D., M.P.H.
Division of Infectious Diseases
Department of Pediatrics
Gray-Jackson Building 504
Massachusetts General Hospital
Boston, MA 02114
Fax: 617-726-7416', 'Wants to screen to look for PhoP regulon inhibitors in Salmonella enterica serovar Typhimuriam.

Starting from an overnight culture of serovar Typhimurium grown in minimal media with 2 mM MgCl2:  Wash the bacteria x 2 in M9 minimal media without magnesium, then resuspend (10x concentrated) in M9 with no magnesium.  Then inoculate cultures of M9 with 10 mM or 10 microM MgCl2 with the overnight grown bacteria to an OD of approximately (10x dilution from overnight).  Grow for 10 hours at 37.  Compare bacterial density.  So simple!!  And it seems very reproducible in
5 ml cultures.
 
It is clear from experiments looking at a PhoP mutant, that PhoP is required for optimal growth in low [microM] Mg, but not in the [mM] range.  Thus compounds that selectively inhibit growth in low Mg but not in high Mg are potential PhoP inhibits that would then go on to the second round of screening, in which we would look at the expression of other PhoP related genes in a PhoP constitutive strain under high Mg conditions which thus would distinguish true PhoP inhibition from compounds that selectively inhibit MgtA which is the gene controlled by PhoP that is required for low Mg survival.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (626, 0, '2004-06-21 00:00:00', 'Frank', 'Stegmeier', 'fstegmeier@rics.bwh.harvard.edu', '617-525-4513', NULL, 'Frank is carrying out an RNAi screen to identify genes that, when knocked down, result in  a variety of cell cycle defects in human cells (HeLa, with GFP-H2B Histone; and also HepG2 stained with Ab against cytoskeletal markers).  He is collaborating with Grzegorz Nelepa of Wade Harper''s lab.', NULL, NULL, NULL, '506084840');
INSERT INTO screensaver_user VALUES (629, 0, '2002-01-02 00:00:00', 'Christine', 'Field', 'cfield@hms.harvard.edu', '617-432-3727', 'HMS SGM-529', NULL, NULL, NULL, NULL, '50464547');
INSERT INTO screensaver_user VALUES (632, 0, '2004-06-21 00:00:00', 'Grzegorz', 'Nalepa', 'grzegorz_nalepa@hms.harvard.edu', '617-432-6594', NULL, 'Grzegorz is carrying out an RNAi screen to identify genes that, when knocked down, result in  a variety of cell cycle defects in human cells (HeLa, with GFP-H2B Histone; and also HepG2 stained with Ab against cytoskeletal markers).  He is collaborating with Frank Stegmeier of Steve Elledge''s lab.', NULL, NULL, NULL, '606028590');
INSERT INTO screensaver_user VALUES (577, 1, '2004-02-12 00:00:00', 'John', 'Tallarico', 'john_tallarico@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '80513402');
INSERT INTO screensaver_user VALUES (634, 0, '2006-11-03 00:00:00', 'Rana', 'Anjum', 'rana_anjum@hms.harvard.edu', '617-432-1281', '617-285-8890 (cell)
', 'I am actually helping Greg with some of his experiments. I am mostly going to plate cells and do washes and also use the plate reader and microscope.
', NULL, NULL, NULL, '305685912605');
INSERT INTO screensaver_user VALUES (635, 0, '2004-10-06 00:00:00', 'Milan', 'Bajmoczi', 'Milan.Bajmoczi@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, '90501240');
INSERT INTO screensaver_user VALUES (574, 1, '2004-10-06 00:00:00', 'David', 'Golan', 'david_golan@hms.harvard.edu', '617-432-2256', NULL, NULL, NULL, NULL, NULL, '70040050');
INSERT INTO screensaver_user VALUES (637, 0, '2006-02-07 00:00:00', 'Michelle', 'Mendoza', 'michelle_mendoza@hms.harvard.edu', '617--43-2-1281', '02-07-06: Visually screening siRNA', '', NULL, NULL, NULL, '70659581');
INSERT INTO screensaver_user VALUES (639, 0, '2005-01-14 00:00:00', 'Vikram', 'Rajashekara', 'VRAJASHEKARA@PARTNERS.ORG', '617-724-7795', 'Massachusetts General Hospital
#149, 13th Street
Room 3232
3rd Floor, East
Charlestown, MA 02129', 'goes by Vik', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (641, 0, '2004-02-22 00:00:00', 'Christina', 'Yordan', 'Christina.Yordan@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (643, 0, '2004-02-25 00:00:00', 'Rachel', 'Squillace', 'rsquillace@childhooddiseases.org', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (644, 0, '2006-10-10 00:00:00', 'Sang-Gyun', 'Kim', 'sang_kim2@hms.harvard.edu', '617-432-4898', '', 'working with Greg and Max', NULL, NULL, NULL, '10683289');
INSERT INTO screensaver_user VALUES (646, 0, '2002-10-22 00:00:00', 'Nestor', 'Tomycz', 'nestor_tomycz@student.hms.harvard.edu', '(617) 432-9340', NULL, 'Using ICCB plate readers only; not carrying out a screen.', NULL, NULL, NULL, '60486972');
INSERT INTO screensaver_user VALUES (184, 1, '2004-02-12 00:00:00', 'Dan', 'Finley', 'daniel_finley@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (647, 0, '2005-02-09 00:00:00', 'Kyle', 'Brown', 'kmbrown@fas.harvard.edu', '617-496-5540', NULL, NULL, NULL, NULL, NULL, '90605852');
INSERT INTO screensaver_user VALUES (648, 0, '2006-07-10 00:00:00', 'Matt', 'Dedmon', 'matthew_dedmon@hms.harvard.edu', '617-432-3212', '', 'Ecommons: mmd20
ID reactivated 10/04/2006  by SMJ', NULL, NULL, NULL, '50655385');
INSERT INTO screensaver_user VALUES (649, 0, '2005-10-12 00:00:00', 'Eunah', 'Chung', 'eunah_chung@hms.harvard.edu', '617-432-4964', 'Sitting in Ruderman Lab (tel. 2-1105).', 'ecommons=EC35', NULL, NULL, NULL, '30603028');
INSERT INTO screensaver_user VALUES (651, 0, '2004-08-19 00:00:00', 'Qing', 'Sheng', 'qing_sheng@dfci.harvard.edu', '617-632-3089', 'Smith 812', 'Qing will be using the Synergy palte reader only', NULL, NULL, NULL, '30536290');
INSERT INTO screensaver_user VALUES (652, 0, '2006-06-01 00:00:00', 'Sean', 'Irwin', 'sean_irwin@hms.harvard.edu', '', '', 'using the Biomek FX', NULL, NULL, NULL, '70657732');
INSERT INTO screensaver_user VALUES (653, 0, '2004-02-22 00:00:00', 'Monty', 'Krieger', 'Monty.Krieger@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (655, 0, '2005-02-01 00:00:00', 'William', 'Lin', 'wlin@fas.harvard.edu', NULL, NULL, 'Undergraduate working in the Clardy lab, collaborating on screen with Tweeny Kau.', NULL, NULL, NULL, '50575535');
INSERT INTO screensaver_user VALUES (656, 0, '2002-01-02 00:00:00', 'Jamie', 'Terr', 'Jamie.Terr@has.missing.email', NULL, 'HMS C2-666', 'Finished rotation in King Lab in December 2001.', NULL, NULL, NULL, '50555429');
INSERT INTO screensaver_user VALUES (657, 0, '2004-01-08 00:00:00', 'Yakov', 'Peter', 'yakov_peter@hms.harvard.edu', '617-432-0643', NULL, 'Using plate readers only, not carrying out a screen.', NULL, NULL, NULL, '90566059');
INSERT INTO screensaver_user VALUES (276, 1, '2004-02-12 00:00:00', 'Dan', 'Goodenough', 'daniel_goodenough@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (659, 0, '2004-10-22 00:00:00', 'Derek', 'Sturtevant', 'derek_sturtevant@hms.harvard.edu', '617-432-2398', 'Armenise I, 4th floor', 'Ecommons: ds63', NULL, NULL, NULL, '70589044');
INSERT INTO screensaver_user VALUES (660, 0, '2006-12-14 00:00:00', 'Shite', 'Sebastian', 'shitesebastian@yahoo.com', '617-432-5509', '', 'NSRB screener', NULL, NULL, NULL, '206060610');
INSERT INTO screensaver_user VALUES (664, 0, '2003-05-07 00:00:00', 'Assen', 'Marintchev', 'assen_marintchev@hms.harvard.edu', '617-432-3212', NULL, 'Plate reader use only.', NULL, NULL, NULL, '405598760');
INSERT INTO screensaver_user VALUES (666, 0, '2006-10-20 00:00:00', 'Alicia', 'Zhou', 'ayzhou@fas.harvard.edu', '617-432-3972', '', 'using SpectraMax M5 for Alamar Blue assay', NULL, NULL, NULL, '50668118');
INSERT INTO screensaver_user VALUES (667, 0, '2003-09-09 00:00:00', 'Lee', 'Resta', 'leeresta@yahoo.com', '617-768-8271', 'Cardiovascular Division 65 Landsdowne St. Cambridge', 'Using Tomo''s server acc''t.', NULL, NULL, NULL, '40599517');
INSERT INTO screensaver_user VALUES (672, 0, '2006-09-20 00:00:00', 'Gabriella', 'Garufi', 'ggarufi@bsd.uchicago.edu', '773-834-8152', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (497, 1, '2006-05-02 00:00:00', 'Carl', 'Novina', 'carl_novina@dfci.harvard.edu', '617-582-7961', '', '5-2-06 SPR - He is reformatting a siRNA library here using the vario.  Tara Love is a postdoc in his lab and the details of the protocol are in the comments section of her user record.', NULL, NULL, NULL, '90628607');
INSERT INTO screensaver_user VALUES (21, 1, '2004-02-12 00:00:00', 'Kai', 'Wucherpfennig', 'wucherpf@mbcrr.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '70308126');
INSERT INTO screensaver_user VALUES (675, 0, '2005-10-06 00:00:00', 'Ehud (Udi)', 'Qimron', 'udi@hms.harvard.edu', '617-432-3129', '', 'uses SpectraMax M5 plate reader -- kinetic reads for 18 hours at a time', NULL, NULL, NULL, '70629410');
INSERT INTO screensaver_user VALUES (676, 0, '2003-09-03 00:00:00', 'Xiao (Carol)', 'Fang', 'fang@fas.harvard.edu', '617-432-5498', NULL, ' 6177211600(cellphone)
We are not going to do screening. We want to use the plate reader because
the volume is smaller there, so it can save us some compounds.
The fluorescent compound is a small compound, a fluorescein- UDP GlcNac.
We are going to do a titration. the titration compound is a 17
polypeptide.', NULL, NULL, NULL, '40608729');
INSERT INTO screensaver_user VALUES (687, 0, '2004-07-06 00:00:00', 'Michael', 'Baldwin', 'mbaldwin@mcw.edu', '414-456-8419', NULL, 'NSRB screener', NULL, NULL, NULL, '80640722');
INSERT INTO screensaver_user VALUES (690, 0, '2006-01-03 00:00:00', 'Lai', 'Xu', 'lai_xu@hms.harvard.edu', '617-432-6593', NULL, 'They are working on the FX', NULL, NULL, NULL, '90601032');
INSERT INTO screensaver_user VALUES (691, 0, '2002-06-17 00:00:00', 'Sung', 'Kang', 'skang@cbr.med.harvard.edu', '617-278-3268', 'Alpert  142', 'data folder is on data3', NULL, NULL, NULL, '10550203');
INSERT INTO screensaver_user VALUES (692, 0, '2004-09-27 00:00:00', 'Marc', 'van de Wetering', 'vandewetering@niob.knaw.nl', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (693, 0, '2002-03-07 00:00:00', 'Kimberly (Kim)', 'Carey', 'kcarey@zoo.uvm.edu', '802-656-1146', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (586, 1, '2002-03-07 00:00:00', 'Gary', 'Ward', 'gward@zoo.uvm.edu', '802-656-4868', '214 Stafford Hall, 95 Carrigan Drive, Burlington VT 05405', 'Gary Ward FAX     802-656-8749', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (694, 0, '2002-12-19 00:00:00', 'Jingdong', 'Tian', 'jingdong_tian@hms.harvard.edu', '617-432-7561', 'Alpert 514', 'uses plate reader only (not screening).   Jan. 2003-est. use=a few plates (5 min.) several times a week', NULL, NULL, NULL, '10496551');
INSERT INTO screensaver_user VALUES (51, 5, '2004-02-12 00:00:00', 'George', 'Church', 'church@rascal.med.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '70119137');
INSERT INTO screensaver_user VALUES (696, 0, '2004-11-29 00:00:00', 'Kaylene', 'Simpson', 'kaylene_simpson@hms.harvard.edu', '617-432-3972', NULL, NULL, NULL, NULL, NULL, '70627582');
INSERT INTO screensaver_user VALUES (698, 0, '2003-06-11 00:00:00', 'Julia', 'Etchin', 'julia_etchin@dfci.harvard.edu', '617-632-4853', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (699, 0, '2005-12-22 00:00:00', 'Jessie', 'Hanrahan', 'jessie_hanrahan@hms.harvard.edu', '617-432-1281', NULL, 'Collaborating with Max Hsia', NULL, NULL, NULL, '30614275');
INSERT INTO screensaver_user VALUES (701, 0, '2005-10-28 00:00:00', 'Kamakshi', 'Sishtla', 'ksishtla@anl.gov', NULL, 'Argonne National Laboratory 
9700 South Cass Avenue 
Building 202, Room A357
Argonne, IL 60439-4833
fax: 630-214-0648', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (704, 0, '2004-02-22 00:00:00', 'Kate', 'Crane', 'Kate.Crane@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (705, 0, '2006-04-12 00:00:00', 'Andrew', 'Revel', 'andrew_revel@hms.harvard.edu', '617-432-0832', '', 'using Analyst plate reader', NULL, NULL, NULL, '70636603');
INSERT INTO screensaver_user VALUES (707, 0, '2002-05-16 00:00:00', 'Ryan', 'Murphey', 'ryan_murphey@student.hms.harvard.edu', '617-355-7014', '', 'no need for server account.
9/30/06 - email is either not correct or no longer active - removing from active screening users list', NULL, NULL, NULL, '30536789');
INSERT INTO screensaver_user VALUES (708, 0, '2005-10-27 00:00:00', 'Herbert', 'Wetli', 'hwetli@hsph.harvard.edu', '617-432-2533', NULL, 'ecommons hw57', NULL, NULL, NULL, '30650026');
INSERT INTO screensaver_user VALUES (709, 0, '2004-11-16 00:00:00', 'Steve', 'Isakoff', 'Steven_Isakoff@dfci.harvard.edu', '617-432-3972', NULL, NULL, NULL, NULL, NULL, '40542892');
INSERT INTO screensaver_user VALUES (710, 0, '2006-09-08 00:00:00', 'Awo Dede', 'Osafo-Addo', 'adosafo@fas.harvard.edu', '(617)493-3932', '', '', NULL, NULL, NULL, '706401631');
INSERT INTO screensaver_user VALUES (225, 2, '2004-02-12 00:00:00', 'Dyann', 'Wirth', 'dfwirth@hsph.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '70107198');
INSERT INTO screensaver_user VALUES (713, 0, '2005-11-22 00:00:00', 'Jun', 'Park', 'jpark13@partners.org', '617-643-2873', NULL, NULL, NULL, NULL, NULL, '206572270');
INSERT INTO screensaver_user VALUES (714, 0, '2004-06-16 00:00:00', 'Rachel', 'Pearline', 'rachel_pearline@hms.harvard.edu', '', '', '9/30/06 - email is no longer active - removing from active screening users list', NULL, NULL, NULL, '705909561');
INSERT INTO screensaver_user VALUES (9, 17, '2004-02-12 00:00:00', 'Joan', 'Brugge', 'joan_brugge@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '50480984');
INSERT INTO screensaver_user VALUES (715, 0, '2004-02-22 00:00:00', 'Mohammed', 'Yousaf', 'Mohammed.Yousaf@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (716, 0, '2006-03-08 00:00:00', 'Jue (Jade)', 'Shi', 'jue_shi@hms.harvard.edu', '617-432-3724', NULL, 'March 2006: Using Microscope room to develop assay for small molecule screen.', NULL, NULL, NULL, '70661985');
INSERT INTO screensaver_user VALUES (717, 0, '2006-09-11 00:00:00', 'Erica', 'Larschan', 'elarschan@rics.bwh.harvard.edu', '617-525-4523', '', 'Collaborating with DRSC on Drosphila RNAi screen.', NULL, NULL, NULL, '60500673');
INSERT INTO screensaver_user VALUES (393, 2, '2006-09-11 00:00:00', 'Mitzi', 'Kuroda', 'mkuroda@genetics.harvard.edu', '617-525-4520', '', '', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (718, 0, '2005-03-16 00:00:00', 'Maria', 'Siri', 'sirim@ohsu.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (720, 0, '2004-03-18 00:00:00', 'Jun', 'Yin', 'jun_yin@hms.harvard.edu', '617-4320930', NULL, NULL, NULL, NULL, NULL, '10600456');
INSERT INTO screensaver_user VALUES (426, 1, '2004-03-18 00:00:00', 'Christopher', 'Walsh', 'christopher_walsh@hsm.harvard.edu', '617-432-1715', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (721, 0, '2004-06-03 00:00:00', 'Eric', 'Joseph', 'eric_joseph@hms.harvard.edu', '617-432-2701', NULL, 'Collaborating with Nicky Tolliday', NULL, NULL, NULL, '706130260');
INSERT INTO screensaver_user VALUES (722, 0, '2005-11-17 00:00:00', 'Alina', 'Iuga', 'iuga@cbr.med.harvard.edu', NULL, NULL, 'Will use Hogan lab common fileserver acc''t. Is not starting/carrying out a screen  at this point.', NULL, NULL, NULL, '106207080');
INSERT INTO screensaver_user VALUES (723, 0, '2004-02-22 00:00:00', 'Rachel', 'Legmann', 'Rachel.Legmann@has.missing.email', NULL, NULL, 'NSRB screener.
This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '60479100');
INSERT INTO screensaver_user VALUES (246, 1, '2004-02-22 00:00:00', 'John', 'Collier', 'john_collier@hms.harvard.edu', '', '', 'NSRB screener
This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, '30459083');
INSERT INTO screensaver_user VALUES (725, 0, '2002-01-02 00:00:00', 'Daegun', 'Kim', 'daegun_kim@hms.harvard.edu', '617-432-0072', 'HMS SGM 509', NULL, NULL, NULL, NULL, '90549693');
INSERT INTO screensaver_user VALUES (726, 0, '2003-10-08 00:00:00', 'Greg', 'Tochtrop', 'gregory_tochtrop@hms.harvard.edu', '617-432-4964', NULL, NULL, NULL, NULL, NULL, '20569875');
INSERT INTO screensaver_user VALUES (727, 0, '2006-09-12 00:00:00', 'Yumei', 'Leng', 'yleng@rics.bwh.acu', '(617)525-4517', '', 'Allergy Lab, BWH
ID is blank, source unknown', NULL, NULL, NULL, '012612060');
INSERT INTO screensaver_user VALUES (418, 1, '2005-05-09 00:00:00', 'Gary', 'Ruvkun', 'Gary.Ruvkun@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, '40036679');
INSERT INTO screensaver_user VALUES (136, 1, '2004-02-12 00:00:00', 'Lewis', 'Cantley', 'lcantley@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '30408551');
INSERT INTO screensaver_user VALUES (730, 0, '2006-03-10 00:00:00', 'Nicole', 'Clay', 'clay@molbio.mgh.harvard.edu', '617-320-0197', NULL, NULL, NULL, NULL, NULL, '40646779');
INSERT INTO screensaver_user VALUES (113, 1, '2005-12-01 00:00:00', 'Terry', 'Moy', 'moy@molbio.mgh.harvard.edu', '617-643-3323', NULL, NULL, NULL, NULL, NULL, '30466829');
INSERT INTO screensaver_user VALUES (114, 4, '2005-12-01 00:00:00', 'Fred', 'Ausubel', 'ausubel@molbio.mgh.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (480, 1, '2004-11-05 00:00:00', 'Stephen', 'Juris', 'juris1sj@cmich.edu', '989-774-3257', 'Central Michigan University
268 Dow Science
Mount Pleasant, MI 48859', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (63, 3, '2005-05-10 00:00:00', 'Hongbo', 'Luo', 'Hongbo.Luo@childrens.harvard.edu', '617-919-2303', NULL, NULL, NULL, NULL, NULL, '60627827');
INSERT INTO screensaver_user VALUES (483, 1, '2006-02-23 00:00:00', 'Julia', 'Breger', 'jbreger@partners.org', '508-579-7000', NULL, 'Julia is the Research Associate who will be performing the C.Elegans screen for Terry Mylonakis for NSRB', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (258, 2, '2006-03-23 00:00:00', 'Eleftherios', 'Mylonakis', 'emylonakis@partners.org', '6177263812', 'MGH, Division of Infectious Diseases
55 Fruit Street
Gray Jackson 5, Room GRJ-504
Boston, MA  02114-2696
617-726-7416 (fax)', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (196, 2, '2006-11-22 00:00:00', 'Peter', 'Palese', 'peter.palese@mssm.edu', '212-241-7318', 'One Gustave L. Levy Place
Box 1124
New York, NY 10029 ', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (581, 1, '2005-05-10 00:00:00', 'Jochen', 'Reiser', 'jreiser@partners.org', '617-726-9363', NULL, NULL, NULL, NULL, NULL, '60597294');
INSERT INTO screensaver_user VALUES (439, 1, '2002-06-13 00:00:00', 'Xinmin', 'Li', 'xinmin_li@hms.harvard.edu', '617-432-1856', 'C2-531', 'data folder on data6
1/10/06 - Email from Xinmin. Says he is not using facility anymore. ', NULL, NULL, NULL, '505612591');
INSERT INTO screensaver_user VALUES (440, 2, '2004-02-12 00:00:00', 'John', 'Flanagan', 'flanagan@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10308488');
INSERT INTO screensaver_user VALUES (685, 1, '2006-09-01 00:00:00', 'Dan', 'Chinnapen', 'dan.chinnapen@childrens.harvard.edu', '617-919-2578', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (237, 2, '2006-07-06 00:00:00', 'Wayne', 'Lencer', 'wayne.lencer@childrens.harvard.edu', '617-919-2573', '', 'NSRB screener', NULL, NULL, NULL, '70266318');
INSERT INTO screensaver_user VALUES (616, 1, '2003-07-17 00:00:00', 'Mara', 'Duncan', 'mduncan@mednet.ucla.edu', '(310) 825-8363', NULL, 'Mara C. DuncanPayne LabUCLA School of MedicineDepartment of Biological Chemistry33-257 CHSP.O. Box 951737Los Angeles CA 90095-1737', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (44, 2, '2004-02-12 00:00:00', 'Greg', 'Payne', 'gpayne@mednet.ucla.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (125, 4, '2005-12-14 00:00:00', 'Bal Ram', 'Singh', 'bsingh@umassd.edu', '508-999-8588', 'University of Massachusetts                             
Department of Chemistry and Biochemistry 
285 Old Westport Rd. 
Dartmouth, MA 02747 USA 
Phone: 508-999-8588 
Fax: 508-999-8451', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (144, 2, '2005-05-10 00:00:00', 'Marlene', 'Belfort', 'belfort@wadsworth.org', '518-473-3345', NULL, 'NSRB screener; on sabbatical at MIT from 4/05 to 6/05; local phone number is 617-324-0418', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (538, 1, '2003-10-14 00:00:00', 'Kevin', 'Bitterman', 'kevin_bitterman@student.hms.harvard.edu', '617-432-3932', NULL, NULL, NULL, NULL, NULL, '50518361');
INSERT INTO screensaver_user VALUES (523, 2, '2004-02-12 00:00:00', 'David', 'Sinclair', 'david_sinclair@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '20517174');
INSERT INTO screensaver_user VALUES (423, 2, '2004-09-17 00:00:00', 'Douglas', 'Johnson', 'douglas.johnson@uvm.edu', '802-656-8203', NULL, NULL, NULL, NULL, NULL, '50147193');
INSERT INTO screensaver_user VALUES (517, 1, '2005-10-04 00:00:00', 'Thorsten', 'Schlaeger', 'schlaeger@enders.tch.harvard.edu', '617-919-2082', 'Dept. of Hematology/Oncology', NULL, NULL, NULL, NULL, '60525102');
INSERT INTO screensaver_user VALUES (604, 1, '2002-01-02 00:00:00', 'David', 'Takeda', 'david_takeda@student.hms.harvard.edu', '617-732-6581', 'BWH Thorn 630', NULL, NULL, NULL, NULL, '40501371');
INSERT INTO screensaver_user VALUES (10, 2, '2004-12-10 00:00:00', 'Anindya', 'Dutta', 'Anindya.Dutta@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, '40406271');
INSERT INTO screensaver_user VALUES (678, 1, '2002-05-14 00:00:00', 'Josh', 'Armstrong', 'jarmstro@uclink.berkeley.edu', '510-559-5921', '800 Buchanan St., Albany CA 94710', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (501, 2, '2004-02-12 00:00:00', 'Sakis', 'Theologis', 'theo@nature.berkeley.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (550, 2, '2004-05-14 00:00:00', 'Chris', 'Da Fonseca', 'cdafonseca@med.miami.edu', '305-243-7687', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (176, 3, '2004-05-14 00:00:00', 'Kurt', 'Schesser', 'kschesser@med.miami.edu', NULL, NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (340, 1, '2003-02-27 00:00:00', 'John', 'Wheeler', 'jwheeler@childhooddiseases.org', '(203)458-7100 ext.203', '530 Whitfield St., Guilford, CT  06437', 'Rachel Squillace:rsquillace@childhooddiseases.org', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (151, 5, '2004-02-22 00:00:00', 'Jonathon', 'Rothberg', 'Jonathon.Rothberg@has.missing.email', NULL, NULL, 'This user''s date created was changed from null to 02/22/2004 on 07/25/2006, correcting an erroneous date to a date that is approximately correct. The actual date created was somewhere between 02/20/2004 and 02/25/2004/.
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (46, 1, '2006-01-13 00:00:00', 'Timothy', 'Haggerty', 'thaggerty@partners.org', '978-232-1243', 'Timothy J. Haggerty, PhD
Research Fellow
Mass General Hospital
Department of Pathology
978-232-1243
thaggerty@partners.org', 'Although supported via the MGH Pathology Dept., Tim works from a company in Beverly founded by James Kurnick.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (47, 2, '2006-01-13 00:00:00', 'James', 'Kurnick', 'James.Kurnick@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, '60209758');
INSERT INTO screensaver_user VALUES (514, 1, '2004-11-09 00:00:00', 'Linda', 'Lieberman', 'linda_lieberman@hms.harvard.edu', '617-432-4157', NULL, 'NSRB screener', NULL, NULL, NULL, '60625670');
INSERT INTO screensaver_user VALUES (69, 2, '2004-11-09 00:00:00', 'Darren', 'Higgins', 'darren_higgins@hms.harvard.edu', '617-432-4156', NULL, 'NSRB screener', NULL, NULL, NULL, '20524731');
INSERT INTO screensaver_user VALUES (420, 1, '2002-02-19 00:00:00', 'Ryan', 'Senaratne', 'rhsenara@uclink4.berkeley.edu', NULL, 'Berkeley CA', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (421, 2, '2004-02-12 00:00:00', 'Lee W.', 'Riley', 'lwriley@berkeley.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (217, 1, '2003-02-13 00:00:00', 'Rami', 'Hannoush', 'hannoush@fas.harvard.edu', '857-222-7264', NULL, NULL, NULL, NULL, NULL, '80588127');
INSERT INTO screensaver_user VALUES (218, 3, '2004-02-12 00:00:00', 'Matthew', 'Shair', 'shair@chemistry.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (702, 1, '2003-05-30 00:00:00', 'Anthony (Tony)', 'Letai', 'anthony_letai@dfci.harvard.edu', '617-632-2348', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (686, 2, '2004-02-12 00:00:00', 'Stanley', 'Korsmeyer', 'stanley_korsmeyer@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '80510519');
INSERT INTO screensaver_user VALUES (345, 1, '2005-10-12 00:00:00', 'Andre', 'Bernards', 'abernard@helix.mgh.harvard.edu', '617-726-5620', NULL, NULL, NULL, NULL, NULL, '60341362');
INSERT INTO screensaver_user VALUES (115, 3, '2003-01-31 00:00:00', 'Jeremiah', 'Helm', 'jshelm@Princeton.EDU', '609-258-1165', NULL, 'Address:Jeremiah Helm c/o Walker LabFrick LabsWashington Road and William StreetPrinceton, NJ 08544Suzanne Walker (609)258-1149; Dan Kahn (609) 258-6368.His collaborators Hanan and Lan have also signed the Statement of Understanding and they are filed with Jeremiah''s.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (65, 12, '2004-02-12 00:00:00', 'Suzanne', 'Walker', 'suzanne_walker@hms.harvard.edu', NULL, NULL, 'Moved from Princeton July 2004.', NULL, NULL, NULL, '30603060');
INSERT INTO screensaver_user VALUES (508, 3, '2003-09-03 00:00:00', 'Benjamin', 'Gross', 'bjgross@fas.harvard.edu', '617-432-5498', NULL, '11-2-04 Working with Brian Kraybill to pilot a screen for inhibitors of O-GlcNAc transferase using a fluorescence polarization assay similar to the one  used very successfully last year with the bacterial transglycosylase MurG.  Will submit an application soon.', NULL, NULL, NULL, '60608717');
INSERT INTO screensaver_user VALUES (153, 1, '2005-05-26 00:00:00', 'Dan', 'Fraenkel', 'fraenkel@hms.harvard.edu', '617-432-1912', NULL, '5/10/05 Dan still needs to construct screening strains. CS will provide him with the  drug sensitized yeast strains originally from Russell Dorer.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (505, 1, '2004-11-03 00:00:00', 'Julie', 'Williams', 'jmwilliz@umich.edu', '734-763-0621', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (252, 2, '2004-11-03 00:00:00', 'Alnawaz', 'Rehemtulla', 'Alnawaz.Rehemtulla@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (633, 2, '2004-08-09 00:00:00', 'Anna', 'Mandinova', 'anna.mandinova@cbrc2.mgh.harvard.edu', '617-724--7795', 'Bldg149, Charlestown', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (302, 5, '2004-08-09 00:00:00', 'Paolo', 'Dotto', 'gdotto@partners.org', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (278, 1, '2004-07-02 00:00:00', 'Sanjay', 'Desai', 'sdesai@niaid.nih.gov', '301-435-7552', 'Sanjay Desai, MD, PhD
Bldg. 4, Room 126
LMVR/NIAID/NIH
9000 Rockville Pike
Bethesda, MD 20892
FAX: (301) 402-0079', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (70, 1, '2002-06-19 00:00:00', 'Yang-Gyun', 'Kim', 'ygkimmit@hotmail.com', '617-253-4710', NULL, 'Data folder on data3.Yang-gyun will be handing this project over to a new student in July or August. At that time, Jim can set up a new user file for the student and copy the details of the screen into it.  The new student will continue to use Yang-gyun''s server account.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (71, 2, '2004-02-12 00:00:00', 'Alexander', 'Rich', 'Alexander.Rich@has.missing.email', ' 617-253-4715', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (446, 1, '2004-07-07 00:00:00', 'Michael', 'Gonzales', 'mgonzales@molsci.org', '510-647-0690', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (52, 2, '2004-07-07 00:00:00', 'Roger', 'Brent', 'Roger.Brent@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (354, 3, '2005-10-06 00:00:00', 'James', 'Cunningham', 'jcunningham@rics.bwh.harvard.edu', NULL, NULL, 'NSRB screener', NULL, NULL, NULL, '90047515');
INSERT INTO screensaver_user VALUES (300, 1, '2005-01-11 00:00:00', 'David', 'Haslam', 'haslam@kids.wustl.edu', '314-286-2888', 'Department of Pediatrics and Molecular Microbiology, Washington University School of Medicine
Box 8202, 6th Floor, MPRB
660 S. Euclid Ave
St. Louis, MO 63110', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (26, 4, '2004-07-07 00:00:00', 'Albert', 'Edge', 'albert_edge@meei.harvard.edu', '617-573-4452', 'Massachusetts Eye and Ear Infirmary', '9-27-04: Have good Ab marker for differentiation; still making luciferase construct for reporter assay.', NULL, NULL, NULL, '60189552');
INSERT INTO screensaver_user VALUES (684, 2, '2005-10-06 00:00:00', 'Kartik', 'Chandran', 'kchandran@rics.bwh.harvard.edu', '617-732-5853', '', 'NSRB screener
ecommons KC12', NULL, NULL, NULL, '80545975');
INSERT INTO screensaver_user VALUES (183, 1, '2002-01-02 00:00:00', 'David Christopher ', 'Bragg', 'bragg@helix.mgh.harvard.edu', '617-726-5729', 'MGH-East CNY 149', NULL, NULL, NULL, NULL, '105476010605');
INSERT INTO screensaver_user VALUES (101, 3, '2004-02-12 00:00:00', 'Xandra', 'Breakefield', 'breakefield@helix.mgh.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10271258');
INSERT INTO screensaver_user VALUES (378, 1, '2004-07-06 00:00:00', 'Aaron', 'Neiman', 'aaron.neiman@sunysb.edu', '631-632-1543', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (311, 2, '2004-10-13 00:00:00', 'Marc', 'Montminy', 'montminy@salk.edu', '858-453-4100', NULL, '10-13-04 Lab member Dong Lee will likely carry out this screen; Dong is not yet in users db but has signed data sharing agmnt.
10-22-04 - Dong added to usersDB (nicky)
', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (330, 1, '2004-07-06 00:00:00', 'Stephen', 'Orlicky', 'orlicky@mshri.on.ca', '416-586-4800', 'Samuel Lunenfeld Research Institute
600 University Avenue room 1080
Toronto Ontario M5G 1X5', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (331, 2, '2004-07-06 00:00:00', 'Michael', 'Tyers', 'tyers@mshri.on.ca', '416-586-8371', 'Samuel Lunenfeld Research Institute
600 University Avenue room 1080
Toronto Ontario M5G 1X5', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (554, 1, '2003-05-07 00:00:00', 'Mark', 'Bedford', 'mbedford@sprd1.mdacc.tmc.edu', '(512) 237-9539', 'Smithville Texas', 'Mark started this screen when he was a postdoc in Phil Leder''s lab.', NULL, NULL, NULL, '60442762');
INSERT INTO screensaver_user VALUES (625, 1, '2002-11-27 00:00:00', 'Lorena', 'Pont-Lezica', 'pontlez@fas.harvard.edu', '617-495-9247', NULL, NULL, NULL, NULL, NULL, '30555368');
INSERT INTO screensaver_user VALUES (536, 2, '2004-02-12 00:00:00', 'Catherine', 'Dulac', 'dulac@fas.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (425, 2, '2004-11-16 00:00:00', 'Lizbeth', 'Hedstrom', 'hedstrom@brandeis.edu', '781-736-2333', 'Department of Biochemistry, Brandeis University', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (42, 4, '2005-08-19 00:00:00', 'Brian', 'Kay', 'bkay@anl.gov', '630-252-3824', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (320, 2, '2005-01-21 00:00:00', 'Greg', 'Hoffman', 'greg_hoffman@hms.harvard.edu', '617-432-4849', NULL, '7/05 Collaborating with Yuangqing Xu (Gunawardena lab) on RNAi screen.', NULL, NULL, NULL, '10583217');
INSERT INTO screensaver_user VALUES (2, 16, '2004-02-12 00:00:00', 'John', 'Blenis', 'john_blenis@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '80239475');
INSERT INTO screensaver_user VALUES (29, 2, '2002-06-14 00:00:00', 'Leon', 'Murphy', 'leon_murphy@hms.harvard.edu', '617-432-4849', 'LHRRB 601', 'data folder on data6', NULL, NULL, NULL, '305087010');
INSERT INTO screensaver_user VALUES (261, 1, '2002-06-27 00:00:00', 'Liyun', 'Liu', 'liyunliu@fas.harvard.edu', '617-495-3716', '16 Divinity Ave. Room 4054', 'Will share server account with Bridget Wagner. ', NULL, NULL, NULL, '305161411');
INSERT INTO screensaver_user VALUES (262, 2, '2004-02-12 00:00:00', 'Woodland', 'Hastings', 'hastings@fas.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (689, 1, '2005-01-11 00:00:00', 'Michael', 'Rogers', 'michael.rogers@childrens.harvard.edu', '617-919-2252', 'Division of Vascular Biology, Childrens Hospital', 'NSRB screener', NULL, NULL, NULL, '60571570');
INSERT INTO screensaver_user VALUES (382, 2, '2005-01-11 00:00:00', 'Robert', 'D''Amato', 'robert.d''amato@tch.harvard.edu', '617/355-6234 x1351', 'Childrens Hospital, Surgical Research, Enders 10
300 Longwood Ave, Boston, MA 02115', 'NSRB screener', NULL, NULL, NULL, '10358361');
INSERT INTO screensaver_user VALUES (373, 3, '2004-04-14 00:00:00', 'Neil', 'Green', 'neil.green@vanderbilt.edu', '615-343-0453', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (459, 1, '2002-04-15 00:00:00', 'Yihong', 'Ye', 'yihong_ye@hms.harvard.edu', '432-1611', 'LHRRB-612', 'March 2005: Moved to  NIH (Kidney Inst.) to set up his own lab. 

data folder=data6', NULL, NULL, NULL, '205462630');
INSERT INTO screensaver_user VALUES (182, 4, '2004-02-12 00:00:00', 'Tom', 'Rapoport', 'tom_rapoport@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10430046');
INSERT INTO screensaver_user VALUES (45, 1, '2006-10-05 00:00:00', 'Damian', 'Krysan', ' damian_krysan@urmc.rochester.edu', '585-275-5594', '', '', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (682, 1, '2005-01-11 00:00:00', 'Eric', 'Sundberg', 'sundberg@bbri.org', '617-658-7882', 'Boston Biomedical Research Institute
64 Grove Street
Watertown, MA  02472', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (591, 1, '2004-01-05 00:00:00', 'Myung Soo', 'Kang', 'mkang@rics.bwh.harvard.edu', '617-525-4277', 'Channing Laboratory', 'id reactivated on 6/21/06 upon return to screening facility', NULL, NULL, NULL, '404925931');
INSERT INTO screensaver_user VALUES (39, 4, '2004-02-12 00:00:00', 'Elliott', 'Kieff', 'elliott_kieff@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '70288869');
INSERT INTO screensaver_user VALUES (234, 1, '2006-06-09 00:00:00', 'Pankaj', 'Seth', 'pseth@bidmc.harvard.edu', '617-667-2029', '', '', NULL, NULL, NULL, '30534158');
INSERT INTO screensaver_user VALUES (235, 3, '2006-06-09 00:00:00', 'Vikas', 'Sukhatme', 'Vikas.Sukhatme@has.missing.email', '', '', '', NULL, NULL, NULL, '90410032');
INSERT INTO screensaver_user VALUES (342, 3, '2005-03-16 00:00:00', 'Rosalie', 'Sears', 'searsr@ohsu.edu', '503-494-6885', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (350, 1, '2003-11-13 00:00:00', 'Shu Qin', 'Jiang', 'sjiang@bbri.org', '617-658-7833', NULL, 'NSRB screener', NULL, NULL, NULL, '404962970');
INSERT INTO screensaver_user VALUES (351, 2, '2003-11-13 00:00:00', 'Henry', 'Paulus', 'Paulus@bbri.org', '(617) 658-7800', 'Boston Biomedical Research Institute
64 Grove Street
Watertown, MA  02472-2829
FAX:  (617) 972-1753
http://www.bbri.org
Telephone switchboard operator: 617-658-7700', 'Director and Senior Scientist, Boston Biomedical Research Institute
Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, HMS
NSRB screener', NULL, NULL, NULL, '300763032');
INSERT INTO screensaver_user VALUES (337, 3, '2002-01-30 00:00:00', 'Ethan', 'Lee', 'ethan.lee@vanderbilt.edu', '615-322-1307', '', '4-12-06 Ethan was a postdoc in the Marc Kirschner Lab (HMS Cell Biology) when he carried out screen #135. A few years ago, he started his own lab at Vanderbilt University (TN). Today, this record was updated with Ethan''s current Vanderbilt information', NULL, NULL, NULL, '60490589');
INSERT INTO screensaver_user VALUES (166, 1, '2006-02-03 00:00:00', 'Sadhana', 'Chauhan', 'sachauha@UTMB.EDU', '409-772-3158', 'University of Texas Medical Branch
Department of Microbiology & Immunology
3.148 Keiller Bldg, Route 0609
301 University Blvd.
Galveston, TX 77555-0609', 'NSRB screener
Ecommons:  SC114', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (516, 1, '2006-12-08 00:00:00', 'Sonia', 'Sharma', 'sharma@cbr.med.harvard.edu', '617-278-3266', '', '', NULL, NULL, NULL, '30620704');
INSERT INTO screensaver_user VALUES (83, 5, '2004-02-12 00:00:00', 'Anjana', 'Rao', 'arao@cbr.med.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '50148807');
INSERT INTO screensaver_user VALUES (61, 1, '2006-09-25 00:00:00', 'Ernesto', 'Abel-Santos', 'ernesto.abelsantos@unlv.edu', '702-895-2608', 'Department of Chemistry
University of Nevada - Las Vegas
4505 Maryland Pkwy-Box 454003
Las Vegas, NV 89154', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (683, 3, '2002-01-24 00:00:00', 'Peter', 'Buckett', 'pbuckett@hsph.harvard.edu', '617-432-2533', 'HSPH, Bld 2, Room 255', 'Took over from Jing Xu after Jing left HSPH (2/1/02).', NULL, NULL, NULL, '905648110724');
INSERT INTO screensaver_user VALUES (285, 6, '2004-02-12 00:00:00', 'Marianne', 'Wessling-Resnick', 'wessling@hsph.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '80322178');
INSERT INTO screensaver_user VALUES (284, 3, '2002-01-02 00:00:00', 'Jing', 'Xu', 'jxu@hsph.harvard.edu', '617-432-2533', 'HSPH Building #2', 'Left HMS.  Screen taken over on 2/1/2002 by Peter Buckett.  
7-28-04 Now goes by Jing Brown', NULL, NULL, NULL, '90551698');
INSERT INTO screensaver_user VALUES (191, 3, '2005-02-22 00:00:00', 'Joan', 'Mecsas', 'Joan.mecsas@tufts.edu', '617 636-2742', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (107, 4, '2005-03-07 00:00:00', 'Olaf', 'Schneewind', 'oschnee@bsd.uchicago.edu', '773-834-9060', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (500, 1, '2005-11-16 00:00:00', 'Bernard', 'Weisblum', 'weisblum@wisc.edu', '608-262-0972', 'Pharmacology Department
University of Wisconsin Medical School
1300 University Avenue
Madison, WI 53706

608-262-0972 (desk)
608-263-2490 (lab)
608-262-1257 (fax)
608-238-6663 (home)', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (148, 1, '2005-05-10 00:00:00', 'Kelly', 'Tseng', 'tseng@enders.tch.harvard.edu', '617-355-2100', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (149, 2, '2005-05-10 00:00:00', 'Mark', 'Keating', 'Mark.Keating@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (385, 2, '2002-11-27 00:00:00', 'Kristine', 'O''Brien', 'kobrien@brandeis.edu', '781-736-2387', NULL, '-first name pronounced Kristina! -no Harvard ID', NULL, NULL, NULL, '10432553');
INSERT INTO screensaver_user VALUES (322, 4, '2004-02-12 00:00:00', 'Melissa', 'Moore', 'mmoore@brandeis.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (628, 4, '2006-04-19 00:00:00', 'Cliff', 'Yoon', 'cyoon@rics.bwh.harvard.edu', '617-413-2298', '', 'IX Micro user
Ecommons jcy2', NULL, NULL, NULL, '30297482');
INSERT INTO screensaver_user VALUES (99, 11, '2004-06-21 00:00:00', 'Steve', 'Elledge', 'selledge@genetics.med.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (406, 4, '2005-12-22 00:00:00', 'Abe', 'Brass', 'abrass@partners.org', '617-525-4515', '77 Avenue Louis Pasteur
NRB Room 160', 'Note: MGH GI Fellow.  Only using Microscope for readout at this time 12/22/05. 
Ecommons ID: ALB13', NULL, NULL, NULL, '505636690');
INSERT INTO screensaver_user VALUES (375, 4, '2006-01-04 00:00:00', 'Rob', 'McDonald', 'rmcdonald@rics.bwh.harvard.edu', '617-525-4515', '', '', NULL, NULL, NULL, '80603053');
INSERT INTO screensaver_user VALUES (98, 4, '2006-05-01 00:00:00', 'Guang1', 'Hu', 'ghu@rics.bwh.harvard.edu', '617-525-4513', '', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (154, 1, '2006-11-07 00:00:00', 'Brent', 'Passer ', 'bpasser@partners.org', '617-726-6798', 'Neurosurgery Dept. ', '', NULL, NULL, NULL, '10635284');
INSERT INTO screensaver_user VALUES (155, 2, '2006-11-07 00:00:00', 'Robert', 'Martuza', 'rmartuza@partners.org', '', '', '', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (587, 1, '2002-05-17 00:00:00', 'Tomosaburo (Tomo)', 'Takahashi', 'ttakahashi@rics.bwh.harvard.edu', '617-768-8281', '65 Landsdowne St., Cambridge MA', 'Richard T. Lee, M.D. Cardiovascular Division, Brigham and Women''s HospitalPartners Research Facility, Room 27965 Landsdowne St. Cambridge, MA   02139 phone 617-768-8272fax 617-768-8270Laboratory web site:  http://vascular.bwh.harvard.edu/RTLee/index.htm', NULL, NULL, NULL, '505662930606');
INSERT INTO screensaver_user VALUES (349, 4, '2004-02-12 00:00:00', 'Richard', 'Lee', 'rlee@rics.bwh.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (434, 1, '2004-07-06 00:00:00', 'Jon', 'Aster', 'jaster@rics.bwh.harvard.edu', '617-278-0032', NULL, NULL, NULL, NULL, NULL, '90318071');
INSERT INTO screensaver_user VALUES (615, 2, '2003-05-02 00:00:00', 'Brian', 'Perkins', 'bperkins@fas.harvard.edu', '617-495-2599', NULL, NULL, NULL, NULL, NULL, '60533881');
INSERT INTO screensaver_user VALUES (260, 6, '2004-02-12 00:00:00', 'John', 'Dowling', 'dowling@mcb.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '30136543');
INSERT INTO screensaver_user VALUES (150, 2, '2004-04-06 00:00:00', 'Giovanni', 'Widmer', 'giovanni.widmer@tufts.edu', '508-839-7944', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (249, 1, '2003-07-14 00:00:00', 'Brian', 'Smart', 'bsmart@u.washington.edu', '206-616-4264', NULL, 'PI email: gelb@chem.washington.edu, tel: 206-543-7142, Fax: 206-685-8665  Gelb has signed data sharing agreement. ', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (250, 2, '2004-02-12 00:00:00', 'Michael', 'Gelb', 'gelb@chem.washington.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (503, 1, '2002-01-30 00:00:00', 'Art', 'Horwich', 'horwich@hhmiart.med.yale.edu', '203-737-4431', NULL, 'Dr. Wayne Fenton, Yale School of Medicine/HHMI, Boyer Center Rm 143, 295 Congress Ave., New Haven, CT  06510.   wayne.fenton@yale.edu  203-737-4428', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (399, 1, '2002-05-14 00:00:00', 'Yunde', 'Zhao', 'zhao@pop.salk.edu', NULL, NULL, 'Will move to UCSD as Ass''t Prof summer of 2002.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (400, 2, '2004-02-12 00:00:00', 'Joanne', 'Chory', 'chory@salk.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (318, 4, '2002-01-30 00:00:00', 'Qing', 'Liu', 'ching_liu@hms.harvard.edu', NULL, 'SGM-610', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (728, 1, '2005-11-08 00:00:00', 'Matt', 'Stremlau', 'stremlau@student.hms.harvard.edu', '617-632-4357', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (264, 2, '2005-11-08 00:00:00', 'Joe', 'Sodroski', 'joseph_sodroski@dfci.harvard.edu', '617-632-3371', 'affilitated with HMS Pathology Dept. and HSPH', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (11, 1, '2003-04-29 00:00:00', 'Nava', 'Zaarur', 'nava_zaarur@yahoo.com', '617-638-5973', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (12, 3, '2004-02-12 00:00:00', 'Michael', 'Sherman', 'sherman@biochem.bumc.bu.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (571, 3, '2006-12-13 00:00:00', 'Dennis', 'Kasper', 'dennis_kasper@hms.harvard.edu', '', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (82, 2, '2006-01-11 00:00:00', 'Paul', 'de Figueiredo', 'pjdefigueiredo@tamu.edu', '979-458-2977', '', 'Paul is a collaborator of Akiko Shimamura (DFCI)  and also of James Huang (Baylor College of Medicine).
James Huang has also signed a data sharing agreement (on file).', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (481, 5, '2004-07-07 00:00:00', 'Michael', 'Stiffler', 'stiffler@fas.harvard.edu', '617-384-9231', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (482, 6, '2002-10-22 00:00:00', 'Gavin', 'MacBeath', 'gavin_macbeath@harvard.edu', '(617) 495-9488', NULL, 'ulrik@MIT.EDU', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (242, 1, '2004-09-17 00:00:00', 'Thanat', 'Chookajorn', 'chookaj@fas.harvard.edu', '617-496-5540', NULL, NULL, NULL, NULL, NULL, '50613011');
INSERT INTO screensaver_user VALUES (243, 3, '2004-09-17 00:00:00', 'Dan', 'Hartl', 'dhartl@oeb.harvard.edu', '617-496-3917', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (95, 2, '2005-10-31 00:00:00', 'Jose', 'Teixeira', 'teixeira@helix.mgh.harvard.edu', '617-724-1616', NULL, 'ecommons: jmt3
Note: Jose is affiliated with the group of Patricia Donahoe at MGH.', NULL, NULL, NULL, '10429447');
INSERT INTO screensaver_user VALUES (216, 3, '2006-01-05 00:00:00', 'Raymond', 'Koski', 'raymond.koski@l2dx.com', '203 589-2029', 'L2 Diagnostics, LLC
300 George St., Suite 309
New Haven, CT 06511', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (565, 2, '2006-01-05 00:00:00', 'Karen', 'Anthony', 'karen.anthony@l2dx.com; kg_anthony@yahoo.com', '203 503 0383', 'L2 Diagnostics, LLC
300 George Street, Suite 309
New Haven, CT 06511', 'NSRB screener
Ecommons ID: KA41', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (542, 2, '2002-01-02 00:00:00', 'Archana', 'Bommi-Reddy', 'archana_bommi-reddy@dfci.harvard.edu', '617-432-2205', 'DFCI Mayer 453', NULL, NULL, NULL, NULL, '40568743');
INSERT INTO screensaver_user VALUES (543, 3, '2004-02-12 00:00:00', 'William', 'Kaelin', 'william_kaelin@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10318629');
INSERT INTO screensaver_user VALUES (460, 1, '2006-03-02 00:00:00', 'Mark', 'Poznansky', 'Mark_Poznansky@dfci.harvard.edu', '617-724-6375', 'AIDS Research Center
149 13th Street
Charlestown, MA 02129', 'NSRB screener', NULL, NULL, NULL, '30359534');
INSERT INTO screensaver_user VALUES (600, 1, '2004-09-02 00:00:00', 'Handan', 'Kaplan', 'handan_kaplan@hms.harvard.edu', '617-432', NULL, NULL, NULL, NULL, NULL, '606055720');
INSERT INTO screensaver_user VALUES (507, 2, '2004-09-02 00:00:00', 'Roberto', 'Kolter', 'rkolter@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '30238958');
INSERT INTO screensaver_user VALUES (72, 2, '2005-05-10 00:00:00', 'Yuk-ching', 'Tse-Dinh', 'Yuk-ching_Tse-Dinh@nymc.edu', '914-594-4061', 'Department of Biochemistry & Molecular Biology
New York Medical College
Valhalla, NY 10595
Tel: 914-594-4061
Fax: 914-594-4058', 'NSRB screener
alternate email: yukching@gmail.edu
ecommons yt36 reactivated 6/26/06.  reactivated again 12/11/06 through 6/11/07 - SMJ', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (444, 2, '2004-12-13 00:00:00', 'Robert', 'Finberg', 'robert.finberg@umassmed.edu', '508-856-1886', 'Department of Medicine
University of Massachusetts Medical School', 'NSRB screener', NULL, NULL, NULL, '70167417');
INSERT INTO screensaver_user VALUES (96, 1, '2002-02-08 00:00:00', 'Xiaolan', 'Ye', 'Xiaolan.Ye@has.missing.email', '617-432-5697', '360 WAB', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (97, 2, '2004-02-12 00:00:00', 'Linda', 'Buck', 'lbuck@fhcrc.org', NULL, NULL, NULL, NULL, NULL, NULL, '30392809');
INSERT INTO screensaver_user VALUES (359, 2, '2004-05-27 00:00:00', 'Warren', 'Kruger', 'wd_kruger@fccc.edu', '215-728-3030', 'Fox Chase Cancer Center
333 Cottman Ave.
Philadelphia, PA 19111', 'Postdoc Xulen Chen is carrying out screen at ICCB.  


', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (402, 2, '2002-01-30 00:00:00', 'Nick', 'Westwood', 'njw3@st-and.ac.uk', NULL, NULL, 'left ICCB 7/01', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (413, 1, '2003-06-18 00:00:00', 'Jean-Claude', 'Mollet', 'jmollet@citrus.ucr.edu', NULL, NULL, 'lord@ucrac1.ucr.edu', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (414, 2, '2004-02-12 00:00:00', 'Elizabeth', 'Lord', 'lord@citrus.ucr.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (187, 2, '2006-12-11 00:00:00', 'Donald', 'Moir', 'dmoir@microbiotix.com', '508-757-2800 ext. 102', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (405, 1, '2003-06-19 00:00:00', 'Homan', 'Chan', 'ho_chan@dfci.harvard.edu', '617-632-5393', NULL, 'david_livingston@dfci.harvard.edu', NULL, NULL, NULL, '90569376');
INSERT INTO screensaver_user VALUES (323, 3, '2004-02-12 00:00:00', 'David', 'Livingston', 'david_livingston@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (343, 1, '2004-03-04 00:00:00', 'Jianping', 'Jin', 'Jianping_Jin@hms.harvard.edu', '617-432-6593', NULL, 'Will use plate reader to read out luminescent assay as part of RNAi pilot screen.', NULL, NULL, NULL, '30602005');
INSERT INTO screensaver_user VALUES (233, 6, '2004-03-04 00:00:00', 'Wade', 'Harper', 'wade_harper@hms.harvard.edu', '617-432-6590', NULL, 'RNAi screens in collaboration with Elledge lab.', NULL, NULL, NULL, '80268629');
INSERT INTO screensaver_user VALUES (533, 1, '2005-05-26 00:00:00', 'Betty', 'Chan', 'bchan@fas.harvard.edu', '617-432-0457', NULL, NULL, NULL, NULL, NULL, '30555082');
INSERT INTO screensaver_user VALUES (509, 2, '2005-05-26 00:00:00', 'Tom', 'Ellenberger', 'tome@hms.harvard.edu', '617-432-0458', '', '5/10/06 Over the winter Tom Ellenberger moved his lab from HMS BCMP Dept. to Washington University, St. Louis MO', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (650, 2, '2006-10-19 00:00:00', 'Mike', 'LaFleur', 'mlafleur78@yahoo.com', '617-373-3267', '', 'lafleur.m@neu.edu', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (241, 4, '2006-01-09 00:00:00', 'Kim', 'Lewis', 'k.lewis@neu.edu', '617-373-8238', 'Department of Biology
Northeastern University
360 Huntington Avenue
Mugar 405
Boston, MA 02115', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (267, 4, '2003-12-15 00:00:00', 'Tiago', 'Outeiro', 'outeiro@wi.mit.edu', '617-258-6517', NULL, 'New email address: touteiro@partners.org', NULL, NULL, NULL, '70629240');
INSERT INTO screensaver_user VALUES (58, 8, '2004-02-12 00:00:00', 'Susan', 'Lindquist', 'lindquist_admin@wi.mit.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (279, 4, '2004-10-05 00:00:00', 'Sven', 'Heinrich', 'heinrich@wi.mit.edu', '617-258-6815', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (504, 4, '2004-03-18 00:00:00', 'Smitha', 'Jagadish', 'jagadish@wi.mit.edu', '617-258-5190', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (537, 1, '2003-02-13 00:00:00', 'Geoffrey', 'Burns', 'gburns@cvrc.mgh.harvard.edu', '617-726-6470', NULL, 'will give CES his ID number when he obtains a Harvard ID.Calum Macrae co-signed Geoff''s data sharing agreement as PI, though he is not really Geoff''s PI (both are former Fishman lab members).', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (40, 2, '2004-02-12 00:00:00', 'Calum', 'Macrae', 'cmacrae@partners.org', NULL, NULL, NULL, NULL, NULL, NULL, '50393682');
INSERT INTO screensaver_user VALUES (212, 2, '2002-01-24 00:00:00', 'Bob', 'Shapiro', 'robert_shapiro@hms.harvard.edu', '617-432-4010', NULL, NULL, NULL, NULL, NULL, 'on  file');
INSERT INTO screensaver_user VALUES (127, 3, '2005-05-18 00:00:00', 'Samuel', 'Miller', 'millersi@u.washington.edu', '206-616-5107', 'Department of Genome Sciences, University of Washington
K-140, HSB, Box 357710
1959 Pacific St. NE
Seattle, WA 98195', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (126, 2, '2005-05-18 00:00:00', 'Heather', 'Felise', 'hrb@u.washington.edu', '206-616-5108', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (76, 3, '2003-02-12 00:00:00', 'Steven', 'Balk', 'sbalk@caregroup.harvard.edu', '617-667-3918', NULL, NULL, NULL, NULL, NULL, '701915390');
INSERT INTO screensaver_user VALUES (451, 2, '2003-04-30 00:00:00', 'Alice', 'Shaw', 'Alice_Shaw@dfci.harvard.edu', '617-253-0264', NULL, NULL, NULL, NULL, NULL, '20330104');
INSERT INTO screensaver_user VALUES (304, 3, '2004-02-12 00:00:00', 'Tyler', 'Jacks', 'tjacks@mit.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (251, 2, '2004-12-22 00:00:00', 'Vineet', 'Gupta', 'VGUPTA3@PARTNERS.ORG', '617-726-3301', NULL, 'ecommons: vg13

Vineet is also carrying out this screen as an RNAi screen using the TRC shRNA lentiviral library at the MGH screening facility--currently has access to 1100 genes (6000 constructs). Soon to have access to 15000 additional  constructs (5000 more genes).
Vineet Gupta, Ph. D.
Instructor in Medicine, Harvard Medical School and
Assistant in Biology, Massachusetts General Hospital
Division of Nephrology, MGH
149 13th Street, Rm 8000
Charlestown, MA 02129
Ph: 617-726-3301 |  Fax: 617-726-5669
Email: vgupta3@partners.org  |  vineet_gupta@hms.harvard.edu', NULL, NULL, NULL, '50591875');
INSERT INTO screensaver_user VALUES (486, 5, '2006-05-01 00:00:00', 'Jennifer', 'Philips', 'jphilips@partners.org', '617-432-7673', '', '', NULL, NULL, NULL, '30542924');
INSERT INTO screensaver_user VALUES (19, 20, '2004-02-12 00:00:00', 'Norbert', 'Perrimon', 'perrimon@rascal.med.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10305926');
INSERT INTO screensaver_user VALUES (570, 5, '2004-07-07 00:00:00', 'Bernard', 'Mathey-Prevot', 'bprevot@receptor.med.harvard.edu', '617-632-3535', NULL, 'Director of the Drosophila RNAi Screening Center (DRSC).', NULL, NULL, NULL, '60309272');
INSERT INTO screensaver_user VALUES (84, 5, '2002-01-30 00:00:00', 'Sara', 'Cherry', 'scherry@genetics.med.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (511, 5, '2003-07-02 00:00:00', 'Ram', 'Dasgupta', 'ramanuj.dasgupta@med.nyu.edu', '212-263-8159 ', 'NYU School of Medicine/Pharmacology 
550 First Ave. 
MSB-493 
New York, NY 10016 
', 'An RNAi screen only at this point . Ram is looking for  activators and inhibitors of the Drosophila wingless pathway. He uses a wingless dependent luciferase reporter.', NULL, NULL, NULL, '905716990');
INSERT INTO screensaver_user VALUES (427, 5, '2005-11-08 00:00:00', 'Gyeong Hun', 'Baeg', 'gbaeg@genetics.harvard.edu', '617-432-7571', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (535, 4, '2002-01-24 00:00:00', 'Haley', 'Hieronymus', 'hierony@fas.harvard.edu', '617-632-5105', 'Dana Farber, Smith 916', NULL, NULL, NULL, NULL, '90518577');
INSERT INTO screensaver_user VALUES (170, 12, '2004-02-12 00:00:00', 'Pamela', 'Silver', 'pamela_silver@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '20410981');
INSERT INTO screensaver_user VALUES (169, 4, '2002-01-02 00:00:00', 'Tweeny', 'Kau', 'kau@fas.harvard.edu', '617-632-5109', 'DFCI Smith 920', NULL, NULL, NULL, NULL, '90518372');
INSERT INTO screensaver_user VALUES (326, 4, '2004-02-26 00:00:00', 'Garo', 'Toby', 'garabet_toby@dfci.harvard.edu', '617-632--5105', NULL, NULL, NULL, NULL, NULL, '306034190');
INSERT INTO screensaver_user VALUES (619, 1, '2004-09-30 00:00:00', 'Pete', 'Bayliss', 'Peter_Bayliss@dfci.harvard.edu', NULL, NULL, 'Zebrafish screen, decided not to provide access to screening room or server account.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (194, 2, '2004-09-30 00:00:00', 'Tom', 'Roberts', 'Thomas_roberts@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (204, 2, '2006-01-04 00:00:00', 'Morris', 'White', 'morris.white@childrens.harvard.edu', '617-919-2846', '', '', NULL, NULL, NULL, '50220303');
INSERT INTO screensaver_user VALUES (192, 2, '2002-02-28 00:00:00', 'Michael', 'Zimmer', 'zimmer@helix.mgh.harvard.edu', '617-726-1408', '910 Jackson Bldg MGH ', '-Othon''s contact info:iliopoul@helix.mgh.harvard.eduTel. 724-3404 page 724-5700(#31128)-Getting advice from Brian DeDecker.-data folder  in data2', NULL, NULL, NULL, '20567988');
INSERT INTO screensaver_user VALUES (193, 3, '2004-02-12 00:00:00', 'Othon', 'Iliopoulos', 'iliopoul@helix.mgh.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '20408065');
INSERT INTO screensaver_user VALUES (77, 1, '2005-11-17 00:00:00', 'Jackie', 'Hua', 'yuanyuan.hua@childrens.harvard.edu', '617-595-2715', '', 'ecommons: YH54
Childrens ID: 118354', NULL, NULL, NULL, '10656117');
INSERT INTO screensaver_user VALUES (78, 2, '2005-11-17 00:00:00', 'Mike', 'Greenberg', 'Michael.Greenberg@childrens.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (224, 1, '2004-02-17 00:00:00', 'Katya', 'Ravid', 'ravid@biochem.bumc.bu.edu', '617-638-5053', NULL, 'Katya will come alone or with Hao.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (316, 2, '2006-11-03 00:00:00', 'Nicholas', 'Mantis', 'nmantis@wadsworth.org', '518-402-2750', 'Carolyn McGuinness
 Wadsworth Center
 120 New Scotland Ave
 DAI Room 4005
 Albany, NY 12208 
', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (572, 2, '2003-05-28 00:00:00', 'Shahram', 'Misaghi', 'shahram_misaghi@student.hms.harvard.edu', '617-432-4788', NULL, NULL, NULL, NULL, NULL, '105365370');
INSERT INTO screensaver_user VALUES (207, 7, '2004-02-12 00:00:00', 'Hidde', 'Ploegh', 'Hidde_Ploegh@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '50413012');
INSERT INTO screensaver_user VALUES (347, 2, '2003-05-30 00:00:00', 'Domenic', 'Tortorella', 'Domenico.Tortorella@mssm.edu', '212-241-5447', NULL, 'Dom now has his own lab at Mt. Sinai School of Medicine, Dept. of Microbiology, in NYC.Mount Sinai School of MedicineDepartment of MicrobiologyOne Gustave L. Levy PlaceBox 1124New York, NY 10029phone: 212-241-5447fax: 212-534-1684', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (555, 1, '2004-04-06 00:00:00', 'Paula', 'Smith', 'psmith@enders.tch.harvard.edu', NULL, NULL, 'Note: 04/06/04 - Screen 345 will be carried out using our compounds (natural product extracts) but likely performed in low throughput in the Clapham lab -- assay details to be worked out still
06/21/04 Paula picked up natural product extract (96-well) plates from the ICCB.', NULL, NULL, NULL, '10432731');
INSERT INTO screensaver_user VALUES (197, 2, '2004-04-06 00:00:00', 'David', 'Clapham', 'dclapham@enders.tch.harvard.edu', '617-355--6163', NULL, NULL, NULL, NULL, NULL, '30474015');
INSERT INTO screensaver_user VALUES (585, 1, '2005-07-14 00:00:00', 'Pei-yong', 'Shi', 'ship@wadsworth.org', '518-473-7487', 'Division of Infectious Diseases
Wadsworth Center
NY State Dept. of Health', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (688, 1, '2006-10-05 00:00:00', 'Takbum', 'Ohn', 'tohn@rics.bwh.harvard.edu', '', '', '', NULL, NULL, NULL, '606868740');
INSERT INTO screensaver_user VALUES (677, 2, '2006-09-20 00:00:00', 'Paul', 'Anderson ', 'panderson@rics.bwh.harvard.edu', '617-525-1202', 'BWH Div. Rheumatology, Immunology, Allergy; Smith 652, Jimmy Fund Bldg, ', '', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (598, 1, '2005-05-10 00:00:00', 'Lily', 'Lee', 'lily_lee@hms.harvard.edu', '617-432-1216', '', 'Ecommons: LL45', NULL, NULL, NULL, '70364921');
INSERT INTO screensaver_user VALUES (219, 2, '2005-05-10 00:00:00', 'Jim', 'Hogle', 'Jim.Hogle@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (478, 2, '2002-01-30 00:00:00', 'Russell', 'Dorer', 'RDORER@PARTNERS.ORG', '617-496-1384', 'Harvard Biolabs', '2003: Russell finished his postdoc in the Murray lab and moved to a fellowship in the Pathology Dept. at BWH.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (479, 3, '2004-02-12 00:00:00', 'Andrew', 'Murray', 'amurray@mcb.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (409, 2, '2004-03-09 00:00:00', 'Jon', 'Goguen', 'jon.goguen@umassmed.edu', '508-856-2490', 'Jon D. Goguen
Dept of Molecular Genetics and Microbiology
University of Massachusetts Medical School
55 Lake Avenue North
Worcester, MA 01655

', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (157, 2, '2004-02-18 00:00:00', 'Ed', 'McBride', 'emcbride@tufts-nemc.org', '617-636-8407', NULL, 'Ed will be performing the screening', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (158, 3, '2004-02-18 00:00:00', 'Alan', 'Kopin', 'akopin@tufts-nemc.org', '617-636-4834', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (640, 1, '2002-06-27 00:00:00', 'Rocky', 'Onda', 'honda@rics.bwh.harvard.edu', '617-278-0395', 'LMRC room 301', 'data folder on data3', NULL, NULL, NULL, '30425960');
INSERT INTO screensaver_user VALUES (638, 2, '2004-02-12 00:00:00', 'David', 'Kwiatkowski', 'dk@zk.bwh.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '60156689');
INSERT INTO screensaver_user VALUES (469, 3, '2006-08-11 00:00:00', 'Adam', 'Castoreno', 'adam_castoreno@dfci.harvard.edu', '617-582-8583', '', '', NULL, NULL, NULL, '305366572');
INSERT INTO screensaver_user VALUES (470, 4, '2002-01-02 00:00:00', 'Ulrike', 'Eggert', 'ulrike_eggert@hms.harvard.edu', '617-432-3728', 'HMS SGM-529', ' (Riki)
8/31/06 Riki was a postdoc with Tim Mitchison but as of 4/1/06 is a Professor at DFCI/HMS. ', NULL, NULL, NULL, '10566533');
INSERT INTO screensaver_user VALUES (352, 3, '2002-01-18 00:00:00', 'Rob', 'Flaumenhaft', 'rflaumen@caregroup.harvard.edu', '667-0627', 'Research East, BIDMC 41 Louis Pasteur', NULL, NULL, NULL, NULL, '604974430');
INSERT INTO screensaver_user VALUES (381, 4, '2002-06-17 00:00:00', 'Patrick', 'Hogan', 'hogan@cbr.med.harvard.edu', '617-278-3057', 'Alpert 1st floor', NULL, NULL, NULL, NULL, '50156526');
INSERT INTO screensaver_user VALUES (361, 1, '2002-01-24 00:00:00', 'Gael', 'McGill', 'gmcgill@student.med.harvard.edu', '617-632-4898', 'DFCI-Dana D630A', 'Lokey signed Statement of Understanding as well. Until 4/02, was storing data on Lokey server account. Started using own account  at that time.', NULL, NULL, NULL, '80466811');
INSERT INTO screensaver_user VALUES (49, 4, '2004-02-12 00:00:00', 'David E.', 'Fisher', 'david_fisher@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (561, 1, '2004-07-06 00:00:00', 'Piotr', 'Gornicki', 'Piotr.Gornicki@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (562, 2, '2004-07-06 00:00:00', 'Robert', 'Haselkorn', 'rh01@uchicago.edu', '773-702-1069', 'Molecular Genetics and Cell Biology
University of Chicago', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (608, 1, '2002-01-02 00:00:00', 'Mei', 'Lu', 'meilu@rics.bwh.harvard.edu', '617-525-5238', 'HIM', 'Has stopped screening at ICCB. Kosik lab is carrying out screens at LDDN.', NULL, NULL, NULL, '10444586');
INSERT INTO screensaver_user VALUES (367, 2, '2004-02-12 00:00:00', 'Kenneth', 'Kosik', 'kosik@cnd.bwh.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '60030561');
INSERT INTO screensaver_user VALUES (662, 1, '2006-06-29 00:00:00', 'Elizabeth', 'Rico-Bautista', 'ericobau@hsph.harvard.edu', '617-432-2065', '', 'ecommons ER36', NULL, NULL, NULL, '90655795');
INSERT INTO screensaver_user VALUES (92, 4, '2004-02-12 00:00:00', 'Dieter', 'Wolf', 'dwolf@hsph.harvard.edu', '', '', '', NULL, NULL, NULL, '60444048');
INSERT INTO screensaver_user VALUES (407, 1, '2004-11-16 00:00:00', 'Frederic', 'Bushman', 'bushman@mail.med.upenn.edu', '215-573-8732', 'Department of Microbiology, University of Pennsylvania', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (627, 2, '2005-09-21 00:00:00', 'Trei', 'Martin', 'gwmartin@post.harvard.edu', '617-258-7479', 'Lab located at MIT', 'Full name Glover (Trei) Martin', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (13, 5, '2005-09-21 00:00:00', 'Lee', 'Gehrke', 'lee_gehrke@hms.harvard.edu', '617-253-7608', 'c/o HST Division M.I.T.

77 Massachusetts Ave.

Cambridge, MA 02139

phone: 617-253-7608

fax: 617-253-3459

lee_gehrke@hms.harvard.edu
', 'Professor in Microbiology Dept. HMS, Lab located at MIT', NULL, NULL, NULL, '60218471');
INSERT INTO screensaver_user VALUES (398, 2, '2004-07-06 00:00:00', 'Joseph', 'Barbieri', 'jtb01@mcw.edu', '414-456-8412', 'Medical College of Wisconsin 
8701 Watertown Plk. Rd. 
Milwaukee,  WI 53226
fax:      414-456-6535', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (547, 3, '2002-04-16 00:00:00', 'Ann', 'Cassidy-Stone', 'acstone@ucdavis.edu', '(530) 752-7235', '3215 Life Science AdditionMolecular and Cellular BiologyUniversity of California, DavisDavis, Ca 95616', 'data folder=data6', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (394, 4, '2004-02-12 00:00:00', 'Jodi', 'Nunnari', 'jmnunnari@ucdavis.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (601, 5, '2002-01-02 00:00:00', 'Nathan', 'Moerke', 'moerke@fas.harvard.edu', '617-432-3211', 'HMS C1-103', '5-3-06 SPR - removed from screening users list due to bounceback emails saying unrecognized', NULL, NULL, NULL, '405009280');
INSERT INTO screensaver_user VALUES (80, 16, '2004-02-12 00:00:00', 'Gerhard', 'Wagner', 'gerhard_wagner@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '30361369');
INSERT INTO screensaver_user VALUES (215, 5, '2006-11-30 00:00:00', 'Ricard', 'Rodriguez', 'ricard_rodriguez@hms.harvard.edu', '617-432-3211', '', '', NULL, NULL, NULL, '20687789');
INSERT INTO screensaver_user VALUES (441, 5, '2002-05-16 00:00:00', 'Vladimir (Vlado)', 'Gelev', 'vladimir_gelev@hms.harvard.edu', '617-432-3211', 'C1-103', NULL, NULL, NULL, NULL, '60554501');
INSERT INTO screensaver_user VALUES (620, 5, '2006-07-06 00:00:00', 'Bryan', 'Vought', 'bryan_vought@hms.harvard.edu', '617-432-3212', '', '10/06 cell phone:781-801-3020 ', NULL, NULL, NULL, '20532181');
INSERT INTO screensaver_user VALUES (429, 2, '2005-08-19 00:00:00', 'Robert', 'Ricciardi', 'ricciardi@biochem.dental.upenn.edu', '215-898-3905', 'Levy Research Building, Room 251
4010 Locust Street
Philadelphia, PA 19104
fax: 215-898-8385', 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (560, 2, '2006-01-31 00:00:00', 'Richard', 'Lu', 'rlu2@partners.org', '617-768-8741', NULL, 'Working with Jason Heindl from Marcia Goldbergs lab, will be starting an RNAi screen soon. ', NULL, NULL, NULL, '90483439');
INSERT INTO screensaver_user VALUES (296, 4, '2005-09-27 00:00:00', 'Marcia', 'Goldberg', 'MGOLDBERG1@PARTNERS.ORG', '617-768-8740', 'Bacterial Pathogenesis
65 Landsdowne Street
Room 425
Cambridge, MA  02139', 'NSRB screener', NULL, NULL, NULL, '30148746');
INSERT INTO screensaver_user VALUES (295, 2, '2005-09-27 00:00:00', 'Jason', 'Heindl', 'heindl@fas.harvard.edu', '617-768-8741', 'Bacterial Pathogenesis
65 Landsdowne Street
Room 425
Cambridge, MA  02139', 'NSRB screener', NULL, NULL, NULL, '90573144');
INSERT INTO screensaver_user VALUES (397, 1, '2004-07-07 00:00:00', 'Donald', 'Crampton', 'dcrampton@hms.harvard.edu', '617-432-3130', NULL, NULL, NULL, NULL, NULL, '50551431');
INSERT INTO screensaver_user VALUES (222, 6, '2004-07-07 00:00:00', 'Charles', 'Richardson', 'Charles.Richardson@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, '50132366');
INSERT INTO screensaver_user VALUES (573, 1, '2004-07-06 00:00:00', 'Marcy', 'Hernick', 'hernickm@umich.edu', NULL, 'Chemistry Department, University of Michigan', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (238, 2, '2004-07-06 00:00:00', 'Carol', 'Fierke', 'fierke@umich.edu', NULL, 'Chemistry Department, University of Michigan', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (24, 20, '2004-02-12 00:00:00', 'Stephen', 'Lory', 'stephen_lory@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '60532575');
INSERT INTO screensaver_user VALUES (85, 12, '2006-03-06 00:00:00', 'Roger Scott', 'Smith', 'roger_smith@hms.harvard.edu', '617-432-5098', NULL, '36/06: /0He is using the Wallac for a luciferase assay and working with Brian Kraybill
2006-03-09: Roger wants to start piloting a small-molecule screen immediately.', NULL, NULL, NULL, '30579887');
INSERT INTO screensaver_user VALUES (89, 12, '2002-04-23 00:00:00', 'Ann', 'Yonetani', 'ann_yonetani@hms.harvard.edu', '617-432-2398', 'D1-403', 'Steve L. tel. 617-432-5099', NULL, NULL, NULL, '50498115');
INSERT INTO screensaver_user VALUES (134, 12, '2002-10-09 00:00:00', 'Hemantha', 'Kulasekara', 'hemantha_kulasekara@hms.harvard.edu', '617-432-5098', NULL, NULL, NULL, NULL, NULL, '90545825');
INSERT INTO screensaver_user VALUES (335, 12, '2004-11-02 00:00:00', 'Jin', 'Huang', 'jin_huang@hms.harvard.edu', '617-432-5092', NULL, NULL, NULL, NULL, NULL, '90545582');
INSERT INTO screensaver_user VALUES (724, 12, '2003-01-02 00:00:00', 'Vincent (Vince)', 'Lee', 'vlee@hms.harvard.edu', '617-432-5092', 'Alpert 360', 'SGM 626 access 12/2/2005  SJ', NULL, NULL, NULL, '405627450');
INSERT INTO screensaver_user VALUES (680, 12, '2002-06-19 00:00:00', 'David', 'Adamovich', 'david_adamovich@student.hms.harvard.edu', '617-432-5098', 'Alpert 365', 'data folder on data3.', NULL, NULL, NULL, '205369260');
INSERT INTO screensaver_user VALUES (202, 1, '2002-01-24 00:00:00', 'Valeria', 'Fantin', 'vfantin@genetics.med.harvard.edu', '617.432-7578', 'Alpert 6th Floor', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (203, 2, '2004-02-12 00:00:00', 'Philip', 'Leder', 'leder@rascal.med.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '70133091');
INSERT INTO screensaver_user VALUES (173, 1, '2003-12-19 00:00:00', 'Won', 'Choe', 'wchoe@partners.org', '617-726-2061', NULL, NULL, NULL, NULL, NULL, '70600536');
INSERT INTO screensaver_user VALUES (174, 3, '2004-02-12 00:00:00', 'Ray', 'Chung', 'rtchung@partners.org', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (673, 1, '2004-10-13 00:00:00', 'Lesly', 'Temesvari', 'LTEMESV@clemson.edu', '864-656-6387', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (226, 3, '2002-06-06 00:00:00', 'Kwa', 'Liou', 'Kwa_Liou@student.hms.harvard.edu', '617-432-2892', 'D2-633', 'Kwa is pronounced like "kwai." Data file on data6.', NULL, NULL, NULL, '905186150');
INSERT INTO screensaver_user VALUES (227, 4, '2004-02-12 00:00:00', 'Peter', 'Howley', 'peter_howley@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '50390977');
INSERT INTO screensaver_user VALUES (594, 4, '2002-07-01 00:00:00', 'Martha', 'Marvin', 'martha_marvin@hms.harvard.edu', '617-432-0044', NULL, '--from Mark Mercola''s lab ,now collaborating with Spyros''s lab--in communication with Rick Lee et al., who are doing a similar screen.--data folder on data3.', NULL, NULL, NULL, '30459016');
INSERT INTO screensaver_user VALUES (54, 8, '2004-02-12 00:00:00', 'Spyros', 'Artavanis-Tsakonas', 'tsakonas@helix.mgh.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (306, 4, '2002-01-02 00:00:00', 'Brian', 'DeDecker', 'bdedecker@partners.org', '617-432-3708', 'SGM 610', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (388, 4, '2004-11-23 00:00:00', 'Pad', 'Padmanabhan', 'rp55@georgetown.edu', '202-687-2092', 'Dept. of Microbiology and Immunology, Georgetown University School of Medicine', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (383, 1, '2003-10-31 00:00:00', 'Daniel', 'Lim', 'danlim@MIT.EDU', '617-452-2443', 'MIT Cancer Center', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (384, 2, '2003-10-31 00:00:00', 'Michael', 'Yaffe', 'myaffe@mit.edu', '617-452-2103', 'MIT Cancer Center', 'PI', NULL, NULL, NULL, '80457448');
INSERT INTO screensaver_user VALUES (4, 11, '2004-02-12 00:00:00', 'Don', 'Coen', 'donald_coen@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (309, 5, '2004-01-29 00:00:00', 'Allen', 'Dodson', 'dodson@fas.harvard.edu', '617-432-1789', NULL, NULL, NULL, NULL, NULL, '405730540');
INSERT INTO screensaver_user VALUES (506, 5, '2003-04-04 00:00:00', 'Can (Rick)', 'Cui', 'can_cui@student.hms.harvard.edu', '617-432-0324', 'SGM 309', '2-4-04 Requested SR access again for access to plate reader for follow-up work. Not planning HTS work.', NULL, NULL, NULL, '50536122');
INSERT INTO screensaver_user VALUES (195, 5, '2003-05-28 00:00:00', 'Arianna', 'Loregian', 'arianna.loregian@unipd.it', '(617) 432 1789', NULL, 'Arianna left the Coen lab in the spring of 2004 to return  to her position in Italy. Her email address was updated on 4-22-04.', NULL, NULL, NULL, '60571430');
INSERT INTO screensaver_user VALUES (231, 2, '2004-07-07 00:00:00', 'Salomon', 'Amar', 'samar@bu.edu', '617-638-4983', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (104, 3, '2002-04-16 00:00:00', 'Marci', 'Surpin', 'msurpin@pop.ucr.edu', '909-787-2152', NULL, 'data folder=data6', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (60, 6, '2004-02-12 00:00:00', 'Natasha', 'Raikhel', 'nraikhel@citrus.ucr.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (59, 3, '2002-05-14 00:00:00', 'Jan', 'Zouhar', 'Jan.Zouhar@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (706, 3, '2003-06-18 00:00:00', 'Mien', 'Van de Ven', 'mien@citrus.ucr.edu', '909-787-2486', NULL, 'nraikhel@citrus.ucr.edu909-787-6370', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (313, 1, '2004-07-06 00:00:00', 'Michael', 'Detmar', 'michael.detmar@cbrc2.mgh.harvard.edu', '617-724-1170', 'Department of Dermatology, MGH', 'Never initiated this screen (obtained a position and left MGH shortly after filing the application).', NULL, NULL, NULL, '80423136');
INSERT INTO screensaver_user VALUES (529, 1, '2003-10-09 00:00:00', 'Hanna', 'Radomska', 'hradomsk@bidmc.harvard.edu', '617-667-4298', NULL, 'Will use Susumu''s server acc''t.', NULL, NULL, NULL, '50443884');
INSERT INTO screensaver_user VALUES (103, 3, '2004-02-12 00:00:00', 'Daniel', 'Tenen', 'dtenen@bidmc.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '30084853');
INSERT INTO screensaver_user VALUES (522, 4, '2003-06-11 00:00:00', 'Becky', 'Lynch', 'rebecca_lynch@dfci.harvard.edu', '617-632-4853', NULL, 'Will give us Harvard ID number when she gets the ID.David A. Frank, M.D., Ph.D.Department of Medical OncologyDana-Farber Cancer InstituteAssistant Professor of MedicineHarvard Medical SchoolMayer 522B44 Binney St.Boston, MA 02115tel: 617-632-4714fax: 617-632-6356e-mail: david_frank@dfci.harvard.edu', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (363, 7, '2004-02-12 00:00:00', 'David', 'Frank', 'david_frank@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '80362366');
INSERT INTO screensaver_user VALUES (362, 4, '2005-10-27 00:00:00', 'Erik', 'Nelson', 'erik_nelson@dfci.harvard.edu', '617-632-4717', NULL, NULL, NULL, NULL, NULL, '80513321');
INSERT INTO screensaver_user VALUES (294, 2, '2005-01-11 00:00:00', 'Kenneth', 'Kaye', 'kkaye@rics.bwh.harvard.edu', '617-525-4256', 'Channing Laboratory, Department of Medicine, BWH', 'NSRB screener', NULL, NULL, NULL, '60125406');
INSERT INTO screensaver_user VALUES (286, 2, '2002-11-19 00:00:00', 'Oliver', 'Rando', 'orando@cgr.harvard.edu', '617-384-9238', NULL, '11/02: Christina Yordan may carry out  most of the work for this screen.', NULL, NULL, NULL, '80381395');
INSERT INTO screensaver_user VALUES (636, 1, '2002-01-02 00:00:00', 'Spencer', 'Williams', 'spencerw@uclink.berkeley.edu', '(510) 643 8889', NULL, 'Dr Spencer J WilliamsBertozzi GroupChemistry DepartmentUC BerkeleyBerkeley, CAUSA 94720', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (147, 2, '2004-02-12 00:00:00', 'Carolyn', 'Bertozzi', 'bertozzi@cchem.berkeley.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (719, 2, '2004-07-06 00:00:00', 'Leslie', 'Matthews', 'leslie_matthews@dfci.harvard.edu', '617-632-4352', 'Cancer Immunology & AIDS, DFCI', '9/9/05 - Left DFCI July 2005. Wayne Marasco will have someone else continue her screens.', NULL, NULL, NULL, '506 0279 60');
INSERT INTO screensaver_user VALUES (596, 3, '2004-07-06 00:00:00', 'Wayne', 'Marasco', 'wayne_marasco@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10325528');
INSERT INTO screensaver_user VALUES (199, 5, '2003-03-14 00:00:00', 'Toshi', 'Taniguchi', 'toshiyasu_taniguchi@dfci.harvard.edu', '617-632-2083', NULL, '11/19/04 Toshi has moved to the Fred Hutchison Inst. in Seattle. Clark Chen has taken over screen # 272 and another D''Andrea postdoc will take over screen #412.', NULL, NULL, NULL, '905262000');
INSERT INTO screensaver_user VALUES (200, 10, '2004-02-12 00:00:00', 'Alan', 'D''Andrea', 'alan_dandrea@dfci.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '40086560');
INSERT INTO screensaver_user VALUES (582, 5, '2006-06-09 00:00:00', 'Richard', 'Kennedy', 'richard_kennedy@dfci.harvard.edu', '617-632-0712', '', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (443, 5, '2004-11-19 00:00:00', 'Clark', 'Chen', 'cchen1@partners.org', '617-632-5145', NULL, NULL, NULL, NULL, NULL, '604135413');
INSERT INTO screensaver_user VALUES (16, 1, '2006-10-05 00:00:00', 'Alejandro', 'Gutierrez', ' alejandro_gutierrez@dfci.harvard.edu', '617-642-7515', '', '', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (17, 2, '2006-10-05 00:00:00', 'A. Thomas', 'Look', 'thomas_look@dfci.harvard.edu', '617-632-5826', '', '', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (32, 1, '2005-08-19 00:00:00', 'Eric', 'Vimr', 'ervimr@uiuc.edu', '217-333-8502', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (521, 10, '2002-04-10 00:00:00', 'Yan', 'Feng', 'yan.feng@pharma.novartis.com', '432-2700', 'SGM 509', 'New email address at Novartis: yan.feng@pharma.novartis.com
Old email was: yan_feng@hms.harvard.edu', NULL, NULL, NULL, '60511152');
INSERT INTO screensaver_user VALUES (520, 8, '2002-05-01 00:00:00', 'Mei', 'Han', 'mei_han@hms.harvard.edu', '617-432-0072', 'SGM 509', NULL, NULL, NULL, NULL, '70571870');
INSERT INTO screensaver_user VALUES (658, 8, '2002-07-12 00:00:00', 'Chi', 'Zhang', 'czhang2@partners.org', NULL, 'SGM 509', 'Chi''s data folder is on data3', NULL, NULL, NULL, '70562669');
INSERT INTO screensaver_user VALUES (589, 3, '2002-01-24 00:00:00', 'Randy', 'Peterson', 'peterson@cvrc.mgh.harvard.edu', '617.726-6902', 'MGH Charlestown', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (412, 4, '2004-02-12 00:00:00', 'Mark', 'Fishman', 'mark.fishman@pharma.novartis.com', NULL, NULL, NULL, NULL, NULL, NULL, '90023594');
INSERT INTO screensaver_user VALUES (396, 6, '2005-03-07 00:00:00', 'Yoshihiro', 'Kawaoka', 'kawaokay@svm.vetmed.wisc.edu', '608-265-4925', NULL, 'NSRB screener', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (729, 1, '2004-07-06 00:00:00', 'Winfried', 'Weissenhorn', 'weissen@embl-grenoble.fr', '476-207-281', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (456, 1, '2002-01-30 00:00:00', 'Alexei', 'Kisselev', 'alexei_kisselev@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '60456801');
INSERT INTO screensaver_user VALUES (404, 3, '2004-02-12 00:00:00', 'Alfred', 'Goldberg', 'alfred_goldberg@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '40082344');
INSERT INTO screensaver_user VALUES (579, 1, '2004-07-06 00:00:00', 'Christiane', 'Kummer', 'ckummer@scripps.edu', '858-784-7121', NULL, 'phone number 858-822-6496', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (220, 2, '2004-07-06 00:00:00', 'Mark', 'Ginsberg', 'ginsberg@scripps.edu', '858-784-7124', NULL, 'Department of Cell Biology
10550 North Torrey Pines Road, VB-2
fax: 858-784-7343', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (248, 18, '2004-01-07 00:00:00', 'Jidong', 'Zhu', 'jidong_zhu@hms.harvard.edu', '617-432-3596', NULL, NULL, NULL, NULL, NULL, '50601498');
INSERT INTO screensaver_user VALUES (7, 35, '2004-02-12 00:00:00', 'Junying', 'Yuan', 'junying_yuan@hms.harvard.edu', '617-432-4170', NULL, NULL, NULL, NULL, NULL, '20214325');
INSERT INTO screensaver_user VALUES (213, 18, '2005-10-05 00:00:00', 'Tsuyoshi', 'Furuya', 'tsuyoshi_furuya@hms.harvard.edu', '617-432-1945', NULL, 'ecommons id tf21', NULL, NULL, NULL, '50646203');
INSERT INTO screensaver_user VALUES (614, 18, '2002-01-02 00:00:00', 'Mike', 'Boyce', 'boyce@fas.harvard.edu', '617-432-4188', 'HMS SGM-419', '9/30/06 - email is either not correct or no longer active - removing from active screening users list', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (73, 18, '2004-07-06 00:00:00', 'Mamoru', 'Shibata', 'mamoru_shibata@hms.harvard.edu', '617-432-4195', NULL, NULL, NULL, NULL, NULL, '10566495');
INSERT INTO screensaver_user VALUES (339, 18, '2006-03-10 00:00:00', 'Emily', 'Hsu', 'emily_hsu@hms.harvard.edu', '617-432-', NULL, 'Emily''s mentor in the  Yuan lab is Junichi Hitomi.', NULL, NULL, NULL, '70664224');
INSERT INTO screensaver_user VALUES (303, 18, '2006-10-16 00:00:00', 'Kai', 'Long', 'kai_long@hms.harvard.edu', '617-432-4188', '', '', NULL, NULL, NULL, '60684391');
INSERT INTO screensaver_user VALUES (269, 18, '2006-06-09 00:00:00', 'Junichi', 'Hitomi', 'junichi_hitomi@hms.harvard.edu', '', '', '', NULL, NULL, NULL, '50607399');
INSERT INTO screensaver_user VALUES (419, 18, '2006-09-15 00:00:00', 'Marta', 'Lipinski', 'marta_lipinski@hms.harvard.edu', '617-432-4195', '', '', NULL, NULL, NULL, '405696691');
INSERT INTO screensaver_user VALUES (239, 18, '2002-04-02 00:00:00', 'Alexei', 'Degterev', 'alexei_degterev@hms.harvard.edu', '2-4188', 'SGM-419', NULL, NULL, NULL, NULL, '304983800');
INSERT INTO screensaver_user VALUES (458, 18, '2003-01-30 00:00:00', 'Ivelisse', 'Sanchez', 'ivelisse_sanchez@hms.harvard.edu', '617-432-4172', 'SGM 419', 'Ivelisse will move to a professorship at the BU School of Medicine in Feb. 2003.', NULL, NULL, NULL, '10420598');
INSERT INTO screensaver_user VALUES (74, 11, '2003-06-30 00:00:00', 'Ryan', 'Van Wagoner', 'Ryan_VanWagoner@hms.harvard.edu', '617-432-2850', NULL, 'NTONE account in BCMP users.', NULL, NULL, NULL, '20585986');
INSERT INTO screensaver_user VALUES (75, 22, '2004-02-12 00:00:00', 'Jon', 'Clardy', 'jon_clardy@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '30511654');
INSERT INTO screensaver_user VALUES (145, 11, '2004-11-09 00:00:00', 'Rahmat', 'Bano', 'drreban@yahoo.com', '617-4325373', NULL, NULL, NULL, NULL, NULL, '10622670');
INSERT INTO screensaver_user VALUES (175, 11, '2004-08-31 00:00:00', 'Lauren', 'Junker', 'lauren_junker@hms.harvard.edu', NULL, NULL, '8-31-04: functional temporary email= lmj8@cornell.edu ', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (210, 11, '2004-02-02 00:00:00', 'Mary Lynn', 'Baniecki', 'marylynn_baniecki@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (645, 11, '2003-10-17 00:00:00', 'Derek', 'Martyn', 'derek_martyn@hms.harvard.edu', '617-432-3801', NULL, NULL, NULL, NULL, NULL, '506001650605');
INSERT INTO screensaver_user VALUES (551, 11, '2002-01-30 00:00:00', 'Jon', 'Hoyt', 'jhoyt@hms.harvard.edu', NULL, NULL, 'Jon Hoyt--Formerly in King Lab. Member of Mitchison lab as of June 1 2004. Carrying out RNAi screens in collaboration with the Perrimon lab. ', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (28, 33, '2002-06-14 00:00:00', 'Randy', 'King', 'randy_king@hms.harvard.edu', '617-432-3629', 'C2-666', NULL, NULL, NULL, NULL, '60425205');
INSERT INTO screensaver_user VALUES (695, 11, '2002-06-14 00:00:00', 'Noel', 'Peters', 'noel_peters@hms.harvard.edu', NULL, 'C2-666', NULL, NULL, NULL, NULL, '70506041');
INSERT INTO screensaver_user VALUES (545, 11, '2003-03-14 00:00:00', 'Rick', 'Gregory', 'richard_gregory@hms.harvard.edu', '617-432-4964', NULL, 'Former postdoc with Alan D''Andrea, initially a collaborator on screen #272. As of 9/04, a postdoc with Randy King. Rick is doing follow-up work on Jon Hoyt''s luciferase screen hits and doing an RNAi small screen.
9-05 Rick has left the King lab to run a group at Genzyme. It has not yet been determined who will take over his screens.', NULL, NULL, NULL, '805312730606');
INSERT INTO screensaver_user VALUES (525, 11, '2002-01-29 00:00:00', 'Qinghua', 'Shi', 'qinghua_shi@hms.harvard.edu', '2-4964', 'C-666', '7/1/04--may have left HMS.', NULL, NULL, NULL, '30569075');
INSERT INTO screensaver_user VALUES (494, 11, '2006-07-27 00:00:00', 'Qiqi', 'Cui', 'qiqi_cui@hms.harvard.edu', '617-432-4954', '', '', NULL, NULL, NULL, '506794540');
INSERT INTO screensaver_user VALUES (411, 11, '2002-12-19 00:00:00', 'Deanna', 'Mele', 'dmele705@hotmail.com', '617-432-4964', 'C-666', 'server on data3', NULL, NULL, NULL, '10586275');
INSERT INTO screensaver_user VALUES (105, 11, '2003-04-01 00:00:00', 'Nathaniel', 'Hathaway', 'nathaniel_hathaway@student.hms.harvard.edu', NULL, 'SGM 666', NULL, NULL, NULL, NULL, '505552080');
INSERT INTO screensaver_user VALUES (159, 1, '2004-07-22 00:00:00', 'Cindy', 'Roy', 'croy@enders.tch.harvard.edu', '617-919-2117', NULL, NULL, NULL, NULL, NULL, '20541636');
INSERT INTO screensaver_user VALUES (160, 3, '2004-07-22 00:00:00', 'Nancy', 'Andrews', 'nancy_andrews@hms.harvard.edu', '617-919-2116', NULL, NULL, NULL, NULL, NULL, '50203387');
INSERT INTO screensaver_user VALUES (253, 3, '2002-01-02 00:00:00', 'Julia', 'Lamenzo', 'jlamenzo@hms.harvard.edu', '617-432-3938', 'HMS SGM-620', NULL, NULL, NULL, NULL, '50405079');
INSERT INTO screensaver_user VALUES (254, 4, '2004-02-12 00:00:00', 'Paul', 'Clemons', 'paul_clemons@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '30449347');
INSERT INTO screensaver_user VALUES (164, 6, '2002-01-24 00:00:00', 'Stephen', 'DeWall', 'dewall@crystal.harvard.edu', '617.355-5249', 'Children''s Hospital', NULL, NULL, NULL, NULL, '805340190');
INSERT INTO screensaver_user VALUES (165, 11, '2004-02-12 00:00:00', 'Stephen', 'Harrison', 'schadmin@crystal.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10023025');
INSERT INTO screensaver_user VALUES (631, 6, '2006-07-18 00:00:00', 'Aaron', 'Schmidt', 'aaron_schmidt@hms.harvard.edu', '617-432-5604', '', 'NSRB screener', NULL, NULL, NULL, '20636440');
INSERT INTO screensaver_user VALUES (463, 6, '2002-02-08 00:00:00', 'Gary', 'Frey', 'frey@xtal200.harvard.edu', NULL, NULL, 'Data folder on data2.', NULL, NULL, NULL, '905325450');
INSERT INTO screensaver_user VALUES (663, 6, '2006-03-16 00:00:00', 'Jeff', 'Cruzan', 'cruzan@crystal.harvard.edu', '617-432-5604', NULL, 'NSRB', NULL, NULL, NULL, '90480790');
INSERT INTO screensaver_user VALUES (36, 1, '2004-07-06 00:00:00', 'Jerry', 'Pelletier', 'jerry.pelletier@mcgill.ca', '514-398-2323', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (502, 4, '2006-05-09 00:00:00', 'Justin Jang Hann', 'Chu', 'janghann_chu@hms.harvard.edu', '617-432-5612', '', '5/9/06-using Microscopes and requested by Melody to be added as a user and have access to microscope room. -KS ', NULL, NULL, NULL, '80664605');
INSERT INTO screensaver_user VALUES (268, 7, '2005-01-11 00:00:00', 'Priscilla', 'Yang', 'priscilla_yang@hms.harvard.edu', '617-432-5415', 'Armenise 641', 'NSRB screener for most screens (but not all).', NULL, NULL, NULL, '106028310');
INSERT INTO screensaver_user VALUES (697, 4, '2005-01-11 00:00:00', 'Jessica', 'Masse', 'jessica_masse@hms.harvard.edu', '617-432-5415', 'Armenise 641', 'NSRB screener', NULL, NULL, NULL, '10624827');
INSERT INTO screensaver_user VALUES (121, 2, '2006-02-07 00:00:00', 'Robert', 'Husson', 'robert.husson@childrens.harvard.edu', '617-919-2883', NULL, 'NSRB screener', NULL, NULL, NULL, '60025843');
INSERT INTO screensaver_user VALUES (670, 5, '2004-10-21 00:00:00', 'Carolyn', 'Robinson', 'carolyn_robinson@hms.harvard.edu', '617-432-4953', NULL, NULL, NULL, NULL, NULL, '40596771');
INSERT INTO screensaver_user VALUES (117, 13, '2004-02-12 00:00:00', 'Marc', 'Kirschner', 'marc@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '90412388');
INSERT INTO screensaver_user VALUES (167, 5, '2002-02-08 00:00:00', 'Danielle', 'Margalit', 'Danielle.Margalit@has.missing.email', NULL, 'SGM 610', 'screen continued by Alan Hebert as of 7/1/01.', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (356, 5, '2002-01-02 00:00:00', 'Susannah', 'Rankin', 'susannah_rankin@hms.harvard.edu', '617-432-2293', 'HMS C1-502', 'Jan ''02 collaborator: Rachel Legmann, Ph.D Research scientist Harvard Medical School Department of Microbiology & Molecular Genetics 200 longwood Ave, Boston, MA 02115 Tel:617-432 1931 (lab) email:rlegmann@hms.harvard.edu 
NSRB screener', NULL, NULL, NULL, '80446055');
INSERT INTO screensaver_user VALUES (492, 5, '2002-01-24 00:00:00', 'Alan', 'Hebert', 'alan_hebert@hms.harvard.edu', '617.432-3708', 'Room #610 Seeley Mudd Bldg.', 'D. RayChaudhuri Dept. of Microbiol. & Mol. Biol.Tufts Medical School Boston, MA 02111 Ph (617) 636-6753 Fax (617) 636-0337 ', NULL, NULL, NULL, '105658040');
INSERT INTO screensaver_user VALUES (116, 5, '2002-01-30 00:00:00', 'Jeffrey', 'Peterson', 'Jeffrey.Peterson@fccc.edu', NULL, NULL, 'Moved to Fox Chase Cancer Center 2004.
Jeff Peterson, Ph.D.
Associate Member, Tumor Cell Biology
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA  19111

Phone: (215) 728-3568
Fax: (215) 728-3574
Email: Jeffrey.Peterson@fccc.edu', NULL, NULL, NULL, '10494494');
INSERT INTO screensaver_user VALUES (94, 8, '2003-07-07 00:00:00', 'Sean', 'Whelan', 'swhelan@hms.harvard.edu', '617-432-1923', '', 'NSRB screener
7/27/06 - at the time Sean''s record was created in 7/03, he mentioned that Adam Schmucker would be working on screens in his lab. A record (user #313) was created for Adam Schmucker containing only his name. Adam never visited our screening room, and is not associated with any screen. User #313 was deleted from the database on this day.', NULL, NULL, NULL, '40565647');
INSERT INTO screensaver_user VALUES (93, 3, '2006-07-27 00:00:00', 'Rebeca', 'Burdeinick-Kerr', 'rebeca_burdeinick-kerr@hms.harvard.edu', '617-432-1927', '', '', NULL, NULL, NULL, '60678960');
INSERT INTO screensaver_user VALUES (654, 7, '2006-07-24 00:00:00', 'Joseph', 'Mougous', 'Joseph_Mougous@hms.harvard.edu', '617-432-1937', '', 'Joseph will be piloting screening assays directed towards identifying inhibitors of a kinase known to regulate type III secretion in Pseudomonas.  It is currently not clear whether this will be an ICCB-L or an NSRB screen.  No application has been filed yet.', NULL, NULL, NULL, '20633913');
INSERT INTO screensaver_user VALUES (138, 14, '2004-02-12 00:00:00', 'John', 'Mekalanos', 'jmekalanos@hms.harvard.edu', '617-432-1935', 'Armenise 4th floor', NULL, NULL, NULL, NULL, '70161001');
INSERT INTO screensaver_user VALUES (137, 7, '2002-05-02 00:00:00', 'Deb', 'Hung', 'dhung@partners.org', '617-432-0832', 'D1-408', 'Has both NSRB and ICCB screens.', NULL, NULL, NULL, '80260458');
INSERT INTO screensaver_user VALUES (468, 3, '2006-02-28 00:00:00', 'Erol', 'Fikrig', 'erol.fikrig@yale.edu', '203-785-2453', '', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (370, 14, '2004-02-12 00:00:00', 'Tomas', 'Kirchhausen', 'kirchhausen@crystal.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '90164252');
INSERT INTO screensaver_user VALUES (369, 8, '2002-02-19 00:00:00', 'Thomas', 'Nieland', 'nieland@cbr.med.harvard.edu', NULL, NULL, 'Monty KriegerBiology Department MIT Room 68-483 77 Massachusetts Ave Cambridge, MA 02139 Tel.:   617-253-6793 Fax:    617-258-5851 EM:  Krieger@MIT.edu', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (703, 8, '2002-01-24 00:00:00', 'Rene', 'Maehr', 'maehr@cbr.med.harvard.edu', '278-3224', NULL, NULL, NULL, NULL, NULL, '50543943');
INSERT INTO screensaver_user VALUES (661, 8, '2002-04-09 00:00:00', 'Eric', 'Macia', 'macia@cbr.med.harvard.edu', '617-278-3210', 'Alpert  #128', 'Data folder in data6.Taking over screen from Chris Brunner, effective immediately. ', NULL, NULL, NULL, '80569440');
INSERT INTO screensaver_user VALUES (430, 8, '2002-01-24 00:00:00', 'Christian', 'Brunner', 'Brunner@cbr.med.harvard.edu', '278-3147', 'WAB Room 128', 'Left Kirchhausen lab and this screen 3/02.  Screen continued by Eric Macia.', NULL, NULL, NULL, '60510105');
INSERT INTO screensaver_user VALUES (476, 8, '2002-02-14 00:00:00', 'Ramiro', 'Massol', 'massol@cbr.med.harvard.edu', '617-278-3210', 'WAB-128', NULL, NULL, NULL, NULL, '60552592');
INSERT INTO screensaver_user VALUES (131, 42, '2002-01-24 00:00:00', 'Makoto', 'Kinoshita', 'makoto_kinoshita@hms.harvard.edu', '617.432-3728', 'SGM 529', NULL, NULL, NULL, NULL, '40532390');
INSERT INTO screensaver_user VALUES (31, 69, '2004-02-12 00:00:00', 'Timothy', 'Mitchison', 'timothy_mitchison@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '80464150');
INSERT INTO screensaver_user VALUES (671, 42, '2002-02-22 00:00:00', 'Michelle', 'Pflumm', 'michelle_pflumm@hms.harvard.edu', '617-432-3035', 'ICCB', NULL, NULL, NULL, NULL, '405670890');
INSERT INTO screensaver_user VALUES (559, 42, '2003-03-19 00:00:00', 'Zoltan', 'Maliga', 'maliga@fas.harvard.edu; zoltan.maliga@gmail.com', '617-432-4953', NULL, NULL, NULL, NULL, NULL, '40488227');
INSERT INTO screensaver_user VALUES (209, 42, '2002-02-22 00:00:00', 'Justin', 'Yarrow', 'justin_yarrow@hms.harvard.edu', NULL, 'ICCB SGM 509', NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (161, 42, '2002-01-30 00:00:00', 'Katrina', 'Schulberg', 'kschulberg@hms.harvard.edu', '', 'SGM 613', '', NULL, NULL, NULL, '50554171');
INSERT INTO screensaver_user VALUES (449, 42, '2002-04-10 00:00:00', 'Zach', 'Perlman', 'zperlman@fas.harvard.edu', '617-432-3804', 'SGM 5th floor', NULL, NULL, NULL, NULL, '105005911');
INSERT INTO screensaver_user VALUES (711, 42, '2002-02-15 00:00:00', 'Thomas', 'Mayer', ' mayer@biochem.mpg.de', NULL, 'ICCB', 'Left the ICCB to start own lab in Munich 12/01. New contact info:Thomas U. Mayer Max Planck Institute for Biochemistry Dept. of Cell Biology Am Klopferspitz 18a 82152 Munich Phone: + 49 89 8578 3145 Fax: 	 + 49 89 8578 3138 E-mail: mayer@biochem.mpg.de', NULL, NULL, NULL, '80509782');
INSERT INTO screensaver_user VALUES (609, 42, '2002-03-26 00:00:00', 'Shahla', 'Movahedi', 'shahla_movahedi@hms.harvard.edu', '432-0076', 'SGM 508', NULL, NULL, NULL, NULL, '604472331');
INSERT INTO screensaver_user VALUES (674, 42, '2002-12-13 00:00:00', 'Nicky', 'Tolliday', 'nicola_tolliday@hms.harvard.edu', '617-432-2701', 'SGM610', NULL, NULL, NULL, NULL, '10483581');
INSERT INTO screensaver_user VALUES (679, 42, '2003-05-30 00:00:00', 'Maria', 'Wigger', 'unknn@hms.edu', NULL, NULL, 'Maria left the ICCB in January 2001.', NULL, NULL, NULL, '20515767');
INSERT INTO screensaver_user VALUES (668, 42, '2002-01-02 00:00:00', 'Byung-Hyune', 'Choi', 'bchoi@hms.harvard.edu', '617-432-0072', 'HMS SGM 509', NULL, NULL, NULL, NULL, '60534616');
INSERT INTO screensaver_user VALUES (548, 42, '2005-09-28 00:00:00', 'Melody', 'Tsui', 'melody_tsui@hms.harvard.edu', NULL, NULL, 'Cell phone number: 215-888-1855 ', NULL, NULL, NULL, '60653992');
INSERT INTO screensaver_user VALUES (30, 42, '2003-04-22 00:00:00', 'Aaron', 'Straight', 'Aaron.Straight@has.missing.email', NULL, NULL, NULL, NULL, NULL, NULL, '90493221');
INSERT INTO screensaver_user VALUES (445, 42, '2003-04-22 00:00:00', 'Guillaume', 'Charras', 'gcharras@hms.harvard.edu', '617-432-3724', NULL, NULL, NULL, NULL, NULL, '20570180');
INSERT INTO screensaver_user VALUES (91, 42, '2006-05-05 00:00:00', 'Katharina', 'Ribbeck', 'katharina_ribbeck@hms.harvard.edu', '617-432-3724', '', 'ecommons KR29', NULL, NULL, NULL, '90664379');
INSERT INTO screensaver_user VALUES (432, 3, '2003-09-04 00:00:00', 'Arminja', 'Kettenbach', 'arminja_kettenbach@hms.harvard.edu', '617-432-3949', 'SGM 408', NULL, NULL, NULL, NULL, '105474311');
INSERT INTO screensaver_user VALUES (5, 8, '2004-02-12 00:00:00', 'Frank', 'McKeon', 'Frank_McKeon@hms.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '90298801');
INSERT INTO screensaver_user VALUES (630, 3, '2002-01-24 00:00:00', 'Venkatesh', 'Natarajan', 'venkatesh_natarajan@hms.harvard.edu', '617.432-3948', 'SGM #608', 'Using F. McKeon server account', NULL, NULL, NULL, '90545574');
INSERT INTO screensaver_user VALUES (473, 8, '2004-07-06 00:00:00', 'Jill', 'DeJong', 'jill_de_jong@dfci.harvard.edu', '617-730-0222', NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (133, 16, '2004-02-12 00:00:00', 'Leonard', 'Zon', 'zon@rascal.med.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10240603');
INSERT INTO screensaver_user VALUES (265, 8, '2005-03-04 00:00:00', 'Kim', 'Dooley', 'dooley@enders.tch.harvard.edu', '617-919-2074', NULL, NULL, NULL, NULL, NULL, '70517256');
INSERT INTO screensaver_user VALUES (669, 8, '2004-06-02 00:00:00', 'Nelson', 'Hsia', 'nhsia@enders.tch.harvard.edu', '617-355-7273', NULL, NULL, NULL, NULL, NULL, '70589605');
INSERT INTO screensaver_user VALUES (314, 8, '2002-01-02 00:00:00', 'Howard', 'Stern', 'hstern@partners.org', '617-355-7014', 'Children''s Enders-650', NULL, NULL, NULL, NULL, '70506513');
INSERT INTO screensaver_user VALUES (132, 8, '2004-07-06 00:00:00', 'Paula', 'Fraenkel', 'pfraenkel@bidmc.harvard.edu', '617-667-2131', NULL, NULL, NULL, NULL, NULL, '30311922');
INSERT INTO screensaver_user VALUES (453, 8, '2004-02-11 00:00:00', 'Trista', 'North', 'tenorth@enders.tch.harvard.edu', '617-919-2077', NULL, NULL, NULL, NULL, NULL, '805708800');
INSERT INTO screensaver_user VALUES (513, 3, '2004-07-07 00:00:00', 'Hans', 'Clevers', 'clevers@niob.knaw.nl', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (282, 34, '2002-01-02 00:00:00', 'Bridget', 'Wagner', 'wagner@slsiris.harvard.edu', '617-496-7039', 'Cambridge Converse 209', NULL, NULL, NULL, NULL, '10382653');
INSERT INTO screensaver_user VALUES (35, 51, '2004-02-12 00:00:00', 'Stuart', 'Schreiber', 'stuart_schreiber@harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (642, 34, '2003-04-01 00:00:00', 'Bill', 'Winston', 'Bill.Winston@has.missing.email', '', '', '', NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (416, 34, '2002-01-30 00:00:00', 'Rebecca', 'Butcher', 'butcher@fas.harvard.edu', '617-495-8393', NULL, NULL, NULL, NULL, NULL, '90451588');
INSERT INTO screensaver_user VALUES (557, 34, '2002-02-22 00:00:00', 'Jason', 'Wong', 'wong@slsiris.harvard.edu', '617-495-8393', NULL, NULL, NULL, NULL, NULL, '60613850');
INSERT INTO screensaver_user VALUES (568, 34, '2002-06-07 00:00:00', 'Aly', 'Shamji', 'shamji@slsiris.harvard.edu', '617-496-7039', NULL, 'data file on data6', NULL, NULL, NULL, '20485329');
INSERT INTO screensaver_user VALUES (681, 34, '2002-12-11 00:00:00', 'Ethan', 'Perlstein', 'perlst@fas.harvard.edu', '617-899-9901', NULL, 'Will share Schreiber lab copy of ICCB key for after hours access to labs.Has data from small-scale screens of compound plates in Schreiber lab. ', NULL, NULL, NULL, '40555323');
INSERT INTO screensaver_user VALUES (111, 34, '2004-09-02 00:00:00', 'Gopal', 'Ramachandran', 'gsr@mit.edu', '617-233-9930', NULL, 'Gopal is affiliated with the HST program at MIT and works there in Bonnie Berger''s lab.', NULL, NULL, NULL, '30591240');
INSERT INTO screensaver_user VALUES (433, 34, '2002-01-02 00:00:00', 'Stan', 'Shaw', 'shaw@slsiris.harvard.edu', '617-726-6902', 'MGH Charlestown (Fishman Lab)', NULL, NULL, NULL, NULL, '80244193');
INSERT INTO screensaver_user VALUES (712, 34, '2002-01-02 00:00:00', 'Bimal', 'Desai', 'bdesai@fas.harvard.edu', '617-495-8394', NULL, NULL, NULL, NULL, NULL, '30483308');
INSERT INTO screensaver_user VALUES (371, 34, '2002-05-09 00:00:00', 'Shyam', 'Krishnan', 'krishnan@slsiris.harvard.edu', '617-495-8393/94', 'Oxford St.', NULL, NULL, NULL, NULL, '105005830');
INSERT INTO screensaver_user VALUES (665, 34, '2002-02-06 00:00:00', 'Seung Bum', 'Park', 'sbpark@slsiris.harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO screensaver_user VALUES (288, 34, '2005-02-16 00:00:00', 'Jiong', 'Yang', 'jiong_yang@harvard.edu', NULL, NULL, NULL, NULL, NULL, NULL, '10662427');
INSERT INTO screensaver_user VALUES (700, 1, '2006-09-15 00:00:00', 'Stefan', 'Richter', 'stefan.richter@sbcglobal.net', '(773) 702-1640', 'The University of Chicago
920 East 58th Street
CLSC 607
Chicago, IL 60637', 'NSRB screener', NULL, NULL, NULL, '');
INSERT INTO screensaver_user VALUES (15, 4, '2006-09-15 00:00:00', 'Dominique', 'Missiakas', 'dmissiak@bsd.uchicago.edu', '(773) 834-8161', 'The University of Chicago
920 East 58th Street
CLSC Room 609A
Chicago, IL 60637', 'NSRB screener', NULL, NULL, NULL, '');


/* screensaver_user_role_type */

INSERT INTO screensaver_user_role_type VALUES (2, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (1, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (4, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (3, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (5, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (7, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (6, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (9, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (8, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (10, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (12, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (11, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (13, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (15, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (14, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (17, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (16, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (19, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (18, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (21, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (20, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (23, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (22, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (24, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (26, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (25, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (28, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (27, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (29, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (31, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (30, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (32, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (33, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (35, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (34, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (36, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (37, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (39, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (38, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (40, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (41, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (42, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (43, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (44, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (45, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (47, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (46, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (49, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (48, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (51, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (50, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (52, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (54, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (53, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (56, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (55, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (58, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (57, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (60, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (59, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (61, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (63, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (62, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (65, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (64, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (66, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (68, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (67, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (69, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (71, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (70, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (72, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (73, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (75, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (74, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (76, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (78, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (77, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (80, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (79, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (82, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (81, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (83, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (84, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (85, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (86, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (87, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (88, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (89, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (90, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (91, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (92, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (94, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (93, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (95, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (97, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (96, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (99, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (98, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (101, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (100, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (103, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (102, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (104, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (105, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (107, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (106, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (108, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (110, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (109, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (111, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (112, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (114, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (113, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (115, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (117, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (116, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (118, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (119, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (120, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (121, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (123, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (122, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (125, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (124, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (127, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (126, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (128, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (130, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (129, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (131, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (133, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (132, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (134, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (136, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (135, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (138, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (137, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (140, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (139, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (141, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (142, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (144, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (143, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (145, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (146, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (147, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (149, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (148, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (150, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (151, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (152, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (153, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (155, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (154, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (156, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (158, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (157, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (160, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (159, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (161, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (162, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (163, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (165, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (164, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (166, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (167, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (168, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (170, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (169, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (171, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (172, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (174, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (173, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (175, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (176, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (177, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (178, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (179, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (180, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (181, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (182, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (183, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (184, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (185, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (187, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (186, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (189, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (188, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (191, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (190, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (193, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (192, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (194, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (195, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (196, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (197, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (198, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (200, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (199, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (201, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (203, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (202, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (204, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (205, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (207, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (206, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (208, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (209, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (210, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (212, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (211, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (213, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (214, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (215, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (216, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (218, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (217, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (219, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (220, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (222, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (221, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (223, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (224, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (225, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (227, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (226, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (228, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (229, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (230, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (231, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (233, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (232, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (235, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (234, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (236, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (237, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (238, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (239, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (241, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (240, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (243, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (242, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (244, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (245, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (246, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (247, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (248, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (250, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (249, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (251, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (252, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (254, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (253, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (255, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (256, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (257, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (258, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (259, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (260, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (262, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (261, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (263, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (264, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (265, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (266, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (267, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (268, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (269, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (270, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (271, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (272, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (274, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (273, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (275, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (276, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (277, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (278, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (279, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (280, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (281, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (282, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (283, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (285, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (284, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (286, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (287, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (288, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (289, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (290, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (291, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (292, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (294, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (293, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (296, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (295, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (297, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (298, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (299, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (300, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (301, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (302, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (303, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (304, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (305, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (306, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (307, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (308, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (309, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (310, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (311, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (312, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (313, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (314, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (315, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (316, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (318, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (317, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (319, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (320, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (322, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (321, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (323, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (324, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (325, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (326, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (327, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (328, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (329, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (331, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (330, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (332, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (333, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (334, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (335, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (337, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (336, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (338, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (339, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (340, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (342, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (341, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (343, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (344, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (345, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (346, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (347, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (349, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (348, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (351, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (350, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (352, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (353, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (354, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (355, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (356, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (357, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (359, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (358, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (360, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (361, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (363, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (362, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (364, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (365, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (366, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (367, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (368, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (370, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (369, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (371, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (373, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (372, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (374, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (375, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (376, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (377, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (378, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (379, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (380, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (381, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (382, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (384, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (383, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (385, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (386, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (387, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (388, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (389, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (390, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (391, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (393, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (392, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (394, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (396, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (395, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (397, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (398, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (400, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (399, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (401, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (402, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (404, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (403, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (405, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (406, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (407, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (409, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (408, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (410, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (411, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (412, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (414, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (413, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (415, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (416, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (418, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (417, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (419, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (421, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (420, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (423, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (422, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (425, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (424, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (426, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (427, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (429, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (428, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (430, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (431, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (432, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (433, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (434, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (435, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (436, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (437, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (438, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (440, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (439, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (441, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (442, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (443, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (444, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (445, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (446, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (447, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (448, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (449, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (450, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (451, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (452, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (453, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (454, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (455, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (456, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (457, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (458, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (459, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (460, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (461, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (462, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (463, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (464, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (465, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (466, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (468, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (467, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (470, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (469, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (471, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (472, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (473, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (474, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (475, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (476, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (477, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (479, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (478, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (480, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (482, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (481, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (483, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (484, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (485, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (486, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (487, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (488, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (489, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (490, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (491, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (492, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (493, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (494, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (495, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (497, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (496, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (498, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (499, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (500, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (501, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (502, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (503, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (504, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (505, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (506, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (507, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (508, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (509, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (510, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (511, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (512, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (513, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (514, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (515, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (516, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (517, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (519, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (518, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (521, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (520, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (522, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (523, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (524, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (525, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (526, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (527, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (528, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (529, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (530, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (531, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (532, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (533, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (534, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (535, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (536, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (537, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (538, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (539, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (540, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (541, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (543, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (542, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (544, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (545, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (546, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (547, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (548, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (549, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (550, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (551, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (552, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (553, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (554, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (555, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (556, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (557, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (558, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (559, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (560, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (562, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (561, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (563, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (564, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (565, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (566, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (567, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (568, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (569, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (570, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (571, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (572, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (573, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (574, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (575, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (577, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (576, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (578, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (579, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (580, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (581, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (582, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (583, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (584, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (585, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (586, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (587, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (588, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (589, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (590, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (591, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (592, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (593, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (594, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (595, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (596, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (597, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (598, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (599, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (600, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (601, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (602, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (603, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (604, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (605, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (606, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (607, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (608, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (609, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (610, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (611, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (612, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (613, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (614, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (615, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (616, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (617, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (618, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (619, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (620, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (621, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (622, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (623, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (624, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (625, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (626, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (627, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (628, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (629, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (630, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (631, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (632, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (633, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (634, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (635, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (636, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (637, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (638, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (639, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (640, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (641, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (642, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (643, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (644, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (645, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (646, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (647, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (648, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (649, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (650, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (651, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (652, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (653, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (654, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (655, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (656, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (657, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (658, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (659, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (660, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (661, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (662, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (663, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (664, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (665, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (666, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (667, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (668, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (669, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (670, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (671, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (672, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (673, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (674, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (675, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (676, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (677, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (678, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (679, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (680, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (681, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (682, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (683, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (684, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (685, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (686, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (687, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (688, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (689, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (690, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (691, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (692, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (693, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (694, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (695, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (696, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (697, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (698, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (699, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (700, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (701, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (702, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (703, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (704, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (705, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (706, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (707, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (708, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (709, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (710, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (711, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (712, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (713, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (714, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (715, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (716, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (717, 'rnaiScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (718, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (719, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (720, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (721, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (722, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (723, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (724, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (725, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (726, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (727, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (728, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (729, 'compoundScreeningRoomUser');
INSERT INTO screensaver_user_role_type VALUES (730, 'compoundScreeningRoomUser');


/* turn off lab_head constraint for bulk load of screening_room_user table */

alter table screening_room_user drop constraint fk_screening_room_user_to_lab_head;


/* screening_room_user */

INSERT INTO screening_room_user VALUES (1, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (3, 'Graduate Student', false, 4, NULL);
INSERT INTO screening_room_user VALUES (6, 'Research Assistant', false, 7, NULL);
INSERT INTO screening_room_user VALUES (8, 'Research Assistant', false, 9, NULL);
INSERT INTO screening_room_user VALUES (14, 'Research Assistant', false, 15, NULL);
INSERT INTO screening_room_user VALUES (18, 'Research Assistant', false, 19, NULL);
INSERT INTO screening_room_user VALUES (20, 'Postdoc', false, 21, NULL);
INSERT INTO screening_room_user VALUES (22, 'Graduate Student', false, 23, NULL);
INSERT INTO screening_room_user VALUES (25, 'Postdoc', false, 26, NULL);
INSERT INTO screening_room_user VALUES (27, 'Graduate Student', false, 28, NULL);
INSERT INTO screening_room_user VALUES (33, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (34, 'ICCB Fellow', false, 35, NULL);
INSERT INTO screening_room_user VALUES (37, 'Graduate Student', false, 19, NULL);
INSERT INTO screening_room_user VALUES (38, 'Postdoc', false, 39, NULL);
INSERT INTO screening_room_user VALUES (41, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (43, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (48, 'Unassigned', false, 49, NULL);
INSERT INTO screening_room_user VALUES (50, 'Unassigned', false, 51, NULL);
INSERT INTO screening_room_user VALUES (53, 'Postdoc', false, 54, NULL);
INSERT INTO screening_room_user VALUES (55, 'Postdoc', false, 56, NULL);
INSERT INTO screening_room_user VALUES (57, 'Postdoc', false, 58, NULL);
INSERT INTO screening_room_user VALUES (62, 'Research Assistant', false, 63, NULL);
INSERT INTO screening_room_user VALUES (64, 'Graduate Student', false, 65, NULL);
INSERT INTO screening_room_user VALUES (67, 'Postdoc', false, 68, NULL);
INSERT INTO screening_room_user VALUES (79, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (81, 'Research Assistant', false, 82, NULL);
INSERT INTO screening_room_user VALUES (86, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (87, 'Graduate Student', false, 65, NULL);
INSERT INTO screening_room_user VALUES (88, 'Postdoc', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (90, 'Graduate Student', false, 49, NULL);
INSERT INTO screening_room_user VALUES (100, 'Unassigned', false, 101, NULL);
INSERT INTO screening_room_user VALUES (102, 'Postdoc', false, 103, NULL);
INSERT INTO screening_room_user VALUES (106, 'Graduate Student', false, 107, NULL);
INSERT INTO screening_room_user VALUES (109, 'Postdoc', false, 110, NULL);
INSERT INTO screening_room_user VALUES (112, 'Unassigned', false, 9, NULL);
INSERT INTO screening_room_user VALUES (118, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (119, 'Graduate Student', false, 94, NULL);
INSERT INTO screening_room_user VALUES (122, 'Postdoc', false, 123, NULL);
INSERT INTO screening_room_user VALUES (124, 'Unassigned', false, 125, NULL);
INSERT INTO screening_room_user VALUES (128, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (129, 'Postdoc', false, 130, NULL);
INSERT INTO screening_room_user VALUES (135, 'Unassigned', false, 136, NULL);
INSERT INTO screening_room_user VALUES (139, 'Postdoc', false, 140, NULL);
INSERT INTO screening_room_user VALUES (141, 'Unassigned', false, 65, NULL);
INSERT INTO screening_room_user VALUES (142, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (143, 'Postdoc', false, 144, NULL);
INSERT INTO screening_room_user VALUES (146, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (152, 'Unassigned', false, 4, NULL);
INSERT INTO screening_room_user VALUES (156, 'Research Assistant', false, 9, NULL);
INSERT INTO screening_room_user VALUES (162, 'Unassigned', false, 7, NULL);
INSERT INTO screening_room_user VALUES (163, 'Postdoc', false, 83, NULL);
INSERT INTO screening_room_user VALUES (168, 'Research Assistant', false, 28, NULL);
INSERT INTO screening_room_user VALUES (171, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (172, 'Postdoc', false, 24, NULL);
INSERT INTO screening_room_user VALUES (177, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (178, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (179, 'Graduate Student', false, 51, NULL);
INSERT INTO screening_room_user VALUES (180, 'Unassigned', false, 165, NULL);
INSERT INTO screening_room_user VALUES (185, 'Unassigned', false, 12, NULL);
INSERT INTO screening_room_user VALUES (186, 'Research Assistant', false, 187, NULL);
INSERT INTO screening_room_user VALUES (188, 'Research Assistant', false, 189, NULL);
INSERT INTO screening_room_user VALUES (190, 'Graduate Student', false, 191, NULL);
INSERT INTO screening_room_user VALUES (198, 'Graduate Student', false, 170, NULL);
INSERT INTO screening_room_user VALUES (201, 'Research Assistant', false, 200, NULL);
INSERT INTO screening_room_user VALUES (205, 'Research Assistant', false, 76, NULL);
INSERT INTO screening_room_user VALUES (206, 'Postdoc', false, 207, NULL);
INSERT INTO screening_room_user VALUES (208, 'Postdoc', false, 138, NULL);
INSERT INTO screening_room_user VALUES (211, 'Postdoc', false, 212, NULL);
INSERT INTO screening_room_user VALUES (214, 'Graduate Student', false, 123, NULL);
INSERT INTO screening_room_user VALUES (221, 'Postdoc', false, 222, NULL);
INSERT INTO screening_room_user VALUES (223, 'Postdoc', false, 123, NULL);
INSERT INTO screening_room_user VALUES (228, 'Postdoc', false, 151, NULL);
INSERT INTO screening_room_user VALUES (229, 'Graduate Student', false, 31, NULL);
INSERT INTO screening_room_user VALUES (230, 'Research Assistant', false, 31, NULL);
INSERT INTO screening_room_user VALUES (232, 'Postdoc', false, 233, NULL);
INSERT INTO screening_room_user VALUES (236, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (240, 'Unassigned', false, 241, NULL);
INSERT INTO screening_room_user VALUES (244, 'Postdoc', false, 114, NULL);
INSERT INTO screening_room_user VALUES (245, 'Postdoc', false, 133, NULL);
INSERT INTO screening_room_user VALUES (247, 'Research Assistant', false, 28, NULL);
INSERT INTO screening_room_user VALUES (255, 'Postdoc', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (256, 'Postdoc', false, 151, NULL);
INSERT INTO screening_room_user VALUES (257, 'Unassigned', false, 231, NULL);
INSERT INTO screening_room_user VALUES (259, 'Graduate Student', false, 28, NULL);
INSERT INTO screening_room_user VALUES (263, 'Research Assistant', false, 204, NULL);
INSERT INTO screening_room_user VALUES (266, 'Graduate Student', false, 225, NULL);
INSERT INTO screening_room_user VALUES (270, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (271, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (272, 'Postdoc', false, 170, NULL);
INSERT INTO screening_room_user VALUES (273, 'Unassigned', false, 274, NULL);
INSERT INTO screening_room_user VALUES (275, 'Graduate Student', false, 31, NULL);
INSERT INTO screening_room_user VALUES (277, 'Graduate Student', false, 191, NULL);
INSERT INTO screening_room_user VALUES (280, 'Unassigned', false, 9, NULL);
INSERT INTO screening_room_user VALUES (281, 'Graduate Student', false, 75, NULL);
INSERT INTO screening_room_user VALUES (283, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (287, 'Postdoc', false, 235, NULL);
INSERT INTO screening_room_user VALUES (289, 'Postdoc', false, 83, NULL);
INSERT INTO screening_room_user VALUES (290, 'Unassigned', false, 7, NULL);
INSERT INTO screening_room_user VALUES (292, 'Postdoc', false, 39, NULL);
INSERT INTO screening_room_user VALUES (293, 'Postdoc', false, 294, NULL);
INSERT INTO screening_room_user VALUES (297, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (298, 'Graduate Student', false, 7, NULL);
INSERT INTO screening_room_user VALUES (299, 'Graduate Student', false, 260, NULL);
INSERT INTO screening_room_user VALUES (301, 'Unassigned', false, 7, NULL);
INSERT INTO screening_room_user VALUES (305, 'Unassigned', false, 92, NULL);
INSERT INTO screening_room_user VALUES (307, 'Postdoc', false, 260, NULL);
INSERT INTO screening_room_user VALUES (308, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (310, 'Postdoc', false, 182, NULL);
INSERT INTO screening_room_user VALUES (312, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (315, 'Postdoc', false, 120, NULL);
INSERT INTO screening_room_user VALUES (120, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (317, 'Research Assistant', false, 318, NULL);
INSERT INTO screening_room_user VALUES (319, 'Other', false, 31, NULL);
INSERT INTO screening_room_user VALUES (321, 'Unassigned', false, 322, NULL);
INSERT INTO screening_room_user VALUES (324, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (325, 'Unassigned', false, 19, NULL);
INSERT INTO screening_room_user VALUES (327, 'Research Assistant', false, 117, NULL);
INSERT INTO screening_room_user VALUES (328, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (329, 'Graduate Student', false, 9, NULL);
INSERT INTO screening_room_user VALUES (332, 'Postdoc', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (333, 'Unassigned', false, 80, NULL);
INSERT INTO screening_room_user VALUES (334, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (336, 'Postdoc', false, 337, NULL);
INSERT INTO screening_room_user VALUES (338, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (341, 'Research Assistant', false, 342, NULL);
INSERT INTO screening_room_user VALUES (344, 'Research Assistant', false, 2, NULL);
INSERT INTO screening_room_user VALUES (346, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (348, 'Research Assistant', false, 349, NULL);
INSERT INTO screening_room_user VALUES (353, 'Graduate Student', false, 207, NULL);
INSERT INTO screening_room_user VALUES (355, 'Graduate Student', false, 123, NULL);
INSERT INTO screening_room_user VALUES (357, 'Unassigned', false, 352, NULL);
INSERT INTO screening_room_user VALUES (358, 'Postdoc', false, 359, NULL);
INSERT INTO screening_room_user VALUES (360, 'Postdoc', false, 108, NULL);
INSERT INTO screening_room_user VALUES (108, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (364, 'Postdoc', false, 35, NULL);
INSERT INTO screening_room_user VALUES (365, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (366, 'Postdoc', false, 51, NULL);
INSERT INTO screening_room_user VALUES (368, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (372, 'Research Assistant', false, 373, NULL);
INSERT INTO screening_room_user VALUES (374, 'Graduate Student', false, 94, NULL);
INSERT INTO screening_room_user VALUES (376, 'Postdoc', false, 311, NULL);
INSERT INTO screening_room_user VALUES (377, 'Research Assistant', false, 76, NULL);
INSERT INTO screening_room_user VALUES (379, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (380, 'Research Assistant', false, 94, NULL);
INSERT INTO screening_room_user VALUES (386, 'Postdoc', false, 65, NULL);
INSERT INTO screening_room_user VALUES (387, 'Graduate Student', false, 274, NULL);
INSERT INTO screening_room_user VALUES (389, 'Unassigned', false, 83, NULL);
INSERT INTO screening_room_user VALUES (390, 'Postdoc', false, 5, NULL);
INSERT INTO screening_room_user VALUES (391, 'Postdoc', false, 99, NULL);
INSERT INTO screening_room_user VALUES (392, 'Postdoc', false, 393, NULL);
INSERT INTO screening_room_user VALUES (395, 'Graduate Student', false, 396, NULL);
INSERT INTO screening_room_user VALUES (401, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (403, 'Postdoc', false, 404, NULL);
INSERT INTO screening_room_user VALUES (408, 'Postdoc', false, 409, NULL);
INSERT INTO screening_room_user VALUES (189, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (410, 'Postdoc', false, 42, NULL);
INSERT INTO screening_room_user VALUES (415, 'Graduate Student', false, 75, NULL);
INSERT INTO screening_room_user VALUES (417, 'Postdoc', false, 418, NULL);
INSERT INTO screening_room_user VALUES (422, 'Research Assistant', false, 423, NULL);
INSERT INTO screening_room_user VALUES (424, 'Research Assistant', false, 425, NULL);
INSERT INTO screening_room_user VALUES (428, 'Postdoc', false, 429, NULL);
INSERT INTO screening_room_user VALUES (431, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (435, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (23, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (436, 'Unassigned', false, 125, NULL);
INSERT INTO screening_room_user VALUES (437, 'Research Assistant', false, 28, NULL);
INSERT INTO screening_room_user VALUES (438, 'Research Assistant', false, 26, NULL);
INSERT INTO screening_room_user VALUES (442, 'Postdoc', false, 63, NULL);
INSERT INTO screening_room_user VALUES (447, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (448, 'Unassigned', false, 274, NULL);
INSERT INTO screening_room_user VALUES (450, 'Research Assistant', false, 222, NULL);
INSERT INTO screening_room_user VALUES (452, 'Graduate Student', false, 268, NULL);
INSERT INTO screening_room_user VALUES (454, 'Graduate Student', false, 170, NULL);
INSERT INTO screening_room_user VALUES (455, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (457, 'Postdoc', false, 99, NULL);
INSERT INTO screening_room_user VALUES (461, 'Graduate Student', false, 2, NULL);
INSERT INTO screening_room_user VALUES (462, 'Postdoc', false, 207, NULL);
INSERT INTO screening_room_user VALUES (464, 'Postdoc', false, 160, NULL);
INSERT INTO screening_room_user VALUES (465, 'Graduate Student', false, 170, NULL);
INSERT INTO screening_room_user VALUES (466, 'Postdoc', false, 117, NULL);
INSERT INTO screening_room_user VALUES (467, 'Postdoc', false, 468, NULL);
INSERT INTO screening_room_user VALUES (471, 'Research Assistant', false, 42, NULL);
INSERT INTO screening_room_user VALUES (472, 'Postdoc', false, 260, NULL);
INSERT INTO screening_room_user VALUES (474, 'Postdoc', false, 66, NULL);
INSERT INTO screening_room_user VALUES (66, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (475, 'Unassigned', false, 5, NULL);
INSERT INTO screening_room_user VALUES (477, 'Research Assistant', false, 19, NULL);
INSERT INTO screening_room_user VALUES (484, 'Other', false, 396, NULL);
INSERT INTO screening_room_user VALUES (485, 'Postdoc', false, 95, NULL);
INSERT INTO screening_room_user VALUES (487, 'Postdoc', false, 182, NULL);
INSERT INTO screening_room_user VALUES (488, 'Postdoc', false, 94, NULL);
INSERT INTO screening_room_user VALUES (489, 'Graduate Student', false, 68, NULL);
INSERT INTO screening_room_user VALUES (490, 'Postdoc', false, 54, NULL);
INSERT INTO screening_room_user VALUES (491, 'Postdoc', false, 107, NULL);
INSERT INTO screening_room_user VALUES (110, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (493, 'Research Assistant', false, 318, NULL);
INSERT INTO screening_room_user VALUES (495, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (496, 'Postdoc', false, 497, NULL);
INSERT INTO screening_room_user VALUES (498, 'Graduate Student', false, 51, NULL);
INSERT INTO screening_room_user VALUES (499, 'Research Assistant', false, 138, NULL);
INSERT INTO screening_room_user VALUES (510, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (512, 'Research Assistant', false, 200, NULL);
INSERT INTO screening_room_user VALUES (515, 'Postdoc', false, 316, NULL);
INSERT INTO screening_room_user VALUES (518, 'Unassigned', false, 519, NULL);
INSERT INTO screening_room_user VALUES (524, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (526, 'Graduate Student', false, 75, NULL);
INSERT INTO screening_room_user VALUES (527, 'Graduate Student', false, 75, NULL);
INSERT INTO screening_room_user VALUES (528, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (530, 'Graduate Student', false, 370, NULL);
INSERT INTO screening_room_user VALUES (531, 'Unassigned', false, 125, NULL);
INSERT INTO screening_room_user VALUES (532, 'Unassigned', false, 65, NULL);
INSERT INTO screening_room_user VALUES (534, 'Graduate Student', false, 107, NULL);
INSERT INTO screening_room_user VALUES (539, 'Postdoc', false, 121, NULL);
INSERT INTO screening_room_user VALUES (540, 'Other', false, 28, NULL);
INSERT INTO screening_room_user VALUES (541, 'Unassigned', false, 4, NULL);
INSERT INTO screening_room_user VALUES (544, 'Graduate Student', false, 28, NULL);
INSERT INTO screening_room_user VALUES (546, 'Research Assistant', false, 24, NULL);
INSERT INTO screening_room_user VALUES (549, 'Unassigned', false, 222, NULL);
INSERT INTO screening_room_user VALUES (552, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (553, 'Research Assistant', false, 2, NULL);
INSERT INTO screening_room_user VALUES (130, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (519, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (556, 'Postdoc', false, 181, NULL);
INSERT INTO screening_room_user VALUES (181, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (558, 'Unassigned', false, 2, NULL);
INSERT INTO screening_room_user VALUES (563, 'Postdoc', false, 174, NULL);
INSERT INTO screening_room_user VALUES (564, 'Graduate Student', false, 196, NULL);
INSERT INTO screening_room_user VALUES (566, 'Graduate Student', false, 13, NULL);
INSERT INTO screening_room_user VALUES (567, 'Postdoc', false, 26, NULL);
INSERT INTO screening_room_user VALUES (68, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (569, 'Postdoc', false, 92, NULL);
INSERT INTO screening_room_user VALUES (575, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (576, 'Postdoc', false, 577, NULL);
INSERT INTO screening_room_user VALUES (56, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (578, 'Graduate Student', false, 218, NULL);
INSERT INTO screening_room_user VALUES (580, 'Graduate Student', false, 13, NULL);
INSERT INTO screening_room_user VALUES (583, 'Graduate Student', false, 138, NULL);
INSERT INTO screening_room_user VALUES (584, 'Research Assistant', false, 2, NULL);
INSERT INTO screening_room_user VALUES (588, 'Unassigned', false, 274, NULL);
INSERT INTO screening_room_user VALUES (274, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (590, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (592, 'Unassigned', false, 28, NULL);
INSERT INTO screening_room_user VALUES (593, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (595, 'Unassigned', false, 302, NULL);
INSERT INTO screening_room_user VALUES (597, 'Research Assistant', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (599, 'Graduate Student', false, 388, NULL);
INSERT INTO screening_room_user VALUES (602, 'Postdoc', false, 123, NULL);
INSERT INTO screening_room_user VALUES (123, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (603, 'Graduate Student', false, 170, NULL);
INSERT INTO screening_room_user VALUES (605, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (606, 'Graduate Student', false, 9, NULL);
INSERT INTO screening_room_user VALUES (607, 'Graduate Student', false, 233, NULL);
INSERT INTO screening_room_user VALUES (610, 'Research Assistant', false, 571, NULL);
INSERT INTO screening_room_user VALUES (611, 'Research Assistant', false, 5, NULL);
INSERT INTO screening_room_user VALUES (612, 'Research Assistant', false, 19, NULL);
INSERT INTO screening_room_user VALUES (613, 'Research Assistant', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (617, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (618, 'Other', false, 65, NULL);
INSERT INTO screening_room_user VALUES (621, 'Unassigned', false, 291, NULL);
INSERT INTO screening_room_user VALUES (291, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (622, 'Graduate Student', false, 7, NULL);
INSERT INTO screening_room_user VALUES (623, 'Graduate Student', false, 75, NULL);
INSERT INTO screening_room_user VALUES (624, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (626, 'Postdoc', false, 99, NULL);
INSERT INTO screening_room_user VALUES (629, 'Unassigned', false, 31, NULL);
INSERT INTO screening_room_user VALUES (632, 'Graduate Student', false, 233, NULL);
INSERT INTO screening_room_user VALUES (140, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (577, 'ICCB Fellow', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (634, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (635, 'Unassigned', false, 574, NULL);
INSERT INTO screening_room_user VALUES (574, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (637, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (639, 'Research Assistant', false, 302, NULL);
INSERT INTO screening_room_user VALUES (641, 'Unassigned', false, 286, NULL);
INSERT INTO screening_room_user VALUES (643, 'Postdoc', false, 151, NULL);
INSERT INTO screening_room_user VALUES (644, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (646, 'Graduate Student', false, 184, NULL);
INSERT INTO screening_room_user VALUES (184, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (647, 'Graduate Student', false, 243, NULL);
INSERT INTO screening_room_user VALUES (648, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (649, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (651, 'Postdoc', false, 323, NULL);
INSERT INTO screening_room_user VALUES (652, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (653, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (655, 'Other', false, 75, NULL);
INSERT INTO screening_room_user VALUES (656, 'Graduate Student', false, 28, NULL);
INSERT INTO screening_room_user VALUES (657, 'Unassigned', false, 276, NULL);
INSERT INTO screening_room_user VALUES (276, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (659, 'Research Assistant', false, 138, NULL);
INSERT INTO screening_room_user VALUES (660, 'Postdoc', false, 571, NULL);
INSERT INTO screening_room_user VALUES (664, 'Unassigned', false, 80, NULL);
INSERT INTO screening_room_user VALUES (666, 'Graduate Student', false, 9, NULL);
INSERT INTO screening_room_user VALUES (667, 'Research Assistant', false, 349, NULL);
INSERT INTO screening_room_user VALUES (672, 'Postdoc', false, 15, NULL);
INSERT INTO screening_room_user VALUES (497, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (21, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (675, 'Postdoc', false, 222, NULL);
INSERT INTO screening_room_user VALUES (676, 'Graduate Student', false, 65, NULL);
INSERT INTO screening_room_user VALUES (687, 'Postdoc', false, 398, NULL);
INSERT INTO screening_room_user VALUES (690, 'Graduate Student', false, 233, NULL);
INSERT INTO screening_room_user VALUES (691, 'Postdoc', false, 381, NULL);
INSERT INTO screening_room_user VALUES (692, 'Postdoc', false, 513, NULL);
INSERT INTO screening_room_user VALUES (693, 'Graduate Student', false, 586, NULL);
INSERT INTO screening_room_user VALUES (586, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (694, 'Unassigned', false, 51, NULL);
INSERT INTO screening_room_user VALUES (51, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (696, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (698, 'Research Assistant', false, 363, NULL);
INSERT INTO screening_room_user VALUES (699, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (701, 'Research Assistant', false, 42, NULL);
INSERT INTO screening_room_user VALUES (704, 'Unassigned', false, 352, NULL);
INSERT INTO screening_room_user VALUES (705, 'Postdoc', false, 138, NULL);
INSERT INTO screening_room_user VALUES (707, 'Graduate Student', false, 133, NULL);
INSERT INTO screening_room_user VALUES (708, 'Postdoc', false, 285, NULL);
INSERT INTO screening_room_user VALUES (709, 'Postdoc', false, 9, NULL);
INSERT INTO screening_room_user VALUES (710, 'Graduate Student', false, 225, NULL);
INSERT INTO screening_room_user VALUES (225, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (713, 'Postdoc', false, 251, NULL);
INSERT INTO screening_room_user VALUES (714, 'Research Assistant', false, 9, NULL);
INSERT INTO screening_room_user VALUES (9, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (715, 'Postdoc', false, 117, NULL);
INSERT INTO screening_room_user VALUES (716, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (717, 'Postdoc', false, 393, NULL);
INSERT INTO screening_room_user VALUES (393, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (718, 'Research Assistant', false, 342, NULL);
INSERT INTO screening_room_user VALUES (720, 'Postdoc', false, 426, NULL);
INSERT INTO screening_room_user VALUES (426, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (721, 'Graduate Student', false, 31, NULL);
INSERT INTO screening_room_user VALUES (722, 'Postdoc', false, 381, NULL);
INSERT INTO screening_room_user VALUES (723, 'Research Assistant', false, 246, NULL);
INSERT INTO screening_room_user VALUES (246, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (725, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (726, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (727, 'Other', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (418, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (136, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (730, 'Postdoc', false, 114, NULL);
INSERT INTO screening_room_user VALUES (113, 'Postdoc', false, 114, NULL);
INSERT INTO screening_room_user VALUES (114, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (480, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (63, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (483, 'Research Assistant', false, 258, NULL);
INSERT INTO screening_room_user VALUES (258, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (196, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (581, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (439, 'Postdoc', false, 440, NULL);
INSERT INTO screening_room_user VALUES (440, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (685, 'Postdoc', false, 237, NULL);
INSERT INTO screening_room_user VALUES (237, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (616, 'Unassigned', false, 44, NULL);
INSERT INTO screening_room_user VALUES (44, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (125, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (144, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (538, 'Graduate Student', false, 523, NULL);
INSERT INTO screening_room_user VALUES (523, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (423, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (517, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (604, 'Graduate Student', false, 10, NULL);
INSERT INTO screening_room_user VALUES (10, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (678, 'Postdoc', false, 501, NULL);
INSERT INTO screening_room_user VALUES (501, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (550, 'Graduate Student', false, 176, NULL);
INSERT INTO screening_room_user VALUES (176, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (340, 'Postdoc', false, 151, NULL);
INSERT INTO screening_room_user VALUES (151, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (46, 'Postdoc', false, 47, NULL);
INSERT INTO screening_room_user VALUES (47, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (514, 'Postdoc', false, 69, NULL);
INSERT INTO screening_room_user VALUES (69, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (420, 'Postdoc', false, 421, NULL);
INSERT INTO screening_room_user VALUES (421, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (217, 'Postdoc', false, 218, NULL);
INSERT INTO screening_room_user VALUES (218, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (702, 'Postdoc', false, 686, NULL);
INSERT INTO screening_room_user VALUES (686, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (345, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (115, 'Unassigned', false, 65, NULL);
INSERT INTO screening_room_user VALUES (65, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (508, 'Graduate Student', false, 65, NULL);
INSERT INTO screening_room_user VALUES (153, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (505, 'Graduate Student', false, 252, NULL);
INSERT INTO screening_room_user VALUES (252, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (633, 'Postdoc', false, 302, NULL);
INSERT INTO screening_room_user VALUES (302, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (278, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (70, 'Postdoc', false, 71, NULL);
INSERT INTO screening_room_user VALUES (71, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (446, 'Postdoc', false, 52, NULL);
INSERT INTO screening_room_user VALUES (52, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (300, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (26, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (684, 'Postdoc', false, 354, NULL);
INSERT INTO screening_room_user VALUES (354, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (183, 'Postdoc', false, 101, NULL);
INSERT INTO screening_room_user VALUES (101, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (378, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (311, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (330, 'Unassigned', false, 331, NULL);
INSERT INTO screening_room_user VALUES (331, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (554, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (625, 'Graduate Student', false, 536, NULL);
INSERT INTO screening_room_user VALUES (536, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (425, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (42, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (320, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (2, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (29, 'Postdoc', false, 2, NULL);
INSERT INTO screening_room_user VALUES (261, 'Unassigned', false, 262, NULL);
INSERT INTO screening_room_user VALUES (262, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (689, 'Postdoc', false, 382, NULL);
INSERT INTO screening_room_user VALUES (382, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (373, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (459, 'Postdoc', false, 182, NULL);
INSERT INTO screening_room_user VALUES (182, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (45, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (682, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (591, 'Postdoc', false, 39, NULL);
INSERT INTO screening_room_user VALUES (39, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (234, 'Postdoc', false, 235, NULL);
INSERT INTO screening_room_user VALUES (235, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (342, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (350, 'Research Assistant', false, 351, NULL);
INSERT INTO screening_room_user VALUES (351, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (337, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (166, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (516, 'Postdoc', false, 83, NULL);
INSERT INTO screening_room_user VALUES (83, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (61, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (683, 'Postdoc', false, 285, NULL);
INSERT INTO screening_room_user VALUES (285, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (284, 'Graduate Student', false, 285, NULL);
INSERT INTO screening_room_user VALUES (191, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (107, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (500, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (148, 'Postdoc', false, 149, NULL);
INSERT INTO screening_room_user VALUES (149, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (385, 'Postdoc', false, 322, NULL);
INSERT INTO screening_room_user VALUES (322, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (628, 'Postdoc', false, 99, NULL);
INSERT INTO screening_room_user VALUES (99, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (406, 'Postdoc', false, 99, NULL);
INSERT INTO screening_room_user VALUES (375, 'Postdoc', false, 99, NULL);
INSERT INTO screening_room_user VALUES (98, 'Postdoc', false, 99, NULL);
INSERT INTO screening_room_user VALUES (154, 'Other', false, 155, NULL);
INSERT INTO screening_room_user VALUES (155, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (587, 'Postdoc', false, 349, NULL);
INSERT INTO screening_room_user VALUES (349, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (434, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (615, 'Postdoc', false, 260, NULL);
INSERT INTO screening_room_user VALUES (260, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (150, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (249, 'Postdoc', false, 250, NULL);
INSERT INTO screening_room_user VALUES (250, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (503, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (399, 'Postdoc', false, 400, NULL);
INSERT INTO screening_room_user VALUES (400, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (318, 'ICCB Fellow', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (728, 'Graduate Student', false, 264, NULL);
INSERT INTO screening_room_user VALUES (264, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (11, 'Postdoc', false, 12, NULL);
INSERT INTO screening_room_user VALUES (12, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (571, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (82, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (481, 'Graduate Student', false, 482, NULL);
INSERT INTO screening_room_user VALUES (482, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (242, 'Postdoc', false, 243, NULL);
INSERT INTO screening_room_user VALUES (243, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (95, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (216, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (565, 'Other', false, 216, NULL);
INSERT INTO screening_room_user VALUES (542, 'Postdoc', false, 543, NULL);
INSERT INTO screening_room_user VALUES (543, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (460, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (600, 'Postdoc', false, 507, NULL);
INSERT INTO screening_room_user VALUES (507, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (72, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (444, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (96, 'Unassigned', false, 97, NULL);
INSERT INTO screening_room_user VALUES (97, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (359, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (402, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (413, 'Unassigned', false, 414, NULL);
INSERT INTO screening_room_user VALUES (414, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (187, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (405, 'Postdoc', false, 323, NULL);
INSERT INTO screening_room_user VALUES (323, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (343, 'Postdoc', false, 233, NULL);
INSERT INTO screening_room_user VALUES (233, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (533, 'Graduate Student', false, 509, NULL);
INSERT INTO screening_room_user VALUES (509, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (650, 'Postdoc', false, 241, NULL);
INSERT INTO screening_room_user VALUES (241, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (267, 'Graduate Student', false, 58, NULL);
INSERT INTO screening_room_user VALUES (58, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (279, 'Postdoc', false, 58, NULL);
INSERT INTO screening_room_user VALUES (504, 'Research Assistant', false, 58, NULL);
INSERT INTO screening_room_user VALUES (537, 'Postdoc', false, 40, NULL);
INSERT INTO screening_room_user VALUES (40, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (212, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (127, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (126, 'Postdoc', false, 127, NULL);
INSERT INTO screening_room_user VALUES (76, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (451, 'Postdoc', false, 304, NULL);
INSERT INTO screening_room_user VALUES (304, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (251, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (486, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (19, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (570, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (84, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (511, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (427, 'Postdoc', false, 19, NULL);
INSERT INTO screening_room_user VALUES (535, 'Graduate Student', false, 170, NULL);
INSERT INTO screening_room_user VALUES (170, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (169, 'Graduate Student', false, 170, NULL);
INSERT INTO screening_room_user VALUES (326, 'Postdoc', false, 170, NULL);
INSERT INTO screening_room_user VALUES (619, 'Postdoc', false, 194, NULL);
INSERT INTO screening_room_user VALUES (194, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (204, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (192, 'Postdoc', false, 193, NULL);
INSERT INTO screening_room_user VALUES (193, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (77, 'Postdoc', false, 78, NULL);
INSERT INTO screening_room_user VALUES (78, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (224, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (316, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (572, 'Graduate Student', false, 207, NULL);
INSERT INTO screening_room_user VALUES (207, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (347, 'Postdoc', false, 207, NULL);
INSERT INTO screening_room_user VALUES (555, 'Postdoc', false, 197, NULL);
INSERT INTO screening_room_user VALUES (197, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (585, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (688, 'Postdoc', false, 677, NULL);
INSERT INTO screening_room_user VALUES (677, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (598, 'Postdoc', false, 219, NULL);
INSERT INTO screening_room_user VALUES (219, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (478, 'Postdoc', false, 479, NULL);
INSERT INTO screening_room_user VALUES (479, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (409, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (157, 'Postdoc', false, 158, NULL);
INSERT INTO screening_room_user VALUES (158, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (640, 'Postdoc', false, 638, NULL);
INSERT INTO screening_room_user VALUES (638, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (469, 'Postdoc', false, 470, NULL);
INSERT INTO screening_room_user VALUES (470, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (352, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (381, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (361, 'Graduate Student', false, 49, NULL);
INSERT INTO screening_room_user VALUES (49, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (561, 'Unassigned', false, 562, NULL);
INSERT INTO screening_room_user VALUES (562, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (608, 'Graduate Student', false, 367, NULL);
INSERT INTO screening_room_user VALUES (367, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (662, 'Postdoc', false, 92, NULL);
INSERT INTO screening_room_user VALUES (92, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (407, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (627, 'Postdoc', false, 13, NULL);
INSERT INTO screening_room_user VALUES (13, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (398, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (547, 'Postdoc', false, 394, NULL);
INSERT INTO screening_room_user VALUES (394, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (601, 'Graduate Student', false, 80, NULL);
INSERT INTO screening_room_user VALUES (80, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (215, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (441, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (620, 'Postdoc', false, 80, NULL);
INSERT INTO screening_room_user VALUES (429, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (560, 'Postdoc', false, 296, NULL);
INSERT INTO screening_room_user VALUES (296, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (295, 'Graduate Student', false, 296, NULL);
INSERT INTO screening_room_user VALUES (397, 'Postdoc', false, 222, NULL);
INSERT INTO screening_room_user VALUES (222, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (573, 'Postdoc', false, 238, NULL);
INSERT INTO screening_room_user VALUES (238, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (24, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (85, 'Postdoc', false, 24, NULL);
INSERT INTO screening_room_user VALUES (89, 'Research Assistant', false, 24, NULL);
INSERT INTO screening_room_user VALUES (134, 'Postdoc', false, 24, NULL);
INSERT INTO screening_room_user VALUES (335, 'Postdoc', false, 24, NULL);
INSERT INTO screening_room_user VALUES (724, 'Postdoc', false, 24, NULL);
INSERT INTO screening_room_user VALUES (680, 'Graduate Student', false, 24, NULL);
INSERT INTO screening_room_user VALUES (202, 'Postdoc', false, 203, NULL);
INSERT INTO screening_room_user VALUES (203, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (173, 'Postdoc', false, 174, NULL);
INSERT INTO screening_room_user VALUES (174, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (673, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (226, 'Graduate Student', false, 227, NULL);
INSERT INTO screening_room_user VALUES (227, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (594, 'Postdoc', false, 54, NULL);
INSERT INTO screening_room_user VALUES (54, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (306, 'Postdoc', false, 54, NULL);
INSERT INTO screening_room_user VALUES (388, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (383, 'Postdoc', false, 384, NULL);
INSERT INTO screening_room_user VALUES (384, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (4, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (309, 'Graduate Student', false, 4, NULL);
INSERT INTO screening_room_user VALUES (506, 'Graduate Student', false, 4, NULL);
INSERT INTO screening_room_user VALUES (195, 'Postdoc', false, 4, NULL);
INSERT INTO screening_room_user VALUES (231, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (104, 'Postdoc', false, 60, NULL);
INSERT INTO screening_room_user VALUES (60, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (59, 'Postdoc', false, 60, NULL);
INSERT INTO screening_room_user VALUES (706, 'Unassigned', false, 60, NULL);
INSERT INTO screening_room_user VALUES (313, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (529, 'Unassigned', false, 103, NULL);
INSERT INTO screening_room_user VALUES (103, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (522, 'Research Assistant', false, 363, NULL);
INSERT INTO screening_room_user VALUES (363, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (362, 'Postdoc', false, 363, NULL);
INSERT INTO screening_room_user VALUES (294, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (286, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (636, 'Postdoc', false, 147, NULL);
INSERT INTO screening_room_user VALUES (147, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (719, 'Postdoc', false, 596, NULL);
INSERT INTO screening_room_user VALUES (596, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (199, 'Postdoc', false, 200, NULL);
INSERT INTO screening_room_user VALUES (200, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (582, 'Postdoc', false, 200, NULL);
INSERT INTO screening_room_user VALUES (443, 'Postdoc', false, 200, NULL);
INSERT INTO screening_room_user VALUES (16, 'Postdoc', false, 17, NULL);
INSERT INTO screening_room_user VALUES (17, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (32, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (521, 'Postdoc', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (520, 'Postdoc', false, 521, NULL);
INSERT INTO screening_room_user VALUES (658, 'Postdoc', false, 521, NULL);
INSERT INTO screening_room_user VALUES (589, 'Postdoc', false, 412, NULL);
INSERT INTO screening_room_user VALUES (412, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (396, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (729, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (456, 'Postdoc', false, 404, NULL);
INSERT INTO screening_room_user VALUES (404, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (579, 'Postdoc', false, 220, NULL);
INSERT INTO screening_room_user VALUES (220, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (248, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (7, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (213, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (614, 'Graduate Student', false, 7, NULL);
INSERT INTO screening_room_user VALUES (73, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (339, 'Research Assistant', false, 7, NULL);
INSERT INTO screening_room_user VALUES (303, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (269, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (419, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (239, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (458, 'Postdoc', false, 7, NULL);
INSERT INTO screening_room_user VALUES (74, 'Postdoc', false, 75, NULL);
INSERT INTO screening_room_user VALUES (75, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (145, 'Postdoc', false, 75, NULL);
INSERT INTO screening_room_user VALUES (175, 'Postdoc', false, 75, NULL);
INSERT INTO screening_room_user VALUES (210, 'Postdoc', false, 75, NULL);
INSERT INTO screening_room_user VALUES (645, 'Postdoc', false, 75, NULL);
INSERT INTO screening_room_user VALUES (551, 'Research Assistant', false, 28, NULL);
INSERT INTO screening_room_user VALUES (28, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (695, 'Research Assistant', false, 28, NULL);
INSERT INTO screening_room_user VALUES (545, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (525, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (494, 'Postdoc', false, 28, NULL);
INSERT INTO screening_room_user VALUES (411, 'Research Assistant', false, 28, NULL);
INSERT INTO screening_room_user VALUES (105, 'Graduate Student', false, 28, NULL);
INSERT INTO screening_room_user VALUES (159, 'Postdoc', false, 160, NULL);
INSERT INTO screening_room_user VALUES (160, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (253, 'Research Assistant', false, 254, NULL);
INSERT INTO screening_room_user VALUES (254, 'ICCB Fellow', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (164, 'Postdoc', false, 165, NULL);
INSERT INTO screening_room_user VALUES (165, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (631, 'Graduate Student', false, 165, NULL);
INSERT INTO screening_room_user VALUES (463, 'Postdoc', false, 165, NULL);
INSERT INTO screening_room_user VALUES (663, 'Postdoc', false, 165, NULL);
INSERT INTO screening_room_user VALUES (36, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (502, 'Postdoc', false, 268, NULL);
INSERT INTO screening_room_user VALUES (268, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (697, 'Research Assistant', false, 268, NULL);
INSERT INTO screening_room_user VALUES (121, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (670, 'Research Assistant', false, 117, NULL);
INSERT INTO screening_room_user VALUES (117, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (167, 'Research Assistant', false, 117, NULL);
INSERT INTO screening_room_user VALUES (356, 'Postdoc', false, 117, NULL);
INSERT INTO screening_room_user VALUES (492, 'Research Assistant', false, 117, NULL);
INSERT INTO screening_room_user VALUES (116, 'Postdoc', false, 117, NULL);
INSERT INTO screening_room_user VALUES (94, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (93, 'Postdoc', false, 94, NULL);
INSERT INTO screening_room_user VALUES (654, 'Postdoc', false, 138, NULL);
INSERT INTO screening_room_user VALUES (138, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (137, 'Postdoc', false, 138, NULL);
INSERT INTO screening_room_user VALUES (468, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (370, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (369, 'Graduate Student', false, 370, NULL);
INSERT INTO screening_room_user VALUES (703, 'Graduate Student', false, 370, NULL);
INSERT INTO screening_room_user VALUES (661, 'Unassigned', false, 370, NULL);
INSERT INTO screening_room_user VALUES (430, 'Graduate Student', false, 370, NULL);
INSERT INTO screening_room_user VALUES (476, 'Postdoc', false, 370, NULL);
INSERT INTO screening_room_user VALUES (131, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (31, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (671, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (559, 'Graduate Student', false, 31, NULL);
INSERT INTO screening_room_user VALUES (209, 'Graduate Student', false, 31, NULL);
INSERT INTO screening_room_user VALUES (161, 'Research Assistant', false, 31, NULL);
INSERT INTO screening_room_user VALUES (449, 'Graduate Student', false, 31, NULL);
INSERT INTO screening_room_user VALUES (711, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (609, 'Research Assistant', false, 31, NULL);
INSERT INTO screening_room_user VALUES (674, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (679, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (668, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (548, 'Research Assistant', false, 31, NULL);
INSERT INTO screening_room_user VALUES (30, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (445, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (91, 'Postdoc', false, 31, NULL);
INSERT INTO screening_room_user VALUES (432, 'Postdoc', false, 5, NULL);
INSERT INTO screening_room_user VALUES (5, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (630, 'Postdoc', false, 5, NULL);
INSERT INTO screening_room_user VALUES (473, 'Postdoc', false, 133, NULL);
INSERT INTO screening_room_user VALUES (133, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (265, 'Postdoc', false, 133, NULL);
INSERT INTO screening_room_user VALUES (669, 'Postdoc', false, 133, NULL);
INSERT INTO screening_room_user VALUES (314, 'Postdoc', false, 133, NULL);
INSERT INTO screening_room_user VALUES (132, 'Postdoc', false, 133, NULL);
INSERT INTO screening_room_user VALUES (453, 'Postdoc', false, 133, NULL);
INSERT INTO screening_room_user VALUES (513, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (282, 'ICCB Fellow', false, 35, NULL);
INSERT INTO screening_room_user VALUES (35, 'Unassigned', false, NULL, NULL);
INSERT INTO screening_room_user VALUES (642, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (416, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (557, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (568, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (681, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (111, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (433, 'Postdoc', false, 35, NULL);
INSERT INTO screening_room_user VALUES (712, 'Graduate Student', false, 35, NULL);
INSERT INTO screening_room_user VALUES (371, 'Unassigned', false, 35, NULL);
INSERT INTO screening_room_user VALUES (665, 'Postdoc', false, 35, NULL);
INSERT INTO screening_room_user VALUES (288, 'Postdoc', false, 35, NULL);
INSERT INTO screening_room_user VALUES (700, 'Other', false, 15, NULL);
INSERT INTO screening_room_user VALUES (15, 'Unassigned', false, NULL, NULL);


/* reinstate the lab_head trigger */

alter table screening_room_user add constraint fk_screening_room_user_to_lab_head foreign key (lab_head_id) references screening_room_user;


/* screen */

INSERT INTO screen VALUES (62, 0, '2005-12-01 00:00:00', 'Small Molecule', 'Increase C. elegans survival in the presence of the Enterococcus faecalis pathogen.', NULL, '2006-05-11 00:00:00', 'A screen for compounds that increase C. elegans survival in the presence of the Enterococcus faecalis pathogen. A worm line mutant for the sec-1 gene, a protein kinase involved in the innate immune response, will be used for the screen.  Thus, it might be possible to identify compounds that stimulate the activity of the remaining components of the C. elegans innate immune response.', 'Notified that must provide PO. 

Must pipet worms into 96-well plates by hand so screen will start at a small scale. Screen will probably be scaled up at a later date, once the Ausubel lab obtains an instrument that efficiently plates worms in microplates.

20-25 worms/96-well.  Worms will be infected with E. Faecalis for ~ 8 hours before plating into test compounds. Growth will be monitored by dissecting microscope (visual inspection) after 7-8 days. Anitbiotics might score as positives so a secondary screen is to check the effect of screening positives on E. faecalis growth.', '', '', NULL, NULL, 113, 114, 544);
INSERT INTO screen VALUES (61, 1, '2006-08-11 00:00:00', 'RNAi', 'An RNAi screen to identify novel components of the mTOR signalling network.', NULL, '2006-10-04 00:00:00', 'An RNAi screen to identify novel components of the mTOR signalling network.', '8/11/06 Hela cells.', '', '', NULL, NULL, 320, 2, 639);
INSERT INTO screen VALUES (72, 0, '2004-12-15 00:00:00', 'Small Molecule', 'Inhibit translocation of anthrax  toxin into host cells.', '2005-01-07 00:00:00', NULL, 'A screen for compounds that inhibit translocation of anthran toxin into host cells.  The screen protocol is based on the cytotoxicity of a protein fusion between the N-terminus of anthrax lethal factor and the catalytic domain of diphtheria toxin.  Entry of this fusion protein (LFn-DTA) into CHO cells depends on the protective antigen (PA) moiety of anthrax toxin.  Cytotoxicity is apparent after 24 hours, and cell viability can be monitored with a commercially available colorimetric formazan reagent (WST-1).  Positive hits in this screen will be defined as those compounds that inhibit the cytotoxic effect of LFn-DTA toward CHO cells.', '2006-06-27: Steve Juris is moving to a faculty position in Michigan in July 2006.  Status of this project is unknown at this time, but some component may be taken over by Deb Hung.', '', '', NULL, NULL, 480, 480, 460);
INSERT INTO screen VALUES (97, 0, '2005-05-10 00:00:00', 'Small Molecule', 'Inhibit  translocation of the serine/threonine protein kinase Akt to the plasma membrane.  ', NULL, '2006-06-13 00:00:00', 'A screen for compounds that  inhibit  translocation of the serine/threonine protein kinase Akt to the plasma membrane.  ', '4-25-05:Dear Dr. ShamuWe are definitely going to conduct the screening in your facility.  We have already established the cell based assay system.  The post-doc fellow who will fully devote to this project will join the lab on July 1.  We would like to meet you in July or August to discuss the details.

Best regards, Hongbo

2-05:Letter of support written.

6-13-06: Met with Jo to discuss image-based data deposition.  He will provide a spreadsheet with a listing of interesting plate/wells based on cell morphology classification using a visual scan of images.    ', '', '', NULL, NULL, 63, 63, 501);
INSERT INTO screen VALUES (98, 0, '2006-03-23 00:00:00', 'Small Molecule', 'Prevent killing of C. elegans by Candida spp.', NULL, '2006-05-23 00:00:00', 'A screen for compounds that prevent killing of C. elegans by Candida spp.', 'This will be the counterscreen for a screen for compounds that prevent killing of C. elegans by F. tularensis.  However, this screen will be established first.', '', '', NULL, NULL, 483, 258, 603);
INSERT INTO screen VALUES (138, 0, '2006-11-22 00:00:00', 'Small Molecule', 'Inhibit influenza A virus replication.', NULL, NULL, 'A screen for compounds that inhibit influenza A virus replication.  This screen utilizes transient transfection of host cells with a firefly luciferase reporter, which serves as a marker for viral replication in response to infection with live virus.', '2006-11-24: screen will be piloted by Heinrich Hoffman starting 12/4/06.  The protocol currently includes removal of cell culture medium, but hopefully this step can be eliminated.', '', '', NULL, NULL, 196, 196, 658);
INSERT INTO screen VALUES (145, 0, '2005-05-10 00:00:00', 'Small Molecule', 'Upregulate or downregulate B7-1, a novel podocyte injury molecule that causes proteinuria.', NULL, NULL, 'A screen for compounds that upregulate or downregulate B7-1, a novel podocyte injury molecule that causes proteinuria.', 'Letter of support written Feb. 2005.', '', '', NULL, NULL, 581, 581, 503);
INSERT INTO screen VALUES (146, 0, '2002-06-13 00:00:00', 'Small Molecule', 'Stimulate axon outgrowth in rodent neuronal cells in the presence of a peptide from the extracellular domain of Nogo protein, a myelin-associated inhibitor. ', NULL, NULL, 'A screen for compounds that stimulate axon outgrowth in rodent neuronal cells in the presence of a peptide from the extracellular domain of Nogo protein, a myelin-associated inhibitor.   Compounds are added to neuronal cells at approximately the same time as Nogo peptide. Cells are incubated for 1-2 days, then fixed and stained with DAPI and rhodamine phalloidin.  Neuronal outgrowth is monitored by automated microscopy.', 'Will pilot several different  neuronal cell lines--PC-12, N2a, and NG108 cells.', NULL, NULL, NULL, NULL, 439, 440, 212);
INSERT INTO screen VALUES (144, 1, '2002-01-30 00:00:00', 'Small Molecule', 'Stimulate or inhibit b-catenin degradation in Xenopus egg extracts. ', NULL, NULL, 'Screen for compounds that stimulate or inhibit b-catenin degradation in Xenopus egg extracts.', 'There were several hits but they were never followed up.', 'BETACATENIN', 'BCateninLuciferase', NULL, NULL, 337, 337, 135);
INSERT INTO screen VALUES (154, 0, '2006-09-01 00:00:00', 'Small Molecule', 'Inhibit cholera toxin vesicular transport from the plasma membrane to the ER of  host cells and the retro-translocation of a portion of the toxin (CT) from the ER to the cytosol. ', NULL, NULL, 'A screen for compounds that inhibit cholera toxin vesicular transport from the plasma membrane to the ER of  host cells and the retro-translocation of a portion of the toxin (CT) from the ER to the cytosol. ', '9/1/06 Referred to Riki Eggert''s cell staining protocol (#118).', '', '', NULL, NULL, 685, 237, 643);
INSERT INTO screen VALUES (155, 0, '2003-07-17 00:00:00', 'Small Molecule', 'Affect clathrin-dependent trafficking in the yeast S. cerevisiae.', NULL, NULL, 'A screen for compounds that affect clathrin-dependent trafficking in the yeast S. cerevisiae.   Traffic between the TGN and endosomes involves the evolutionarily conserved heterotrimeric  AP-1 and monomeric GGA clathrin adaptors.  Both types of adaptors bind to clathrin and transported transmembrane cargo, thus both are capable of fulfilling the essential role of recruiting clathrin to sites of vesicle formation. It is currently unclear whether AP-1 and GGAs mediated two independent pathways or cooperate in the same pathway or some combination of the two.  This screen takes advantage of the known synthetic lethality in yeast between AP-1 mutants and mutations in the GGA proteins.  Either GGA or AP-1 are sufficient for normal clathrin dependant trafficking and viability but cells containing mutations in both GGA and AP-1 are either severely compromised for clathrin trafficking or dead depending on the nature of the mutations.  The rational for this screen is that a chemical that inhibits AP-1 dependant trafficking would be lethal to cells with mutations in GGA genes but not wild-type cells.   Screening positives are compounds that are lethal or deleterious to cells carrying deletions in GGA genes but not to wild-type cells.   ', 'Yeast strains carry deletions in the drug efflux pumps pdr5 and snq2  to increase sensitivity to inhibitors.  Growth measured 24 H after compound addition using Wallac (Abs 490) Plates are covered and vortexed  gently first.
Update from Mara 11/7/03:So far none of my follow-ups have been a home run.  I have one chemical that
has a strong specific growth effect on my mutant and not on the wild-type or
on the mutant in the parallel pathway.  In my tests so-far, the chemical
doesn''t seem to be causing a defect in traficking.  I have a couple of
assays left to do, some of them will be a bit tricky because I''ll have to
take into account the growth effect.  I''m not so worried that this chemical
may not be the home run because I expected that I might get some chemicals
that cause a growth defect without specifically targeting AP-1 dependant
traffic.
8/5/04 None of Mara''s data should be entered into a future database. From an email from Mara: "I didn''t pursue any of the hits I obtained in my short stay at ICCB.  In my secondary screens, very few compound rehit and none of those passed my additional screens.  I performed a more successful screen using the Diverset E collection from Chembridge here.  The diverset compounds demonstrated a 60% rehit rate and one family of compounds showed strong effects in my additional screens. I am following up those hits and as UCLA purchases more libraries I plan to continue screening more compounds."', NULL, NULL, NULL, NULL, 616, 44, 310);
INSERT INTO screen VALUES (159, 0, '2005-12-14 00:00:00', 'Small Molecule', 'Inhibit botulinum toxin light chain endopeptidase (serotype A) activity.', NULL, NULL, 'A screen for compounds that inhibit botulinum toxin light chain endopeptidase (serotype A) activity.', '', '', '', NULL, NULL, 125, 125, 545);
INSERT INTO screen VALUES (173, 0, '2005-05-10 00:00:00', 'Small Molecule', 'Inhibit splicing of the M.tuberculosis RecA intein.', NULL, '2005-05-10 00:00:00', 'A screen for compounds that inhibit splicing of the M. tuberculosis RecA intein.  This screen will use an E. coli-based protocol, in which the MTB RecA intein is fused to a thymidylate synthase (TS) reporter.  Splicing will render the reporter strain sensitive to trimethoprim, and positive hits are defined as compounds that permit growth of the reporter strain in the presence of trimethoprim.', '4/12/05: assay has not been validated in multi-well format.  Belfort is on sabbatical at MIT from April to mid-June 2005.
5/11/2006: Su Chiang and Brian Kraybill confirm that none of the hits from the primary screen using this assay confirmed when retested. ', '', '', NULL, NULL, 144, 144, 499);
INSERT INTO screen VALUES (174, 0, '2003-10-14 00:00:00', 'Small Molecule', 'Modulate activity of the human decetylase Sirt1 .', NULL, '2003-10-14 00:00:00', 'A screen for compounds that modulate the activity of the human decetylase Sirt1.  A fluorescence-based assay developed by Biomol (Fluor de Lys) will be used to measure the activity of purified Sirt1 protein.  Hits are compounds that activate the deacetylase. A positive control is resveratrol.', '6/29/06 David Sinclair wrote that this screen is complete and that they did get hits!', '', '', NULL, NULL, 538, 523, 324);
INSERT INTO screen VALUES (206, 0, '2004-09-17 00:00:00', 'Small Molecule', 'Affect the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans.', NULL, NULL, 'A screen for compounds that affect the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans.', NULL, NULL, NULL, NULL, NULL, 423, 423, 420);
INSERT INTO screen VALUES (212, 0, '2005-10-04 00:00:00', 'Small Molecule', 'Activate hematopoietic pathways (or inhibit alternative developmental pathways) in mouse embryonic stem cells. ', NULL, NULL, 'A screen for compounds that  activate hematopoietic pathways (or inhibit alternative developmental pathways) in mouse embryonic stem cells. ', '', '', '', NULL, NULL, 517, 517, 527);
INSERT INTO screen VALUES (219, 0, '2002-02-08 00:00:00', 'Small Molecule', 'Are Cy motif mimetic chemicals and that inhibit cyclin dependent kinases. ', NULL, NULL, 'A screen for compounds that are Cy motif mimetic chemicals and that inhibit cyclin dependent kinases. ', '8/5/04 Email from David Takeda. This screen ended some time ago without positive results.', NULL, NULL, NULL, NULL, 604, 10, 153);
INSERT INTO screen VALUES (220, 0, '2002-05-21 00:00:00', 'Small Molecule', 'Affect auxin-mediated signalling in Arabadopsis thaliana.', NULL, NULL, 'A screen for compounds that affect auxin-mediated signalling in Arabadopsis thaliana.', NULL, NULL, NULL, NULL, NULL, 678, 501, 202);
INSERT INTO screen VALUES (6, 1, '2004-05-14 00:00:00', 'Small Molecule', 'Suppress the lethality of the Y. pestis YpkA effector expressed in the yeast S. cerevisiae.', '2004-05-24 00:00:00', '2004-05-24 00:00:00', 'A screen for compounds that suppress the lethality of the Y. pestis YpkA effector expressed in the yeast S. cerevisiae. YpkA disrupts the actin-based cytoskeleton by acting on the RhoA family of GTPases.  YpkA contains eukaryotic-like RhoA binding domains that are involved in blocking phagocytosis by macrophages. YpkA has strong growth-suppressive activity in S. cerevisiae, and this property is exploited in this screen.  The ypkA gene was placed under the control of a galactose-inducible promoter and introduced into yeast.  In the presence of galactose, YpkA is expressed and inhibits growth of the yeast.  Positive hits in this screen were defined as compounds that rescue this growth defect.', '1/20/05: Schesser reports that 1 of the 7 most promising cherry picks was reordered, and that they have seen "partial but reproducible" results with that.  They are now modifying their expression system before studying this further.  Also, Schesser filed an NIH grant application for funds to pursue the followup work but will have to file a resubmission for March 2005 deadline.  It sounds as if he does not have anyone committed full-time to this project at present.', '', '', NULL, NULL, 550, 176, 368);
INSERT INTO screen VALUES (5, 1, '2004-05-18 00:00:00', 'Small Molecule', 'Suppress the lethality of the Y. pestis YopE effector expressed in the yeast S. cerevisiae.', '2004-05-24 00:00:00', '2004-05-24 00:00:00', 'A screen for compounds that suppress the lethality of the Y. pestis YopE effector expressed in the yeast S. cerevisiae.', '', '', '', NULL, NULL, 550, 176, 369);
INSERT INTO screen VALUES (252, 0, '2003-02-27 00:00:00', 'Small Molecule', 'Selectively inhibit the growth of mouse cells (MEFs) deleted for tsc2 (tuberous sclerosis complex 2) and p53 but not MEFs deleted for p53 alone.', NULL, NULL, 'A screen for compounds that selectively inhibit the growth of mouse cells (MEFs) deleted for tsc2 (tuberous sclerosis complex 2) and p53  but not MEF"s deleted for only p53.  The two cell lines will be treated in parallel with compounds.  Viability will be  assayed by measuring ATP levels using  the CellTiter 96? AQueous Non-Radioactive Cell Proliferation Assay (MTS) from Promega (Cat # G5430). 
', 'This assay has been performed in 96-well plates (on ~3000 compounds at TRI).  John will transfer the assay to 384-well plates before performing a pilot screen here at ICCB.
Note: this screen is the same as that proposed by Rocky Onda (Kwiatkowski group) - Screen#235 - and the cell line used here came from the Kwiatkowski group.', NULL, NULL, NULL, NULL, 340, 151, 271);
INSERT INTO screen VALUES (253, 0, '2006-01-13 00:00:00', 'Small Molecule', 'Upregulate tumor recognition, in order to increase the efficacy of melanoma cancer vaccines.', NULL, NULL, 'A screen for compounds that  upregulate tumor recognition, in order to increase the efficacy of melanoma cancer vaccines.', '8/10/06 Tim and Kurnick are applying for funding. Screening will not start until funding is obtained.', '', '', NULL, NULL, 46, 47, 549);
INSERT INTO screen VALUES (254, 0, '2004-11-09 00:00:00', 'Small Molecule', 'Affect  intracellular replication of the bacterium Listeria monocytogenes.', NULL, '2005-05-25 00:00:00', 'A screen for compounds that affect intracellular replication of the bacterium Listeria monocytogenes.  Bone marrow-derived macrophages will be treated with compound and then infected with L. monocytogenes expressing GFP.  Growth of the bacteria will be monitored using automated microscopy.  Several phenotypes will be scored as positive hits in this screen, including reduced growth and reduced ability to spread between host cells.', 'This lab has already carried out a successful RNAi screen using essentially the same high-throughput protocol.', '', '', NULL, NULL, 514, 69, 431);
INSERT INTO screen VALUES (262, 0, '2002-02-19 00:00:00', 'Small Molecule', 'Inhibit the biosynthetic pathway of aspartate family amino acids in Mycobacterium tuberculosis (TB ).', NULL, NULL, 'A screen for compounds that inhibit the biosynthetic pathway of aspartate family amino acids in Mycobacterium tuberculosis (TB ).', NULL, NULL, NULL, NULL, NULL, 420, 421, 165);
INSERT INTO screen VALUES (265, 0, '2003-02-13 00:00:00', 'Small Molecule', 'Affect the secretory pathway of monkey BS-C1 cells.', NULL, NULL, 'A screen for compounds that affect the secretory pathway of monkey BS-C1 cells.  Cells are infected with recombinant adenovirus expressing VSV G (ts)-GFP fusion protein.  At 40oC, this protein is retained in the ER.  At 32oC, it can move to the plasma membrane. At 20oC it is retained in the Golgi apparatus.  Compounds are added to the cells, incubated  for one hour at 40oC and then for 3 hours at either 20oC or 32oC. The cells are then fixed and examined by automated microscopy.  Hit compounds are those that cause accumulation of the VSV G-GFP protein in a discrete secretory compartment.', 'Rami will start by screening the carpanone like DOS library made by Brian Goess and Lawrence Chan in Matt Shair''s lab.', NULL, NULL, NULL, NULL, 217, 218, 269);
INSERT INTO screen VALUES (267, 1, '2006-01-05 00:00:00', 'Small Molecule', 'Inhibit the conversion of D-alanine to L-alanine by purified, recombinant alanine racemase.', NULL, '2006-05-04 00:00:00', 'A screen for compounds that inhibit the conversion of D-alanine to L-alanine by purified, recombinant alanine racemase.  This is a coupled enzyme assay, in which L-alanine is subsequently deaminated by L-alanine dehydrogenase to produce pyruvate and NADH.  NADH formation is monitored by fluorescent readout.', 'Screen 614 is the counterscreen to this screen.', '', '', NULL, NULL, 216, 216, 546);
INSERT INTO screen VALUES (268, 0, '2003-05-30 00:00:00', 'Small Molecule', 'In a yeast system, inhibit the activity of Bcl-xl.', NULL, NULL, 'A screen for compounds that, in a yeast system, inhibit the activity of Bcl-xl.  S. cerevisiae strains made to overexpress the mammalian death protein Bax die. Bax lethality can be supressed by co-expressing Bcl-xl.  Compounds were added to yeast expressing Bax and Bcl-xl. Positives were those that caused Bax/Bcl-xl expressing yeast to die but did not affect a control strain that expressed neither Bax nor Bcl-xl. ', '5-30-03 Talked with Tony re: his screen. It was not carried out using a "super" drug-sensitized yeast strain (likely only erg6 deletion). Approximately one dozen "unimpressive weak positives" were found and none have been pursued further.  The Testsets currently in ABase should not be imported into a future ICCB results database. ', 'BCL-2FAM', 'YM1423VV', NULL, NULL, 702, 686, 296);
INSERT INTO screen VALUES (275, 0, '2005-10-12 00:00:00', 'Small Molecule', 'When added to mouse embryonic fibroblasts carrying a mutant NF2 (neurofibromatosis type 2) gene, inhibit synthetically cell proliferation and/or cell survival. ', NULL, NULL, 'A screen for compounds that when added to mouse embryonic fibroblasts carrying a mutant NF2 (neurofibromatosis type 2) gene, inhibit synthetically cell proliferation and/or cell survival.  ', '', '', '', NULL, NULL, 345, 345, 532);
INSERT INTO screen VALUES (158, 2, '2003-01-31 00:00:00', 'Small Molecule', 'Inhibit the function of the E. coli glycosyl transferase Mur G.', '2003-08-19 00:00:00', '2003-08-20 00:00:00', 'A screen for compounds that inhibit the function of the E. coli glycosyltransferase MurG.  The MurG gene product is required for bacterial cell wall synthesis and is well conserved within all bacteria that have peptidoglycan in their cell walls.  An FP assay has been developed that measures the binding of MurG to a fluorescent (fluorescein-labelled) analogue of UDP-GlcNAc.  Screening positives are compounds that inhibit binding of GlcNAc to Mur G. ', 'Results from first part of screen published in: Helm, J. S., Hu, Y., Chen, L., Gross, B., Walker, S. (2003). Identification of Active-Site Inhibitors of MurG Using a Generalizable, High-Throughput Glycosyltransferase Screen. J. Am. Chem. Soc. 125 (37), 11168-11169.', 'EcoliMurG', 'EcoliMurG', NULL, NULL, 115, 65, 267);
INSERT INTO screen VALUES (156, 2, '2005-01-03 00:00:00', 'Small Molecule', 'Inhibit human O-GlcNAc transferase (OGT), an enzyme that adds a single O-linked GlcNAc to serine and threonine residues of proteins localized in the cytoplasm and nucleus of eukaryotic cells.', '2005-01-14 00:00:00', '2005-01-14 00:00:00', 'A screen for compounds that  inhibit human O-GlcNAc transferase (OGT), an enzyme that adds a single O-linked GlcNAc to serine and threonine residues of proteins localized in the cytoplasm and nucleus of eukaryotic cells.  OGT is essential and highly conserved.  This novel type of glycosylation has been shown to be involved in signal transduction pathways and transcriptional regulation. Recombinant OGT has been expressed in and purified from E. coli cells.  A fluorescence polarization assay will be used.', NULL, NULL, NULL, NULL, NULL, 508, 65, 462);
INSERT INTO screen VALUES (157, 2, '2006-05-10 00:00:00', 'Small Molecule', 'Inhibit human O-GlcNAc transferase (OGT) in a kinetic assay. OGT is a nodal point in the hexosamine biosynthetic pathway, which is involved in complications of diabetes. ', NULL, NULL, 'A screen for compounds that inhibit human O-GlcNAc transferase (OGT) in a kinetic assay.  OGT is an enzyme that adds a single O-linked GlcNAc to serine and threonine residues of proteins localized in the cytoplasm and nucleus of eukaryotic cells. OGT is a nodal point in the hexosamine biosynthetic pathway, which is involved in complications of diabetes. The assay is based on the same concept as the Z"-LYTE assay sold by Invitrogen.  A peptide substrate for OGT is labeled with a FRET pair (in this case EDANS and Dabcyl) is reacted with the 500uM donor substrate (UDP-GlcNAc) and 100nM OGT.  After ~4h the glycosylation reaction is complete.  Trypsin (1ug/20uL rxn) is added and allowed to react for 1h.  The plate is then read for total fluorescence intensity at 535 nm.  Glycosylation occurs immediately N-terminal to the single trypsin site of the petide and confers resistance to proteolysis.  Under the conditions described above, a fourfold difference in fluorescence intensity is observed.  ', '', '', '', NULL, NULL, 508, 65, 616);
INSERT INTO screen VALUES (280, 0, '2005-05-26 00:00:00', 'Small Molecule', 'Inhibit the in vivo activity of the S. cerevisiae enzymes Phosphoglucose isomerase (PGI1)and Hexokinase 2 (HXK2).', NULL, NULL, 'A screen for compounds that  inhibit the in vivo activity of the S. cerevisiae enzymes Phosphoglucose isomerase (PGI1)and Hexokinase 2 (HXK2).', '', '', '', NULL, NULL, 153, 153, 509);
INSERT INTO screen VALUES (281, 0, '2004-11-03 00:00:00', 'Small Molecule', 'Inhibit activity of the  mammalian Proprotein Convertase (PC) Furin.', NULL, NULL, 'A screen for compounds that inhibit activity of the  mammalian Proprotein Convertase (PC) Furin.', NULL, NULL, NULL, NULL, NULL, 505, 252, 429);
INSERT INTO screen VALUES (64, 1, '2005-01-12 00:00:00', 'Small Molecule', 'Activate Notch signalling in 293 cells', NULL, NULL, 'A screen for compounds that activate Notch signalling in 293 cells.  In keratinocytes, Notch is thought to have tumor supressor activity - this screen is to pilot steps in 293 cells prior to working with primary keratinocytes.  Following proteolytic activation and translocation to the nucleus, Notch is recruited to its target genes via interaction with RBP-J/CBF1, an essential DNA-binding component of the Notch pathway.  A reporter construct, consisting of 12 copies of the RBP-J binding site from the Epstein Barr virus TP1 promoter coupled to firefly luciferase, will be transfected into 293 cells, together with a constitutively expressed Renilla luciferase construct.  Compounds will be added and luciferase levels measured using the Dual luciferase assay (Promega).  Co-transfection of an activated Notch construct will serve as a positive control.  Screening positives are compounds that cause an increase in firefly luciferase levels, without increasing Renilla luciferase levels.', 'This screen is to pilot steps prior to working with primary mouse keratinocytes (screen 413)', NULL, NULL, NULL, NULL, 633, 302, 470);
INSERT INTO screen VALUES (63, 1, '2004-08-09 00:00:00', 'Small Molecule', 'Activate Notch signalling in mouse primary keratinocytes.', '2005-01-25 00:00:00', '2005-01-25 00:00:00', 'A screen for compounds that activate Notch signalling in mouse primary keratinocytes.  In keratinocytes, Notch is thought to have tumor supressor activity.  Following proteolytic activation and translocation to the nucleus, Notch is recruited to its target genes via interaction with RBP-J/CBF1, an essential DNA-binding component of the Notch pathway.  A reporter construct, consisting of 12 copies of the RBP-J binding site from the Epstein Barr virus TP1 promoter coupled to firefly luciferase, will be transfected into mouse primary keratinocytes, together with a constitutively expressed Renilla luciferase construct.  Compounds will be added and luciferase levels measured using the Dual luciferase assay (Promega).  Co-transfection of an activated Notch construct will serve as a positive control.  Screening positives are compounds that cause an increase in firefly luciferase levels, without increasing Renilla luciferase levels.', 'Anna will pilot miniaturization to 384-well.
01/12/05 (NT) - Anna and Vik will pilot this screen in 293 cells (screen 470).', NULL, NULL, NULL, NULL, 633, 302, 413);
INSERT INTO screen VALUES (291, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Are antagonists of the plasmodial surface anion channel (PSAC), an ion channel induced on human red blood cells infected with the malarial parasite, Plasmodium falciparum.', NULL, NULL, 'A screen for compounds that are antagonists of the plasmodial surface anion channel (PSAC), an ion channel induced on human red blood cells infected with the malarial parasite, Plasmodium falciparum.  The assay is a simple, yet quantitatively robust osmotic lysis assay based on the swelling and lysis of infected red cells in solutes that permeate through PSAC.  Single wavelength absorbance measurements are made 20 minutes after adding infected cells to test compounds and a simple sorbitol solution.', '5-5-06 A cherry pick was done for a Sanjay Desai screen, requested by the Broad Inst. last week. It was likely this screen. He carried it out at the Broad "last winter." Thus we have included it as a cherry pick visit associated with this screen.-CES  ', '', '', NULL, NULL, 278, 278, 379);
INSERT INTO screen VALUES (292, 0, '2002-06-20 00:00:00', 'Small Molecule', 'Inhibit binding of the Z-DNA binding domain of E3L (a vaccinia protein) to Z-DNA.', NULL, NULL, 'A screen for compounds that inhibit binding of the Z-DNA binding domain of E3L (a vaccinia protein) to Z-DNA.  A yeast strain will be  constructed that has a reporter gene controlled by E3L binding to Z-DNA in the promoter. Compounds will be added to the strain and expression of the reporter gene will be monitored.  Screening positives are compounds that inhibit E3L-dependent transcription.', 'Yang-Gyun is currently developing this screen. He is in the process of choosing a reporter gene. Luciferase, GFP, and Ura3 will all be tested. The readout for the assay will depend on the choice of the reporter.

August 2004- Alex Rich now collaborating with Cetek on a screen relating to this one. It is a NERCE effort. ', '', '', NULL, NULL, 70, 71, 234);
INSERT INTO screen VALUES (293, 0, '2004-07-07 00:00:00', 'Small Molecule', 'Inhibit activation of the yeast S. cerevisiae mating pathway.', NULL, NULL, 'A screen for compounds that inhibit activation of the yeast S. cerevisiae mating pathway.', NULL, NULL, NULL, NULL, NULL, 446, 52, 401);
INSERT INTO screen VALUES (303, 0, '2005-01-11 00:00:00', 'Small Molecule', 'Inhibit Shiga toxin activity.', NULL, '2005-06-16 00:00:00', 'A screen for compounds that inhibit Shiga toxin activity.', '2006-06-27: general assay protocol published, but specific protocol used here has not been received.', '', '', NULL, NULL, 300, 300, 468);
INSERT INTO screen VALUES (304, 0, '2004-07-07 00:00:00', 'Small Molecule', 'Increase the conversion of stem cells to hair cells in the mouse inner ear.', NULL, NULL, 'A screen for compounds that increase the conversion of stem cells to hair cells in the mouse inner ear.', '', '', '', NULL, NULL, 26, 26, 405);
INSERT INTO screen VALUES (297, 1, '2006-06-19 00:00:00', 'Small Molecule', 'Inhibit VSV entry (non-imaging screen).', NULL, '2006-10-12 00:00:00', 'A screen for compounds that inhibit VSV entry into cells (non-imaging screen).', 'In screen 630, Kartik will be using VSV particles pseudotyped with Ebola GP and containing a luciferase reporter for entry.  This screen (632) with VSV pseudotyped with VSV GP is a counterscreen and will be performed to identify inhibitors that are specific to Ebola.  Since viral replication following entry is a function of the VSV core and not the viral glycoprotein, and is thus the same in both pseudotypes, these screens are for Ebola GP-dependent entry only.', '', '', NULL, NULL, 684, 354, 632);
INSERT INTO screen VALUES (296, 1, '2006-06-16 00:00:00', 'Small Molecule', 'Inhibit Ebola virus entry into cells (non-imaging screen).', NULL, '2006-10-12 00:00:00', 'A screen for compounds that inhibit Ebola virus entry into cells (non-imaging screen).', 'Kartik will be using VSV particles pseudotyped with Ebola GP and containing a luciferase reporter for entry.  A counterscreen (screen 632) with VSV pseudotyped with VSV GP will be performed to identify inhibitors that are specific to Ebola.  Since viral replication following entry is a function of the VSV core and not the viral glycoprotein, and is thus the same in both pseudotypes, these screens are for Ebola GP-dependent entry only.', '', '', NULL, NULL, 684, 354, 630);
INSERT INTO screen VALUES (307, 0, '2002-02-15 00:00:00', 'Small Molecule', 'Prevent/disrupt intracellular aggregation of  the torsinA protein. ', NULL, NULL, 'A screen for compounds that prevent/disrupt intracellular aggregation of  the torsinA protein. ', NULL, NULL, NULL, NULL, NULL, 183, 101, 161);
INSERT INTO screen VALUES (308, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Improve the function of human enzymes implicated in different metabolic diseases.', NULL, NULL, 'A screen for compounds that improve the function of human enzymes implicated in different metabolic diseases.  This screen proposes to use yeast reporter strains whose viability depends on the activity of exogenously introduced human enzymes.', '7/6/04 Aaron emailed me to let me know that his grant for this screen was not funded. He continues to search for additional funds.', NULL, NULL, NULL, NULL, 378, 378, 388);
INSERT INTO screen VALUES (309, 0, '2004-10-13 00:00:00', 'Small Molecule', 'Affect the activity of the transcriptional activator CREB (cAMP response element binding protein) monitored using a cAMP response element (CRE) reporter gene.', NULL, NULL, 'A screen for compounds that affect the activity of the transcriptional activator CREB (cAMP response element binding protein) monitored using a cAMP response element (CRE) reporter gene.', '10-13-04 Lab member Dong Lee will likely carry out this screen; Dong is not yet in users db but has signed data sharing agmnt.', NULL, NULL, NULL, NULL, 311, 311, 424);
INSERT INTO screen VALUES (310, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit the interaction between cyclin E and Cdc4.', NULL, NULL, 'A screen for compounds that inhibit the interaction between cyclin E and Cdc4.  This is a fluorescence polarization assay using a fluorescein-labeled peptide derived from cyclin E.  ', 'This screen was already carried out in 384-well format using a Maybridge library in collaboration with Eric Brown at McMaster University.', NULL, NULL, NULL, NULL, 330, 331, 381);
INSERT INTO screen VALUES (311, 0, '2003-05-08 00:00:00', 'Small Molecule', 'Specifically inhibit protein arginine N-methyltransferase (PRMT) activity. ', NULL, NULL, 'A screen for compounds that specifically inhibit protein arginine N-methyltransferase (PRMT) activity. ', 'Results published in 2004.', 'ARGMET', 'ArgMet', NULL, NULL, 554, 554, 289);
INSERT INTO screen VALUES (312, 0, '2004-03-23 00:00:00', 'Small Molecule', 'Increase cell surface expression of the mouse pheromone receptor V1R in BSC1 cells. ', NULL, NULL, 'A  screen for compounds that increase cell surface expression of the mouse pheromone receptor V1R in BSC1 cells. ', 'myc-tagged receptors, bsc1 cells, adeno infection with viruses of receptors; looking to promote cell surface expression of V1R mouse pheromone receptors; control receptors (constitutively cell surface) = human receptors', NULL, NULL, NULL, NULL, 625, 536, 344);
INSERT INTO screen VALUES (313, 0, '2004-11-19 00:00:00', 'Small Molecule', 'Inhibit the inosine 5''-monophosphate dehydrogenase enzyme of Cryptosporidium parvum.', '2004-11-18 00:00:00', '2004-11-18 00:00:00', 'A screen for compounds that inhibit the inosine 5"-monophosphate dehydrogenase enzyme of Cryptosporidium parvum.  Positive hits in this screen are defined as compounds that inhibit the production of NADH in an in vitro fluorogenic or colorimetric assay using purified recombinant C. parvum IMPDH.', '', '', '', NULL, NULL, 425, 425, 449);
INSERT INTO screen VALUES (314, 0, '2005-08-19 00:00:00', 'Small Molecule', 'Inhibit Bacillus anthracis IMPDH.', NULL, NULL, 'A screen for compounds that inhibit Bacillus anthracis IMPDH.', '2006-06-26: Brian Kay has left Argonne, and this project has been reassigned to Rosemarie Wilton (rwilton@anl.gov; 630-252-3238).

3/14/06: hit summary sent.', '', '', NULL, NULL, 42, 42, 518);
INSERT INTO screen VALUES (60, 1, '2002-06-14 00:00:00', 'Small Molecule', 'Inhibit ERK MAP kinase docking with downstream effectors.', NULL, NULL, 'A screen for compounds that inhibit ERK MAP kinase docking with downstream effectors.  An FP assay will be developed using recombinant ERK2 protein and a peptide from the transcription factor Elk-1.', '10/6/03 Just started pursuing the FP approach. Original cytoblot  strategy has not worked due to lack of good Ab reagents. ', NULL, NULL, NULL, NULL, 29, 2, 214);
INSERT INTO screen VALUES (317, 0, '2002-06-27 00:00:00', 'Small Molecule', 'Inhibit the activity of dinoflagellate luciferase.', NULL, NULL, 'A screen for compounds that inhibit the activity of dinoflagellate luciferase. Purified dino luciferase will be incubated with compounds ~30 minutes. Substrate, puriifed from the dinoflagellate, will be added and activity (luminescence) read on a plate reader.  ', 'Note: dinoflagellate luciferase is structurally different than firefly and renilla luciferase.  Inhibitors found in this screen may have no effect on the firefly or renilla enzymes.', NULL, NULL, NULL, NULL, 261, 262, 236);
INSERT INTO screen VALUES (321, 0, '2005-01-11 00:00:00', 'Small Molecule', 'Inhibit the interaction between anthrax toxin protective antigen (PA) and its receptor (CMG2).', NULL, '2006-09-27 00:00:00', 'A screen for compounds that inhibit the interaction between anthrax toxin protective antigen (PA) and its receptor (CMG2).  This screen will employ a FRET-based assay using Alexa dyes to detect interaction between PA and the extracellular domain of CMG2.', '1/31/05: Michael is still developing his assay and does not expect to begin piloting until spring/summer 2005.', '', '', NULL, NULL, 689, 382, 463);
INSERT INTO screen VALUES (316, 1, '2004-07-07 00:00:00', 'Small Molecule', 'Inhibit the protease activity of the light chain of botulinum neurotoxin serotype B. ', NULL, NULL, 'A screen for compounds that inhibit the protease activity of the light chain of botulinum neurotoxin serotype B.  This screen employs yeast reporter strains, in which the yeast homolog of synaptobrevin has been converted into a substrate for botulinum toxin light chain.  Regulated expression of light chain leads to cleavage of the yeast substrate and death of the cell.  Screening positives are compounds that allow botulinum light chain-expressing yeast to live.', '', '', '', NULL, NULL, 373, 373, 398);
INSERT INTO screen VALUES (315, 1, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit the protease activity of the light chain of botulinum neurotoxin serotype C. ', '2004-07-19 00:00:00', '2004-07-19 00:00:00', 'A screen for compounds that inhibit the protease activity of the light chain of botulinum neurotoxin serotype C.  This screen employs yeast reporter strains, in which the yeast homolog of synaptobrevin has been converted into a substrate for botulinum toxin light chain.  Regulated expression of light chain leads to cleavage of the yeast substrate and death of the cell.  Screening positives are compounds that allow botulinum light chain-expressing yeast to live.', '1/20/05: After confirmation with cherry picks, 14 promising compounds were reordered from the vendor.  None of these retested, and MS analysis did not reveal obvious explanations.  Additional compounds were reordered based on the original screen results and on medchem recommendations from Greg Cuny, and 1 of the first 4 shows good and reproducible results.', '', '', NULL, NULL, 373, 373, 383);
INSERT INTO screen VALUES (337, 0, '2002-04-15 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of the mammalian AAA ATPase p97, which is thought to be a ubiquitin-dependent chaperone.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of the mammalian AAA ATPase p97, which is thought to be a ubiquitin-dependent chaperone.  The ATPase activity of purified mouse p97 is assayed after compound addition using  a malachite green assay for released phosphate.', 'March 2005: Yihong just moved to NIH to start his own lab. He has a few weak hits from this screen that he plans to pursue at NIH in collaboration with chemists there. ', 'ATPasep97', 'ATPasep97', NULL, NULL, 459, 182, 186);
INSERT INTO screen VALUES (340, 0, '2006-10-05 00:00:00', 'Small Molecule', 'Disrupt cell wall integrity of the yeast S. cerevisiae.', NULL, NULL, 'A screen for compounds that disrupt cell wall integrity of the yeast S. cerevisiae. A sensitive cell-based, assay that detects cell lysis caused by cell wall stress in S. cerevisiae has been developed.  Cell lysis is the terminal phenotype of cells with damaged cell walls and leads to the release of intracellular enzymes such as adenylate kinase.  Adenylate kinase is detectable using a commercially available luciferase-coupled assay (Toxi-Light, Promega).  Briefly, cells are grown to log phase overnight, transferred to microtiter plates, treated with test compounds, and incubated for 4-6 hr at ambient temperature.  The Toxi-Light assay solution is then added directly to the well and luminescence is read after 30min using a plate reader. ', '8/22/06 Anticipates ready to screen in Jan. 2007. Experiments in 96-well plates with wild type cells exposed to the caspofungin, an inhibitor of 1,3-?-glucan synthesis that causes cell lysis, show a signal-to-background ratio of ~30:1 with a preliminary Z score of 0.8 based on multiple plates done on different days.  We are currently developing the assay with yeast cell wall mutants to increase the sensitivity of the assay.  In addition, we are pursuing further optimization studies to increase the array density of the procedure.  Our plan is to first perform a screen with wild type cells and subsequently examine cell wall mutants.
12/4/06 Damian now plans to do screen in March 2007.  Will start with wt W303 strain.', '', '', NULL, NULL, 45, 45, 648);
INSERT INTO screen VALUES (341, 0, '2005-01-11 00:00:00', 'Small Molecule', 'Inhibit superantigen-mediated T cell activation ', NULL, NULL, 'A screen for compounds that inhibit superantigen-mediated T cell activation.  This screen seeks to identify inhibitors of the interaction between superantigens (SAGs) and MHC and TCR molecules.', '2006-04-20: on hold indefinitely due to resource limitations.

11/29/04: this group is developing three different assay protocols, one cell-based GFP assay and two FRET-based in vitro assays.', '', '', NULL, NULL, 682, 682, 466);
INSERT INTO screen VALUES (346, 0, '2004-01-05 00:00:00', 'Small Molecule', 'Inhibit  function of the Epstein Barr virus EBNA-1 protein in human cells. ', '2004-05-28 00:00:00', '2004-05-28 00:00:00', 'A screen for compounds that inhibit  function of the Epstein Barr virus EBNA-1 protein in human cells.  This screen employs an EBNA-1-dependent promoter driving expression of luciferase.', NULL, NULL, NULL, NULL, NULL, 591, 39, 333);
INSERT INTO screen VALUES (347, 0, '2006-06-09 00:00:00', 'RNAi', 'An siRNA screen to identify factors important for growth regulation of renal cell carcinoma.', NULL, '2006-10-16 00:00:00', 'An siRNA screen to identify factors important for growth regulation of renal cell carcinoma.  Growth of isogenic tumor (VHL-) and non-tumor cell lines (VHL+) will be compared after siRNA transfection.  Growth/non-growth is assayed by imaging after fixing and staining cells with DAPI.', '6/22/06 Screening human siRNAs.  Will probably start with 50 nM screening concentration. Will try 384-well plates.  Will  try HiPerFect. Is currently using Lipofectamine. Current control construct is PLK1.  Will compare forward vs. reverse transfection protocols.  Will use Cell Titre Glo as assay readout.  Needs to develop this protocol too.  Will talk to Emily Hsu and Junichi Hitomi.
9/7/06 Has optimized protocol using HiPerfect (1.4 ul per well, low toxicity) and reverse transfection. In p384-well plates.  Plan to screen at 50nM.  Compared with Lipofectamine, Hiperfect was better (in terms of toxicity);  compared with forward transfection, reverse better overall and very reproducible. 
11/21/06 Pankaj and Guang are using the cellWoRx to readout their assay. They have a Metamorph program for quantitating their results.  Tranfecting at 50nM. Will do 72 Hour knockdown. ', '', '', NULL, NULL, 234, 235, 628);
INSERT INTO screen VALUES (348, 0, '2005-03-16 00:00:00', 'Small Molecule', 'stimulate Myc protein destabilization and degradation', NULL, NULL, 'A screen for compounds that stimulate Myc protein destabilization and degradation.', 'Maria and Kristi will pilot experiments for this screen using a dual luciferase reporter with the known bioactives collection.
03/16/05 - Maria and Kristi found that Renilla signal was too low.  They will optimize/revise conditions back in the lab and return after the move to Kendall Square.', NULL, NULL, NULL, NULL, 342, 342, 478);
INSERT INTO screen VALUES (349, 0, '2003-11-13 00:00:00', 'Small Molecule', 'Inhibit self-splicing of the M. tuberculosis protein RecA.', NULL, '2003-11-13 00:00:00', 'A screen for proteins that inhibit self-splicing of the M. tuberculosis protein RecA.  The RecA intein is fused to GFP in such a way that its presence prevents GFP chromophore formation. The fusion protein is expressed in E. coli in inclusion bodies, solubilized in 8M urea and treated wit 4,4"-dipyridine disulfide to prevent premature splicing. For the assay, this fusion protein is diluted, compounds added,  and the re-folding reaction started by addition of a thiol or TCEP.  Screening positives are compounds that result in a decrease in GFP signal as read on a plate reader  ', '11-13-03 Splicing reaction will go to completion overnight at RT and is robust. They will pilot taking multiple readings (T=0, 3H, 6H, 12H, 24H) to see which one(s) give the best information.

collaborator Jens Eckstein is eliminated.

5/12/05: converted to NSRB screen', '', '', NULL, NULL, 350, 351, 327);
INSERT INTO screen VALUES (143, 1, '2006-04-12 00:00:00', 'Small Molecule', 'Stimulate beta-catenin degradation and inhibit Axin turnover in Xenopus egg extracts.', NULL, NULL, 'A screen for compounds that stimulate beta-catenin degradation and inhibit Axin turnover in Xenopus egg extracts.', 'Lab member Curtis Thorne will carry out this screen.', '', '', NULL, NULL, 337, 337, 605);
INSERT INTO screen VALUES (350, 0, '2006-02-03 00:00:00', 'Small Molecule', 'Inhibit Yersinia pestis plasminogen activator (Pla).', NULL, '2006-04-25 00:00:00', 'A screen for compounds that inhibit Yersinia pestis plasminogen activator (Pla).', '', '', '', NULL, NULL, 166, 166, 563);
INSERT INTO screen VALUES (353, 0, '2006-12-08 00:00:00', 'RNAi', 'An RNAi screen for genes that regulate NFAT nuclear translocation.', NULL, NULL, 'An RNAi screen for genes that regulate NFAT nuclear translocation.', '', '', '', NULL, NULL, 516, 83, 660);
INSERT INTO screen VALUES (352, 1, '2004-07-07 00:00:00', 'Small Molecule', 'Inhibit the Wnt beta-catenin signalling pathway in human HEK 293 cells.', NULL, NULL, 'A screen for compounds that inhibit the Wnt beta-catenin signalling pathway in human HEK 293 cells.', NULL, NULL, NULL, NULL, NULL, 513, 513, 404);
INSERT INTO screen VALUES (354, 0, '2006-09-25 00:00:00', 'Small Molecule', 'Affect germination of Bacillus anthracis spores.', NULL, NULL, 'A screen for compounds that affect germination of Bacillus anthracis spores.', '2006-09: will need to repilot using validated Sterne strain from Core A, which has just been ordered.', '', '', NULL, NULL, 61, 61, 646);
INSERT INTO screen VALUES (184, 2, '2002-02-08 00:00:00', 'Small Molecule', 'Prevent iron uptake by mammalian cells.', NULL, NULL, 'A screen for compounds that prevent iron uptake by mammalian cells.', 'Took over from Jing Xu Brown but as of 12/10/04 has never started screening.', NULL, NULL, NULL, NULL, 683, 285, 152);
INSERT INTO screen VALUES (185, 2, '2005-06-07 00:00:00', 'Small Molecule', 'Differentiate between different mammalian cell pathways of iron uptake (e.g., transferrin versus non-transferrin bound iron). ', NULL, '2005-06-22 00:00:00', 'A screen for compounds that differentiate between different mammalian cell pathways of iron uptake (e.g., transferrin versus non-transferrin bound iron). ', '6/7/05 Peter has been piloting this screen for ~ 1 month and seems to have optimized assay conditions.
11/21/06 Emailed Peter to recommend screening more recently acquired libraries.', '', '', NULL, NULL, 683, 285, 511);
INSERT INTO screen VALUES (183, 2, '2002-01-24 00:00:00', 'Small Molecule', 'Prevent iron uptake by mammalian cells--assay by well fluorescence and imaging', NULL, NULL, 'Screen for compounds that prevent iron uptake by mammalian cells.  HeLa cells are loaded with calcein-AM, which binds iron in the cell and fluoresces.  After compounds are added, the cells are exposed to Fe-NTA which, when taken up by the cells, quenches the fluorescence of calcein-AM.', 'Jing Xu married name =Brown.', 'FeUPTAKE', 'CalceinQuenching', NULL, NULL, 284, 285, 108);
INSERT INTO screen VALUES (357, 0, '2005-02-24 00:00:00', 'Small Molecule', 'Inhibit type III secretion in Gram-negative bacteria.', NULL, '2005-04-08 00:00:00', 'A screen for compounds that inhibit type III secretion in Gram-negative bacteria.', '2006-07-18: Dana Harmon has taken over as lead screener on this project.

2006-04-20: Joan says that Cynthia will be able to resume the screen during Summer 2006, but only for a limited amount of time.', '', '', NULL, NULL, 191, 191, 472);
INSERT INTO screen VALUES (358, 0, '2005-03-07 00:00:00', 'Small Molecule', 'Inhibit Bacillus anthracis sortase A.', NULL, '2005-07-14 00:00:00', 'A screen for compounds that inhibit Bacillus anthracis sortase A.', '8/1/05: primary screen conducted by Anthony Maresso and Justin Kern.', '', '', NULL, NULL, 107, 107, 476);
INSERT INTO screen VALUES (359, 0, '2005-11-16 00:00:00', 'Small Molecule', 'Inhibit cell wall synthesis and membrane stability.', NULL, NULL, 'A screen for compounds that inhibit cell wall synthesis and membrane stability.', '', '', '', NULL, NULL, 500, 500, 543);
INSERT INTO screen VALUES (360, 0, '2005-05-10 00:00:00', 'Small Molecule', 'Drive proliferation in rat cardiomyocytes.', NULL, NULL, 'A screen for compounds that drive proliferation in rat cardiomyocytes.', 'May 2005: Kelly and Mark Keating have been in touch with Rich Lee, who previously did a related screen, to confirm that the two screens are not  competitive.', '', '', NULL, NULL, 148, 149, 502);
INSERT INTO screen VALUES (334, 1, '2004-08-23 00:00:00', 'Small Molecule', 'Inhibit  pre-mRNA splicing in mammalian cells.', NULL, NULL, 'A screen for compounds that inhibit  pre-mRNA splicing in mammalian cells.', NULL, NULL, NULL, NULL, NULL, 385, 322, 414);
INSERT INTO screen VALUES (333, 1, '2002-11-27 00:00:00', 'Small Molecule', 'Inhibit nonesense-mediated mRNA decay. ', NULL, NULL, 'A screen for compounds that inhibit nonesense-mediated mRNA decay.  Cell lines have been constructed that express lucifersase reporter mRNAs subject to nonesense-mediated decay. Compounds are added to the cells and luciferase activity is measured using the dual luciferase reporter system. Positives are compounds that increase luciferase activity over background. ', NULL, NULL, NULL, NULL, NULL, 385, 322, 251);
INSERT INTO screen VALUES (4, 3, '2006-05-01 00:00:00', 'RNAi', 'Mammalian genes required for mitochondrial proliferation.', NULL, '2006-09-19 00:00:00', 'An RNAi  screen for mammalian genes required for mitochondrial proliferation.', 'Will definitely screen mouse druggable genome. May screen human genome as well. 
6/20/06 Will screen at 100nM final in 96-well plates (100ul per well) and therefore has requested 20 ul of 1 uM library for his duplicate screen.  He prefers to do the transfections etc. in his own lab and has therefore requested that we provide him with 20ul of 1 uM stock in a conical bottom 96-well plate which he will then freeze.', '', '', NULL, NULL, 628, 99, 608);
INSERT INTO screen VALUES (1, 3, '2006-05-01 00:00:00', 'RNAi', 'Human genes encoding host factors required for HIV infection and replication. ', NULL, '2006-08-08 00:00:00', 'An RNAi screen for human genes encoding host factors required for HIV infection and replication. ', '5/1/06 Abe has been attempting to pilot screen in 384-well plate. However, due to biocontainment issues (no known 384-well plate readers in BL2+ labs at HMS), this screen may be carried out in 96-well format.
6/28/06 Abe believes he has conditions worked out for the 384-well reverse transfection of his cells.  ', '', '', NULL, NULL, 406, 99, 607);
INSERT INTO screen VALUES (2, 3, '2006-05-01 00:00:00', 'RNAi', 'Human genes required in U2OS osteosarcoma cells for DNA damage sensing, checkpoint activation, and repair of the initial DNA damage.  ', NULL, '2006-07-26 00:00:00', 'An RNAi  screen for human genes required in U2OS osteosarcoma cells for DNA damage sensing, checkpoint activation,  and repair of the initial DNA damage.  ', 'IR signal.  Microscopy assay. Stain Phospho H3 and DAPI, and possibly histone H2AX (phosph. in response to IR). ', '', '', NULL, NULL, 375, 99, 610);
INSERT INTO screen VALUES (3, 3, '2006-05-01 00:00:00', 'RNAi', 'Mouse genes important for mouse embryonic stem (ES) cell self-renewal. ', NULL, '2006-06-28 00:00:00', 'An RNAi screen for mouse genes important for mouse embryonic stem (ES) cell self-renewal. When knocked down, cells differentiate. The cells express GFP from an ES-cell specific promoter (the OCT4 promoter).  The cells are constitutively green unless differentiation is induced. When differentiation is induced, OCT4 turns off, GFP expression goes down, and eventually the cells are not green. Positive control siRNAs for the assay are OCT4 and  Nanog (these genes have the desired phenotype when knocked down).  The assay is read out by FACS. Score % GFP pos vs. GFP neg. Cannot fix the cells.   
', '5/5/06 Ready to go. In 96-well plates, assay =FACS based. Will probably screen at 50nM. Will probably transfect at 100ul volume; reverse transfection. Can take siRNA from stock of 1 uM. Usng BWH FACS, can screen 2-4 plates/day currently. Will be getting FACS in the Elledge lab soon. ', '', '', NULL, NULL, 98, 99, 612);
INSERT INTO screen VALUES (361, 0, '2006-11-07 00:00:00', 'Small Molecule', 'Increase the  spread of oncolytic Herpes Simplex Virus (HSV) in prostate cancer cells.', NULL, NULL, 'A screen for compounds that increase the  spread of oncolytic Herpes Simplex Virus (HSV) in prostate cancer cells.', '', '', '', NULL, NULL, 154, 155, 657);
INSERT INTO screen VALUES (362, 0, '2002-05-17 00:00:00', 'Small Molecule', 'Induce differentiation of mouse embryonic stem cells (CGR8) into cardiac myocytes. ', NULL, NULL, 'A screen for compounds that induce differentiation of mouse embryonic stem cells (line CGR8) into cardiac myocytes.  A cell line bearing a cardiac myocyte-specific  promoter driving expression of GFP will be constructed.  Compounds will be added to the cells and  levels of GFP expression will be monitored over several days using automated microscopy.  ', 'Will make a stable cell line first. May also try viral infection of reporter construct.  Initial experiments will look at live cells over several days (phase + GFP monitored).  10 x magnification should be sufficient.  Once experimental conditions have been worked out, cells may be fixed and DAPI and GFP monitored.   Automatic analysis of images my be possible with Metamorph.Bernadette Lord worked on this project as a technician with Tomo until summer 2003.', NULL, NULL, NULL, NULL, 587, 349, 201);
INSERT INTO screen VALUES (363, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Disrupt or stabilize the Notch/CSL/mastermind ternary complex on DNA.', NULL, NULL, 'A screen for compounds that disrupt or stabilize the Notch/CSL/mastermind ternary complex on DNA.', 'Collaboration with the lab of Steve Blacklow.', NULL, NULL, NULL, NULL, 434, 434, 396);
INSERT INTO screen VALUES (306, 1, '2003-05-02 00:00:00', 'Small Molecule', 'Disrupt normal eye and retinal development in zebrafish.', NULL, NULL, 'A screen for compounds that disrupt normal eye and retinal development in zebrafish. A zebrafish line has been constucted that has GFP under control of a rod cell-specific  promoter (from the opsin gene).  Compounds are added to 24 hour embyros,  and the fish will be examined (every day for several days) using a dissecting scope.  Positives are compounds that prevent GFP expression or produce abnormal eye morphology/retinal development.  This samples from this screen will also be used in a screen for compounds that perturb hair cell development in the zebrafish ear (#291).', 'Will screen Known Bioactives collections only.  These samples stained later and used for Screen#291 too.', NULL, NULL, NULL, NULL, 615, 260, 288);
INSERT INTO screen VALUES (305, 1, '2003-05-14 00:00:00', 'Small Molecule', 'Perturb hair cell development in the zebrafish ear.', NULL, NULL, 'A screen for compounds that perturb hair cell development in the zebrafish ear. This screen is done on the same samples used for Screen #288. A zebrafish line (bearing GFP under control of a rod cell-specific  promoter (from the opsin gene) has been constructed to screen for compounds that disrupt normal eye and retinal development. Compounds are added to 24 hour embyros,  and the fish are examined for eye defects every 24 hours for several days. Four to five days post fertilization, the fish will be stained with a vital dye called DASPEI that stains hair cells preferentially. Ear hair cell development will then be visualized in the GFP channel using a dissecting scope.', 'Will screen Known Bioactives collections only.  Jonathan Masui, a new postdoc in the Dowling lab, is most interested in the results of this screen.', NULL, NULL, NULL, NULL, 615, 260, 291);
INSERT INTO screen VALUES (277, 1, '2004-04-07 00:00:00', 'Small Molecule', 'Induce sexual differentiation of the intracellular parasite Cryptosporidium parvum in culture.', NULL, NULL, 'A screen for compounds that induce sexual differentiation of the intracellular parasite Cryptosporidium parvum in culture.', '1/11/05: assay development proceeding slowly due to lack of personnel.', NULL, NULL, NULL, NULL, 150, 150, 347);
INSERT INTO screen VALUES (276, 1, '2004-04-06 00:00:00', 'Small Molecule', 'Promote growth of the intracellular parasite Cryptosporidium parvum in culture.', NULL, NULL, 'A screen for compounds that promote growth of the intracellular parasite Cryptosporidium parvum in culture.  C. parvum is difficult to culture in vitro.  In this assay epithelial cell monolayers cultured in 96 well plates will be infected with surface sterilized oocysts and incubated with compounds.  Cell will be fixed 24, 48 and 96 hours post infection and fluorescence-based immunohistochemistry will be performed using a parasite specific antibody to quantitate parasite density.  A positive compound is one that increases parasite density.', '1/11/05: assay development proceeding slowly due to lack of personnel.', NULL, NULL, NULL, NULL, 150, 150, 346);
INSERT INTO screen VALUES (364, 0, '2003-07-14 00:00:00', 'Small Molecule', 'Inhibit human group X secreted phospholipase A2.', NULL, NULL, 'A screen for compounds that inhibit human group X secreted phospholipase A2 (sPLA2).  This enzyme hydrolyzes membrane phospholipids to release a free fatty acid and a lysophospholipid.  When this free fatty acid is arachidonic acid it is converted into eicosanoids that are potent mediators of inflammation.  sPLA2 activity is measured fluorimetrically by monitoring the transfer of monomeric pyrene-fatty acid from a pyrene-labeled phospholipid vesicle to BSA in solution.  Monomeric pyrene-fatty acid:BSA emits fluorescence at ~ 395 nm following excitation at ~342 nm, whereas pyrene-labeled phospholipid vesicles do not.  A screening positive shows reduced fluorescence at 395.', NULL, NULL, NULL, NULL, NULL, 249, 250, 309);
INSERT INTO screen VALUES (83, 4, '2006-11-30 00:00:00', 'Small Molecule', 'Inhibit binding of the translation initiation factors eIF4G to eIF4E to each other.  ', NULL, NULL, 'A screen for compounds that inhibit binding of the translation initiation factors eIF4G to eIF4E to each other.  A fluorescence polarization assay using purified mouse eIF4E and an 11 amino acid fluorescein-labeled eIF4G peptide.  eIF4E is the most limiting translation initiation factor and its overexpression is oncogenic.  When proteins that inhibit 4E/4G interaction are overexpressed, the transformed state of some cells lines is reversed.', '11/30/06--Continuation of screen #126. Nate Moerke will  leave the Wagner lab soon and Ricard is taking over the project.', '', '', NULL, NULL, 215, 80, 659);
INSERT INTO screen VALUES (367, 0, '2002-01-30 00:00:00', 'Small Molecule', 'Inhibit protein folding by the bacterial chaperonin GroEL/GroES complex. ', NULL, NULL, 'Screen for compounds that inhibit protein folding by the bacterial chaperonin GroEL/GroES complex.  An in vitro assay is used to monitor folding of MDH protein by purified GroEL/GroES complex.  ATP and NAD are added at the start of the folding reaction and the formation of NADH, catalyzed by properly folded MDH, is measured using a plate reader.', NULL, NULL, NULL, NULL, NULL, 503, 503, 146);
INSERT INTO screen VALUES (368, 0, '2002-05-21 00:00:00', 'Small Molecule', 'Suppress the phenotypes of an Arabidopsis thaliana auxin overproduction mutant.', NULL, NULL, 'A screen for compounds that suppress the phenotypes of an Arabidopsis thaliana auxin overproduction mutant.', NULL, NULL, NULL, NULL, NULL, 399, 400, 203);
INSERT INTO screen VALUES (356, 1, '2002-01-30 00:00:00', 'Small Molecule', 'Disrupt formation of intracellular aggresomes caused by mutant superoxide dismutase in cos-1 cells.', NULL, NULL, 'Screen for compounds that disrupt formation of intracellular aggregates ("aggresomes") caused by expression of mutant superoxide dismutase (SOD).  SOD-containing aggresomes are present in the neurons of patients with Amyotrophic Lateral Sclerosis (ALS).  In this screen, cos-1 cells stably expressing mutant SOD fused to GFP are exposed to compound for 18 hours, and the presence of SOD-containing aggresomes is assayed by microscopy.', NULL, NULL, NULL, NULL, NULL, 318, 318, 140);
INSERT INTO screen VALUES (355, 1, '2002-12-11 00:00:00', 'Small Molecule', 'Inhibit neurofilament  formation in SW13 cells, a human adrenal carcinoma line that does not express vimentin.  ', NULL, NULL, 'A screen for compounds that inhibit neurofilament  formation in SW13 cells, a human adrenal carcinoma line that lacks endogenous vimentin protein (vimentin will form filaments with neurofilament proteins).  Adenoviruses expressing neurofilament proteins (NFL-GFP fusion protein and NFH protein) are used to infect SW13.2 cells. Compounds are added to the cells soon after the infection. The assembly of the two neurofilament subunits is directly visualized using automated fluorescence microscopy, looking for filamentous GFP staining.   Hit compounds are ones that inhibit the filamentous pattern of GFP. ', '1/15/03: So far, Qing and Lisa have screened NINDS collection and no hits have been identified yet.  ', NULL, NULL, NULL, NULL, 318, 318, 253);
INSERT INTO screen VALUES (369, 0, '2005-11-08 00:00:00', 'Small Molecule', 'Decrease the inhibition of HIV infection caused by expression of the monkey TRIM5 protein.', NULL, NULL, 'A screen for compounds that decrease the inhibition of HIV infection caused by expression of the monkey TRIM5 protein. A  human cell line has been constructed  that expresses monkey TRIM5 and is blocked to HIV infection.  The cells will be incubated with small molecules and then infected using a single round, non-infectious HIV reporter virus that encodes luciferase (can be used in a BL2 facility).  Screening positives are compounds that cause increase in lucifierase activity relative to background.  
', '', '', '', NULL, NULL, 728, 264, 541);
INSERT INTO screen VALUES (370, 0, '2003-04-29 00:00:00', 'Small Molecule', 'Inhibit Hsp-72 dependent refolding of heat-damaged luciferase in mammalian cells.', NULL, NULL, 'A screen for compounds that inhibit Hsp-72 dependent refolding of heat-damaged luciferase in mammalian cells.  A prostate carcinoma PC-3 cell line has been  constructed that expresses luciferase. The cells will be  plated, compounds added, and the cells heat shocked at 45 C before luciferase activity in the cells is measured.  Cells with active Hsp72 will be able to re-fold the heat-damaged luciferase, while cells incubated  with compounds that inhibit Hsp72 will not.  Screening positives are compounds whose application results in low levels of luciferase activity in heat shocked cells, but normal luciferase activity in non-heat  shocked cells.', '', 'HSP72_Luciferase', 'HSP72_Luciferase', NULL, NULL, 11, 12, 284);
INSERT INTO screen VALUES (371, 0, '2006-12-14 00:00:00', 'Small Molecule', 'Inhibit production of O-polysaccharide in Francisella tularensis.', NULL, NULL, 'A screen for compounds that inhibit production of O-polysaccharide in Francisella tularensis.', '2006-12-14: Brian Kraybill has worked with this group on assay development, but they have not yet piloted in the facility.', '', '', NULL, NULL, 571, 571, 663);
INSERT INTO screen VALUES (372, 0, '2006-01-11 00:00:00', 'Small Molecule', 'Supress the slow growth phenotype of S. cerevisiae cells bearing a deletion of SDO1 (Shwachman-Diamond Ortholog 1).', NULL, '2006-05-24 00:00:00', 'A screen for compounds that supress the slow growth phenotype of S. cerevisieae cells bearing a deletion of SDO1 (Shwachman-Diamond Ortholog 1), the yeast ortholog of the human SBDS protein, which is involved in Shwachman Diamond Syndrome (SDS).  SDS is a congenital disorder characterized by bone marrow cytopenias, pancreatic insufficiency, and skeletal abnormalities.', 'Paul is a collaborator of Akiko Shimamura (DFCI)  and also of James Huang (Baylor College of Medicine).
Clayton Knight will be travelling to Boston to carry out the screen.', '', '', NULL, NULL, 82, 82, 548);
INSERT INTO screen VALUES (211, 4, '2004-12-09 00:00:00', 'Small Molecule', 'Inhibit the interaction of the PDZ3 domain of the mouse scaffold protein PSD95 (PSD95-PDZ3) with the CRIPT C-terminal peptide. ', NULL, NULL, 'A screen for compounds that  inhibit the interaction of the PDZ3 domain of the mouse scaffold protein PSD95 (PSD95-PDZ3) with the CRIPT C-terminal peptide.  A fluorescence polarization assay will be carried out.', NULL, NULL, NULL, NULL, NULL, 481, 482, 455);
INSERT INTO screen VALUES (208, 4, '2004-12-09 00:00:00', 'Small Molecule', 'Inhibit the interaction of the PDZ1 domain of the mouse scaffold protein PSD95 (PSD95-PDZ1) with the CRIPT C-terminal peptide.', NULL, NULL, 'A screen for compounds that inhibit the interaction of the PDZ1 domain of the mouse scaffold protein PSD95 (PSD95-PDZ1) with the CRIPT C-terminal peptide. A fluorescence polarization assay will be carried out.', NULL, NULL, NULL, NULL, NULL, 481, 482, 457);
INSERT INTO screen VALUES (209, 4, '2002-10-22 00:00:00', 'Small Molecule', 'Induce different "states" in the EGF signaling pathway as assessed using antibody microarrays.', NULL, NULL, 'Adherent cells will be grown in 96-well plates.  Compound stock solution will be pin-transferred into tissue culture medium
containing a low concentration of EGF in 96 well plates.  At the
appropriate stage of cell growth, we will add the compound-containing medium to the cells.  Following a 30 minute incubation, supernatant will be removed and the cells lysed.  The lysates will then be transferred to 384-well plates containing microarrays of capture antibodies that recognize different proteins in the EGF signaling pathway.  After a 1
hour incubation, the plates will be washed and a cocktail of
fluorescently-labeled detection antibodies added to each well.', 'Will screen Known Bioactives as pilot screen on 10/22/02.', NULL, NULL, NULL, NULL, 482, 482, 243);
INSERT INTO screen VALUES (207, 4, '2004-12-09 00:00:00', 'Small Molecule', 'Inhibit the interaction of the PDZ2 domain of the mouse scaffold protein PSD95 (PSD95-PDZ2) with the CRIPT C-terminal peptide.', NULL, NULL, 'A screen for compounds that  inhibit the interaction of the PDZ2 domain of the mouse scaffold protein PSD95 (PSD95-PDZ2) with the CRIPT C-terminal peptide.  A fluorescence polarization assay will be carried out.', NULL, NULL, NULL, NULL, NULL, 481, 482, 456);
INSERT INTO screen VALUES (210, 4, '2004-07-07 00:00:00', 'Small Molecule', 'Inhibit the binding of PDZ domains to peptides derived from mouse proteins involved in synaptic signaling.', '2004-12-03 00:00:00', '2004-12-03 00:00:00', 'A screen for compounds that inhibit the binding of PDZ domains to peptides derived from mouse proteins involved in synaptic signaling.  Mike has arrayed 15 PDZ domains as spots in the bottom of each well of a 384-well plate.  These will be bound with a mix of 3 fluorescently-labelled peptides derived from known PDZ-binding partners that bind to some or many of the 15 domains.  For the high throughput assay, compounds will be added to the peptide mix, in buffer, and then pipetted into special microplates into which the PDZ domains have been arrayed. Screening positives are compounds that disrupt binding of  the peptides to  any of the PDZ-domain spots, thus causing the appearance of  non-fluorescent spot (s) in a background of fluorescent spots. ', '7-14-04 Mike is planning to start with known bioactives.  

12-9-04 Mike is delaying starting this screen in HTS phase due to technological difficulties with an arrayer (located in the CGR).  For the time being, this assay will be used as a secondary screen but Mike hopes it will be possible one day to run it  as a primary screen in HTS mode.', NULL, NULL, NULL, NULL, 481, 482, 407);
INSERT INTO screen VALUES (373, 0, '2004-09-17 00:00:00', 'Small Molecule', 'Affect sex determination in Plasmodium falcuparum.', NULL, NULL, 'A screen for compounds that affect sex determination in Plasmodium falcuparum.', NULL, NULL, NULL, NULL, NULL, 242, 243, 419);
INSERT INTO screen VALUES (324, 5, '2006-09-06 00:00:00', 'Small Molecule', 'Inhibit dengue virus cell fusion.', NULL, NULL, 'A screen for compounds that inhibit dengue virus cell fusion.', '2006-09: this screen was transferred from Jeff Cruzan to Aaron Schmidt.  The previous screen number is 587.', '', '', NULL, NULL, 631, 165, 644);
INSERT INTO screen VALUES (374, 0, '2005-10-31 00:00:00', 'Small Molecule', 'Activate the Mullerian inhibiting substance (MIS) type II receptor in monkey kidney (COS) cells.', NULL, '2006-10-26 00:00:00', 'A screen for compounds that activate the Mullerian inhibiting substance (MIS) type II receptor in monkey kidney (COS) cells. A luciferase reporter assay using a MIS-responsive promoter has been established.  Screening positives will be compounds that activate transcription of the reporter, in the absence of added MIS,  in COS cells expressing the MIS type II receptor, but do not activate transcription of the reporter in cells (screened in parallel) that do not express the MIS type II receptor.', 'I believe the MIS-respnsive promoter that will be used is the BRE  promoter. It was mentioned that this promoter is NOT MIS-specific. It responds to several other extracellular signals.  No MIS-specific responsive promoter is known. ', '', '', NULL, NULL, 95, 95, 537);
INSERT INTO screen VALUES (266, 1, '2006-05-03 00:00:00', 'Small Molecule', 'Inhibit L-alanine dehydrogenase.', NULL, NULL, 'A screen for compounds that inhibit L-alanine dehydrogenase.  This is a purified protein assay utilizing fluorescent readout of NADH production.', '2006-05-03: this screen is the counterscreen for screen 546.', '', '', NULL, NULL, 565, 216, 614);
INSERT INTO screen VALUES (274, 1, '2002-01-24 00:00:00', 'Small Molecule', 'Kill von Hippel-Lindau protein (VHL)-/- (7860 renal carcinoma) cells but not isogenic VHL+/+ cells.
', NULL, NULL, 'A screen for compounds that kill von Hippel-Lindau protein (VHL)-/- (7860 renal carcinoma) cells but not isogenic VHL+/+ cells.  7860 renal carcinoma cells are VHL-/-.  Two cell lines are used in the screen.  One, VHL(+) is stably transfected with a retroviral vector that expresses the VHL protein.  The other (VHL -/-) is stably transfected with an empty retroviral vector.  The two lines will be plated separately and compounds will be added.  The ability of the cells to proliferate will be assayed by measuring BrdU incorporation over time (cells are stained with Abs against BrdU), calcein incorporation (live cells retain fluorescent calcein), or mitochondrial function (JC-1 based assay).', 'NOTE: 3 different methods are used by Archana and Julia to monitor cell viability/proliferation after compound treatment. In theory these are 3 different assays/screens, but for ease of bookeeping (1-21-03) they will be considered as one screen (Bommi-Reddy differential cytotoxicity VHL-/- vs. VHL +/+).  All data from these screens is recorded in LADB (Gorenstein et al.).', NULL, NULL, NULL, NULL, 542, 543, 132);
INSERT INTO screen VALUES (273, 1, '2003-01-22 00:00:00', 'Small Molecule', 'Stabilize the Hypoxia-inducible Factor-1 (Hif-1) gene product', NULL, NULL, 'A screen for compounds that stabilize the oxygen degradation domain (ODD) of Hypoxia-inducible Factor-1 (Hif-1).  This domain is sufficient to render heterologous proteins unstable in the presence of O2, and contains the VHL-binding site.  Under normal O2 conditions, Hif-1 is targeted for degradation by VHL, through Hif-1-ODD.  Hela cells transfected with a Hif1-ODD:GFP fusion construct, or GFP alone, will be incubated overnight with compound (under normal O2 conditions), and then read on a plate reader.  A screening positive is a compound that results in high fluorescence with Hif1-ODD:GFP but low fluorescence with GFP alone.
', 'Note: This screen was started in Oct 02.
Div J2 has been screened', NULL, NULL, NULL, NULL, 542, 543, 265);
INSERT INTO screen VALUES (375, 0, '2006-04-20 00:00:00', 'Small Molecule', 'Act as fugetaxins.', NULL, NULL, 'A screen for compounds that act as fugetaxins.', '', '', '', NULL, NULL, 460, 460, 606);
INSERT INTO screen VALUES (376, 0, '2004-09-02 00:00:00', 'Small Molecule', 'Inhibit the production of ornibactin in Burkholderia cepacia.', NULL, NULL, 'A screen for compounds that inhibit the production of ornibactin in Burkholderia cepacia.  Ornibactin plays a key role in the interaction between Burkholderia cepacia and Pseudomonsa aeruginosa during cystic fibrosis infection.', NULL, NULL, NULL, NULL, NULL, 600, 507, 417);
INSERT INTO screen VALUES (218, 1, '2005-05-10 00:00:00', 'Small Molecule', 'Lead to the DNA damage response and subsequent cell death due to accumulation of a covalent intermediate between the Yersinia pestis topoisomerase I enzyme and cleaved DNA.', NULL, '2005-07-06 00:00:00', 'A screen for compounds that lead to the DNA damage response and subsequent cell death due to accumulation of a covalent intermediate between the Yersinia pestis topoisomerase I enzyme and cleaved DNA.  This screen will be performed in E. coli expressing Y. pestis topo I under the control of an arabinose-inducible promoter.  This strain also carries a luciferase reporter gene directed by a DNA damage-inducible promoter.  Positive hits are defined as compounds that induce luciferase production.', '', '', '', NULL, NULL, 72, 72, 500);
INSERT INTO screen VALUES (217, 1, '2005-11-01 00:00:00', 'Small Molecule', 'Lead to the DNA damage response and subsequent cell death due to accumulation of a covalent intermediate between the Yersinia pestis topoisomerase I enzyme and cleaved DNA.', NULL, NULL, 'A screen for compounds that lead to the DNA damage response and subsequent cell death due to accumulation of a covalent intermediate between the Yersinia pestis topoisomerase I enzyme and cleaved DNA.  This screen will be conducted using an E. coli strain of lower membrane permeability than the strain used in screen 500.', '', '', '', NULL, NULL, 72, 72, 538);
INSERT INTO screen VALUES (366, 1, '2005-11-02 00:00:00', 'Small Molecule', 'Affect TLR signaling in cells stimulated with TNF-alpha.', NULL, NULL, 'A screen for compounds that affect TLR signaling in cells stimulated with TNF-alpha.  This screen will employ a HEK293 cell line that stably expresses TLRs.  The cells will be transfected with an NF-kB luciferase reporter construct, incubated with compounds, and then stimulated with TNF-alpha.  Cells will be lysed and luminescence read 6-8 hours later using a plate reader.  TNA-alpha stimulation in this protocol increases luciferase activity, and positive hits in this screen are defined as those compounds that inhibit this stimulation.', 'This screen originated as a counterscreen to screen 459 (a screen for compounds that affect TLR signaling in cells infected with lymphocytic choriomeningitis virus).', '', '', NULL, NULL, 444, 444, 539);
INSERT INTO screen VALUES (365, 1, '2004-12-13 00:00:00', 'Small Molecule', 'Affect TLR signaling in cells infected with lymphocytic choriomeningitis virus (LCMV).', NULL, NULL, 'A screen for compounds that affect TLR signaling in cells infected with lymphocytic choriomeningitis virus (LCMV).  This screen will employ a HEK293 cell line that stably expresses TLRs.  The cells will be transfected with an NF-kB luciferase reporter construct, incubated with compounds, and then stimulated with LCMV.  Cells will be lysed and luminescence read 6-8 hours later using a plate reader.  LCMV stimulation in this protocol increases luciferase activity approximately 15-fold, and positive hits in this screen are defined as those compounds that inhibit this stimulation.', '4/3/06: hit summary sent.', '', '', NULL, NULL, 444, 444, 459);
INSERT INTO screen VALUES (377, 0, '2002-02-08 00:00:00', 'Small Molecule', 'Increase the lifespan of C. elegans.', NULL, NULL, 'A screen for compounds that increase the lifespan of C. elegans.', NULL, NULL, NULL, NULL, NULL, 96, 97, 154);
INSERT INTO screen VALUES (378, 0, '2004-05-27 00:00:00', 'Small Molecule', 'Allow growth of S. cerevisiae cells expressing the I278T mutant of human Cystathionine beta-synthase (CBS).', '2004-06-02 00:00:00', '2004-06-02 00:00:00', 'A screen for compounds that allow growth of S. cerevisiae cells expressing the I278T mutant of human Cystathionine beta-synthase (CBS).', NULL, NULL, NULL, NULL, NULL, 359, 359, 370);
INSERT INTO screen VALUES (261, 1, '2003-07-24 00:00:00', 'Small Molecule', 'Inhibit productive infection of human red blood cells by the malaria parasite P. falciparum.', NULL, NULL, 'A screen for compounds that inhibit productive infection of human red blood cells by the malaria parasite P. falciparum.', 'Heard about this screen in July 2003 from Dyann Wirth. She faxed/sent email with hit data 7-24-03. ', NULL, NULL, NULL, NULL, 402, 402, 311);
INSERT INTO screen VALUES (260, 1, '2002-01-30 00:00:00', 'Small Molecule', 'Affect mammalian host cell invasion by the parasite Toxoplasma gondii.', NULL, NULL, 'Screen for compounds that affect mammalian host cell invasion by the parasite Toxoplasma gondii.', '5/9/03 Screened ChemBridge DiverSet E 1-51 and GLL 386-404. Hits from both. Manuscript in preparation.', 'TOXOINVASION', 'FLUOR-TOXO-INV', NULL, NULL, 402, 402, 141);
INSERT INTO screen VALUES (379, 0, '2003-06-18 00:00:00', 'Small Molecule', 'Inhibit the adhesion of lily pollen tubes to the SCA (stigma/stylar cysteine rich adhesion protein)/pectin matrix.  ', NULL, NULL, 'A screen for compounds that inhibit the adhesion of lily pollen tubes to the SCA (stigma/stylar cysteine rich adhesion protein)/pectin matrix.  Compounds were added to lily pollen tubes in the presence of SCA/pectin matrix and adhesion was scored after 4 hours using a dissecting microscope.  ', '6-18-03: 14 positives identified. 8 re-tested and of these, only 1 appears to have an effect on pollen tube adhesion.  More experiments are underway.', 'LilyPollen', 'LilyPollenAdhesion', NULL, NULL, 413, 414, 302);
INSERT INTO screen VALUES (380, 0, '2006-12-11 00:00:00', 'Small Molecule', 'Inhibit the S. aureus replicative DNA helicase.', NULL, NULL, 'A screen for compounds that inhibit the S. aureus replicative DNA helicase.', '2006-12: this assay is based on the ability of the helicase to unwind a substrate consisting of two annealed oligonucleotides, one labeled with a fluorescent moiety at its 5 end, and the other with a quencher at its 3 terminus.  The oligonucleotides form a Y-shaped annealed pair, consisting of 30 annealed residues and an additional 30 noncomplementary unannealed residues.  When annealed, the fluorescent label (6-FAM) and quencher (BHQ1) are held in close proximity, resulting in a low background level of fluorescence.  In the presence of a functional helicase and ATP, the duplex is unwound. One strand is then captured by a complementary unlabeled strand, present in molar excess, which prevents reannealing of the fluorescent and quencher strands.  This results in a measurable increase in fluorescence over time; this increase continues in a nearly linear manner for at least 40 minutes at room temperature and is completely ATP-dependent. The assay has been validated in 96-well format, and validation in 384-well format is underway.  Readout may be done as an endpoint value (RFU) or as a two- or multi-point slope value (RFU/min).  Z'' scores above 0.5 are obtained routinely when the assay is run in a two-point slope format.  In addition to providing excellent Z'' scores, the slope format also reduces interference from fluorescing and quenching compounds in the collection.', '', '', NULL, NULL, 187, 187, 661);
INSERT INTO screen VALUES (381, 0, '2003-06-19 00:00:00', 'Small Molecule', 'Bind to a mutant ATP binding site in the yeast AAA ATPase TIP49 and inhibit ATPase activity in the mutant but not wildtype enzyme.', '2003-08-01 00:00:00', '2003-08-01 00:00:00', 'A screen for compounds that bind to a mutant ATP binding site in the yeast AAA ATPase TIP49 and inhibit ATPase activity in the mutant but not wildtype enzyme.  A strain bearing the appropriate point mutation in TIP49  has been constructed in an snq2 pdr5 (drug sensitizing) background.  This strain grows as well as the wt TIP49 strain in the same background at 30oC but grows more slowly than wt at lower temperatures.  Compounds will be added to cells and screening positives are those that inhibit growth of the TIP49 mutant but not the wt control strain. ', '03/04/03: application reviewed and tentatively accepted pending final revisions.  Final application accepted 05/13/03.
Seeking a bump compound to fit in the mutant active site "hole" of TIP49.
Note: The human homologue of yTIP49 (hTIP49) 70% identical to the yeast protein. TIP49 is essential in yeast and hTIP49 does not rescue lethality. The ATPase domain of the protein is essential for function. TIP49 is part of a transcrition complex and also has an RNA-binding role in ribosomal biogenesis. In yeast, it has been shown to play a role in cell size control. hTIP49 has been shown to be associated with the c-myc oncoprotein and is thought to act with myc to cause cell transformation/apopotosis. In zebrafish, TIP49, together with B-catenin, seems to play a role in the control of organ size.', NULL, NULL, NULL, NULL, 405, 323, 304);
INSERT INTO screen VALUES (382, 0, '2006-05-01 00:00:00', 'RNAi', 'Human proteins that are regulators of the Cdc25A phosphatase and  whose levels are controlled by the ubiquitin proteasome pathway. ', NULL, NULL, 'An RNAi  screen for human proteins that are regulators of the Cdc25A phosphatase and  whose levels are controlled by the ubiquitin proteasome pathway. ', '3/2/06 (application)We would like to look for molecules that are involved in the signaling pathway that controls cdc25A degradation. ', '', '', NULL, NULL, 343, 233, 609);
INSERT INTO screen VALUES (383, 0, '2005-05-26 00:00:00', 'Small Molecule', 'Inhibit binding of calcineurin to a peptide fragment of the DSCR1 (Down Syndrome Critical Region 1) protein.', '2005-09-14 00:00:00', '2005-09-15 00:00:00', 'A screen for compounds that inhibit binding of calcineurin to a peptide fragment of the DSCR1 (Down Syndrome Critical Region 1) protein. A fluorescence polarization screen has been developed to monitor binding of the phosphatase calcineurin (43 kD) to a fluorescently labeled fragment  (6 kD) of the DSCR1 protein. ', '', '', '', NULL, NULL, 533, 509, 508);
INSERT INTO screen VALUES (172, 1, '2006-10-19 00:00:00', 'Small Molecule', 'Are potentiators of the antifungal drug miconazole and that are active against multidrug tolerant persister cells of Candida albicans biofilms.', NULL, NULL, 'A screen for compounds that are potentiators of the antifungal drug miconazole and that are active against multidrug tolerant persister cells of Candida albicans biofilms.', 'Screening of Candida albicans biofilms for miconazole potentiators.


Innoculate a single colony of Candida albicans from an agar plate into 10 ml liquid YPD media in a 125 ml baffled flask. Perform for each strain, DSY1024 and CAF4-2.

Grow overnight at 30C with shaking.

Harvest cells by centrifugation, wash with PBS and re-suspend in 10 ml RPMI 1640.

Standardize optical density 600nm = 0.1 in 1.5 liters RPMI 1640. (typically overnight OD600= 20.0)

Dispense 30 ?l of diluted culture into each well of 384-well plates for strain CAF4-2. Dispense DSY1024 for positive control wells. 1.5 liters is sufficient for 120 384-well plates.

Grow for 48 hours at 37C with shaking to allow biofilms to form.

Dump supernatant and add 30 ?l RPMI 1640 with 100 ?g/ml miconazole nitrate to each well.

Add 10 ?g/ml compounds to wells and incubate for 24 hours at 37C with shaking.

Dump supernatant and add 30 ml RPMI 1640 with 1 mg/ml final concentration XTT.

Incubate for 6 hours at 37C with shaking.

Measure OD450nm and subtract OD690. 

***NOTE***

Im experimenting with using alamar blue instead of XTT. Its a similar metabolic indicator thats advantageous because its nontoxic and does not involve hazardous waste disposal.

', '', '', NULL, NULL, 650, 241, 654);
INSERT INTO screen VALUES (171, 1, '2006-01-09 00:00:00', 'Small Molecule', 'Act as antibacterial prodrugs.', NULL, NULL, 'A screen for compounds that act as antibacterial prodrugs.  This screen will use a pooled library of E. coli deletion mutants to identify compounds that are converted intracellularly into antimicrobial compounds.  A mutant lacking a converting enzyme is expected to survive treatment with a prodrug, whereas cells containing the converting enzyme will be killed.  This screen requires a counterscreen with wild-type E. coli.', '1/9/06: application will be submitted for review after satisfactory piloting data are acquired.', '', '', NULL, NULL, 241, 241, 547);
INSERT INTO screen VALUES (187, 3, '2003-12-15 00:00:00', 'Small Molecule', 'Suppress the cytotoxicity of alpha-synuclein in the yeast S. cerevisiae.', NULL, '2003-12-15 00:00:00', 'A screen for compounds suppress the cytotoxicity of alpha-synuclein in the yeast S. cerevisiae.', 'pdr1 pdr3 knockout yeast strain used.

12/21/05 - 643 C16 and 656 C15 strong hits', NULL, NULL, NULL, NULL, 267, 58, 329);
INSERT INTO screen VALUES (186, 3, '2003-12-15 00:00:00', 'Small Molecule', 'Suppress the cytotoxicity of Huntingtin in the yeast S. cerevisiae as monitored by a growth/non-growth assay.', NULL, '2003-12-15 00:00:00', 'A screen for compounds that suppress the cytotoxicity of Huntingtin in the yeast S. cerevisiae.', 'pdr1 pdr3 drug senstive yeast strain is used for this screen.

3-17-04 Smitha has taken over this screen as Tiago writes up his thesis.
9-2-04 Smitha told me that most all initial positives from this screen were false because of spontaneous suppressors that grow up in some wells. Thus, this screening method is not robust and will be abandoned in favor of a new method (see Smitha''s screen #418). Note:  the spontaneous suppressors  don''t respire well and can be identified via tetrazolium dye staining. ', NULL, NULL, NULL, NULL, 267, 58, 330);
INSERT INTO screen VALUES (188, 3, '2004-10-05 00:00:00', 'Small Molecule', 'Reverse or promote prion conformation of Aplysia californica neuronal CPEB (a cytosolic polyadenylation element binding protein).', '2004-10-05 00:00:00', '2004-10-05 00:00:00', 'A screen for compounds that reverse or promote prion conformation of Aplysia californica neuronal CPEB (a cytosolic polyadenylation element binding protein).', NULL, NULL, NULL, NULL, NULL, 279, 58, 422);
INSERT INTO screen VALUES (136, 4, '2005-02-25 00:00:00', 'Small Molecule', 'Affect ftsZ function and septum formation during E. coli  cell division--sulA knockout, whole cell assay.', NULL, '2005-06-22 00:00:00', 'A screen for compounds that affect ftsZ function and septum formation during E. coli  cell division--sulA knockout, whole cell assay.', '6/19/06: Do not send screen title to Novartis! 
On Jun 16, 2006, at 8:58 PM, Marc Kirschner wrote:
Dear Caroline,
	Hold off on that for now.  We may want to approach Novartis or some other company with the results of the screen as they are.
Marc', '', '', NULL, NULL, 670, 117, 473);
INSERT INTO screen VALUES (189, 3, '2004-09-02 00:00:00', 'Small Molecule', 'Suppress the cytotoxicity of Huntingtin in the yeast S. cerevisiae as monitored by tetrazolium dye staining.', NULL, NULL, 'A screen for componds that suppress the cytotoxicity of Huntingtin in the yeast S. cerevisiae as monitored by tetrazolium (WST-1 Dojindo) dye staining.', '9-2-04 Smitha told me that most all initial positives from screen #330 were false because of spontaneous suppressors that grow up in some wells. Thus, this screening method is not robust and will be abandoned in favor of a new method (this new screen #418). Note:  the spontaneous suppressors  don''t respire well and can be identified via tetrazolium dye staining. 
June 2005: Dojindo is in Maryland. http://www.dojindo.com/products/alphasearch/dojindodtl1.cfm?alphafield=WST%2D9bb&Prodname=WST-9
 There are several companies which sell the dye. But, Dojindo works out the cheapest if you are planning to use huge amounts of it. I used WST-1 which gave me the best values in the plate reader. I am also sending you an email correspondence that I had with Coy at Dojindo. 

Hope this helps.

Smitha

------------
Dear Smitha:

Thank you for your inquiry.

Following is the information on the preparation of WST-1 and 1-Methoxy PMS working solution for proliferation and cytotoxicity assays.

Preparation of the working solution for 500 tests (96-well plate x 5
plates):
1. Dissolve 16.3 mg WST-1 in 4.5 mL of 20mM HEPES buffer (pH7.4). 2. Dissolve 7 mg 1-Methoxy PMS in 10 mL ddH2O or HEPES buffer. 3. Add 0.5 mL of the 1-Methoxy PMS solution from step 2 to the WST-1 solution from step 1. 4. If necessary, filter sterilize the working solution from step 3, using 0.22 um membrane filter.

The working solution is stable for 3 days at 0-5 C and for 1 month at -20 C.

Please let me know if I can be of further assistance.
Thank you.

Sincerely,
Coy
', NULL, NULL, NULL, NULL, 504, 58, 418);
INSERT INTO screen VALUES (386, 0, '2003-02-13 00:00:00', 'Small Molecule', 'Increase or decrease the heart rate of zebrafish.', NULL, NULL, 'A screen for compounds that increase or decrease the heart rate of zebrafish.  A transgenic zebrafish line has been constructed that expresses GFP under the control of the cardiac myosin light chain promoter and thus the fish have green hearts.  A Metamorph algorithm has been developed that allows for automated analysis of heart movement (which correlates with heart rate) after images of the fish have been captured by automated microscopy. ', NULL, NULL, NULL, NULL, NULL, 537, 40, 270);
INSERT INTO screen VALUES (387, 0, '2002-01-30 00:00:00', 'Small Molecule', 'Inhibit the activity of human angiogenin.', NULL, NULL, 'Screen for compounds that inhibit the activity of human angiogenin, a protein with RNase activity that can induce angiogenesis.  An in vitro assay for angiogenin RNase activity was developed using purified angiogenin and a small (approx. 5 nucleotide) RNA analogue that fluoresces when cleaved.', 'All results published: Kao et al. (2002), PNAS 99:10066-10071., and in Jenkins et al. (2003), PROTEINS: Struc., Func., and Gen. 50:81-93.
Quenchers (secondary assay) data entered in ActivityBase JJ010828-01 as plates 1-7, but should have been entered as NCI Structural Diversity Set plates 53-59.
April 2001--Richard Kao is a former postdoc of the Shapiro lab. ', 'ANGIOGENESIS', 'Angiogenin', NULL, NULL, 212, 212, 142);
INSERT INTO screen VALUES (302, 1, '2005-05-18 00:00:00', 'Small Molecule', 'Inhibit the type III secretion system in Salmonella typhimurium.', NULL, '2005-07-25 00:00:00', 'A screen for compounds that inhibit the type III secretion system in Salmonella typhimurium.', '', '', '', NULL, NULL, 127, 127, 506);
INSERT INTO screen VALUES (301, 1, '2005-07-18 00:00:00', 'Small Molecule', 'Inhibit aminoarabinose modification of LPS', NULL, '2005-07-25 00:00:00', 'A screen for compounds that inhibit aminoarabinose modification of LPS.', '', '', '', NULL, NULL, 126, 127, 514);
INSERT INTO screen VALUES (388, 0, '2003-02-12 00:00:00', 'Small Molecule', 'Cause increased binding of the androgen receptor (AR) to a corepressor, NCoR.', NULL, NULL, 'A screen for compounds that cause increased binding of the androgen receptor (AR) to a corepressor, NCoR.', NULL, NULL, NULL, NULL, NULL, 76, 76, 268);
INSERT INTO screen VALUES (66, 1, '2003-12-16 00:00:00', 'Small Molecule', 'Differentially inhibit the proliferation of (or kill) mutant G12D K-ras expressing cells, without affecting wild type MEFs--wt MEFS assay.', NULL, NULL, 'A screen for compounds that differentially inhibit the proliferation of (or kill) mutant G12D K-ras expressing cells, without affecting wild type MEFs--wt MEFS assay.', '8/30/04 - Nicky does not trust data before 3/1/04. Do not enter data before 3/1/04 into database.', NULL, NULL, NULL, NULL, 451, 304, 331);
INSERT INTO screen VALUES (65, 1, '2003-04-30 00:00:00', 'Small Molecule', 'Differentially inhibit the proliferation of (or kill) mutant G12D K-ras expressing cells, without affecting wild type MEFs--G12D K-ras mutant  MEF assay.', NULL, NULL, 'A screen for compounds that differentially inhibit the proliferation of or kill mouse embryonic fibroblasts (MEFs) expressing a mutant G12D allele of K-ras, without affecting wild type MEFs--G12D K-ras mutant  MEF assay.', 'Nicky will pilot proliferation assays (BrdU incorporation, Promega Cell-Titer Glo, Calcein AM) using Hela cells prior to working with the MEFs.  Initial pilots will use the high copy concentration of the known bioactives collection. 
12/4/03 Nicky and Alice likely switch from BrdU cytoblot  assay to a celltitreglow (promega) viability assay.
12/16/03 - switch to CellTiter Glo (promega).  At this time, Kras MEFs will be screened first, and then wt MEFs will be counter-screened at a later date (screen #331).  This is in contrast to the BrdU protocol where both wt and KrasG12D MEFs were screened together.
02/12/04 - still seeing variability issues with Cell TiterGlo.  Try reducing throughput of assay (still using Cell TiterGlo).
8/3/04 - Nicky does not trust data before 3/1/04. Data before 3/1/04 is not for database.
', NULL, NULL, NULL, NULL, 451, 304, 285);
INSERT INTO screen VALUES (391, 0, '2005-10-12 00:00:00', 'Small Molecule', 'Act as small molecule agonists of integrin MAc-1 (CD11b/CD18) that allosterically regulate integrin activation.', NULL, '2006-07-27 00:00:00', 'A screen for compounds that act as small molecule agonists of integrin MAc-1 (CD11b/CD18) that allosterically regulate integrin activation.', 'Activate cell binding to substrate.384-well format.  Take high absorbancy plate, coat plates with ligand, add small molecule, add cells, incubate, 1 wash, cell count with a kit--Cyquant (Molecular Probes); TNB (Promega); luciferase expressing cell line, Cell Titre Glo (Promega). 

Counter screen :+EDTA (integrin-specific binding; want compounds that do not increase binding in the presence of EDTA; + 1 mM Ca 1mM Mg--integrins won''t bind unless actvated by small molecule;  1 mM Mn--cells bind either via integrins or other entities.

Will try 1,2 and possibly 3 as pilots together; may run only 2 as screening assay.

Control compounds that mimic interesting screening positive:  

Also have a cell line that is superactive with regard to adhseion; interested  in looking at things that decrease adhesion (need better controls first). ', '', '', NULL, NULL, 251, 251, 531);
INSERT INTO screen VALUES (71, 4, '2006-05-01 00:00:00', 'RNAi', 'Mouse genes that  encode host factors required for restricting the growth of the non-pathogenic Mycobacterium species M. smegmatis in the murine macrophage-like cell line RAW 264.7.', NULL, NULL, 'An RNAi  screen for mouse genes that  encode host factors required for restricting the growth of the non-pathogenic Mycobacterium species M. smegmatis in the murine macrophage-like cell line RAW 264.7.', 'September 2006 Jen has taken a job at Novartis.  Unclear whether her screen will be continued in the Perrimon lab. ', '', '', NULL, NULL, 486, 19, 611);
INSERT INTO screen VALUES (68, 4, '2004-07-07 00:00:00', 'Small Molecule', 'Affect the morphology of Drosophila tisse culture cells.', NULL, NULL, 'A screen for compounds that affect the morphology of Drosophila tisse culture cells.', '', '', '', NULL, NULL, 570, 19, 400);
INSERT INTO screen VALUES (69, 4, '2002-01-30 00:00:00', 'Small Molecule', 'Inhibit infection of Drosophila DL2 cells by the Drosophila-specific virus DCV--cell viability.', NULL, NULL, 'Screen for compounds that inhibit infection of Drosophila DL2 cells by the Drosophila-specific virus DCV.  Cells are exposed to compounds before infection with the virus.  The extent of productive infection is determined using the "SyTox" live-dead assay, imaging the cells with the autooscope.', '5/9/03 6-mercaptopurine riboside does retest in Sara''s assay but it is not in well 55 P20. It turns out that another compound with the same molecular formula as 6-mercaptopurine riboside is present in 55 P20. Today David provided Sara cherry picks of all 8 potential hits to retest in her assay.
5/1/03 Summary: screened NCI Structural Div. Set and got one hit: 6-mercaptopurine riboside (possibly well PL-0055 P20).  She re-orderd the compound from Sigma, it re-screened 2 years ago. Sara is re-starting the project now and will update us with new info.
', NULL, NULL, NULL, NULL, 84, 19, 137);
INSERT INTO screen VALUES (70, 4, '2005-05-10 00:00:00', 'Small Molecule', 'Affect the Wnt pathway in Drosophila cells.', NULL, '2005-05-12 00:00:00', 'A screen for compounds that affect the Wnt pathway in Drosophila cells.', 'Ram is a new professor at NYU. 6/7/06', '', '', NULL, NULL, 511, 19, 504);
INSERT INTO screen VALUES (67, 4, '2005-11-08 00:00:00', 'Small Molecule', 'Inhibit STAT activity in Drosophila tissue culture cells. ', NULL, NULL, 'A screen for compounds that inhibit STAT activity in Drosophila tissue culture cells. ', 'Publication of RNAi screen using same assay: "Genome-wide RNAi analysis of  JAK/STAT signaling components in Drosophila" Genes Dev. 2005 Aug 15;19(16):1861-70

11/21/05: Met with Baeg. He is making a stable cell line with which to carry out the screen. We talked about the desirablility of including a cell viability counter screen (e.g. Renilla report also stably integrated) for his primary screen.', '', '', NULL, NULL, 427, 19, 542);
INSERT INTO screen VALUES (192, 3, '2002-02-15 00:00:00', 'Small Molecule', 'Inhibit the export of mRNA from the nucleus to the cytosol.', NULL, NULL, 'Screen for compounds that inhibit the export of mRNA from the nucleus to the cytosol.  The export of two substrates, bulk mRNA  and c-fos mRNA, is monitored simultaneously by fluorescence in situ hybridization (visualized using the autoscope). Bulk mRNA export is monitored using an oligo-dT-biotin probe that is bound by streptavidin-Alexa (FITC channel). Export of c-fos mRNA is monitored using a complementary oligo that is directly labeled with Cy3. ', NULL, NULL, NULL, NULL, NULL, 535, 170, 156);
INSERT INTO screen VALUES (191, 3, '2002-01-24 00:00:00', 'Small Molecule', 'Affect nuclear localization  of the forkhead protein in mammalian cells. ', NULL, NULL, 'Screen for compounds that affect nuclear localization  of the forkhead protein in mammalian cells.  Cells transiently expressing a tagged version of forkhead are exposed to compound for one hour, then fixed, stained with Abs that detect forkhead, and imaged using the autoscope.  The amount of forkhead localized to the nucleus in the presence of each compound is quantitated using ICCB-written image analysis programs.', 'Results from first part of the screen published in: Kau, T.R., Schroeder, F., Ramazwamy, S., Wojciechowski, C.L., Zhao, J.J., Roberts, T.M., Clardy, J., Sellers, W.R., Silver, P.A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN deficient tumor cells. Cancer Cell. in Press.', 'FKHR-NU-TRAN', 'FKHR-Nucl-Trans', NULL, NULL, 169, 170, 116);
INSERT INTO screen VALUES (190, 3, '2002-05-30 00:00:00', 'Small Molecule', 'Inhibit activity of the mammalian protein CRM1, a general nuclear export factor.', NULL, NULL, 'A screen for compounds that inhibit activity of the mammalian protein CRM1, a general nuclear export factor.  The assay will be carried out using U2OS cells that express a recombinant protein: HIV Rev, fused to GFP and containing a nuclear export sequence from PKI.  Under normal conditions, this RevGFP is localized in the cytosol.  In the presence of inhibitors of nuclear export, it accumulates in the nucleus.  For the screen, U2OS-RevGFP cells will be treated with compounds, fixed, and then imaged using automated microscopy. Hits will be those compounds that cause RevGFP to be sequestered in the nucleus. ', 'This screen is a collaboration between Tweeny and Tim. They will screen specifically Tim''s combichem library.  Because CRM activity seems particularly sensitive to alkylating agents, the results of this screen will help characterize the members of his library with regard to this property.', NULL, NULL, NULL, NULL, 169, 170, 204);
INSERT INTO screen VALUES (193, 3, '2004-02-26 00:00:00', 'Small Molecule', 'Inhibit export of the 14-3-3 sigma protein from the nucleus of HeLa cells.', NULL, '2004-02-26 00:00:00', 'A screen for compounds that inhibit export of the 14-3-3 sigma protein from the nucleus of HeLa cells.  Compounds will be added to HeLa cells. After incubation for **hours, the cells will be fixed, stained with DAPI and an anti-14-3-3 sigma mAB, and visualized using the automated microscope. Screening positives are compounds that cause accumulation of 14-3-3 sigma in the nucleus.', '6/30/06 Pam emailed that this screen is completed and unlikely to be restarted in her lab.', '', '', NULL, NULL, 326, 170, 342);
INSERT INTO screen VALUES (177, 2, '2004-03-04 00:00:00', 'Small Molecule', 'Inhibit E6-dependent degradation of p53 in vitro.', '2004-10-14 00:00:00', '2004-10-14 00:00:00', 'A screen for compounds that inhibit E6-dependent degradation of p53 in vitro.', '10-14-04 Met with Kwa. His assay is ready to start to pilot on the plate reader in 384-well format.   Has p53-luc construct in cell extract with aded GST-E6.', NULL, NULL, NULL, NULL, 226, 227, 343);
INSERT INTO screen VALUES (392, 0, '2004-09-30 00:00:00', 'Small Molecule', 'Affect development of the zebrafish embryo, especially the circulatory system.', NULL, NULL, 'A screen for compounds that affect development of the zebrafish embryo, especially the circulatory system.', 'Starting with Starr Foundation extracts, 96-350 at a time.', NULL, NULL, NULL, NULL, 619, 194, 421);
INSERT INTO screen VALUES (393, 0, '2006-01-13 00:00:00', 'Small Molecule', 'Increase expression of the IRS-2 protein in primary human pancreatic islet cells.', NULL, '2006-10-26 00:00:00', 'A screen for compounds that increase expression of the IRS-2 protein in primary human pancreatic islet cells. Irs2 is a substrate of the insulin and IGF1 receptor tyrosine kinases and is essential for compensatory beta-cell growth, function, and survival trhoughout life.  Because the assay is carried out on islet cells isolated from humans (from organs donated to scientific research), engineering of the cells to facilitate assay readout is impossible. Thus, the level of IRS-2 mRNA expression will be measured directly, after compound treatment of the cells, using quantitive PCR  or branch DNA (bDNA) technology. ', '1/12/06 Email to Morris and Lynn describing bDNA technology. Randy has offered to help provide protocols. Genospectra website:  http://www.genospectra.com/prod_QP.html ', '', '', NULL, NULL, 204, 204, 550);
INSERT INTO screen VALUES (251, 1, '2002-03-20 00:00:00', 'Small Molecule', 'Induce HIF-dependent transcription and the hypoxia pathway in  mammalian cells under non-hypoxic conditions.', NULL, NULL, 'A screen for compounds that enhance HIF-dependent transcription and the hypoxia pathway in  mammalian cells.  A luciferase assay has been developed to monitor HIF-dependent transcription from the Hypoxia Response Element (HRE). A cell line (VHL+/+; Hep3B cells) carrying a stably integrated HRE-luciferase reporter construct  is used to assay for compounds that induce the HR pathway under non-hypoxic conditions. Control cells (786-0 cells--VHL-/- cells, transfected with a construct expressing the VHL gene and also a luciferase reporter driven by the SV40 promoter) were screened in parallel.', 'Cannot screen PL-0005, Chembridge and PL-0053, NCI Div set.NOTE: 10/18/02 Mike should not screen new version of NCI Diversity Set without consulting Dara and /or Caroline.3/27/03-OK from Becky for Mike to screen  NCI Diversity set ver. 2.', 'HIF-Hypoxia', 'HIF-HypoxiaEnh', NULL, NULL, 192, 193, 177);
INSERT INTO screen VALUES (250, 1, '2002-06-06 00:00:00', 'Small Molecule', 'Inhibit HIF-dependent transcription and the hypoxia pathway in  mammalian cells.', NULL, NULL, 'A screen for compounds that inhibit HIF-dependent transcription and the hypoxia pathway in  mammalian cells.  A luciferase assay has been developed to monitor HIF-dependent transcription from the Hypoxia Response Element (HRE).  In VHL-/- cells (786-0, a renal clear-cell carcinoma line), the hypoxia response is constitutively on and the stably integrated HRE-luciferase reporter construct produces luciferase. This cell line is used to assay for compounds that inhibit the HR.  A control cell line (786-0 cells with a stably integrated luciferase construct driven by the SV40 promoter) was screened in parallel  to eliminate compounds that lower luciferase expression in a non-HRE-dependent manner.', 'Cannot screen PL-0005, Chembridge and PL-0053, NCI Div set.

NOTE: 10/18/02 Mike should not screen new version of NCI Diversity Set without consulting Dara and /or Caroline.
3/27/03-OK from Becky for Mike to screen  NCI Diversity set ver. 2. ', 'HIF-Hypoxia', 'HIF-Hypoxia', NULL, NULL, 192, 193, 208);
INSERT INTO screen VALUES (394, 0, '2006-06-26 00:00:00', 'RNAi', 'An RNAi screen for human genes that modulate the activity of MEF2, a transcription factor that seems to affect synapse formation between CNS neurons in a neuronal-activity dependent manner. ', NULL, '2006-09-19 00:00:00', 'An RNAi screen for human genes that modulate the activity of MEF2, a transcription factor that seems to affect synapse formation between CNS neurons in a neuronal-activity dependent manner. They have shown that stimulating SH-SY5Y  cells, a human neuroblastoma line,  using a combination of the calcium ionophore ionomycin and the phorbol ester PMA, leads to transcriptional activation of endogenously expressed MEF2 and promotes expression of a MEF2-cognitive luciferase reporter by 70 fold.  Our protocol for screen is as follows: SH-SY5Y cells are cotransfected with siRNA, MEF2 luciferase reporter DNA, constitutive activite Renillar reporter together using lipofectamine 2000. 72 hours later cells are treated with inonmycin/PMA and lysed for luciferase activity measurement.', '', '', '', NULL, NULL, 77, 78, 633);
INSERT INTO screen VALUES (395, 0, '2004-02-17 00:00:00', 'Small Molecule', 'Affect bone marrow megakaryocyte differentiation and/or ploidy', NULL, '2004-02-17 00:00:00', 'A screen for compounds that affect bone marrow megakaryocyte differentiation and/or ploidy. Murine bone marrow pre-cursor cells are isolated, plated into 384-well plates, and compounds are added.  Cells are cultured for 4-5 days before fixation, and staining for DNA and a marker of differentiation.  Cells are imaged using an automated microscope.  Positives either enhance or inhibit increase in ploidy/differentiation.', '5/30/06 No updates.', '', '', NULL, NULL, 224, 224, 339);
INSERT INTO screen VALUES (396, 0, '2006-11-03 00:00:00', 'Small Molecule', 'Inhibit the activity of ricin.', NULL, NULL, 'A screen for compounds that inhibit the activity of ricin.  This screen is based on MTT detection of ricin cytotoxicity towards Vero cells.', '2006-11-03: This screen will pilot with a cell-based assay, but they are apparently fairly close to establishing an enzymatic assay.  The enzymatic assay is preferable and will be used if it is appropriate.

NOTE: COMS requires that ricin be kept in a locked freezer, and that a log of ricin quantities be maintained.', '', '', NULL, NULL, 316, 316, 656);
INSERT INTO screen VALUES (336, 1, '2003-05-28 00:00:00', 'Small Molecule', 'Inhibit the activity of yeast peptide N-glycanase (PNGase).', NULL, NULL, 'Inhibit the activity of yeast peptide N-glycanase (PNGase).  Compounds are added to an in vitro enzyme assay in which purified PNGase is incubated with glycosylated RNAse B (purchased commercially) that has been labelled with fluorescein.   Con A, which binds to  glycans on RNAse B, is then added to the reaction.  The amount of glycosylated RNAseB present is quatitated indirectly by measuring the amount of ConA bound to RNAse B via fluorescence polarization (FP).   Screening positives are compounds that prevent glycan removal by PNGase and thus result in high levels of ConA bound to RNase B.', 'Started with ELISA-type assay (June 2003) and then developed completely new assay using Fluorescence Polarization.', NULL, NULL, NULL, NULL, 572, 207, 295);
INSERT INTO screen VALUES (335, 1, '2003-05-30 00:00:00', 'Small Molecule', 'Prevent degradation of MHC class I heavy chain in cells expressing the human cytomegalovirus (hCMV) protein US11.', NULL, NULL, 'A screen for compounds that prevent degradation of MHC class I heavy chain in cells expressing the human cytomegalovirus (hCMV) protein US11.  In cells expression US11, MHC class I HC is degraded via the ER associated degradation (ERAD) pathway.  373MG astrocytomas stably expressing US11 were engineered to stably express the A2 allele of MHC class I HC fused to GFP (A2-GFP).  These cells degrade A2 and thus have a low level of GFP fluorescence as detected using a plate reader.  Compounds were added to the cells and those that caused at least 2-fold increased fluorescence, but were not themselves fluorescent compounds, were scored as positives.   This 2-fold increase in fluorescense is approximately what is seen in the US11 A2-GFP cells when the ERAD pathway is inhibited using proteasome inhibitors. ', '5-30-03: The results from this screen have been written up and Dom is waiting for Hidde''s OK to submit the ms.
There are 2 types of  ABase datasets associated with this screen, the GFP fluorescence data from the US11 A2-GFP cells and also fluorescence data  (fluorescein channel) for the compounds alone in PBS.
2004: Ms published.', 'CMV', 'GFP-US11', NULL, NULL, 347, 207, 297);
INSERT INTO screen VALUES (397, 0, '2004-04-06 00:00:00', 'Small Molecule', 'Modulate TRPC* ion channels.', NULL, NULL, 'A screen for compounds that modulate TRPC* ion channels.   This screen will initially be performed with the TRPC6 or TRPC5 ion channel.  Other channels of interest to be tested at a later date include  TRPM7 and TRPC4.  Cells expressing a single ion channel isoform will be cultured, loaded with the calcium indicator dye, Fluo-4,  and washed.  Cells will be plated into 384-well plates and a base-line fluorescence reading acquired.  Compounds will be added manually (to a few wells at a time) and changes in fluorescence will be monitored over a short time period (ideally imaging every 0.5 s, for 5 minutes).   This screen will be performed in low throughput, and will pilot both a microscope and a plate reader for fluorescence detection.  (Many assay details are still to be determined)', '6-21-04: Paula stopped by to pick up the extract fractions that we had plated for her.', NULL, NULL, NULL, NULL, 555, 197, 345);
INSERT INTO screen VALUES (398, 0, '2005-07-14 00:00:00', 'Small Molecule', 'Affect West Nile virus replication.', NULL, NULL, 'A screen for compounds that affect West Nile virus (WNV) replication.  This screen proposes to use a WNV replicon reporting cell line to screen for potential inhibitors against all targets involved in viral replication. A WNV subgenomic replicon (with a deletion of viral structural genes) was engineered to contain luciferase and Neo genes. Vero cells transfected with the dual reporting replicon under G418 selection contain persistently replicating replicons. Luciferase activity will be used to indicate replication level of the replicon RNA. Incubation of the reporting cell lines with potential inhibitors suppresses viral replication, resulting in a reduction of luciferase activity. Since viral structural genes are deleted in the replicon, no infectious particle is generated.

This assay allows screening for potential inhibitors of any steps of West Nile virus replication, including viral translation and RNA synthesis. Multiple targets (viral protease, helicase, polymerase etc) essential for viral replication will be screened.
', '2006-03-31: tentatively planning to visit for 2-3 days in May/June to pilot this assay in 384-well format.

7/14/05: this assay protocol has been validated in 96-well format with a small chemical library (submitted for publication).', '', '', NULL, NULL, 585, 585, 513);
INSERT INTO screen VALUES (399, 0, '2006-10-05 00:00:00', 'RNAi', 'A screen for siRNAs that  inhibit the assembly of endogenous stress granules and processing bodies in U2OS cells. ', NULL, '2006-11-21 00:00:00', 'A screen for siRNAs that  inhibit the assembly of endogenous stress granules and processing bodies in U2OS cells.  U2OS cells stably transfected with GFP-G3BP (a specific stress granule marker) and RFP-DCP1 (a specific P body marker) will be transfected with siRNAs.  RNAi mediated knock down of specific SG or PB components prevents the assembly of these RNA granules in response to arsenite, an oxidative stressor.  After siRNAs are transfected, cells will be stressed with arsenite, fixed, then SGs and PBs visualized by microscopy.

', '10/3/06  They plan to transfect siRNAs using lipofectamine, but have received a copy of Rob McDonald''s U2OS protocol to try as well.
11/21/06 Takbum will use DRSC Opera to readout his assay--resolution on IXMicro was not good enough and one of Takbum''s stains (P-body marker) was very faint. He and Melody are working with the Evotec reps to get automated analysis of Takbum''s images--currently not available.  Takbum will run down mRNAs for 72 hours before assaying.  He is transfecting with Oligofectamine and not Lipofectamine. Transfecting library siRNAs at 50 nM.', '', '', NULL, NULL, 688, 677, 650);
INSERT INTO screen VALUES (400, 0, '2005-10-13 00:00:00', 'Small Molecule', 'Inhibit poliovirus entry into mammalian cells.', NULL, NULL, 'A screen for compounds that inhibit poliovirus entry into mammalian cells.', 'For technical reasons, using GFP to monitor virus entry into cells is not feasible (low virus yield, GFP unstable in the genome). Thus Lily will start by trying her molecular beacon technology. She will try plate reader and possibly microscope readouts; she might also try out the LiCor reader too.

33 digit code (10/24/05): 520-45310-6600-148136-375049-0003-65491', '', '', NULL, NULL, 598, 219, 533);
INSERT INTO screen VALUES (279, 1, '2002-01-30 00:00:00', 'Small Molecule', 'Inhibit the S. cerevisiae spindle checkpoint. ', NULL, NULL, 'A screen for compounds that inhibit the S. cerevisiae spindle checkpoint.  A yeast strain was constructed that can be made to grow only when the mitotic checkpoint is bypassed.  The strain is also deleted for the genes erg6, pdr1, and pdr3 to increase it sensitivity to drugs.  Growth is assayed by eye or by absorbance measurement 3-5 days after compound addition.', '5/2/03 - Russell says the January 2001 Testsets do contain data about growth inhibition of wild type yeast but not sure from testset documentation which strains are wild type and which are his mutant. Note no ActivityBase or hit information from visits 8/02 to present.

6/10/04-Russell says that he and Andrew are working on a manuscript describing the results of this screen.', 'YEASTSPINDLE', 'YEASTGROWTHRD', NULL, NULL, 478, 479, 138);
INSERT INTO screen VALUES (278, 1, '2002-01-30 00:00:00', 'Small Molecule', 'Allow resistance of S. cerevisiae to  cell cycle arrest caused by mating factor.', NULL, NULL, 'A screen for compounds that allow resistance of S. cerevisiae to  cell cycle arrest caused by mating factor.  Growth of the cells after compound addition is assayed by eye or by absorbance measurement 3-5 days after compound addition.  The purpose of carrying out a screen on this well-characterized pathway is to use the hits to pilot new methods of target identification and to test whether distinct classes of compounds target different branches of the pathway.', 'Confirmed in emails from Russell and Andrew that they have finished work on this screen. Russell even mentioned that he does not intend to publish any of the results from this screen. ', NULL, NULL, NULL, NULL, 478, 479, 139);
INSERT INTO screen VALUES (401, 0, '2005-01-11 00:00:00', 'Small Molecule', 'Inhibit type III secretion in Yersinia pestis.', NULL, '2005-05-19 00:00:00', 'A screen for compounds that inhibit type III secretion in Yersinia pestis.', '', '', '', NULL, NULL, 409, 409, 469);
INSERT INTO screen VALUES (264, 1, '2004-02-18 00:00:00', 'Small Molecule', 'Function as agonists or inverse agonists for the GPCR XXXX.', NULL, '2004-02-18 00:00:00', 'A screen for compounds that function as agonists or inverse agonists for the GPCR, XXXX.  XXXX is a Gi-coupled receptor.  HEK-293 cells will be transiently transfected with a constitutively active allele of XXXX (Mutation?), a chimeric G protein (Gq5i - Gq with C-terminal 5 amino acids from Gi) and an SRE-luciferase reporter construct.  After 24 hours, cells will be stimulated for 6 hours with ligand, followed by lysis and measurement of luciferase activity (using LucLite, Packard).  Positive compounds will either show an increase in signal (agonist) or a decrease in signal (inverse agonist).', 'This screen is a counter screen for # 340.', NULL, NULL, NULL, NULL, 157, 158, 341);
INSERT INTO screen VALUES (263, 1, '2004-02-18 00:00:00', 'Small Molecule', 'Function as agonists or inverse agonists for the novel orphan human GPCR, GPR88.', NULL, '2004-02-18 00:00:00', 'A screen for compounds that function as agonists or inverse agonists for the novel orphan human GPCR, GPR88.  GPR88 is a Gi-coupled receptor.  HEK-293 cells will be transiently transfected with a constitutively active allele of GPR88 (Mutation?), a chimeric G protein (Gq5i - Gq with C-terminal 5 amino acids from Gi) and an SRE-luciferase reporter construct.  After 24 hours, cells will be stimulated for 6 hours with ligand, followed by lysis and measurement of luciferase activity (using LucLite, Packard).  Positive compounds will either show an increase in signal (agonist) or a decrease in signal (inverse agonist).', 'This screen will be performed in parallel with screen 341.', NULL, NULL, NULL, NULL, 157, 158, 340);
INSERT INTO screen VALUES (223, 2, '2004-10-20 00:00:00', 'Small Molecule', 'Suppress a zebrafish model of hereditary hemorrhagic telangiectasia. ', NULL, NULL, 'A screen for compounds that suppress a zebrafish model of hereditary hemorrhagic telangiectasia. ', 'Randy is piloting this screen using known bioactives.', NULL, NULL, NULL, NULL, 589, 412, 427);
INSERT INTO screen VALUES (299, 2, '2003-11-13 00:00:00', 'Small Molecule', 'Inhibit apoptosis of HeLa cells  that  occurs in response to  adaptation to a mitotic block induced by nocadozole.', NULL, '2003-11-13 00:00:00', 'A screen for compounds that inhibit apoptosis of HeLa cells  that  occurs in response to  adaptation to a mitotic block induced by nocadozole.', NULL, NULL, NULL, NULL, NULL, 432, 5, 328);
INSERT INTO screen VALUES (402, 0, '2002-06-27 00:00:00', 'Small Molecule', 'Selectively inhibit the growth of mouse cells (MEFs) deleted for tsc2 (tuberous sclerosis complex 2) and p53  but not MEF''s deleted for only p53.', NULL, NULL, 'A screen for compounds that selectively inhibit the growth of mouse cells (MEFs) deleted for tsc2 (tuberous sclerosis complex 2) and p53  but not MEF"s deleted for only p53.  The two cell lines, grown in 10% serum, will be treated in parallel with compounds. Their growth will be  assayed either by measuring BrDU incorporation or ATP levels. ', '4-14-04: This screen is being carried out by the Rothberg Inst. Rocky/David have no plans to carry out this screen.

July 2003:Rocky is just beginning to pilot this screen. He needs to determine which assay to use to measure cell growth.', NULL, NULL, NULL, NULL, 640, 638, 235);
INSERT INTO screen VALUES (290, 2, '2006-08-11 00:00:00', 'Small Molecule', 'Affect the proportion of binucleate cells in Drosophila cells depleted for Rho Kinase. ', NULL, '2006-10-10 00:00:00', 'A screen for compounds that affect the proportion of binucleate cells in Drosophila cells depleted for Rho Kinase. We will seat cells in 384-well plates, followed by RNAi treatment for several days to partially deplete 
Rho.  When Rho is depleted, cells progress through the cell cycle, replicate and divide DNA, but cannot 
complete the physical separation from one cell into two daughter cells.  As a consequence, cells become 
binucleate.  We will screen RNAi-sensitized cells with chemical libraries to identify compounds that modify 
the proportion of binucleate cells and readout the assay by imaging.  ', '', '', '', NULL, NULL, 469, 470, 640);
INSERT INTO screen VALUES (289, 2, '2002-06-13 00:00:00', 'Small Molecule', 'Affect cytokinesis in HeLa cells.', NULL, NULL, 'A screen for compounds that affect cytokinesis in HeLa cells.', '', '', '', NULL, NULL, 470, 470, 213);
INSERT INTO screen VALUES (288, 2, '2002-01-24 00:00:00', 'Small Molecule', 'Affect cytokinesis in Drosophila tissue culture cells. ', NULL, NULL, 'Screen for compounds that affect cytokinesis in Drosophila tissue culture cells.  Cells are grown overnight in the presence of compounds and the presence of multi-nucleated cells (cells that have replicated and segregated their chromosomes but have not undergone cytokinesis) is scored by microscopy.', '', 'CytokinesisDrosoph', 'CytokinesisDrosoph', NULL, NULL, 470, 470, 118);
INSERT INTO screen VALUES (403, 0, '2002-01-24 00:00:00', 'Small Molecule', 'Inhibit platelet secretion. 
', NULL, NULL, 'Screen for compounds that inhibit release of ATP from human platelets, with the goal of finding compounds that prevent platelet activation.  Platelets that have been exposed to compounds are treated with agonist and release of ATP is monitored by a luciferase assay.', NULL, NULL, NULL, NULL, NULL, 352, 352, 113);
INSERT INTO screen VALUES (295, 1, '2002-06-17 00:00:00', 'Small Molecule', 'Block the interaction of calcineurin with NFAT.', '2003-07-29 00:00:00', '2003-07-29 00:00:00', 'A screen for compounds that block the interaction of calcineurin with NFAT.  An NFAT peptide was identified that interacts with calcineurin. This peptide was fluorescently labeled and compounds inhibiting its binding to calcineurin were identified by FP assay.', '8-01 Patrick and Michael still following up their hits, but have no plans to screen additional compounds.
7-29-03 Michael and May are re-starting screening.
6/21/06 Gerhard Wagner considers himself a PI on this screen. Recommends sending title to NVS.
', 'CnAScreen', 'CnA-FP', NULL, NULL, 381, 381, 225);
INSERT INTO screen VALUES (294, 1, '2002-06-17 00:00:00', 'Small Molecule', 'Inhibit formation of NFAT/AP1 complex on DNA.', NULL, NULL, 'A screen for compounds that inhibit formation of NFAT/AP1 complex on DNA.   Fluorescently labeled fos peptide will be added to a mixture of a DNA oligo, the NFAT DNA-binding domain, and jun peptide. Compound inhibitors of formation of the complex will be identified by FP assay.', 'Still being piloted as of 6/17/02.', NULL, NULL, NULL, NULL, 381, 381, 226);
INSERT INTO screen VALUES (404, 0, '2002-01-24 00:00:00', 'Small Molecule', 'Selectively induce p53-dependent apoptosis in transformed cells.
', NULL, NULL, 'Screen for compounds that selectively induce p53-dependent apoptosis in transformed cells.  Compounds are added to cell extracts made from various mammalian cell lines and caspase-3 activation is monitored using a fluorescent substrate (DEVD-AMC).', 'Jesse Boehm (BBS rotation student spring  ''02) worked on this screen with Gael.', NULL, NULL, NULL, NULL, 361, 49, 124);
INSERT INTO screen VALUES (405, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit acetyl-CoA carboxylase, particularly that of malaria.', NULL, NULL, 'A screen for compounds that inhibit acetyl-CoA carboxylase, particularly that of malaria.  This assay employs yeast reporter strains in which the yeast ACC has been replaced by a target ACC (wheat cytoplasmic ACC, wheat chloroplast ACC, Toxoplasma apicoplast ACC) under the control of the inducible GAL10 promoter.  Positive hits are compounds that inhibit growth of the reporter strain.  Other strains with malaria ACC and human ACC1 and ACC2 are planned.', NULL, NULL, NULL, NULL, NULL, 561, 562, 380);
INSERT INTO screen VALUES (406, 0, '2002-01-24 00:00:00', 'Small Molecule', 'Affect tau binding to microtubules. 
', NULL, NULL, 'Screen for compounds that affect tau binding to microtubules.  GFP-tagged tau protein is expressed in mammalian cells and tau binding to microtubules is assayed in live cells by microscopy.', '4-14-04:This screen or one like it is being carried out at LDDN.', NULL, NULL, NULL, NULL, 608, 367, 117);
INSERT INTO screen VALUES (407, 0, '2006-06-29 00:00:00', 'Small Molecule', 'Affect the SCFSkp2-dependent pathway of p27 proteolysis in human LNCaP prostate cancer cells.', NULL, '2006-10-17 00:00:00', 'A screen for compounds that affect the SCFSkp2-dependent pathway of p27 proteolysis in human LNCaP prostate cancer cells. A screening by imaging assay monitoring fluorescently labelled endogenous p27 levels is being developed. ', '7/5/06 Elizabeth still developing the assay. She will examine stained cells in screening microscope. Needs to work out washing conditions--wand vs. plate washer.', '', '', NULL, NULL, 662, 92, 634);
INSERT INTO screen VALUES (408, 0, '2004-11-19 00:00:00', 'Small Molecule', 'Modulate the activity of vaccinia/variola topoisomerase.', NULL, NULL, 'A screen for compounds that modulate the activity of vaccinia/variola topoisomerase, which is required for poxvirus replication.  Positive hits are defined as compounds that inhibit the purified enzyme in vitro.', '', '', '', NULL, NULL, 407, 407, 450);
INSERT INTO screen VALUES (259, 1, '2006-06-19 00:00:00', 'Small Molecule', 'Affect dengue virus replication.', NULL, NULL, 'A screen for compounds that affect dengue virus replication.', 'The assay will be done in BHK cells expressing a dengue virus reporter (Renilla luciferase) replicon carrying a selectable marker.  Therefore, all cells are expressing the replicon and no transfection is required. The cells are have been tested and are ready for use.  A second cell line expressing a dengue virus reporter with a mutation in the polymerase gene can be used as a control (counterscreen).  The replicon RNA in this case will translate but will not replicate.', '', '', NULL, NULL, 627, 13, 631);
INSERT INTO screen VALUES (258, 1, '2005-10-12 00:00:00', 'Small Molecule', 'Differentially modulate translation of polyadenylated cellular mRNAs versus non-adenylated viral mRNAs', NULL, NULL, 'A screen for compounds that differentially modulate translation of polyadenylated cellular mRNAs versus non-adenylated viral mRNAs', '', '', '', NULL, NULL, 627, 13, 530);
INSERT INTO screen VALUES (409, 0, '2004-07-07 00:00:00', 'Small Molecule', 'Inhibit the endoproteolytic activity of the botulinum neurotoxin light chain serotype A.', '2004-07-12 00:00:00', '2004-07-12 00:00:00', 'A screen for compounds that inhibit the endoproteolytic activity of the botulinum neurotoxin light chain serotype A.  This FRET-based screen employs purified light chain A and a commercially available reporter substrate, SNAPtide (o-Abz/Dnp).  The SNAPtide synthetic peptide contains the native cleavage site for BoNT-A.  The N-terminal fluorophore, o-aminobenzoyl (Abz), is quenched by the C-terminal chromophore, 2,4 nitrophenyl (Dnp).  Cleavage of SNAPtide by BoNT-A restores fluorescence.  Positive hits in this screen are defined as compounds that inhibit cleavage of SNAPtide by purified light chain A.', '9/30/04 - According to Michael Baldwin, they did not screen the Starr Foundation Extracts, plates 1338-1340.', '', '', NULL, NULL, 398, 398, 402);
INSERT INTO screen VALUES (284, 2, '2002-05-03 00:00:00', 'Small Molecule', 'Mimic the effect of DNA damaging agents in an S. cerevisiae mgm101-2 strain.  This strain is respiratory deficient when grown in YPEG at 34?C after it has been exposed to DNA damaging agents.', NULL, NULL, 'A screen for compounds that mimic the effect of DNA damaging agents in an S. cerevisiae mgm101-2 strain.  This strain is respiratory deficient when grown in YPEG at 34?C after it has been exposed to DNA damaging agents. Wild-type and mgm101-2 strains will be incubated with small molecules at room temperature and at 34?C.  Positives will be small molecules that permit normal growth in the wild-type and mgm101-2 strains at room temperature and in the wild-type strain at 34?C but block growth in the mgm101-2 strain at 34?C.', NULL, NULL, NULL, NULL, NULL, 547, 394, 191);
INSERT INTO screen VALUES (282, 2, '2002-05-03 00:00:00', 'Small Molecule', 'Mimic S. cerevisiae mutants in mitochondrial membrane fusion.', NULL, NULL, 'A screen for compounds that mimic mutants in mitochondrial membrane fusion.  The screen will be carried out using a strain bearing the null mutation _dnm1 which is defective in mitochondrial membrane fission.  This mutation rescues mutants in mitochondrial membrane fusion which are dead when grown in YPEG (media in which ethanol + glycerol  are the carbon sources).  This assay will be done at room temperature.  Wild type and _dnm strains (grown in YPEG) will be incubated with small molecules.  Positives will be molecules that are lethal to the wild-type strain, but not to the _dnm1 strain.', NULL, 'YeastMitFusion', 'YeastMitFusion', NULL, NULL, 547, 394, 190);
INSERT INTO screen VALUES (283, 2, '2002-05-03 00:00:00', 'Small Molecule', 'Mimic mutants in S. cerevisiae mitochondrial membrane fission.', NULL, NULL, 'A screen for compounds that mimic mutants in S. cerevisiae mitochondrial membrane fission. This screen uses an fzo1-1 strain, a temperature-sensitive allele of FZO1 which plays a role in mitochondrial membrane fusion.  The strain grows like wild-type at room temperature in YPEG media (containing ethanol+ glycerol as carbon sources; growth in this media requires respiratory proficiency).  At 37?C, this strain is respiratory deficient and dies when grown in YPEG.  This phenotype is rescued when the fzo1-1 mutation is paired with a mutation in a gene involved in mitochondrial membrane fission.  The fzo1-1 strain will be incubated with small molecules in YPEG. Positives will be molecules that allow the fzo1-1 strain to grow at 37?C.  ', NULL, 'YeastMitFission', 'YeastMitFission', NULL, NULL, 547, 394, 189);
INSERT INTO screen VALUES (85, 4, '2002-01-24 00:00:00', 'Small Molecule', 'Inhibit binding of the translation initiation factors eIF4G to eIF4E to each other. ', NULL, NULL, 'A screen for compounds that inhibit binding of the translation initiation factors eIF4G to eIF4E to each other.  A fluorescence polarization assay using purified mouse eIF4E and an 11 amino acid fluorescein-labeled eIF4G peptide.  eIF4E is the most limiting translation initiation factor and its overexpression is oncogenic.  When proteins that inhibit 4E/4G interaction are overexpressed, the transformed state of some cells lines is reversed.', '10/5/05 - Nathan stopped by (Dara) to find out if 49 J08 is a hit in any other screens. He said this is the main compound they are following up on.
6/21/06 Gerhard Wagner wrote that an application to patent this assay has been submitted.
11/30/06 Gerhard, Nate,  and Ricard Rodriguez (a new postdoc in the lab) would like to continue this screen at ICCB-L. We initiated a new screen number (#659) for the new project--the assay protocol might change slightly with regard to automation used etc. ', 'EIF4E/EIF4G', 'FP-EIF4E/EIF4G', NULL, NULL, 601, 80, 126);
INSERT INTO screen VALUES (84, 4, '2002-05-16 00:00:00', 'Small Molecule', 'Inhibit binding of the two human immune proteins CD2 and CD58.', NULL, NULL, 'A screen for compounds that inhibit binding of the two human immune proteins CD2 and CD58.  A fluorescence polarization assay will be carried out.', '5/16/02: Vlado is piloting this screen using long-lived fluorophoes such as Sunnyvale red.  Initially he has tried CD58-sunnyvale red binding to unlabelled CD2, in the presence of an antibody against CD2.  Other fluorophores will be tried and it is possible that other protein pairs (e.g. GP120-CD4) will be used in  a separate screen in the future.', NULL, NULL, NULL, NULL, 441, 80, 200);
INSERT INTO screen VALUES (82, 4, '2006-07-06 00:00:00', 'Small Molecule', 'Interfere with the binding of the transactivation domain of the transcriptional co-activator ARC105 with a small domain of the transcriptional activator SREBP1a. ', NULL, '2006-10-04 00:00:00', 'A screen for compounds that interfere with the binding of the transactivation domain of the transcriptional co-activator ARC105 with a small domain of the transcriptional activator SREBP1a. When ARC105 binds to SREBP1a, many downstream fat metabolic proteins are expressed. A fluorescence polarization assay is being developed to measure binding of FITC-labeled SREBP1a peptide to ARC105 protein.


', '7/6/06 Collaboration with the lab of Anders Naar too. A patent  application on this assay is in the process of being filed. Thus, Gerhard and Anders have requested that the title of this screen not be given to Novartis at this time.', '', '', NULL, NULL, 620, 80, 635);
INSERT INTO screen VALUES (81, 4, '2006-10-10 00:00:00', 'Small Molecule', 'Are fluorescent in fluorescein channel of plate reader--control for FP screen #635.', NULL, NULL, 'A screen for compounds that are fluorescent in fluorescein channel of plate reader--control for FP screen #635.  A fluorescence polarization assay using un-labeled SREBP1a peptide and  ARC105 protein.  Screen #635 measures binding of  fluorescent peptide to ARC105 and this counter screen is necessary to eliminate compounds that score in the assay only because they are fluorescent in the FITC channel.

', '10/10/06 No charge for this screen. It is a counter screen and would not otherwise be separated into its own screen. However, the data will be quite useful to other projects and therefore it is important that they are independently available. ', '', '', NULL, NULL, 620, 80, 651);
INSERT INTO screen VALUES (410, 0, '2005-08-19 00:00:00', 'Small Molecule', 'Inhibit processive DNA synthesis of vaccinia virus.', NULL, NULL, 'A screen for compounds that inhibit processive DNA synthesis of vaccinia virus.', '2006-06-:23 Renee Kontnik in Clardy lab will be the collaborator on the ICBG followup.

2006-04-17: additional cherry picks approved by SC.

3/15/06: hit summary sent.

Protocol published', '', '', NULL, NULL, 429, 429, 517);
INSERT INTO screen VALUES (385, 1, '2006-06-09 00:00:00', 'RNAi', 'An siRNA screen to identify host factors required for spread of Shigella from an infected cell to adjacent cells.', NULL, '2006-10-26 00:00:00', 'An siRNA screen to identify host factors required for spread of Shigella from an infected cell to adjacent cells.', '6/21/06 Tentatively will screen at 50 nM. HeLa cells. Currently using Ambion NeoFX; maybe will try HiPerFect.  Will try to miniaturize to 384 (currently in 12-well plates). Two known genes, when knocked down, are known to give desired phenotype. Trying to find siRNA pools/constructs for those genes. ', '', '', NULL, NULL, 560, 296, 627);
INSERT INTO screen VALUES (384, 1, '2005-10-12 00:00:00', 'Small Molecule', 'Affect intracellular dissemination of Shigella.', NULL, NULL, 'A screen for compounds that affect intracellular dissemination of Shigella.', '', '', '', NULL, NULL, 295, 296, 529);
INSERT INTO screen VALUES (411, 0, '2004-07-07 00:00:00', 'Small Molecule', 'Inhibit the RNA helicase of the lily mottle plant virus.', NULL, NULL, 'A screen for compounds that inhibit the RNA helicase of the lily mottle plant virus.', NULL, NULL, NULL, NULL, NULL, 397, 222, 406);
INSERT INTO screen VALUES (412, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit the bacterial enzyme UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).', NULL, NULL, 'A screen for compounds that inhibit the bacterial enzyme UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC), which catalyzes the first committed step in the biosynthesis of lipidA in Gram-negative bacteria.', NULL, NULL, NULL, NULL, NULL, 573, 238, 382);
INSERT INTO screen VALUES (195, 11, '2006-05-24 00:00:00', 'Small Molecule', 'Inhibit diguanylate cyclase.', NULL, '2006-06-01 00:00:00', 'A screen for compounds that inhibit diguanylate cyclase.', '5/24/06: this screen will be piloted by Vince and Jody Matewish.', '', '', NULL, NULL, 24, 24, 618);
INSERT INTO screen VALUES (194, 11, '2006-03-14 00:00:00', 'Small Molecule', 'Inhibit TLR5 signaling.', NULL, NULL, 'A screen for compounds that inhibit TLR5 signaling.', '2006-03-10: Roger is piloting a luciferase-based assay for this screen.', '', '', NULL, NULL, 85, 24, 586);
INSERT INTO screen VALUES (196, 11, '2002-05-14 00:00:00', 'Small Molecule', 'Slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the essential protein SecA.', NULL, NULL, 'A screen for compounds that slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the essential protein SecA.  The SecA gene in this strain is under the control of an IPTG-inducible promoter. At low levels of IPTG, the bacteria are viable, but not thriving.  Compounds are  added under these conditions and positives are be those that kill P. aeruginosa expressing low levels of SecA  but not  P. aeruginosa expressing wild-type levels of SecA. ', 'Left for grad school in Fall 2002, screen taken over by Hemantha Kulasekara on Sept. 4, 2002.  He has the primary data for all visits after that date. Ann had screened ChemBridge Diverset E and several others (including some DOS libraries), but Hemantha has none of the primary data in electronic form ( only as paper copy).  He does have the hit list from Ann''s work.  As of 10/24/02, Hemantha has finished screening the ChemBridge Microformat library and is following up hits.  He has all primary data from the screen of the Microformat library. Note that the entire Microformat library was not screened in duplicate.  Only the plates that had positives were screened in duplicate.  ', NULL, NULL, NULL, NULL, 89, 24, 195);
INSERT INTO screen VALUES (197, 11, '2003-01-17 00:00:00', 'Small Molecule', 'Slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the essential protein ACP (Acyl carrier Protein) .', NULL, NULL, 'A screen for compounds that slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the essential protein ACP (Acyl carrier Protein) .  The acpP gene in this strain is under the control of an IPTG-inducible promoter (tac promoter). At low levels of IPTG, the bacteria are viable, but not thriving.  Compounds are  added under these conditions and positives are those that kill P. aeruginosa expressing low levels of ACP  but not  P. aeruginosa expressing wild-type levels of ACP. ', NULL, 'PaeruginosaACP', 'PaeruginosaACP', NULL, NULL, 134, 24, 262);
INSERT INTO screen VALUES (198, 11, '2002-10-24 00:00:00', 'Small Molecule', 'Slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the protein complex DNA Gyrase.', NULL, NULL, 'A screen for compounds that slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the essential protein complex DNA Gyrase..  The *** gene in this strain is under the control of an IPTG-inducible promoter. At low levels of IPTG, the bacteria are viable, but not thriving.  Compounds are  added under these conditions and positives are be those that kill P. aeruginosa expressing low levels of *** but not  P. aeruginosa expressing wild-type levels of ***. ', NULL, NULL, NULL, NULL, NULL, 134, 24, 246);
INSERT INTO screen VALUES (199, 11, '2002-10-22 00:00:00', 'Small Molecule', 'Slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the essential protein SecA.', NULL, NULL, 'A screen for compounds that slow the growth of a Pseudomonas aeruginosa strain that expresses sub-wild type levels of the essential protein SecA.  The SecA gene in this strain is under the control of an IPTG-inducible promoter (tac promoter). At low levels of IPTG, the bacteria are viable, but not thriving.  Compounds are  added under these conditions and positives are those that kill P. aeruginosa expressing low levels of SecA  but not  P. aeruginosa expressing wild-type levels of SecA. ', 'Took over Ann Yonetani screen starting Sept. 4, 2002.   Ann had screened ChemBridge Diverset E and several others (including some DOS libraries), but Hemantha has none of the primary data in electronic form ( only as paper copy).  He does have the hit list from Ann''s work.  As of 10/24/02, Hemantha has finished screening the ChemBridge Microformat library and is following up hits.  He has all primary data from the screen of the Microformat library. Note that the entire Microformat library was not screened in duplicate.  Only the plates that had positives were screened in duplicate.', NULL, NULL, NULL, NULL, 134, 24, 245);
INSERT INTO screen VALUES (200, 11, '2002-10-24 00:00:00', 'Small Molecule', 'Inhibit the function of RND multi-drug resistance pumps in  Pseudomonas aeruginosa.', NULL, NULL, 'A screen for compounds that inhibit the function of RND multi-drug resistance pumps in  Pseudomonas aeruginosa.  Cells will be grown in a sub-lethal concentration of antibiotic (chloramphenicol).  Compounds will be added and those that  hit the drug pumps will cause cells to die.  Interesting compounds are those that kill cells in the presence of chloramphenicol but not in the absence of the antibiotic.', NULL, NULL, NULL, NULL, NULL, 134, 24, 247);
INSERT INTO screen VALUES (201, 11, '2004-12-23 00:00:00', 'Small Molecule', 'Supress lethality in S. cerevisiae of expression of the Chlamydia pneumoniae type III secreted protein W (SctW; encoded by an open reading frame CP0433).', '2005-02-11 00:00:00', '2005-02-11 00:00:00', 'A screen for compounds that supress lethality in S. cerevisiae of expression of the Chlamydia pneumoniae type III secreted protein W (SctW; encoded by an open reading frame CP0433).', 'From Jin 1-23-06: I have a screen number #461. This a yeast cell based assay. Last year after I did screening of 118 plates ( 1361-1362, 439, 500-503, 1081-1083, 1338-1340, 1343-1346, 1351-1354, 1357-1360, 1364-1455, 1459), I took a break and requested a cherry-pick. Among the cherry-pick compounds, three were confirmed positive in a yeast assay. I also tested the 3 positive compounds in a mammalian cell based assay and found these 3 were not effective (negative results). Since I am studying the bacterial pathogenesis in human cells, what I really look for is the compounds that work in mammalian cells. Therefore I need more candidate compounds to test in mammalian cells. Can I continue screen #461 to screen more compounds in your libraries? Look forward to your responding.Thanks. Jin', NULL, NULL, NULL, NULL, 335, 24, 461);
INSERT INTO screen VALUES (202, 11, '2003-01-02 00:00:00', 'Small Molecule', 'Prevent type III killing of  CHO cells by Pseudomonas aeruginosa expressing the toxin ExoS.', NULL, NULL, 'A screen for compounds that prevent type III killing of  CHO cells by Pseudomonas aeruginosa expressing the toxin ExoS.', NULL, 'PaeruginosaExoS', 'PaeruginosaExoS', NULL, NULL, 724, 24, 258);
INSERT INTO screen VALUES (203, 11, '2004-11-19 00:00:00', 'Small Molecule', 'Inhibit the activity of ExotoxinA (ExoA), a secreted protein of Pseudomonas aeruginosa that enters host cells by receptor mediated endocytosis.', NULL, NULL, 'A screen for compounds that inhibit the activity of ExotoxinA (ExoA), a secreted protein of Pseudomonas aeruginosa that enters host cells by receptor mediated endocytosis.   It is a potent cytotoxin that arrest translation by modifying elongation factor 2 with ADP-ribose.  Inhibitors of these toxins are of biological interest as several related toxins also inhibit cells via a similar mechanism.
', NULL, NULL, NULL, NULL, NULL, 724, 24, 451);
INSERT INTO screen VALUES (204, 11, '2003-03-20 00:00:00', 'Small Molecule', 'Prevent type III killing of  CHO cells by Pseudomonas aeruginosa expressing the toxin ExoU.', NULL, NULL, 'A screen for compounds that prevent type III killing of  CHO cells by Pseudomonas aeruginosa expressing the toxin ExoU. Compounds are added to CHO cells, followed by bacteria, and incubated for 2 hours.  Gentamycin is then added to stop bacterial protein synthesis.  Viability of the CHO cells is then assayed using the WST cell viability assay  (colorimetric, Roche) and read out using a plate reader  (420nm).  Positives are compounds that give high A420 readings (allow CHO cells to live).', NULL, 'PaerugionsaExoU', 'PaerugionsaExoU', NULL, NULL, 724, 24, 276);
INSERT INTO screen VALUES (205, 11, '2002-06-20 00:00:00', 'Small Molecule', 'Inhibit the ability of the Pseudomonas aeruginosa  enzyme GlmU to produce pyrophosphate.  GlmU is a key enzyme required for bacterial cell wall synthesis. ', NULL, NULL, 'A screen for compounds that inhibit the ability of the Pseudomonas aeruginosa  enzyme GlmU to produce pyrophosphate.  GlmU is a key enzyme required for bacterial cell wall synthesis-- it is a metabolic branchpoint for  both lipopolysaccharide and peptidoglycan synthesis. Purified GlmU catalyzes two reactions, one of which produces pyrophosphate. If  pyrophosphatase is added to the reaction, phosphate is produced which can be quantitated using a malachite green colorometric assay.', NULL, 'PaeruginosaGlmU', 'PaeruginosaGlmU', NULL, NULL, 680, 24, 228);
INSERT INTO screen VALUES (413, 0, '2002-01-24 00:00:00', 'Small Molecule', 'Inhibit proliferation of mouse mammary epithelial cells over-expressing  the neu oncogene.
', NULL, NULL, 'Screen for compounds that inhibit proliferation of mouse mammary epithelial cells over-expressing the neu oncogene but do not inhibit the growth of control cells that do not express neu.', 'All results in Fantin et al., Cancer Cell 2002; 2:29-42.', 'NEUTOX', 'BrdU-Neu', NULL, NULL, 202, 203, 115);
INSERT INTO screen VALUES (414, 0, '2003-12-19 00:00:00', 'Small Molecule', 'Inhibit replication of Hepatitis C in a mammalian liver cell-line.', '2004-08-03 00:00:00', '2004-08-03 00:00:00', 'A screen for compounds that inhibit replication of Hepatitis C in a mammalian liver cell-line.  The Huh7 cell line has been stably transfected with a model Hepatitis C replicon construct such that, when all factors required for Hep C replication are available, transcription of the genes encoding neomycin resistance (Neo) and firefly luciferase occurs (Tanabe et al. 2004, J. of Infectious Disease 189:1129-1139).  Thus, the cells are neomycin resistant and stably express luciferase. Compounds will be added to cells and luciferase activity will be assay >24 hours later. Screening positives are compounds that decrease luciferase activity. ', '12/03: Started to develop an Elisa assay using kits from a company.
6/04: Elisa kits too expensive and not easily enough available, thus a switch was made to a replicon activity reporter assay (luciferase readout).  Won should consider doing a cell viability assay in parallel with this reporter assay.
6/14/05- Correspondence with Nicky Tolliday indicates that this screen has become a Broad screen.', NULL, NULL, NULL, NULL, 173, 174, 332);
INSERT INTO screen VALUES (415, 0, '2004-10-13 00:00:00', 'Small Molecule', 'Restore aggregation of Dictyostelium cells expressing a contitutively activated form of the Rab8 protein (Rab8CA). ', NULL, NULL, 'A screen for compounds that restore aggregation of Dictyostelium cells expressing a contitutively activated form of the Rab8 protein (Rab8CA).    Cells expressing mutant Rab8 may represent a model  for cytoskeletal abnormalities observed in Alzheimer''s Disease.', NULL, NULL, NULL, NULL, NULL, 673, 673, 423);
INSERT INTO screen VALUES (176, 2, '2002-06-06 00:00:00', 'Small Molecule', 'Inhibit binding of human papillomavirus E6 protein to E6AP peptide.', NULL, NULL, 'A screen from compounds that inhibit binding of human papillomavirus (HPV) E6 protein to E6AP peptide.  A fluorescence polarization assay using purified HPV E6 fused to GST  and fluorescein-labeled peptides from E6AP. ', 'Assay was not technically feasible--difficulty making structurally correct peptide that was active at low enough concentration', NULL, NULL, NULL, NULL, 226, 227, 205);
INSERT INTO screen VALUES (175, 2, '2002-06-06 00:00:00', 'Small Molecule', 'Stabilize p53 in cells expressing human papillomavirus E6 protein.', NULL, NULL, 'A screen for compounds that stabilize p53 in cells expressing human papillomavirus (HPV) E6 protein. This is a cell-based screen in which the levels of  a p53-luciferase fusion protein will be monitored using a plate reader.', NULL, NULL, NULL, NULL, NULL, 226, 227, 206);
INSERT INTO screen VALUES (215, 3, '2002-07-01 00:00:00', 'Small Molecule', 'Induce differentiation of mouse embryonic stem cells (line R1) into cardiac myocytes. ', NULL, NULL, 'A screen for compounds that induce differentiation of mouse embryonic stem cells (line R1) into cardiac myocytes.  A cell line bearing a cardiac myocyte-specific  promoter driving expression of Beta-Gal will be used.  Compounds will be added to the cells and  levels of Beta-Gal expression will be monitored over several days using a luminescent beta-Gal substrate that can be detected using a plate reader. ', 'Martha will need to change the media on her cells often--possibly up to 4 times during a single assay. Thus, she will do repeat pin-transfers into the same assay plates on different days.  Each repeat pin-transfer should be noted on the original visit for that assay plate; new visits for each repeat pin-transfer should NOT be created.', NULL, NULL, NULL, NULL, 594, 54, 237);
INSERT INTO screen VALUES (213, 3, '2003-01-17 00:00:00', 'Small Molecule', 'Modulate Notch signalling in Drosophila tissue culture cells.', NULL, NULL, 'A screen for compounds that modulate Notch signalling in Drosophila tissue culture cells. Drosophila KC 167 cells are transiently transfected  with a Notch-dependent luciferase reporter construct and a constitutively active allele of Notch.  Control cells are transfected in parallel with constitutively on luciferase reporter construct.  Compounds are added to the two sets of cells and, after a 24 hour incubation, luciferase activity is measured and compared in the two sets of cells.  Interesting positives are compounds that increase or decrease Notch-dependent transcription relative to the control.', 'Successful as RNAi screen.', NULL, NULL, NULL, NULL, 306, 54, 261);
INSERT INTO screen VALUES (214, 3, '2002-02-15 00:00:00', 'Small Molecule', 'Affect the Notch signalling pathway in mammalian cells--neuronal outgrowth assay.', NULL, NULL, 'Screen for compounds that affect the Notch signalling pathway in mammalian cells.  Two assays are used.  In this assay, upregulation of Notch inhibits neuronal outgrowth in N2a (mouse neuroblastoma) cells as assayed by cell imaging.  The extent of neuronal outgrowth is quantitated after compound addition using an image analysis programs written by Brian.  ', NULL, NULL, NULL, NULL, NULL, 306, 54, 162);
INSERT INTO screen VALUES (216, 3, '2002-01-24 00:00:00', 'Small Molecule', 'Affect the Notch signalling pathway in mammalian cells--transcription assay.', NULL, NULL, 'Screen for compounds that affect the Notch signalling pathway in mammalian cells.  Two assays are used.  In this one, Notch-dependent transcription is monitored in NIH 3T3 cells after compounds addition using the TPC-1 promoter driving production of luciferase. The assay is read on a plate reader.

', 'No hits found using this assay. Thus this data should not be transferred to a new version of ActivityBase.', 'NOTCH', 'NOTCH-ACTIVATOR', NULL, NULL, 306, 54, 110);
INSERT INTO screen VALUES (255, 2, '2003-06-18 00:00:00', 'Small Molecule', 'Alter cell wall synthesis of lily pollen tubes.', NULL, NULL, 'A screen for compounds that alter cell wall synthesis of lily pollen tubes. After the assay for pollen tube adhesion was carried out (screen #180), the pollen tubes on the same plates were scored for thickening of tips and growth arrest. ', '6-18-03: 15 compounds scored as positives in this assay. A secondary screen for the thickening of root tips was carried out on 12 of the 15 compounds. Thickening of root tips is also a sign for altered cell wall synthesis. So far, only 1 of the 12 caused root thickening and is being pursued further. ', 'LilyPollen', 'LilyPollenSyn', NULL, NULL, 706, 60, 303);
INSERT INTO screen VALUES (161, 2, '2005-01-11 00:00:00', 'Small Molecule', 'Inhibit serine proteases from West Nile virus.', NULL, '2005-04-11 00:00:00', 'A screen for compounds that inhibit serine proteases from West Nile virus.  This screen employs purified recombinant WNV protease and the fluorogenic substrate M boc-Gly-Lys-Arg-AMC.  Positive hits are defined as compounds that reduce the ability of WNV protease to cleave the substrate, as evidenced by decreased fluorescence compared to a positive control.', '11/23/04: this assay is functional in 96-well format and has been piloted successfully in 50 ul volumes.', '', '', NULL, NULL, 388, 388, 464);
INSERT INTO screen VALUES (160, 2, '2006-12-13 00:00:00', 'Small Molecule', 'Inhibit replication of dengue virus.', NULL, NULL, 'A screen for compounds that inhibit replication of dengue virus.', '2006-12-13: This screen utilizes a mammalian cell line carrying a dengue replicon with a luciferase reporter.', '', '', NULL, NULL, 388, 388, 662);
INSERT INTO screen VALUES (162, 2, '2005-05-12 00:00:00', 'Small Molecule', 'Inhibit serine proteases from dengue virus.', NULL, '2005-04-11 00:00:00', 'A screen for compounds that inhibit serine proteases from dengue virus.  This screen employs purified recombinant dengue protease and the fluorogenic substrate M boc-Gly-Lys-Arg-AMC.  Positive hits are defined as compounds that reduce the ability of WNV protease to cleave the substrate, as evidenced by decreased fluorescence compared to a positive control.', '5/12/05: this screen was piloted at the same time as screen 464, but not completed due to technical difficulties.  However, this group seems to intend to refine their assay and to return at a later date to complete this screen.', '', '', NULL, NULL, 388, 388, 505);
INSERT INTO screen VALUES (225, 17, '2004-07-06 00:00:00', 'Small Molecule', 'Activate or inhibit the mammalian autophagic response.', NULL, NULL, 'A screen for compounds that activate or inhibit the mammalian autophagic response.', '', '', '', NULL, NULL, 7, 7, 392);
INSERT INTO screen VALUES (230, 17, '2004-07-06 00:00:00', 'Small Molecule', 'Facilitate the formation of ubiquitinated inclusions in striatal neurons.', NULL, NULL, 'A screen for compounds that facilitate the formation of ubiquitinated inclusions in striatal neurons.', '12/03: Junying Yuan contacted us and mentioned that for technical reasons, this screen is on hold.', '', '', NULL, NULL, 73, 7, 390);
INSERT INTO screen VALUES (416, 0, '2003-10-31 00:00:00', 'Small Molecule', 'Inhibit phosphopeptide binding by the Polo Box domain (PBD) of the serine/threonine kinase Plk1.', NULL, '2003-10-31 00:00:00', 'A screen for compounds that inhibit phosphopeptide binding by the Polo Box domain (PBD) of the serine/threonine kinase Plk1.  An FP assay will be developed with which the binding of a fluorescein-labeled phosphopeptide to the Plk1 PBD will be monitored.', 'A Fluorescence Intensity reading may be sufficient to measure binding. This will be piloted.', NULL, NULL, NULL, NULL, 383, 384, 326);
INSERT INTO screen VALUES (329, 4, '2006-05-31 00:00:00', 'Small Molecule', 'Inhibit the human cytomegalovirus (HCMV) UL97 protein kinase.', NULL, NULL, 'A screen for compounds that inhibit the human cytomegalovirus (HCMV) UL97 protein kinase.', '5/31/06: Mentioned in email from Don as "an accepted screen" when wrote to him about sending screen titles to Novartis.  Might have been referring to 9/22/03 application.', '', '', NULL, NULL, 4, 4, 620);
INSERT INTO screen VALUES (330, 4, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit assembly of HSV-I viral particles.', NULL, NULL, 'A screen for compounds that inhibit assembly of HSV-I viral particles.', NULL, NULL, NULL, NULL, NULL, 4, 4, 384);
INSERT INTO screen VALUES (331, 4, '2004-01-29 00:00:00', 'Small Molecule', 'Inhibit Herpes Simplex Virus Type I (HSV-I) infection up to and including HSV-1 early gene expression.', NULL, NULL, 'A screen for compounds that inhibit Herpes Simplex Virus Type I (HSV-I) infection up to and including HSV-1 early gene expression.', 'Allen is working out readout format--GFP expression read in either plate reader or autoscope.

3-24-04: Allen wrote that the Knipe Lab (HMS Microbiology) has patented use of this virus in screening and thus is likely to be on any papers. David Knipe has convinced the HMS biosafety committee to downgrade the virus from BSL2 to BSL1 because the GFP tag interferes with an essential viral protein to a sufficient degree as to lower the risk of infection to humans.', '', '', NULL, NULL, 309, 4, 337);
INSERT INTO screen VALUES (332, 4, '2003-04-04 00:00:00', 'Small Molecule', 'Inhibit the interaction of Herpes Simplex Virus (HSV) DNA polymerase  (Pol) with its processivity factor, UL42. ', '2004-07-20 00:00:00', '2004-07-20 00:00:00', 'A screen for compunds that inhibit the interaction of Herpes Simplex Virus (HSV) DNA polymerase  (Pol) with its processivity factor, UL42.  A fluorescence polarization assay was carried out in which binding of an 18 amino acid Pol peptide (labelled with Oregon  Green) to a 340 amino acid fragment of UL42 (UL42delC340 fused to MBP) was monitored. ', 'Rick is continuing this screen, which was started by Bea Pilger in Winter 2001. The 12-21-01 visit summarizes Bea''s visits.', 'HSsubunit', 'HSsubunitFP', NULL, NULL, 506, 4, 280);
INSERT INTO screen VALUES (328, 4, '2003-06-10 00:00:00', 'Small Molecule', 'Disrupt the interaction  between human cytomegalovirus (HCMV) DNA polymerase subunits UL54 and UL44.', '2004-07-20 00:00:00', '2004-07-20 00:00:00', 'A screen for compounds that disrupt the interaction  between human cytomegalovirus (HCMV) DNA polymerase subunits UL54 and UL44.   A fluorescence polarization (FP) assay has been set up using a peptide from UL54 (labelled with Oregon green) and a large fragment of the UL44 protein (GST-UL44delC290; this is about 2/3 of the protein and carries out all known biochemical activities of UL44). ', '8/04 This screen is now being continued by Rick (Can) Cui of the Coen lab. ', '', '', NULL, NULL, 195, 4, 299);
INSERT INTO screen VALUES (417, 0, '2004-07-07 00:00:00', 'Small Molecule', 'Modulate the binding of  Lipopolysaccharide Induced TNF-alpha Factor (LITAF) to the TNF-alpha promoter.', NULL, NULL, 'A screen for compounds that modulate the binding of  Lipopolysaccharide Induced TNF-alpha Factor (LITAF) to the TNF-alpha promoter.', NULL, NULL, NULL, NULL, NULL, 231, 231, 399);
INSERT INTO screen VALUES (257, 2, '2002-05-03 00:00:00', 'Small Molecule', 'Alter the gravitropic response of Arabidopsis thaliana.', NULL, NULL, 'A screen for compounds that alter the gravitropic response of Arabidopsis thaliana.  Wild type plants can sense the gravity vector and will generally send the shoot up and the roots down, even when the pot or the plate itself is placed on a angle or even 180 degrees relative to the gravity vector. Gravity sensing has some relationship with vacuole development, and one of the things the Raikhel lab focuses on is vacuole biology. Moreover, this is an easy visual screen. The plates will be placed upside down in the incubator. Interesting compounds will cause shoots to grow downward, against the gravity vector.', 'The gravitropic screen did not work in 96 well format. Therefore compounds were never tested in the assay. Thus no data for ActivityBase.', NULL, NULL, NULL, NULL, 104, 60, 187);
INSERT INTO screen VALUES (256, 2, '2002-05-14 00:00:00', 'Small Molecule', 'Affect vacuolar biogenesis in S. cerevisiae and Arabidopsis thaliana.', NULL, NULL, 'A screen for compounds that affect vacuolar biogenesis in  S. cerevisiae and Arabidopsis thaliana.  The primary screen is carried out in the yeast S. cerevisiae, where vps (vacuolar protein sorting) deletion mutants secrete vacuole-targeted carboxypeptidase Y (CPY). After compound addition, CPY secretion from wild-type yeast cells is monitored via dot-blot transfer. Screening positives are compounds that cause secretion of CPY into culture media.  These compounds are subsequently tested in A. thaliana for their effect on vacuolar protein sorting in the plant.  ', '11-27-02 The following hits were provided by Mien:
plate	96well	384well
525	E09	I017
520	A11	B22
524	D9	H17

6-24-04: Natasha sent us a paper :
PNAS | June 22, 2004 | vol. 101 | no. 25 | 9497-9501
Sorting inhibitors (Sortins): Chemical compounds to study vacuolar sorting in Arabidopsis
Jan Zouhar, Glenn R. Hicks and Natasha V. Raikhel
that describes results from this assay in screening a collection of 4800 compounds owned by UCR. The data from the ICCB pilot screen do not seem to be included in the publication.
', NULL, NULL, NULL, NULL, 59, 60, 197);
INSERT INTO screen VALUES (418, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Induce or inhibit transcription/expression of thrombospondin-1 (TSP-1).', NULL, NULL, 'A screen for compounds that induce or inhibit transcription/expression of thrombospondin-1 (TSP-1), a potent angiogenesis inhibitor produced by epithelial and mesenchymal cells.', 'Michael left HMS in the summer of 2004 to take a position at another university.', NULL, NULL, NULL, NULL, 313, 313, 385);
INSERT INTO screen VALUES (419, 0, '2003-10-09 00:00:00', 'Small Molecule', 'Augment the expression or activity of the transcription factor C/EBPalpha in human U937 cells.', '2003-10-09 00:00:00', '2003-10-09 00:00:00', 'A screen for compounds that augment the expression or activity of the transcription factor C/EBPalpha in human U937 cells.  Compounds are added to U937 cells stably expressing a construct  in which a firefly luciferase reporter  gene is  under the control of a tetramer of C/EBP binding sites. Luciferase activity will be measured 24 hours later.  Screening positives are compounds that increase luciferase activity in this cell line, but not in a control line in which expression of renilla luciferase is controlled by mutated C/EBP sites that do not efficiently bind C/EBP.  ', 'Retinoic acid is a good positive control.

Note: have already carried out this screen on 200,000 NCI compounds in collaboration with Bob Shoemaker of NCI-DTP.

Spring 2004: They successfully screen a very high density of cells in each well (>10K) and have shown that cell viability is fine at the time of the assay.', NULL, NULL, NULL, NULL, 529, 103, 322);
INSERT INTO screen VALUES (141, 3, '2003-06-11 00:00:00', 'Small Molecule', 'Modulate the STAT1 signalling pathway.', NULL, NULL, 'A screen for compounds that modulate the STAT1 signalling pathway.  A cell line has been constructed in which a firefly luciferase reporter gene, under the transcriptional control of a STAT-dependent (hybrid) promoter, is stably integrated.  A control cell line with the NF-kB promoter driving expression of  luciferase has also been constructed.  Screening positives are compounds that  activate or inhibit STAT1-dependent production of luciferase, but do not affect TNF-alpha stimulated transcription from the NF-kB promoter. ', 'In collaboration with Bend Research (Oregon), the Frank group has already screened several small-scale combi chem libraries. They are continuing follow-up on interesting hits from those libraries but do not plan to screen further with Bend Research.', NULL, NULL, NULL, NULL, 522, 363, 300);
INSERT INTO screen VALUES (140, 3, '2004-10-13 00:00:00', 'Small Molecule', 'Modulate the STAT3 signalling pathway. ', NULL, NULL, 'A screen for compounds that modulate the STAT3 signalling pathway.  A cell line has been constructed in which a firefly luciferase reporter gene, under the transcriptional control of a STAT3-dependent (hybrid) promoter, is stably integrated.  A control cell line with the NF-kB promoter driving expression of  luciferase has also been constructed.  Screening positives are compounds that  activate or inhibit STAT3-dependent production of luciferase, but do not affect TNF-alpha stimulated transcription from the NF-kB promoter. ', '11-05: The current priority for this screen will be to screen the MMRF Prestwick Collection of small molecules provided to ICCB-L by the MMRF via a grant awarded to David Frank.  The Frank lab will not be charged for screening the MMRF Prestwick Collection. 
4-13-06: This screen is a counterscreen for  #540 and #540 is a counterscreen for this one. Erik is not interested in compounds that hit in both #540 and #425 (these are likely general cell toxics). Screening positives for #425 will be those that do not hit in #540. ', '', '', NULL, NULL, 522, 363, 425);
INSERT INTO screen VALUES (142, 3, '2004-10-13 00:00:00', 'Small Molecule', 'Modulate the STAT5 signalling pathway.', NULL, NULL, 'A screen for compounds that modulate the STAT5 signalling pathway.  A cell line has been constructed in which a firefly luciferase reporter gene, under the transcriptional control of a STAT5-dependent (hybrid) promoter, is stably integrated.  A control cell line with the NF-kB promoter driving expression of  luciferase has also been constructed.  Screening positives are compounds that  activate or inhibit STAT5-dependent production of luciferase, but do not affect TNF-alpha stimulated transcription from the NF-kB promoter. ', NULL, NULL, NULL, NULL, NULL, 522, 363, 426);
INSERT INTO screen VALUES (139, 3, '2005-11-07 00:00:00', 'Small Molecule', 'Modulate the NFKappaB signalling pathway.', NULL, NULL, 'A screen for compounds that modulate the NFKappaB signalling pathway.  A cell line has been constructed in which a firefly luciferase reporter gene, under the transcriptional control of an NF-KB-dependent (hybrid) promoter, is stably integrated. This screen will be done in parallel with a screen for modulators of the STAT3 pathway. Because NFKappaB is activated by TNFalpha, and Stat3 is activated by IL-6, the controls will be unstimulated cells, which will give very little baseline induction of luciferase activity, and cells stimulated with cytokine, which will give a high level of luciferase activity.  Screening positives are compounds that decrease the high level of cytokine induced luciferase activity.  The level of inhibition by a active compound will then be compared to unstimulated cells.
', 'The priority for this screen will be to screen the MMRF Prestwick Collection of small molecules provided to ICCB-L by the MMRF via a grant awarded to David Frank.  The Frank lab will not be charged for screening the MMRF Prestwick Collection. 
4-13-06: This screen is a counterscreen for  #425 and #425 is a counterscreen for this one. Erik is not interested in compounds that hit in both #540 and #425 (these are likely general cell toxics). Screening positives for #540 will be those that do not hit in #425. ', '', '', NULL, NULL, 362, 363, 540);
INSERT INTO screen VALUES (420, 0, '2005-01-11 00:00:00', 'Small Molecule', 'Inhibit the B1R and F10L kinases of vaccinia virus.', NULL, NULL, 'A screen for compounds that inhibit the B1R and F10L kinases of vaccinia virus.', '10/20/04: this screen requires significant assay development.', '', '', NULL, NULL, 294, 294, 465);
INSERT INTO screen VALUES (153, 6, '2006-08-14 00:00:00', 'Small Molecule', 'Inhibit PpkA Kinase', NULL, '2006-09-28 00:00:00', 'A screen for compounds that inhibit PpkA kinase.', '', '', '', NULL, NULL, 654, 138, 641);
INSERT INTO screen VALUES (421, 0, '2002-11-19 00:00:00', 'Small Molecule', 'Specifically inhibit the histone acetylase function of mutated alleles of the yeast gene GCN5 but not of wild-type GCN5.', NULL, NULL, 'A screen for compounds that specifically inhibit the histone acetylase function of mutated alleles of the yeast gene GCN5 but not of wild-type GCN5.  Cells lacking Gcn5p function require exogenous amino acids for growth and grow only in rich medium, not in minimal medium.  Alanine-scanning mutagenesis has been carried out on GCN5.  Mutant alleles exist that have alanines in place of bulky amino acids in the enzyme active-site, but that have wild-type function (i.e. allow growth in minimal medium).  The goal of this screen is to find small molecules with "bumps" that fit into the "holes" in the mutant active site and inhibit only the activity of mutant GCN5.  Strains expressing mutant gcn5 alleles will be screened in parallel with strains expressing wild-type GCN5.', 'Ollie studies chromatin remodelling and in the near future would like to carry out a similar screen using alleles of SNF2, a gene with less well-characterized activity.', NULL, NULL, NULL, NULL, 286, 286, 250);
INSERT INTO screen VALUES (422, 0, '2002-01-24 00:00:00', 'Small Molecule', 'Inhibit activity of  two different bacterial sulfur assimilation enzymes  from M. tuberculosis  (screen in E. coli).
', NULL, NULL, 'Screens for compounds that inhibit the activity of two different bacterial sulfur assimilation enzymes from M. tuberculosis.  The enzymes have been cloned into complementation plasmids and each allows an E. coli knockout strain (a cysteine auxotroph) to survive on minimal media.  Compounds that kill either of these strains but not a control strain will be considered hits.', NULL, 'MtubCysC/CysH', 'MtubComplementation', NULL, NULL, 636, 147, 130);
INSERT INTO screen VALUES (339, 1, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit expression of a GFP reporter driven in a tat-dependent manner by the HIV promoter.', NULL, NULL, 'A screen for compounds that inhibit expression of a GFP reporter driven in a tat-dependent manner by the HIV promoter.', '9/9/05- Leslie Matthews left DFCI July 2005. Wayne Marasco will have someone continue this screen.', NULL, NULL, NULL, NULL, 719, 596, 387);
INSERT INTO screen VALUES (338, 1, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit HIV replication by disrupting the Tat-cyclinT1 interaction.', NULL, NULL, 'A screen for compounds that inhibit HIV replication by disrupting the Tat-cyclinT1 interaction.  This screen will utilize a fluorescence polarization assay.', NULL, NULL, NULL, NULL, NULL, 719, 596, 386);
INSERT INTO screen VALUES (179, 4, '2004-08-09 00:00:00', 'Small Molecule', 'Are agonists of the Fanconi Anemia/BRCA pathway.
', NULL, NULL, 'A screen for small molecules that are agonists of the Fanconi Anemia/BRCA pathway.
', '7/14/05 - Michelle De La Vega is taking over for Maria who is leaving the lab. Toshi is also no longer with the D''Andrea lab.', '', '', NULL, NULL, 199, 200, 412);
INSERT INTO screen VALUES (180, 4, '2003-03-14 00:00:00', 'Small Molecule', 'Inhibit the monoubiquitination and localization to nuclear foci of  FANCD2 (Fanconi Anemia protein D2).', '2003-08-22 00:00:00', '2003-08-25 00:00:00', 'A screen for compounds that inhibit the monoubiquitination and localization to nuclear foci of  FANCD2 (Fanconi Anemia Complex protein D2).  FANCD2 is ubiquitinated by the FA Complex and this targets D2 to nuclear foci.  A stable cell line expressing D2 fused to GFP has been made.   Compounds will be added to  the  cells under conditions (as yet to be determined) that promote nuclear foci formation.  The cells will be  incubated for  ~24 hours, fixed, and analysed by automated microscopy. ', '11/19/04 Toshi has taken a position at the Fred Hutchison Inst. in Seattle and Clark Chen is taking over this project. 
7/05 Maria Stotsky is leaving the lab and Michelle De La Vega is taking over her (RA) role on the screen. ', '', '', NULL, NULL, 199, 200, 272);
INSERT INTO screen VALUES (181, 4, '2006-10-11 00:00:00', 'RNAi', 'RNAi screen to identify targets required for radiation-induced cytotoxicity in human cells.', NULL, NULL, 'RNAi screen to identify targets required for radiation-induced cytotoxicity in human cells.', '10/11/06 Note: An application was never submitted for this screen. It is a key CMCR project and I have had several conversations with RIchard about it. As of Sept. 2006, Richard and his collaborator were still optimizing the assay they were contemplating using--probably HeLa cells, probably the same/similar conditions as used for a pilot screen of Qiagen siRNAs obtained earlier this year by the D''Andrea lab. ', '', '', NULL, NULL, 582, 200, 652);
INSERT INTO screen VALUES (182, 4, '2006-06-09 00:00:00', 'RNAi', 'An siRNA screen to identify targets required for growth of  Fanconi Anemia/BRCA1  mutant cells, but not for isogenic "wild-type" cells. ', NULL, NULL, 'An siRNA screen to identify targets required for growth of  Fanconi Anemia/BRCA1 mutant cells, but not for  isogenic "wild-type" cells. ', '', '', '', NULL, NULL, 582, 200, 629);
INSERT INTO screen VALUES (178, 4, '2004-12-10 00:00:00', 'Small Molecule', 'Prevent RAD6-dependent mutagenic DNA repair in S. cerevisiae in response to ionizing radiation.  ', NULL, NULL, 'A screen for compounds that prevent RAD6-dependent mutagenic DNA repair in S. cerevisiae in response to ionizing radiation.  ', '12-10-04 Clark is going to pilot this screen in 96-well format with growth on solid media.  For this he  will screen known bioactive compounds. We discussed developing this screen as a 384-well based assay in liquid culture. Clark will pilot that condition too. (CES).', NULL, NULL, NULL, NULL, 443, 200, 458);
INSERT INTO screen VALUES (423, 0, '2006-10-05 00:00:00', 'Small Molecule', 'Are toxic to zebrafish thymocytes expressing a Myc transgene, but not to thymocytes not expressing the transgene.', NULL, NULL, 'A screen for compounds that are toxic to zebrafish thymocytes expressing a Myc transgene, but not to thymocytes not expressing the transgene. A zebrafish model of Myc-induced T cell acute lymphoblastic leukemia (T-ALL) has been developed, in which Myc expression is driven by the lymphocyte-specific recombination activating gene 2 (RAG2) promoter.  In addition to Myc, these transgenic fish also carry the green fluorescent protein gene under control of the RAG2 promoter, which makes their thymocytes readily identifyable by fluorescence microscopy.  A synthetic lethal drug screen will be carried out to identify small molecules that show specific cytotoxicity towards thymocytes only in the setting of Myc overexpression. Myc-expressing fish survive only as heterozygotes, and therefore their offspring must be screened for presence of the Myc and GFP transgenes, which cannot be done before 5 days post-fertilization (dpf).  Once identified, these 5-day old transgene-positive embryos will be plated in a 96-well plate, along with 240 mcl of fish water, penicillin, streptomycin, metronidazole.  Test compounds will be added, and these fish will be screened for disappearance of thymic fluoescence.  Based on preliminary data, it appears that the optimal duration of drug treatment is 4 days with control drugs (dexamethasone, methotrexate, and cyclophosphamide).  

', '8/23/06 The maximal number of fish per well which can survive the assay conditions well is currently being determined. 
10/5/06 3 fish/well will be assayed. 240 ul/ water well. Will plan to transfer 900 nl of compound to each well. 
11/8/06- Alejandro wrote that he is now collaborating with Randall Peterson to do his small scale small molecule zebrafish screen (R.P. appears to have own automation and known bioactives libraries). ', '', '', NULL, NULL, 16, 17, 647);
INSERT INTO screen VALUES (424, 0, '2005-08-19 00:00:00', 'Small Molecule', 'Inhibit sialic acid uptake in E. coli.', NULL, NULL, 'A screen for compounds that inhibit sialic acid uptake in E. coli.', '2006-04-20: not expected until Fall 2006 at earliest.', '', '', NULL, NULL, 32, 32, 519);
INSERT INTO screen VALUES (246, 7, '2002-04-10 00:00:00', 'Small Molecule', 'Affect the intracellular localization of the mammalian ARF1-GTPase in BS-C1 cells.', NULL, NULL, 'A screen for compounds that affect the intracellular localization of the mammalian ARF1 GTPase in BS-C1 cells.  Compounds are added to a cell line that stably expresses an ARF1-GFP fusion protein.  ARF1 is normally localized to the Golgi apparatus.  Cells are incubated for one hour at 37oC, fixed, and imaged using automated microscopy. Hits are compounds that mis-localize ARF1.   ', '3-2-04: None of the cherry picked positives followed-up successfully. Screen is completed with no publications. 

This screen was carried out in parallel with screens #198 and #199, which look for compounds that prevent mis-localization of ARF1 in the presence of Brefeldin A and exo1, respectively.', 'FENG, YAN', 'ARF-BFA', NULL, NULL, 521, 521, 185);
INSERT INTO screen VALUES (243, 7, '2002-04-10 00:00:00', 'Small Molecule', 'Affect the secretory pathway of monkey BS-C1 cells.', NULL, NULL, 'A screen for compounds that affect the secretory pathway of monkey BS-C1 cells.  Cells were infected with recombinant adenovirus expressing VSV G (ts)-GFP fusion protein.  At 40oC, this protein is retained in the ER.  At 32oC, it can move to the plasma membrane. At 20oC it is retained in the Golgi apparatus.  Compounds were added to the cells, they were incubated  for one hour at 40oC and then for 3 hours at either 20oC or 32oC. The cells were then fixed and examined by automated microscopy.  Hit compounds were those that caused accumulation of the VSV G-GFP protein in a discrete secretory compartment.', '3-2-04: Yan sent structures of his 20 hits from this screen to me and Andrew.  T. Kirchhausen et al., will pursue all follow-up on these compounds from here on. 
Results Published in: 
 1. Feng, Y., Yu, S., Lasell, T.K., Jadhav, A.P., Macia, E., Chardin, P., Melancon, P., Roth, M., Mitchison, T., Kirchhausen, T. (2003). Exo1: a new chemical inhibitor of the exocytic pathway. Proc. Natl. Acad. Sci. USA. 100, 6469-74.
2. Pelish, H.E., Westwood, N.J., Feng, Y., Kirchhausen, T., Shair, M.D. (2001). Use of Biomimetic Diversity-Oriented Synthesis to Discover Galanthamine-Like Molecules with Biological Properties beyond Those of the Natural Product. J. Am. Chem. Soc. 123, 6740-6741. ', ' ', '', NULL, NULL, 521, 521, 183);
INSERT INTO screen VALUES (244, 7, '2002-05-14 00:00:00', 'Small Molecule', 'Prevent the mis-localization of the mammalian ARF1-GTPase in BS-C1 cells that have been treated with exo1, a small molecule that causes reabsorption of the Golgi by the ER.', NULL, NULL, 'A screen for compounds that prevent the mis-localization of the mammalian ARF1-GTPase in BS-C1 cells that have been treated with exo1, a small molecule that causes reabsorption of the Golgi by the ER.  ARF1 is normally localized to the Golgi apparatus. Compounds are added to a cell line that stably expresses an ARF1-GFP fusion protein.   Cells are incubated for one hour at 37oC and then exo1 is added  to a final concentration of 100uM. After an additional 30 minute incubation,  the cells are fixed and imaged using automated microscopy.   ', 'This screen is carried out in parallel with screens #185 and #198, which look for compounds that cause mislocalization of Arf1 (#185)  and that prevent mis-localization of ARF1 in the presence of Brefeldin A (#198).5/29/03 - Met with Yan; assay not robust enough for screen therefore not carried further.', NULL, NULL, NULL, NULL, 521, 521, 199);
INSERT INTO screen VALUES (245, 7, '2002-04-10 00:00:00', 'Small Molecule', 'Affect nuclear translocation of NFAT in HeLa cells in the  presence of calcium.', NULL, NULL, 'A screen for compounds that affect nuclear translocation of NFAT in HeLa cells in the  presence of calcium.  Cells were infected with recombinant adenovirus expressing an NFAT-4-GFP fusion protein.  Compounds were added and incubated for one hour.  Ca++-ionophore (A23187) was added for another hour. Cells were fixed and imaged using automated microscopy. ', '3-2-04: F. McKeon et al. submitted a paper 1-2 months ago  describing results of this screen.', 'NFAT', 'NFATVIS', NULL, NULL, 521, 521, 184);
INSERT INTO screen VALUES (242, 7, '2002-05-14 00:00:00', 'Small Molecule', 'Prevent the mis-localization of the mammalian ARF1-GTPase in BS-C1 cells that have been treated with Brefeldin A.', NULL, NULL, 'A screen for compounds that prevent the mis-localization of the mammalian ARF1-GTPase in BS-C1 cells that have been treated with Brefeldin A.  Compounds are added to a cell line that stably expresses an ARF1-GFP fusion protein.   Cells are incubated for one hour at 37oC and then Brefeldin A is added to a final concentration of 2.5uM . After an additional 30 minute incubation,  the cells are fixed and imaged using automated microscopy.   ARF1 is normally localized to the Golgi apparatus; Brefeldin A causes the Golgi apparatus to be re-absorbed by the ER. ', '3-2-04: None of the cherry picked positives followed-up successfully. Screen is completed with no publications. 

This screen was carried out in parallel with screens #185 and #199, which look for compounds that cause mislocalization of Arf1 (#185)  and that prevent mis-localization of ARF1 in the presence of exo1 (#199).', 'FENG, YAN', 'ARF-BFA', NULL, NULL, 521, 521, 198);
INSERT INTO screen VALUES (247, 7, '2002-06-14 00:00:00', 'Small Molecule', 'Stimulate proliferation of primary adult rat neuroprogenitor stem cells.', NULL, NULL, 'A screen for compounds that stimulate proliferation of primary adult rat neuroprogenitor stem cells.  The stem cells will be treated with compounds and their proliferation assayed ~3 days later using the ProMega Cell Titre Glo cell viability assay, which is read in the plate reader.  Note that proliferation of these cells does not necessarily correlate with their differentiation into neurons.', 'As Mei pilots this assay, she will try 2 potentially limiting conditions: cell number/well and amount of FGF2 growth factor per well.

**One promising hit in this assay: PL_587 I08 induces proliferation of the stem cells.** 

Yan left the ICCB in March 2004 and transferred follow-up on this screen to his collaborator, Zhigang He at Children''s Hospital.', NULL, NULL, NULL, NULL, 520, 521, 222);
INSERT INTO screen VALUES (248, 7, '2002-06-14 00:00:00', 'Small Molecule', 'Cause differentiation of primary adult rat neuroprogenitor stem cells to neurons, astrocytes, or dendrites.', NULL, NULL, 'A screen for compounds that cause differentiation of primary adult rat neuroprogenitor stem cells to neurons, astrocytes, or dendrites.', NULL, NULL, NULL, NULL, NULL, 520, 521, 223);
INSERT INTO screen VALUES (249, 7, '2002-07-12 00:00:00', 'Small Molecule', 'Stimulate transport of an ER resident protein to the plasma membrane.', NULL, NULL, 'A screen for compounds that stimulate transport of an ER resident protein to the plasma membrane.  The intracellular localization of the marker will be monitored by automated microscopy.', '4-14-04: Chi is planning to finish up at the ICCB soon and may not get to this screen.



There are many variables that need to be worked out  as this screen is piloted.', NULL, NULL, NULL, NULL, 658, 521, 242);
INSERT INTO screen VALUES (222, 2, '2002-12-19 00:00:00', 'Small Molecule', 'Suppress the blood circulation defect in the zebrafish mutant gridlock.', NULL, NULL, 'A screen for compounds that suppress the blood circulation defect in the zebrafish mutant gridlock. The gridlock gene is a hairy-enhancer of split related gene.  Zebrafish gridlock mutants are models of the human disease coarctation of the aorta.  Gridlock mutants have underdeveloped aortas that don"t allow blood flow to the tail.  This condition develops because the mutation promotes the adoption of the venous (rather than arterial) cell fate by angioblasts.  Suppressors of this mutation would be interesting as an illustration of the ability to reverse a genetic developmental defect and because compounds capable of promoting arterial cell fates may have therapeutic value in treating coarctation and other vascular diseases.   Homozygous gridlock mutant zebrafish are mated and the embryos are collected immediately after fertilization.  Three embryos are arrayed in each well of 96-well plates at the 50% epiboly stage and compounds added. The embryos in each well are examined visually at 48 hours postfertilization, and the compound is scored as positive when blood circulation is detected in the tails of all embryos within a well.', NULL, NULL, NULL, NULL, NULL, 589, 412, 254);
INSERT INTO screen VALUES (221, 2, '2002-01-30 00:00:00', 'Small Molecule', 'Affect development of the cardiovascular system in zebrafish embryos. ', NULL, NULL, 'Screen for compounds that affect development of the cardiovascular system in zebrafish embryos.  Zebrafish embryos are grown for several days in the presence of compound and development of their cardiovascular system is monitored by microscopy.', '5-29-03 Only one hit compound from this screen is being followed  up (in collaboration with John Tallarico): PL-0032 P6.

4-5-04: From Randy the results from ABase testset  date 5/18/00 have been published and can be released to the public (ChemBank).  The other data (ABase testset  date 11/29/01) have not been published.  Coincidently, we just began today to
write up the results from 11/29/01.  If you don''t mind holding off on the
release of those data, that would be great.  Hopefully, we will be able to get
them published soon.
', 'ZEBRAFISH', 'ZFISH1', NULL, NULL, 589, 412, 143);
INSERT INTO screen VALUES (272, 3, '2005-03-07 00:00:00', 'Small Molecule', 'Inhibit Ebola virus glycoprotein-mediated entry into cells.', NULL, NULL, 'A screen for compounds that inhibit Ebola virus glycoprotein-mediated entry into cells.', '', '', '', NULL, NULL, 396, 396, 477);
INSERT INTO screen VALUES (270, 3, '2005-08-02 00:00:00', 'Small Molecule', 'Inhibit Ebola virus replication and/or transcription.', NULL, NULL, 'A screen for compounds that inhibit Ebola virus replication and/or transcription.', '', '', '', NULL, NULL, 396, 396, 515);
INSERT INTO screen VALUES (269, 3, '2005-10-19 00:00:00', 'Small Molecule', 'Inhibit vesicular stomatitis virus (VSV) glycoprotein-mediated entry into cells.', NULL, NULL, 'A screen for compounds that inhibit vesicular stomatitis virus (VSV) glycoprotein-mediated entry into cells.', 'This screen originated as a counterscreen within screen 477 (Ebola virus glycoprotein-mediated entry into cells).', '', '', NULL, NULL, 396, 396, 534);
INSERT INTO screen VALUES (271, 3, '2005-08-04 00:00:00', 'Small Molecule', 'Inhibit influenza virus replication and/or transcription.', NULL, NULL, 'A screen for compounds that inhibit influenza virus replication and/or transcription.', '', '', '', NULL, NULL, 396, 396, 516);
INSERT INTO screen VALUES (425, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Stabilize the monomeric conformation of the VP40 matrix protein of filoviruses.', NULL, NULL, 'A screen for compounds that stabilize the monomeric conformation of the VP40 matrix protein of filoviruses.  This screen will employ a fluorescence polarization assay using fluorescein-labeled ssRNA.  Monomeric VP40 should not bind ssRNA under the assay conditions, and positive hits will be defined as compounds that block RNA binding.', 'This will likely be an Ebola screen, via NERCE.', NULL, NULL, NULL, NULL, 729, 729, 391);
INSERT INTO screen VALUES (22, 41, '2002-06-18 00:00:00', 'Small Molecule', 'Inhibit the  ATPase activity of  the mammalian chromosome-associated mitotic  kinesin KID.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin KID.   The ATPase activity of purified KID is assayed (in the absence of microtubules) using a malachite green assay and read in the plate reader.', '5/30/06 Tim says will not continue this screen. ', 'KID_ATPase', 'KID_ATPase', NULL, NULL, 671, 31, 227);
INSERT INTO screen VALUES (426, 0, '2002-01-30 00:00:00', 'Small Molecule', 'Are allosteric inhibitors/activators of 20S Proteasome activity--assay proteasome.', NULL, NULL, 'Screen for compounds that are allosteric inhibitors of 20S proteasome activity.  20S proteasomes, purified from muscle, are incubated in buffer with compound.  Proteasome activity is assayed by addition of the substrate Suc-LLVY-AMC, which fluoresces when cleaved by the proteasome proteases.', '5/9/03 Caroline talked to Alexei several months ago and he told her that there were one or two possible hits that were not followed up due to time constraints.', 'AKPROTEASOME', '20SACTIVITY', NULL, NULL, 456, 404, 134);
INSERT INTO screen VALUES (427, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit the interaction of paxillin with integrins or focal adhesion kinase (FAK).', '2004-08-02 00:00:00', '2004-08-02 00:00:00', 'A screen for compounds that inhibit the interaction of paxillin with integrins or focal adhesion kinase (FAK).  This screen intends to use an ELISA assay that has alrady been piloted in 96-well format.', '10/20/06 update:
Dear Caroline,

I wanted to update you on the work that Im doing with one of the compounds that I found during the screening at the ICCB.

The compound specifically inhibited the interaction of paxillin or leupaxin with ?4 integrin. It had no major effect on the interaction of Hic-5 with ?4 or FAT. Interestingly, a compound which is similar to the active compound and only has one methoxy group shifted from position 5 to position 2 was completely inactive.

The compound reduced Jurkat T cell migration performed in a Transwell migration assay in a dose dependent manner and to the same extend as it is reduced in Jurkat T cells that express ?4 with a mutation (Y991A) that disrupts the paxillin-?4 interaction.

In cell spreading assays on CHO as well as Jurkat T cells incubation with the compound led to increased cell spreading comparable with the used controls. As controls CHO-SD cells expressing the S998D mutation in the ?4 integrin or Jurkat JB4YA cells expressing the Y991A mutation in the ?4 integrin, both of which leading to disruption of paxillin binding show enhanced cell spreading, were used.

I further wanted to let you know, that we are about to apply for a patent on this compound. Im about to put my results together in a manuscript for publication. So please keep this information confidential.

 

Thanks a lot

Best

Christiane

 

 

Christiane Kummer, Ph.D.

Department of Medicine

University of California San Diego

Leichtag Building, room 149

9500 Gilman Drive, MC 0726

La Jolla, CA 92093

phone: 858.822.6496

fax: 858.822.6458

email: ckummer@ucsd.edu', '', '', NULL, NULL, 579, 220, 393);
INSERT INTO screen VALUES (241, 17, '2004-01-07 00:00:00', 'Small Molecule', 'Inhibit the E3 ubiquitin ligase activity of the mammalian  apoptosis inhibitor cIAP1.', NULL, NULL, 'A screen for compounds that inhibit the E3 ubiquitin ligase activity of the mammalian  apoptosis inhibitor cIAP1.', '6/21/06: Do not send this title to NVS. Screen to be continued in Zhu lab when it is established in China. ', '', '', NULL, NULL, 248, 7, 334);
INSERT INTO screen VALUES (226, 17, '2005-10-05 00:00:00', 'Small Molecule', 'Increase expression from the human Beclin 1 promoter and, thus, that might increase autophagy and degradation of neurotoxic proteins.', '2005-02-21 00:00:00', '2006-01-03 00:00:00', 'A screen for compounds that  increase expression from the human Beclin 1 promoter and, thus, that might increase autophagy and degradation of neurotoxic proteins.', '12/2/05 Junying wrote Caroline an email: "Tsuyoshi''s data was a big help with our grant review. Thank you very much for your help. We decided that we probably don''t need to screen for more compounds for that screen right now. Enough to keep Tsuyoshi busy for a while."
6/21/06: Do not send this title to NVS. No further screening is planned.', '', '', NULL, NULL, 213, 7, 528);
INSERT INTO screen VALUES (227, 17, '2002-01-24 00:00:00', 'Small Molecule', 'Rescue PC-12 cells from apoptosis induced by ER stress.', NULL, NULL, 'Screen for compounds that rescue PC-12 cells from caspase12-dependent apoptosis induced by ER stress.  ER stress is induced by treatment with tunicamycin and cell viability (ATP production) is monitored 48 hours after compound addition using the ATPLite reagents from Packard.', '6/21/06 Do not submit title to NVS, will not be re-iniated in Yuan lab.', 'ERSTRESS', 'ERSTRESS', NULL, NULL, 614, 7, 107);
INSERT INTO screen VALUES (228, 17, '2004-08-03 00:00:00', 'Small Molecule', 'Activate the IRE1/xbp-1 ER stress pathway  in mammalian cells.', NULL, NULL, 'A screen for compounds that activate the IRE1/xbp-1 ER stress pathway in mammalian cells.', '10-14-04 from Mike: Just to give you an update on that, I made immortalized MEFs from
Masayuki''s transgenic XBP1 mouse but unfortunately the GFP signal is too
weak to detect in plate format, even with the fancy plate readers that
Dave helped me try. (Masayuki has said they also can''t really see a signal
without FACS.) I''m now cloning the XBP1-GFP reporter into a retrovirus,
which will hopefully let us make stable cell lines that could be used for
screening. I''ll be in touch when I have that up and running and then we
can go ahead with the project.', '', '', NULL, NULL, 614, 7, 410);
INSERT INTO screen VALUES (229, 17, '2006-02-23 00:00:00', 'Small Molecule', 'A screen for compounds  that selectively reduce the levels of mutant or wild type cochlin,  a major secreted protein in the inner ear. ', NULL, '2006-05-03 00:00:00', 'A screen for compounds that selectively reduce the levels of mutant or wild type cochlin.  Encoded by the COCH gene,  cochlin is a major secreted protein in the inner ear and mutants in COCH are known to be responsible for DFNA9, an adult onset deafness syndrome in humans.
', '6/21/06: Do not send this title to NVS. Sufficient chemistry collaboration in place.', '', '', NULL, NULL, 614, 7, 583);
INSERT INTO screen VALUES (231, 17, '2006-03-10 00:00:00', 'Small Molecule', 'A screen for compounds that inhibit TNF-alpha-mediated necrosis in Jurkat cells.', NULL, '2006-04-21 00:00:00', 'A screen for compounds that inhibit TNF-alpha-mediated necrosis in Jurkat cells. Jurkat cells (human T-cells) are treated with TNF-alpha (to induce necrosis)  and compounds are added.  Cell viability is measured 30 hours later using the  "Cell Titre Glow" from Promega.  Compounds that allowed cells to live are considered hits.', 'Continuation of screen #180, with slightly different protocol. No charge for this screen, it is supported by the Yuan U01 grant.
Emily''s mentor in the  Yuan lab is Junichi Hitomi.
6/21/06: Do not send this title to NVS. Sufficient chemistry collaboration in place.', '', '', NULL, NULL, 339, 7, 585);
INSERT INTO screen VALUES (224, 17, '2006-10-16 00:00:00', 'RNAi', 'An siRNA screen for genes that affect the levels of mutant or wild type cochlin,  a major secreted protein in the inner ear. ', NULL, NULL, 'An siRNA screen for genes that affect the levels of mutant or wild type cochlin,  a major secreted protein in the inner ear. ', 'Kai will modify Hong and Mike Boyce''s screen (#583). Need to find positive siRNA.', '', '', NULL, NULL, 303, 7, 653);
INSERT INTO screen VALUES (232, 17, '2006-06-09 00:00:00', 'RNAi', 'An siRNA screen to identify key regulators of the human necroptosis pathway, a novel cellular programmed necrotic cell death pathway. ', NULL, NULL, 'An siRNA screen to identify key regulators of the human necroptosis pathway, a novel cellular programmed necrotic cell death pathway. ', '6/15/06 Trying HiPerfect reagent. Dharmafect 1 did not give good results. Did get good results with Amaxa electroporation but that protocol is very expensive!
6/26/06 HiPerFect works. WIll run down 48 H after transfection, then add TNF for 20H. Will start screening at 50nM siRNA.   Doing forward  transfection. Jurkat cells. 
11/3/06 Tranfections still difficult--have found mouse  cell line (L929) in which screen might be more feasible.  Set up new screen, #655.', '', '', NULL, NULL, 269, 7, 626);
INSERT INTO screen VALUES (233, 17, '2006-11-03 00:00:00', 'RNAi', 'An siRNA screen to identify key regulators of the mouse necroptosis pathway, a novel cellular programmed necrotic cell death pathway. ', NULL, NULL, 'An siRNA screen to identify key regulators of the mouse necroptosis pathway, a novel cellular programmed necrotic cell death pathway. ', '11/3/06 No application submitted. The mouse cell line (L929) used for this screen is more amenable to transfection than the human cell line used in companion screen #626. Reverse transfection, 75 nM screening concentration. ', '', '', NULL, NULL, 269, 7, 655);
INSERT INTO screen VALUES (234, 17, '2006-10-05 00:00:00', 'RNAi', 'An RNAi image-based screen for genes able to induce and suppress autophagy human H4 glioma cells.', NULL, NULL, 'An RNAi image-based screen for genes able to induce and suppress autophagy human H4 glioma cells.', '', '', '', NULL, NULL, 419, 7, 649);
INSERT INTO screen VALUES (235, 17, '2002-04-02 00:00:00', 'Small Molecule', 'Selectively kill SV-40 transformed cells (W-I38var13, a human fibroblast line). ', NULL, NULL, 'A screen for compounds that selectively kill SV-40 transformed cells (WI-38var13, a human fibroblast line).   Transformed and  (isogenic) non-ransformed cells (WI-38 cells) were treated in parallel with compounds. Viability was assayed 48 hours later  using the ATP-lite reagent from Packard.', 'Alexei does not consider this a successful screen. No interesting hits from NCI Div Set. No other libraries screened.  Alexei''s thinks this assay is too broad--too many hits, nothing dramatically selective.  Might have been more selctive if had assayed for a specific property of the transformed cells.', NULL, NULL, NULL, NULL, 239, 7, 181);
INSERT INTO screen VALUES (236, 17, '2002-04-02 00:00:00', 'Small Molecule', 'Inhibit TNF-alpha-mediated necrosis U937 cells.', NULL, NULL, 'A screen for compounds that inhibit TNF-alpha-mediated necrosis. U937 (human B-cells) were treated with zVAD-FMK  (a peptide caspase inhibitor), compounds were added,  and  then the cells were treated with TNF-alpha to induce necrosis.  Cell viability was measured 72 hours later using the ATP-lite reagent from Packard or "Cell Titre Glow" from Promega.  Compounds that allowed cells to live were considered hits.', '3/28/03 - Dara has all hit annotation from all plates screened in the NCI Structural, ChemBridge DiverSet, Peakdale, Maybridge, ChemDiv (587-630,669), MixCom1, MixCom2, Bionet, CEREP, NINDS, ICCB Bioactives (high), FPK, DHPC.
3/28/03 - Data from some visits present at this time has not been entered into ActivityBase and hit data not available (ChemBridge Microformats).
3/10/06-The protocol for this screen is being changed slightly  (e.g. Jurkat cells and no zVAD added) and it is being transferred to Emily Hsu as screen #585.', 'NECROSIS', 'NECROSIS', NULL, NULL, 239, 7, 180);
INSERT INTO screen VALUES (237, 17, '2002-11-12 00:00:00', 'Small Molecule', 'Inhibit binding of an N-terminal peptide derived from the Smac  protein to the BIR3 domain of the caspase inhibitor XIAP. ', NULL, NULL, 'A screen for compounds that inhibit binding of an N-terminal peptide derived from the Smac  protein to the BIR3 domain of the caspase inhibitor XIAP.   A fluorescence polarization assay has been developed that measures binding of the 8aa Smac peptide (labelled  with Oregon green) to the 14 kD BIR3 domain of XIAP.', '6/21/06: Do not send this title to NVS. Junying says follow-up did not work out.', '', '', NULL, NULL, 239, 7, 248);
INSERT INTO screen VALUES (238, 17, '2002-04-02 00:00:00', 'Small Molecule', 'Inhbit Bcl-xl heterodimerization.', NULL, NULL, 'A screen for compounds that inhbit Bcl-xl heterodimerization.  A BH3 peptide, part of the ligand of  Bcl-xl, was flourescently labeled with Oregon Green and mixed with purified, recombinant Bcl-xl.  Fluorescence polarization was measured after compound addition.', 'Results published:  Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J. (2001) Nat Cell Biol. 3(2):173-82. "Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL."
6/21/06: Do not send this title to NVS. Screen will not be re-initiated in Yuan lab.', '', '', NULL, NULL, 239, 7, 179);
INSERT INTO screen VALUES (239, 17, '2002-11-12 00:00:00', 'Small Molecule', 'Inhibit the binding of the pleckstrin homology (PH) domain of  Akt to PIP3.', NULL, NULL, 'A screen for compounds that inhibit the binding of the pleckstrin homology (PH) domain of  Akt to PIP3. A fluorescence polarization assay has been developed that measures binding of labelled  phosphlipids to a GST fusion of the 12 kD PH domain of Akt.', '6/21/06: Do not send this title to NVS. Screen being continued in Degterev lab. Also, Alexei discussing it with Biogen.', '', '', NULL, NULL, 239, 7, 249);
INSERT INTO screen VALUES (240, 17, '2003-01-30 00:00:00', 'Small Molecule', 'Inhibit expanded polyglutamine repeat-induced toxicity in HeLa cells.', NULL, NULL, 'A screen for compounds that inhibit expanded polyglutamine repeat-induced toxicity.  HeLa cells were transiently transfected to express expanded polyglutamine repeats (Q79). Under normal conditions, these cells die within 48 hours.  Compounds were added  and cell viability was measured using the ATP Lite assay (Packard)  for ATP production.  Positives were compounds that prevented ATP depletion relative to untreated cells.  ', 'This screen started in 1999 and Ivelisse screeened ChemBridge DiverSet E and NCI diversity Set  (Structural), plates 1-51 and 53-59.  Hits from ChemBridge are still being followed up (paper in preparation, 1-30-03); no hits from the NCI Diversity Set. Chembridge data only is in ActivityBase.', 'POLYQDEATH', 'ATPVIABILITY', NULL, NULL, 458, 7, 266);
INSERT INTO screen VALUES (17, 10, '2003-06-30 00:00:00', 'Small Molecule', 'Inhibit bacterial N-acyl aminoacid synthetases.', NULL, NULL, 'A screen for compounds that inhibit bacterial N-acyl aminoacid synthetases.  The enzyme FeeM catalyzes the transfer of an acyl group from a thioesterified carrier protein, FeeL, to the amino group of the free amino acid tyrosine.  A colorimetric assay with pure proteins that uses DTNB to detect the liberation of free thiol caused by the acyl transfer reaction has been developed.

  ', 'The assay is fairly straightforward,involving enzyme/substrate addition, incubation at 37 deg, addition of guanidine to denature the proteins, addition of DTNB, then measurement of A412. ', '', '', NULL, NULL, 74, 75, 307);
INSERT INTO screen VALUES (8, 10, '2004-11-09 00:00:00', 'Small Molecule', 'Inhibit Trypanothione Reductase-405 nm readout', '2004-11-09 00:00:00', '2004-11-09 00:00:00', 'A screen for compounds that inhibit Trypanothione Reductase.  Trypanothione Reductase is an NADPH-dependent oxidoreductase that helps to protect trypanosomes from oxidative stress.  Bacterially expressed recombinant protein is mixed with Trypanothione disulphide (substrate) and DTNB (5,5`-dithiobis-(2-nitrobenzoic acid), Ellman"s reagent) in assay buffer, dispensed into 384-well plates, and NADPH is added.  After 60 minutes absorbance at 405nm is monitored.', NULL, NULL, NULL, NULL, NULL, 145, 75, 430);
INSERT INTO screen VALUES (7, 10, '2004-08-31 00:00:00', 'Small Molecule', 'Inhibit formation of Pseudomonas aeruginosa biofilms.', NULL, NULL, 'A screen for compounds that inhibit formation of Pseudomonas aeruginosa biofilms.', '9-1-04: Screen accepted without application submittes. Lauren still working out which strain she will use (e.g. clinical/non-clinical isolate, GFP-expressing or not).  The standard stain for biofilm detection is crystal violet.  We discussed several possible plate reader and microscope assay possibilities.
2-1-06: Application submitted. Lauren will use PAO1 (a  lab strain) and will read out with Promega BacTitreGlo and possibly using absorbance as well.', NULL, NULL, NULL, NULL, 175, 75, 415);
INSERT INTO screen VALUES (9, 10, '2005-10-04 00:00:00', 'Small Molecule', 'Inhibit invasion or growth of the Plasmodium falciparum laboratory strain Dd2 in a whole cell assay.', NULL, NULL, 'A screen for compounds that inhibit invasion or growth of the Plasmodium falciparum laboratory strain Dd2 in a whole cell assay.', 'This P. falciparum strain, Dd2, is resistant to Chloroquine and sensitive to Pyrimethamine.', '', '', NULL, NULL, 210, 75, 526);
INSERT INTO screen VALUES (10, 10, '2005-10-28 00:00:00', 'Small Molecule', 'Inhibit invasion or growth of the Plasmodium falciparum Senegal Field Isolate Sen V56.04 in a whole cell assay.', NULL, NULL, 'A screen for compounds that inhibit invasion or growth of the Plasmodium falciparum Senegal Field Isolate Sen V56.04 in a whole cell assay.', '', '', '', NULL, NULL, 210, 75, 536);
INSERT INTO screen VALUES (11, 10, '2005-10-04 00:00:00', 'Small Molecule', 'Inhibit invasion or growth of the Plasmodium falciparum laboratory strain HB3 in a whole cell assay.', NULL, NULL, 'A screen for compounds that  inhibit invasion or growth of the Plasmodium falciparum laboratory strain HB3 in a whole cell assay.', 'This P. falciparum strain, HB3, is sensitive to Chloroquine and Resistant to Pyrimethamine.', '', '', NULL, NULL, 210, 75, 525);
INSERT INTO screen VALUES (12, 10, '2005-10-28 00:00:00', 'Small Molecule', 'Inhibit invasion or growth of the Plasmodium falciparum Senegal Field Isolate Sen V34.04 in a whole cell assay.', NULL, NULL, 'A screen for compounds that inhibit invasion or growth of the Plasmodium falciparum Senegal Field Isolate Sen V34.04 in a whole cell assay.', '', '', '', NULL, NULL, 210, 75, 535);
INSERT INTO screen VALUES (13, 10, '2004-05-12 00:00:00', 'Small Molecule', 'Inhibit invasion or growth of the Plasmodium falciparum laboratory reference strain 3D7 in a whole cell assay.', '2004-05-12 00:00:00', '2004-05-12 00:00:00', 'A screen for compounds that inhibit invasion or growth of the Plasmodium falciparum laboratory reference strain 3D7 in a whole cell assay.', 'This P. falciparum strain is sensitive to all anti-malarials.', NULL, NULL, NULL, NULL, 210, 75, 367);
INSERT INTO screen VALUES (14, 10, '2005-05-31 00:00:00', 'Small Molecule', 'Inhibit Glutathione Reductase-405 nm readout', NULL, NULL, 'A screen for compounds that inhibit glutathione Reductase.  Glutathione Reductase is an NADPH-dependent oxidoreductase that helps to protect mammals from oxidative stress.  Protein is mixed with NADPH and DTNB (5,5`-dithiobis-(2-nitrobenzoic acid), Ellman"s reagent) in assay buffer, dispensed into 384-well plates, and glutathione disulphide (substrate) is added.  After 90 minutes, absorbance at 405nm is monitored.', '', '', '', NULL, NULL, 645, 75, 510);
INSERT INTO screen VALUES (15, 10, '2005-03-04 00:00:00', 'Small Molecule', 'Inhibit Trypanothione Reductase-340 nm readout.', NULL, NULL, 'A screen for compounds that inhibit Trypanothione Reductase-340 nm readout. ', NULL, NULL, NULL, NULL, NULL, 645, 75, 475);
INSERT INTO screen VALUES (16, 10, '2003-10-17 00:00:00', 'Small Molecule', 'Inhibit the growth of Trypansoma brucei.', '2003-10-30 00:00:00', '2003-10-30 00:00:00', 'A screen for compounds that inhibit the growth of Trypansoma brucei.', '10-17-03 Derek is just beginning to pilot potential assays for his screen.', NULL, NULL, NULL, NULL, 645, 75, 325);
INSERT INTO screen VALUES (89, 10, '2002-06-14 00:00:00', 'Small Molecule', 'Affect cell cycle progression or cyclin stability in mammalian tissue culture cells--luciferase readout. ', NULL, NULL, 'A screen for compounds that affect cell cycle progression or cyclin stability in mammalian tissue culture cells. Adenoviruses bearing cyclin B-luciferase or luciferase alone are used to infect mammalian cells.  The cells are treated with compounds for ~16 hours and then luciferase activity is measured. Assays are read on a plate reader.', 'This screen was run initially by Jon before 3/01 using HeLa cells. He screened ChemBridge 1-51 and NCI Structural Diversity Set (53-59). All those data are in ABase.  The screen was run in both non-synchronized cells and in G0 arrested cells.
When the screen starts again, different cell lines may be used.

9-14-04: Rick Gregory, new King lab postdoc, is following up on hits from this screen.', 'CBCYCLUC', 'CYCLUC_ASYNCH', NULL, NULL, 551, 28, 216);
INSERT INTO screen VALUES (87, 10, '2002-01-30 00:00:00', 'Small Molecule', 'Overide the mitotic checkpoint in HCT-116 cells treated with taxol.', NULL, NULL, 'A screen for compounds that overide the mitotic checkpoint in HCT-116 cells treated with taxol. Cells are synchronized in S-phase with a double thymidine block and  released into 100 nM taxol.  They are then treated with compounds. After ~16 hours, cells are fixed, stained with DAPI, rhodamine phalloidin, and (in some cases) anti-tubulin antibody.   Cell morphology and cell cycle state are assessed by automated microscopy.', NULL, 'SPINCHECK', 'BrdUIncorp384', NULL, NULL, 551, 28, 148);
INSERT INTO screen VALUES (88, 10, '2002-06-14 00:00:00', 'Small Molecule', 'Affect cell cycle progression or cyclin stability in mammalian tissue culture cells-GFP readout.', NULL, NULL, 'A screen for compounds that affect cell cycle progression or cyclin stability in mammalian tissue culture cells.  Adenoviruses bearing cyclin A-, cyclin B-, or actin-GFP fusions are used to infect mammalian cells.  The cells are treated with compounds for ~16 hours, fixed and stained with DAPI. Chromosomes and GFP are visualized using automated microscopy.', 'A similar protocol was used by Esther Pflugger (rotation student) to screen all of ChemBridge DiverSet E (1-51). That data is in ABase.

When Jon restarts this screen he needs to find an optimal cell line.  
When screen starts, may want to make separate records for each different adenovirus infected cell line. ', 'CBCYCGFP', 'CYCGFP', NULL, NULL, 551, 28, 215);
INSERT INTO screen VALUES (91, 10, '2002-06-14 00:00:00', 'Small Molecule', 'Affect mitotic progression (cyclin stability) in Xenopus egg extracts.', NULL, NULL, 'A screen for compounds that affect mitotic progression (cyclin stability) in Xenopus egg extracts. A cyclin-luciferase reporter protein is added to interphase egg extracts. The extracts are then induced to enter mitosis by addition of recombinant cyclin B. Compounds are added, the extracts incubated for 60 minutes and luciferase activity is assayed . Assays are read on the Tundra or on a plate reader.', 'Noel screened all of ChemBridge 1-51, the NCI Div. Set 53-59, the NCI Open Collection 60-36*, and the Pelish GLL library in duplicate before 3/01. All data except for that from the NCI Open Collection and the GLL library are in ABase.  Note Chembridge was actually screened in quadruplicate--2x in 384-well plates and 2x in 1536 PDMS plates; some discrepancies seen between the two plate formats; issue =unresolved.  2 hits from the GLL library did not re-test when re-synthesized by Henry Pelish.', 'XLCYCLUC', 'XLcycluc384', NULL, NULL, 695, 28, 218);
INSERT INTO screen VALUES (92, 10, '2002-06-14 00:00:00', 'Small Molecule', 'Affect cdh1-induced cyclin degradation in Xenopus egg extracts.', NULL, NULL, 'A screen for compounds that affect cdh1-induced cyclin degradation in Xenopus egg extracts. A cyclin-luciferase reporter protein is added to interphase egg extracts. Recombinant cdh1 is then  added followed by compounds. The extracts are incubated for 3 hours and luciferase activity is assayed. Assays are read on the Tundra or on a plate reader.', 'Noel screened ChemBridge 1-51 and the Pelish GLL library before 3/01. All ChemBridge data are in ABase.', 'XLCYCLUC', 'XLCDH1', NULL, NULL, 695, 28, 219);
INSERT INTO screen VALUES (93, 10, '2005-06-14 00:00:00', 'Small Molecule', 'Increase BT-474 cell sensitivity to the humanized monoclonal antibody, herceptin.  Human BT-474 cells overexpress the Her2 receptor protein-tyrosine kinase.', NULL, '2005-06-14 00:00:00', 'A screen for compounds that increase BT-474 cell sensitivity to the humanized monoclonal antibody, herceptin.  Human BT-474 cells overexpress the Her2 receptor protein-tyrosine kinase.', '7/27/06 Rick has left the lab. This screen will be continued by Qiqi Cui, a new postdoc in the King lab. ', '', '', NULL, NULL, 545, 28, 512);
INSERT INTO screen VALUES (94, 10, '2002-06-14 00:00:00', 'Small Molecule', 'Induce chromosme non-disjunction or loss in NTERT-1 cells (human keratinocytes).', NULL, NULL, 'A screen for compounds that induce chromosme non-disjunction or loss in NTERT-1 cells (human keratinocytes).  Compounds are added to the cells, after incubation at 37oC, the cells will be  fixed and processed for FISH.  Probes on chromosomes 8 and 12 will be visualized using automated microscopy.', '7/10/06: Randy says this screen is too technically difficult to carry out! Change status to Dropped Technical!', '', '', NULL, NULL, 525, 28, 220);
INSERT INTO screen VALUES (95, 10, '2006-07-28 00:00:00', 'RNAi', 'An RNAi screen for human genes that, when knocked down, increase BT-474 cell sensitivity to the humanized monoclonal antibody, herceptin. ', NULL, NULL, 'An RNAi screen for genes that, when knocked down, increase BT-474 cell sensitivity to the humanized monoclonal antibody, herceptin. ', '7/27/06 Qiqi is picking up an RNAi screen initiated by Rick Gregory, former postdoc in the King lab.', '', '', NULL, NULL, 494, 28, 638);
INSERT INTO screen VALUES (86, 10, '2002-12-20 00:00:00', 'Small Molecule', 'Inhibit Ubc4-dependent APC11 ubiquitination in vitro.', NULL, NULL, 'A screen for compounds that inhibit Ubc4-dependent APC11 ubiquitination. The goal of this screen is to identify inhibitors of APC11 or UBC4 in order to elucidate the mechanism of ubiquitination and the role of UBC4 in this process.  This screen utilizes FRET (fluorescence resonance energy transfer) to measure the level of ubiquitin chain formation in the presence of E1, Ubc4 and APC11.  CFP and YFP are separately fused to ubiquitin.  When ubiquitin chains are formed, a FRET ratio can be calculated as the measurement of CFP-Ub emission at 550nm divided by the YFP-Ub excitation at 425nm.  Compounds that significantly reduce this FRET ratio are scored as positives.', 'Deanna left for graduate school in August 2003 and Nate Hathaway took over the screen.', 'Ubc4DepAPC11Ubiq', 'Ubc4DepAPC11Ubiq', NULL, NULL, 411, 28, 257);
INSERT INTO screen VALUES (96, 10, '2003-10-09 00:00:00', 'Small Molecule', 'Inhibit Ubc4-dependent APC11 ubiquitination in vitro.', NULL, NULL, 'A screen for compounds that inhibit Ubc4-dependent APC11 ubiquitination. The goal of this screen is to identify inhibitors of APC11 or UBC4 in order to elucidate the mechanism of ubiquitination and the role of UBC4 in this process.  This screen utilizes FRET (fluorescence resonance energy transfer) to measure the level of ubiquitin chain formation in the presence of E1, Ubc4 and APC11.  CFP and YFP are separately fused to ubiquitin.  When ubiquitin chains are formed, a FRET ratio can be calculated as the measurement of CFP-Ub emission at 550nm divided by the YFP-Ub excitation at 425nm.  Compounds that significantly reduce this FRET ratio are scored as positives.', 'Took over screen from Deanna Mele after Deanna left for graduate school, August 2003.', NULL, NULL, NULL, NULL, 105, 28, 323);
INSERT INTO screen VALUES (90, 10, '2002-06-14 00:00:00', 'Small Molecule', 'Affect cell cycle progression or cdc20 stability in mammalian tissue culture cells--luciferase readout. ', NULL, NULL, 'A screen for compounds that affect cell cycle progression or cdc20 stability in mammalian tissue culture cells--luciferase readout. ', NULL, 'CBCYCLUC', 'CDC20ASYNCH', NULL, NULL, 551, 28, 217);
INSERT INTO screen VALUES (428, 0, '2004-07-22 00:00:00', 'Small Molecule', 'Cause internalization of the iron exporter ferroportin in MDCK cells.', NULL, NULL, 'A screen for compounds that cause internalization of the iron exporter ferroportin in MDCK cells.', 'GFP- ferroportin, microscope screen.', NULL, NULL, NULL, NULL, 159, 160, 408);
INSERT INTO screen VALUES (287, 2, '2002-02-28 00:00:00', 'Small Molecule', 'Activate formation of the sea urchin fertilization envelope. ', NULL, NULL, 'A screen for compounds that activate formation of the sea urchin fertilization envelope. The formation of the sea urchin fertilization envelope (which normally occurs upon fertilization of the egg by sperm) is assayed using luminol, which is quantitated with a plate reader.  The normal cascade of events during fertilization results in the release of internal peroxide from the egg and the presence of an endogenous peroxidase catalyzes the light reaction. ', NULL, NULL, NULL, NULL, NULL, 253, 254, 170);
INSERT INTO screen VALUES (286, 2, '2002-10-22 00:00:00', 'Small Molecule', 'Julia''s Generic Screen ', NULL, NULL, 'A screen for compounds that', 'Julia has also worked with Seung Bum Park and Bimal Desai.
Because Julia does many themes and variations on the same screen and because her data is for the  most part not followed by the ICCB screening and informatics groups, we have decided to  keep track only of the dates that  she screens in collaboration with Schreiber lab memebers and will fill in assay information later as needed.
Always Screens DiVJ2 1-10 Unless otherwise noted.', NULL, NULL, NULL, NULL, 253, 254, 244);
INSERT INTO screen VALUES (285, 2, '2002-02-28 00:00:00', 'Small Molecule', 'Overcome the inhibition of cell proliferation caused by Staurosporine, a serine/threoine kinase inhibitor.', NULL, NULL, 'A screen for compounds that overcome the inhibition of cell proliferation caused by Staurosporine.  A549 (human lung carcinoma) cells are grown the presence of  Staurosporine and compound for 20 hours.  The ability of the cells to proliferate is then assayed by measuring BrdU incorporation over 3 hours (cells are stained with Abs against BrdU).', NULL, NULL, NULL, NULL, NULL, 253, 254, 171);
INSERT INTO screen VALUES (323, 5, '2002-01-24 00:00:00', 'Small Molecule', 'Inhibit peptide loading of human MHC class II complex (allele related to susceptiblity to rheumatoid arthritis)', NULL, NULL, 'Screen for compounds that inhibit peptide loading of a human MHC class II complex allele  (DR1), related to susceptiblity to rheumatoid arthritis.  Interaction of purified MHC class II and a fluorescently-labelled peptide, in the presence of the immune protein DM, is assayed by fluorescence polarization.  Hits would affect  the peptide-MHC binding equilibrium.', 'This screen originated in the laboratory of Don Wiley.', NULL, NULL, NULL, NULL, 164, 165, 111);
INSERT INTO screen VALUES (325, 5, '2002-05-13 00:00:00', 'Small Molecule', 'Affect the dissociation of peptide from MHC class II  allele DR1  (an allele related to susceptibility to rheumatoid arthritis).', NULL, NULL, 'A screen from compounds that affect the dissociation of peptide from MHC class II  allele DR1  (an allele related to susceptibility to rheumatoid arthritis). Interaction of purified MHC class II and a fluorescently-labelled peptide, in the presence of the immune protein DM, is assayed by fluorescence polarization after addition of a non-labelled peptide that also binds DR1.  Hits would affect  the rate  at which the labelled peptide dissociates from DR1.', 'This screen is carried out as a continuation of Steve''s screen #111 (Inhibit peptide loading of human MHC class II complex (allele related to susceptiblity to rheumatoid arthritis)). The same plates first processed for #111 (including compound transfer) are subsequently processed for this screen.', '', '', NULL, NULL, 164, 165, 193);
INSERT INTO screen VALUES (326, 5, '2002-02-08 00:00:00', 'Small Molecule', 'Disrupt formation of the fusion-competent conformation of GP-41, an HIV coat protein.', NULL, NULL, 'A screen for compounds that disrupt formation of the fusion-competent conformation of GP-41, an HIV coat protein. This screen uses fluorescence polarization to measure binding of a fluorescein-labeled peptide (derived from the GP-41 ectodomain) to a single polypeptide that mimics trimeric GP-41.', 'Screen originated in the lab of Don Wiley.
9-05: Paper in final stages of publication in PNAS.', 'GP41', 'FP-GP41', NULL, NULL, 463, 165, 150);
INSERT INTO screen VALUES (322, 5, '2002-01-24 00:00:00', 'Small Molecule', 'Inhibit peptide loading of human MHC class II complex  (allele related to susceptiblity to multiple sclerosis)
', NULL, NULL, 'Screen for compounds that inhibit peptide loading of a human MHC class II complex allele related to susceptiblity to multiple sclerosis.  Interaction of purified MHC class II and a fluorescently-labelled peptide, in the presence of the immune protein DM, is assayed by fluorescence polarization.', 'Kai Wucherpfennig  put another postdoc on the screen (Melissa Nicholson) and the screen was carried out at LDDN.', NULL, NULL, NULL, NULL, 164, 165, 112);
INSERT INTO screen VALUES (327, 5, '2006-03-16 00:00:00', 'Small Molecule', 'Inhibit dengue virus cell fusion.', NULL, NULL, 'A screen for compounds that inhibit dengue virus cell fusion.', '2006-09: Jeff Cruzan has left the Harrison lab, and Aaron Schmidt is the new lead screener on this project.  The new screen number is 644.', '', '', NULL, NULL, 663, 165, 587);
INSERT INTO screen VALUES (429, 0, '2004-07-06 00:00:00', 'Small Molecule', 'Inhibit eukaryotic protein synthesis.', NULL, NULL, 'A screen for compounds that inhibit eukaryotic protein synthesis.  This screen has been piloted in 96-well format and is being converted to 384-well format.  The assay involves a dual luciferase system to identify protein synthesis inhibitors of various different classes.', '', '', '', NULL, NULL, 36, 36, 395);
INSERT INTO screen VALUES (343, 3, '2006-06-09 00:00:00', 'RNAi', 'An siRNA screen to identify biochemical pathways that intersect with dengue virus replication within host cells. ', NULL, NULL, 'An siRNA screen to identify biochemical pathways that intersect with dengue virus replication within host cells. The assay will be read out by screening microscope.', '6/5/06: "We plan initially to screen specific human siRNA subsets that target kinases, druggable genome and GPC receptors in order to identify known biochemical pathways that intersect with dengue virus replication within host cells." ', '', '', NULL, NULL, 502, 268, 624);
INSERT INTO screen VALUES (344, 3, '2006-06-02 00:00:00', 'Small Molecule', 'Inhibit dengue virus replication.', NULL, NULL, 'A screen for compounds that inhibit dengue virus replication..', '8/31/06: Piloting experiments will be conducted with both immunostaining- and FRET-based protocols.  The FRET assay is simpler and thus preferred, but it is not known at this time whether it will work.  The imaging screen has been piloted to some degree but is perhaps too labor-intensive for a large-scale screen.

6/2/06: this screen was originally opened under screen ID 467.  It has been reopened under this screen ID because the lead screener has changed from Jessica Masse to Justin Chu.', '', '', NULL, NULL, 502, 268, 623);
INSERT INTO screen VALUES (342, 3, '2006-08-31 00:00:00', 'Small Molecule', 'Modulate poliovirus replication.', NULL, '2006-12-05 00:00:00', 'A screen for compounds that modulate poliovirus replication.', '2006-10-06: This screen consist of screening only known bioactives as a piloting study for a dengue FRET-based assay (screen 623).', '', '', NULL, NULL, 268, 268, 642);
INSERT INTO screen VALUES (345, 3, '2005-01-11 00:00:00', 'Small Molecule', 'Inhibit dengue virus replication.', NULL, NULL, 'A screen for compounds that inhibit dengue virus replication.', '2006-06-01: this screen is formally closed and will be reopened under screen ID 623 with Justin Chu as the new lead screener.', '', '', NULL, NULL, 697, 268, 467);
INSERT INTO screen VALUES (430, 0, '2006-02-07 00:00:00', 'Small Molecule', 'Inhibit the PknA kinase of M. tuberculosis.', NULL, NULL, 'A screen for compounds that inhibit the PknA kinase of M. tuberculosis.', '', '', '', NULL, NULL, 121, 121, 564);
INSERT INTO screen VALUES (134, 4, '2002-02-08 00:00:00', 'Small Molecule', 'Affect ftsZ function and septum formation during E. coli cell division--GTPase assay.', NULL, NULL, 'A screen for compounds that Affect ftsZ function and septum formation during E. coli cell division.  ', 'Screen continued by Alan Hebert 7/1/01.
8/3/04 This screen was done with purified ftsZ and a GTPase assay, not an in vivo assay as for screen # 145.  This work will be published in 2004.
6/19/06: Do not send screen title to Novartis! 
On Jun 16, 2006, at 8:58 PM, Marc Kirschner wrote:
Dear Caroline,
	Hold off on that for now.  We may want to approach Novartis or some other company with the results of the screen as they are.
Marc', 'FTSZ', 'FTSZPOLY', NULL, NULL, 167, 117, 149);
INSERT INTO screen VALUES (135, 4, '2002-01-24 00:00:00', 'Small Molecule', 'Inhibit anthrax toxin entry into and killing of  macrophages.
', NULL, NULL, 'A screen for compounds that inhibit anthrax toxin entry into and killing of human macrophages.  Purified PA (protective antigen) and LF (lethal factor), components of the anthrax toxin, will be added to human macrophages, after pin-transfer of compounds.  Cell killing will be monitored using commercially available reagents.', '6/04 This screen will be continued as  a NERCE screen; Su Chiang will have a leading role, at least initially. 
12/10/04 For statistical purposes this screen should be counted as a John Collier screen (HSM Microbiology).', '', '', NULL, NULL, 356, 117, 131);
INSERT INTO screen VALUES (133, 4, '2002-01-30 00:00:00', 'Small Molecule', 'Affect ftsZ function and septum formation during E. coli cell division--whole cell assay', NULL, NULL, 'Screen for compounds that affect ftsZ function and septum formation during E. coli cell division.  Wild type E. coli and E. coli carrying a temperature sensitive allele of ftsZ are grown at the permissive temperature (30oC) in the presence of compound.  Compounds that differentially affect the growth of the two cell lines at 30oC are considered hits.  The ability of "hit" compounds to cause formation of filamentous E. coli (cells unable to form septums and divide) is then assayed.', '6/19/06: Do not send screen title to Novartis! 
On Jun 16, 2006, at 8:58 PM, Marc Kirschner wrote:
Dear Caroline,
	Hold off on that for now.  We may want to approach Novartis or some other company with the results of the screen as they are.
Marc
', '', '', NULL, NULL, 492, 117, 145);
INSERT INTO screen VALUES (137, 4, '2002-01-30 00:00:00', 'Small Molecule', 'Inhibit actin polymerization in Xenopus egg extracts.', NULL, NULL, 'A screen for compounds that inhibit actin polymerization in Xenopus egg extracts stimulated by PIP2-containing liposomes.  Pyrene-labeled actin monomers and screening compounds are added to egg extract. PIP2-containing liposomes are added to stimulate actin polymerization and the increase in pyrene fluorescence that accompanies actin polymerization is measured over time.', '', 'ACTIN', 'ACTIN-PYRENE', NULL, NULL, 116, 117, 144);
INSERT INTO screen VALUES (319, 2, '2006-03-31 00:00:00', 'Small Molecule', 'Affect VSV entry into cells.', NULL, NULL, 'A screen for compounds that affect VSV entry into cells.  This screen will employ a live VSV carrying a Renilla luciferase reporter.', '3/31/2006: this screen is the counterscreen to 308.  The Renilla luciferase gene is inserted in the P protein gene, allowing functional Renilla luciferase protein to be packaged into the infectious particle.  Cells will be pre-loaded with Renilla substrate; Renilla activity will therefore report directly on entry.  Comparison of data from screens 308 and 604 will assist in separating entry inhibitors from replication inhibitors.', '', '', NULL, NULL, 94, 94, 604);
INSERT INTO screen VALUES (320, 2, '2003-07-07 00:00:00', 'Small Molecule', 'Inhibit replication of the negative-strand RNA virus vesicular stomatitis virus (VSV).', '2004-07-12 00:00:00', '2004-07-12 00:00:00', 'A screen for compounds that inhibit entry and replication of the negative-strand RNA virus vesicular stomatitis virus (VSV).  This screen will employ a live VSV carrying a luciferase reporter.', '3/31/06: assay has been refined and will be piloted by Jennifer Wang (Whelan lab). The counterscreen has been assigned screen ID 604.

11/16/05: Sean has revised his assay substantially and is ready to start piloting.  There will be a counterscreen involved.  Personnel have also changed (Cureton/Wang instead of Taylor/Chmura).

7-7-03 This screen is in the piloting stage. Sean is starting to work with 384-well plates and has not yet determined whether he will use a microscope or plate reader to monitor his assay.  He is also evaluating GFP vs. luciferase as the reporter for viral replication.', '', '', NULL, NULL, 94, 94, 308);
INSERT INTO screen VALUES (318, 2, '2006-07-27 00:00:00', 'RNAi', 'An RNAi screen for human genes that affect the replication of vesicular stomatitis virus (VSV) in human cells.', NULL, NULL, 'An RNAi screen for human genes that affect the replication of vesicular stomatitis virus (VSV) in human cells.', '7/27/06: Will likely use HeLa cells.  Leaning towards a microscopy assay in which VSV containing a GFP reporter is used to infect cells. GFP levels and DAPI staining will be monitored.', '', '', NULL, NULL, 93, 94, 637);
INSERT INTO screen VALUES (147, 6, '2002-06-20 00:00:00', 'Small Molecule', 'Activate quorum sensing in Vibrio cholerae.', NULL, NULL, 'A screen for compounds that activate quorum sensing in Vibrio cholerae.', '10-19-04: still planning to do this screen in collaboration with another Mekalanos postdoc, though assay development is proceeding slowly.', '', '', NULL, NULL, 137, 138, 232);
INSERT INTO screen VALUES (148, 6, '2002-06-20 00:00:00', 'Small Molecule', 'Inhibit cholera toxin production.', NULL, NULL, 'A screen for compounds that inhibit cholera toxin production.  A Vibrio cholerae strain has been constructed that expresses GFP constitutively (to count cells) and also has the cholera toxin promoter driving expression of a tetracycline resistance gene.  Growth conditions during this assay are pH 6.5 at 30oC.  Compound is added to the cells, two hours later, tetracycline is added to the cultures, and cell viability is assay 18-24 later (by quantitating GFP levels in each well). In parallel, the same strain will be assayed with the same compounds but not treated with tetracycline.  Screening positives are compounds that cause decreased growth of the bacteria only in the presence of tetracycline.', 'Converted to NERCE/NSRB project in 2004.
2-28-03 update: I have completed the screen.  Of the
cherry picks ( about 100 cherry picked), I confirmed that over 70% were true
hits and of those, I chose about (15%) 20 of the most potent ones and have
ordered them from Chembridge to try to use them to identify regulators of
CTX production.  Also from the screen, I identified compounds which were
lethal to V. cholera as a second phenotype.  Of those that were cherry
picked (about 110), 95% were confirmed true hits.  From those, again I chose
the most potent ones and based on structural diversity of the hits, chose
about 30 to order from Chembridge.  I am in the process of working out a
transposon method for trying to rapidly identify mechanisms of action (with
many caveats) given the ease of bacterial genetics.  I have also developed a
bacterial-3-hybrid system as another approach.
6-12-03 : Deb deposited data files to Dara. However, they need to be put into a readable format by Deb. Deb is aware of this and will get the data to us at some point.
8/6/04 Deb is in the process of writing a paper to submit to PNAS.
', '', '', NULL, NULL, 137, 138, 229);
INSERT INTO screen VALUES (149, 6, '2002-06-20 00:00:00', 'Small Molecule', 'Inhibit quorum sensing in Vibrio cholerae.', NULL, NULL, 'A screen for compounds that inhibit quorum sensing in Vibrio cholerae.  A library of cholera transposon mutants has been isolated. All  have GFP inserted randomly in the genome such that (as determined by FACS sorting) production of GFP is turned on when the cells are treated with autoinducer extract (which contains the quorum activating/sensing molecule).  Compounds will be added to mixtures of these transposon mutants. Autoinducer will be added and then GFP expression will be assayed by plate reader.  Screening positives are compounds that prevent/reduce GFP production in the presence of autoinducer but not in control cells that were not treated with autoinducer.', '2-28-03 update: this is actually being done in collaboration
with another postdoc in the Mekalanos lab.  So as far as labor, if we were
to get any hits, there would be more man power to follow up.  However, there
have been glitches in the assay development which we are still working on.
Thus, have not started this screen.
10-19-04: still planning to do this screen, though assay development is proceeding slowly.', '', '', NULL, NULL, 137, 138, 231);
INSERT INTO screen VALUES (150, 6, '2002-06-20 00:00:00', 'Small Molecule', 'Inhibit NF KB-dependent transcription in lung epithelial cells induced by Pseudomonas aeruginosa infection.', NULL, NULL, 'A screen for compounds that inhibit NF KB-dependent transcription in lung epithelial cells induced by Pseudomonas aeruginosa infection.  Lung epithelial cells  engineered to express a reporter gene (luciferase) from the NF KB promoter will be treated with compound and then infected with  Pseudomonas aeruginosa.  Luciferase levels will be assayed to determine the level of NF kB-dependent transcription.    ', '2-28-03 update: this screen was based on a construct from a different lab.   However, in the end, what they claimed to have is not exactly what we asked for or thought that they had, so it will take a lot more time to make the construct we need as a reporter.  I apologize for the delay...I had spoken to you about it perhaps a bit early because I wanted to catch you before you left on maternity leave...not realizing the delay that we would have.  However, again, because I don''t want to stretch myself too thin, I think that this is a little back
burner for now, based on the promise of assay #1.
10-19-04: this screen will not be pursued owing to insufficient resources/personnel to support assay development.', NULL, NULL, NULL, NULL, 137, 138, 233);
INSERT INTO screen VALUES (151, 6, '2004-10-22 00:00:00', 'Small Molecule', 'Inhibit efflux pump systems in P. aeruginosa.', '2005-01-14 00:00:00', '2005-01-14 00:00:00', 'A screen for compounds that inhibit efflux pump systems in P. aeruginosa, either directly or by interfering with regulation of these systems.  Positive hits in this screen are defined as compounds that increase the sensitivity of the test strain to specific antibiotics, with inhibition of growth measured via optical density.', '10/15/04: The screen has been piloted in 384-well format. In one set of plates, the screening strain PAO1 will be plated out in LB in 384 well plates and the library will pin transferred to identify compounds that have a direct lethal or inhibitory effect on the strain, in a final volume of 40 microliters.  In a parallel set of plates, the strain is plated out with a cocktail of 5 other antibiotics (carbenicillin, gentamycin, ciprofloxacin, tetracycline, rifampin, and chloramphenicol), to a final volume of 40 microliters.  We have worked out conditions so that the cocktail as a whole, has no effect on growth, taking into account any synergistic effects of the antibiotics. The concentration of each individual antibiotic is only 3-10 fold below the MIC for that given antibiotic.  In other words, the screen is designed so that any small molecule modulator that increases the sensitivity of the strain to any of the 5 given antibiotics by 3-10 fold, should be identified in the screen.  Inhibition of growth is measured by optical density readout at 600 nm.

2/22/06: This protocol is working well, wants to continue screening, will possibly become NSRB funded screen. -Katrina', '', '', NULL, NULL, 137, 138, 428);
INSERT INTO screen VALUES (152, 6, '2002-06-20 00:00:00', 'Small Molecule', 'Activate cholera toxin production at the level of transcription.', NULL, NULL, 'A  screen for compounds that activate cholera toxin production at the level of transcription. A Vibrio cholerae strain has been constructed that expresses GFP constitutively (to count cells) and also has the cholera toxin promoter driving expression of a tetracycline resistance gene.  Growth conditions during this assay are pH 8.5 at 37oC. Compound is added to the cells, two hours later, tetracycline is added to the cultures, and cell viability is assay 18-24 later (by quantitating GFP levels in each well). In parallel, the same strain will be assayed with the same compounds but not treated with tetracycline.  Screening positives are compounds that cause increases growth of the bacteria only in the presence of tetracycline.', '2-28-03 update:cholera toxin production activation - I tried an initial screen but was
not happy enough with the results to continue.  I may come back to this
screen again, but for the time being, don''t want to overextend myself .
8/5/04 The results were not clear and so this screen will definitely not be pursued.', NULL, NULL, NULL, NULL, 137, 138, 230);
INSERT INTO screen VALUES (390, 1, '2006-02-28 00:00:00', 'Small Molecule', 'Inhibit West Nile virus (WNV) infection of mammalian cells.', NULL, '2006-11-02 00:00:00', 'A screen for compounds that inhibit West Nile virus (WNV) infection of mammalian cells.', '8/30/06: Manoj will in fact need to use the ICCB-L scopes for readout.  He says that 10x or 20x should work for him.

2/28/06: Manoj needs to pilot in preparation for filing a formal application.  This will be an imaging screen, and since this assay involves live WNV, all readout will be performed at Yale.', '', '', NULL, NULL, 468, 468, 584);
INSERT INTO screen VALUES (389, 1, '2006-05-01 00:00:00', 'RNAi', 'Human (host) genes required for susceptibility to West Nile virus infection. ', NULL, '2006-11-02 00:00:00', 'An RNAi screen for human (host) genes required for susceptibility to West Nile virus infection. ', '5/9/06 Teleconference with Manoj, Stewart, Su, and Brian. Manoj ready to pilot transfections in 384-well plate when our instrumentation is ready.  Will screen at 50nM, using siRNAs from 1 uM stock plate.   Having problems with Dharmafect 1 toxicity; will try Qiagen Hiperfect and Lipofectamine 2000.
6/21/06 We will be sending you siRNA plates. Manoj (NERCE) will provide assay plates, we will aliquot the siRNAs into the plates (2ul per well of 1 uM each siRNA pool), seal the plates, and send them to Manoj.
', '', '', NULL, NULL, 468, 468, 613);
INSERT INTO screen VALUES (74, 7, '2006-06-01 00:00:00', 'Small Molecule', 'Modulate the enzymatic activity of phosphoinositide kinases or phosphatases that act at distinct steps in cell signaling and trafficking.', NULL, NULL, 'A screen for compounds that modulate the enzymatic activity of phosphoinositide kinases or phosphatases that act at distinct steps in cell signaling and trafficking. This will be a biochemical screen using recombinant proteins.', '', '', '', NULL, NULL, 370, 370, 622);
INSERT INTO screen VALUES (75, 7, '2006-06-01 00:00:00', 'Small Molecule', 'Modulate the appearance of the glucose transporter Glut4 at the cell surface in response to insulin stimulation.', NULL, NULL, 'A screen for compounds that modulate the appearance of the glucose transporter Glut4 at the cell surface in response to insulin stimulation. This assay will be readout using a screening microscope.', '', '', '', NULL, NULL, 370, 370, 621);
INSERT INTO screen VALUES (76, 7, '2003-01-17 00:00:00', 'Small Molecule', 'Inhibit clathrin-mediated endocytosis in mammalian cells.', NULL, NULL, 'A screen for compounds that inhibit clathrin-mediated endocytosis in mammalian cells (Hela).  Endocytosis of fluorescently-labelled recombinant transferrin was scored visually on the autoscope.  A screening positive is a compound that totally inhibits internalization of fluorescent transferrin.', 'AL 021605- TNieland says this data is not reliable and should not be entered into Chembank.

This screen was carried out on ICCB I, ChemBridge DiverSet E, and NCI Structural Diversity Set (version 1), finishing in early 2001.  All of the data is in Activity Base as of Jan. 2003. 
No compounds that specifically inhibited endocytosis were identified, but interesting compounds fell into three groups:
i) affected internalization but not reproducible
ii) pleitropic effects (e.g. pertubation of actin cytoskeleton + endocytosis)
iii) large vacuoles (this class of compounds is being followed up by the kirchhausen group)', 'ENDOCYTOSIS', 'ENDOVIS', NULL, NULL, 369, 370, 264);
INSERT INTO screen VALUES (77, 7, '2003-01-17 00:00:00', 'Small Molecule', 'Inhibit the selective transfer of lipids mediated by the HDL receptor SR-BI. ', NULL, NULL, 'A screen for compounds that inhibit the selective transfer of lipids mediated by the HDL receptor SR-BI.  This screen was carried out using the Analyst plate reader and the results are published: Nieland et al. (2002) PNAS 99: 15422-15427. ', 'This screen was carried out on ICCB I, ChemBridge DiverSet E, and NCI Structural Diversity Set (version 1), finishing in early 2001.  All of the data is in Activity Base as of Jan. 2003. 
6-10-03 Monty Krieger is writing NIH grant to support new screening, possibly by Thomas.', 'ENDOCYTOSIS', 'ENDOHDL', NULL, NULL, 369, 370, 263);
INSERT INTO screen VALUES (78, 7, '2002-01-24 00:00:00', 'Small Molecule', 'Affect the ATPase activity of the chaperone Hsc70.
', NULL, NULL, 'Screen for compounds that affect the ATPase activity of the chaperone Hsc70.  The ATPase activity of purified mammalian Hsc70 is assayed using malachite green.', '4/1/03 - From Tommy, two screens carried out in parallel. One looking for inhibitors of Hsc70 ATPase activity alone, one looking for inhibitors of Hsc70 activation by auxillin. However, in follow up experiments it is not clear whether the auxillin/Hsc70 constructs used for this screen are reproducing the desired phenomenon.', NULL, NULL, NULL, NULL, 703, 370, 122);
INSERT INTO screen VALUES (79, 7, '2002-04-09 00:00:00', 'Small Molecule', 'Affect the GTPase activity of dynamin ', NULL, NULL, 'Screen for compounds that affect the GTPase activity of dynamin.  The GTPase activity of purified mammalian dynamin is assayed using malachite green.', '4/02 Eric has taken this screen over from Chris Brunner, effective immediately. 
4/1/03 - From Tommy Kirchhausen, two screens carried out in parallel. One looking for inhibitors of GTPase activity of dynamin alone, one looking for inhibitors of dynamin after activation by aggregation. By looking at Chris'' primary data Eric chose 20-30 potential dynamin inhibitors and has confirmed that they inhibit GTPase activity using a radioactive assay. He is also checked their effect on dynamin aggregation. He is in the process of doing cell biology assays and Tommy promises data for Activity Base in 1-2 months.

12/21/2005 - Henry Pelish stopped by to find any compounds in CBDivE similar to compound 2 O20. This is a strong hit.
June 2006 Manuscript In Press in Developmental Cell. Tommy would like to continue this screen if possible, perhaps with slightly different assay protocol (TBD).  See 5/22/06 Screening Application.', '', '', NULL, NULL, 661, 370, 182);
INSERT INTO screen VALUES (80, 7, '2002-01-24 00:00:00', 'Small Molecule', 'Affect the GTPase activity of dynamin. ', NULL, NULL, 'Screen for compounds that affect the GTPase activity of dynamin.  The GTPase activity of purified mammalian dynamin is assayed using malachite green.', 'This screen taken over by Eric Macia 4/02. New screening file created in his name.
4/1/03 - From Tommy Kirchhausen, two screens carried out in parallel. One looking for inhibitors of GTPase activity of dynamin alone, one looking for inhibitors of dynamin after activation by aggregation. See Eric Macia record for more information.

12/21/2005 - Henry Pelish stopped by to find any compounds in CBDivE similar to compound 2 O20. This is a strong hit.', '', '', NULL, NULL, 430, 370, 123);
INSERT INTO screen VALUES (73, 7, '2002-02-15 00:00:00', 'Small Molecule', 'Affect Simian Vacuolating virus 40 (SV40) binding, internalization, ER translocation, and possibly other processes (uncoating, transcription, and translation) to/in CV-1 cells.', NULL, NULL, 'A screen for compounds that affect Simian Vacuolating virus 40 (SV40) binding, internalization, ER translocation, and possibly other processes (uncoating, transcription, and translation) to/in CV-1 cells.', NULL, NULL, NULL, NULL, NULL, 476, 370, 157);
INSERT INTO screen VALUES (19, 41, '2002-01-24 00:00:00', 'Small Molecule', 'Interfere with GTP-binding activity of the mammalian septin Nedd5', NULL, NULL, 'Screen for compounds that interfere with GTP-binding activity of the mammalian septin Nedd5.  A fluorescence polarization assay is carried out using purified Nedd5 and BODIPY-labelled GTP.', 'No data for Activity Base, see correspondence from Makoto below.
Date: Mon, 5 May 2003 11:16:46 -0400 
Hi Dara,

Last week Caroline told me to give you the list of my hits in the primary screening. Here is the summary:

1) Screening method: compounds that interfere with fluorescence polarization of BODIPY-GTP by GST-Nedd5 (a mouse septin GTPase), in search of inhibitors for GTP-binding
2) Library: "Russian" library,  plates #1-24
3) positive wells: 4A2*, 4*, 6*, 8*, 10*, 12*, 14*; 4I15, 5G10*, 5K20, 6G16, 7C2, 7C8, 8E10, 8I16, 9E4*,12,14;10E5,11B2, 11C4, 12F5, 12G5, 12L20,14B17, 14G20  (note: * contain similar core structure)
4) Secondary screen results: none of the compounds gave apparent strong effects on cultured human cells at 100uM.
5) Conclusion: Because of the negative results, we suspended further screening. Retrospectively, this fusion protein later turned out to be physiologically irrelevant, hence septin "complex" should have been used.
', NULL, NULL, NULL, NULL, 131, 31, 109);
INSERT INTO screen VALUES (18, 41, '2003-05-02 00:00:00', 'Small Molecule', 'Inhibit interaction between two mammalian septins.', NULL, NULL, 'A screen for compounds that inhibit interaction between two mammalian septins. This screen was carried out in yeast. Interaction between the two septins caused expression of the URA3 gene, which resulted in cell death in the presence of 5-FOA. Inhibitors of the interaction between the two septins allowed cells to live on 5-FOA.', '5/02/03 - After this screen was carried out, it was discovered that the two septins used in the screen are expressed in two different neuronal cell types. Thus the results from the screen likely have no physiological relevance and the results have not been followed up. Screening results should not be entered into any updated screening databases.', 'SEPTIN', 'SEPTINRTH', NULL, NULL, 131, 31, 287);
INSERT INTO screen VALUES (20, 41, '2006-05-31 00:00:00', 'Small Molecule', 'Modulate the response of human cells to inhibitors of the mitotic kinesin Eg5.', NULL, NULL, 'A screen for compounds that modulate the response of human cells to inhibitors of the mitotic kinesin Eg5.', '', '', '', NULL, NULL, 31, 31, 619);
INSERT INTO screen VALUES (21, 41, '2004-11-29 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin MPP1.', NULL, NULL, 'A screen for compounds that  inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin MPP1.  The ATPase activity of the purified motor domain of MPP1 is assayed (in the absence of microtubules) using a malachite green assay and read in the plate reader.', '5/30/06 Tim says will not continue this screen. ', '', '', NULL, NULL, 671, 31, 454);
INSERT INTO screen VALUES (23, 41, '2004-11-29 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin MKlp1.', NULL, NULL, 'A screen for compounds that  inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin MKlp1.  The ATPase activity of the purified motor domain of MKlp1 is assayed (in the absence of microtubules) using a malachite green assay and read in the plate reader.', '5/30/06 Tim says will not continue this screen. ', '', '', NULL, NULL, 671, 31, 452);
INSERT INTO screen VALUES (24, 41, '2004-11-29 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin MKlp2.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin MKlp2.  The ATPase activity of the purified motor domain of MKlp2 is assayed (in the absence of microtubules) using a malachite green assay and read in the plate reader.', '5/30/06 Tim says will not continue this screen. ', '', '', NULL, NULL, 671, 31, 453);
INSERT INTO screen VALUES (25, 41, '2003-06-18 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin KIF-4A.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of  the mammalian chromosome-associated mitotic kinesin KIF-4A.   The ATPase activity of purified KIF-4A is assayed (in the absence of microtubules) using a malachite green assay and read in the plate reader.', '5/30/06 Tim says will not continue this screen. ', 'KIF-4A_ATPase', 'KIF-4A_ATPase', NULL, NULL, 671, 31, 301);
INSERT INTO screen VALUES (26, 41, '2003-06-23 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of Eg5 in the presence of  microtubules.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of Eg5 in the presence of  microtubules. The ATPase activity of purified Eg5 is assayed in the presence of microtubules using a malachite green assay and read in the plate reader.', NULL, 'Eg5', 'Eg5', NULL, NULL, 559, 31, 305);
INSERT INTO screen VALUES (27, 41, '2004-06-16 00:00:00', 'Small Molecule', 'Inhibit the microtubule-dependent ATPase activity of Eg5-367H(L214T), a (L214T) point mutant of the N-terminal motor domain of human Eg5. ', NULL, NULL, ' A screen for compounds that inhibit the microtubule-dependent ATPase activity of Eg5-367H(L214T), a (L214T) point mutant of the N-terminal motor domain of human Eg5. The assay uses malachite green to measure the phosphate generated upon microtubule-stimulated ATP hydrolysis by Eg5.', NULL, NULL, NULL, NULL, NULL, 559, 31, 373);
INSERT INTO screen VALUES (28, 41, '2003-03-19 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of  the human mitotic kinesin MKLP1 in the presence of microtubules.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of  the human mitotic kinesin MKLP1 in the presence of microtubules.   The ATPase activity of purified MKLP1 is assayed in the presence of microtubules using a malachite green assay and read in the plate reader.', 'MKLP1 from Glotzer lab, IMP Vienna.', 'MKLP', 'MKLP', NULL, NULL, 559, 31, 273);
INSERT INTO screen VALUES (29, 41, '2004-07-26 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of  the motor domain of the Xenopus mitotic kinesin KIF2 in the presence of microtubules.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of  the motor domain of the Xenopus mitotic kinesin KIF2 in the presence of microtubules.  The ATPase activity of purified KIF2 is assayed in the presence of microtubules using a malachite green assay and read in the plate reader.', 'Biolgical follow-up of hits will be carried out by Ryoma (Puck) Ohi.  Protein is very similar to XKCM1, screened by Shala Movahedi (#377).  ', NULL, NULL, NULL, NULL, 559, 31, 409);
INSERT INTO screen VALUES (30, 41, '2004-06-16 00:00:00', 'Small Molecule', 'Inhibit the microtubule-dependent ATPase activity of Eg5-367H(P121A), a (P121A) point mutant of the N-terminal motor domain of human Eg5. ', NULL, NULL, 'A screen for compounds that inhibit the microtubule-dependent ATPase activity of Eg5-367H(P121A), a (P121A) point mutant of the N-terminal motor domain of human Eg5. The assay uses malachite green to measure the phosphate generated upon microtubule-stimulated ATP hydrolysis by Eg5.', NULL, NULL, NULL, NULL, NULL, 559, 31, 374);
INSERT INTO screen VALUES (31, 41, '2003-06-23 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of conventional kinesin HC (KHC) in the presence of microtubules.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of conventional kinesin heavy chain (KHC) in the presence of microtubules. The ATPase activity of purified KHC is assayed in the presence of microtubules using a malachite green assay and read in the plate reader.', NULL, NULL, NULL, NULL, NULL, 559, 31, 306);
INSERT INTO screen VALUES (32, 41, '2003-09-09 00:00:00', 'Small Molecule', 'Inhibit the mcrotubule-dependent ATPase activity of Eg5-367H(L214I), a (L214I) point mutant of the N-terminal motor domain of human Eg5. ', NULL, NULL, 'A screen for compounds that inhibit the mcrotubule-dependent ATPase activity of Eg5-367H(L214I), a (L214I) point mutant of the N-terminal motor domain of human Eg5. ', NULL, NULL, NULL, NULL, NULL, 559, 31, 318);
INSERT INTO screen VALUES (33, 41, '2003-03-19 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of  the human mitotic kinesin CENP-E in the presence of microtubules.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of  the human mitotic kinesin CENP-E in the presence of microtubules.   The ATPase activity of purified CENP-E is assayed using a malachite green assay and read in the plate reader.', 'CENP-E from E. Merck.', 'CenpE', 'CenpE', NULL, NULL, 559, 31, 274);
INSERT INTO screen VALUES (34, 41, '2004-06-16 00:00:00', 'Small Molecule', 'Inhibit the microtubule-dependent ATPase activity of Eg5-367H(R119A), a (R119A) point mutant of the N-terminal motor domain of human Eg5. ', NULL, NULL, 'A screen for compounds that inhibit the microtubule-dependent ATPase activity of Eg5-367H(R119A), a (R119A) point mutant of the N-terminal motor domain of human Eg5.  The assay uses malachite green to measure the phosphate generated upon microtubule-stimulated ATP hydrolysis by Eg5.', NULL, NULL, NULL, NULL, NULL, 559, 31, 375);
INSERT INTO screen VALUES (35, 41, '2003-09-09 00:00:00', 'Small Molecule', 'Inhibit the microtubule-dependent ATPase activity of Eg5-367H(Y211M), a (Y211M) point mutant of the N-terminal motor domain of human Eg5.', NULL, NULL, 'A screen for compunds that inhibit the microtubule-dependent ATPase activity of Eg5-367H(Y211M), a (Y211M) point mutant of the N-terminal motor domain of human Eg5. The assay uses malachite green to measure the phosphate generated upon microtubule-stimulated ATP hydrolysis by Eg5.', NULL, NULL, NULL, NULL, NULL, 559, 31, 317);
INSERT INTO screen VALUES (36, 41, '2004-06-16 00:00:00', 'Small Molecule', 'Inhibit the microtubule-dependent ATPase activity of Eg5-367H(E116V), a (E116V) point mutant of the N-terminal motor domain of human Eg5. ', NULL, NULL, 'A screen for compounds that inhibit the microtubule-dependent ATPase activity of Eg5-367H(E116V), a (E116V) point mutant of the N-terminal motor domain of human Eg5.  The assay uses malachite green to measure the phosphate generated upon microtubule-stimulated ATP hydrolysis by Eg5.', NULL, NULL, NULL, NULL, NULL, 559, 31, 376);
INSERT INTO screen VALUES (37, 41, '2003-09-09 00:00:00', 'Small Molecule', 'Inhibit the microtubule-dependent ATPase activity of Eg5-367H(L2), the N-terminal motor domain of human Eg5 with a mutation of the L5a loop that confers  monastrol resistance.', NULL, NULL, 'A screen for compounds that inhibit the microtubule-dependent ATPase activity of Eg5-367H(L2), the N-terminal motor domain of human Eg5 with a mutation of the L5a loop that confers  monastrol resistance.  The assay uses malachite green to measure the phosphate generated upon microtubule-stimulated ATP hydrolysis by Eg5.
', 'Screening the Stavenger library for mutations in the Eg5 drug binding site would be a useful exercise in chemical fingerprinting. It would also be a step for introducing a drug binding site into conventional kinesin. If the mutation does not disrupt function, and is not monastrol-sensitive, it might be possible to screen within other classes of Eg5 inhibitors.

I have 3 mutant Eg5 motor domains:
L2 	- (removal of loop next to drug binding site) - Insensitive to stavenger cmpd, monastrol
Y211M	- monastrol 3 x more potent against this mutant
L214I	- monastrol 40 x less potent against this mutant
', NULL, NULL, NULL, NULL, 559, 31, 316);
INSERT INTO screen VALUES (38, 41, '2005-03-21 00:00:00', 'Small Molecule', 'Inhibit an engineered version of conventional kinesin.', NULL, NULL, 'A screen for compounds that inhibit an engineered version of conventional kinesin. For this screen,  conventional kinesin was modified as follows: a loop5 chimera and the K187A mutation were introduced into conventional kinesin 420 tagged with GFP and HIS. ', '3/21/05: Zoltan says no positives came from this screen and so data not worth entering into the database. He will send us protocols however.', NULL, NULL, NULL, NULL, 559, 31, 479);
INSERT INTO screen VALUES (39, 41, '2002-02-22 00:00:00', 'Small Molecule', 'Affect cell migration using wound healing as a model.', NULL, NULL, 'A screen for compounds that affect cell migration using wound healing as a model. Cell migration is induced by wounding a monolayer of BS-C-1 epithelial cells.  Compounds are added immediately after inducing the wound.  Seven hours later, actin and and DNA are stained. The plates are imaged on the autoscope--decreased cell migration into the wound and  perturbed cell morphology is scored.
', 'Uses the same cells and carried out contemporaneously with Justin''s visual mitosis assay. ', 'JVIS', 'JYWound2', NULL, NULL, 209, 31, 168);
INSERT INTO screen VALUES (40, 41, '2002-02-23 00:00:00', 'Small Molecule', 'Arrest mammalian cells in mitosis, as measured by the number of rounded cells in each well.', NULL, NULL, 'A screen for compounds that arrest mammalian cells in mitosis. BS-C-1 cells growing in a monolayer are imaged 7hrs after the addition of compounds.  Cells blocked in mitosis are round and easily discernible when staining for filamentous actin with phalloidin.', 'Uses the same cells and carried out contemporaneously with Justin''s wound healing assay. ', 'JVIS', 'VISMITOSIS', NULL, NULL, 209, 31, 169);
INSERT INTO screen VALUES (41, 41, '2002-02-08 00:00:00', 'Small Molecule', 'Affect  cell cycle progression of synchronized HeLa cells. ', NULL, NULL, 'A screen for compounds that affect  cell cycle progression of synchronized HeLa cells.  Cells are synchronized in S-phase with a double thymidine block, released and immediately treated with compounds. After ~16 hours, cells are fixed, stained with DAPI, rhodamine phalloidin, and (in some cases) anti-tubulin and anti-phospho Histone H3 antibodies.   Cell morphology and cell cycle state are assessed by automated microscopy. ', '5/9/03 Nicky has excellent annotation text that does not fit in ActivityBase data fields. This annotation should definitely be included when screen is moved to new database.

07/01/04  Anti-phosphoH3 staining using rabbit polyclonal anti-phospho Histone H3 Ser10 and donkey anti-rabbit Alexa-647 antibodies is added to the screen, to detect mitotic cells.  This allows automated scoring of mitotic cells using metamorph quantitation algorithms.  Previous to  this date, only Hoescsht and TRITC-phalloidin were used to stain the cells.', 'CellCycleAnnotation', NULL, NULL, NULL, 161, 31, 151);
INSERT INTO screen VALUES (42, 41, '2002-06-14 00:00:00', 'Small Molecule', 'Overide the mitotic checkpoint in HeLa cells treated with taxol.', NULL, NULL, 'A screen for compounds that overide the mitotic checkpoint in HeLa cells treated with taxol. Cells are synchronized in S-phase with a double thymidine block and  released into 100 nM taxol.  They are then treated with compounds. After ~16 hours, cells are fixed, stained with DAPI, rhodamine phalloidin, and (in some cases) anti-tubulin antibody.   Cell morphology and cell cycle state are assessed by automated microscopy.', NULL, 'MitCheckOverrideTaxol', NULL, NULL, NULL, 161, 31, 221);
INSERT INTO screen VALUES (43, 41, '2002-06-06 00:00:00', 'Small Molecule', 'Override the monastrol (MA) -induced mitotic arrest in BSC cells.', NULL, NULL, 'A screen for compounds that override the monastrol (MA) -induced mitotic arrest.  MA arrests cells in mitosis with monoastral spindles. BSC cells were synchronized with a double thymidine block and grown in the presence of MA for 8 hours. Compounds were transferred onto the cells for 1 hour. The cells were fixed, stained to visualize DNA and the actin cytoskeleton, and imaged using the autoscope.', 'Zach is taking over as lead screener on this screen due to Thomas''s departure from the ICCB (see screen #160).
5/30/06 Tim says will not continue this screen. ', '', '', NULL, NULL, 449, 31, 207);
INSERT INTO screen VALUES (44, 41, '2002-02-15 00:00:00', 'Small Molecule', 'Arrest cells in mitosis.', NULL, NULL, 'Screen for compounds that arrest cells in mitosis. Cytoblots, using the phosphospecific TG-3 antibody, were carried out on cells that had been exposed to compound . TG-3 Ab recognizes  phosphorylated nucleolin specifically, which becomes phosphorylated when cells enter mitosis.', 'Done in collabortion with S. Haggarty, he did the initial cytoblot assay, described in Haggarty et al., Chemistry and Biology, 2000

Results published in Mayer et al., Science 286:971.', 'TG-3', 'TG3Cytoblot', NULL, NULL, 711, 31, 158);
INSERT INTO screen VALUES (45, 41, '2002-02-15 00:00:00', 'Small Molecule', 'Override the monastrol (MA) -induced mitotic arrest in BSC cells.', NULL, NULL, 'A screen for compounds that override the monastrol (MA) -induced mitotic arrest.  MA arrests cells in mitosis with monoastral spindles. BSC cells were synchronized with a double thymidine block and grown in the presence of MA for 8 hours. Compounds were transferred onto the cells for 1 hour. The cells were fixed, stained to visualize DNA and the actin cytoskeleton, and imaged using the autoscope.', 'All of Chembridge library was screened in duplicate.  June 2002: Zach Perlamn took over as lead screener on this screen due to Thomas''s departure from the ICCB (see screen #207).', NULL, NULL, NULL, NULL, 711, 31, 160);
INSERT INTO screen VALUES (46, 41, '2002-02-15 00:00:00', 'Small Molecule', 'That inhibit centrosome reduplication in hydroxyurea (HU)- arrested cells.', NULL, NULL, 'Screen for compounds that inhibit centrosome reduplication in hydroxyurea (HU)- arrested cells. HU-arrested CHO-cells undergo multiple rounds of centrosome duplication.  A quantitative image analysis routine to identify compounds that inhibit the HU-induced centrosome duplication was written by Zach Perlman and used to analyze images of the cells collected on the autoscope.', 'All library plates screened in duplicate.', NULL, NULL, NULL, NULL, 711, 31, 159);
INSERT INTO screen VALUES (47, 41, '2003-05-02 00:00:00', 'Small Molecule', 'Specifically affect the mitotic cytoskeleton.', NULL, NULL, 'A screen for compounds that specifically affect the mitotic cytoskeleton. Screen carried out using the primary screening plates from Justin Yarrow''s wound healing assay. [Justin Yarrow''s screens #168 and #169. Screens for compounds that inhibit cell migration in wound healing, alter cell morphology, or arrest mammalian cells in mitosis. BS-C-1 cells growing in a monolayer are imaged 7hrs after the addition of compounds.  Cells blocked in mitosis are round and easily discernible when staining for filamentous actin with phalloidin.] Thomas identified wells that Justin scored as being arrested in mitosis, stained cells in those wells for tubulin, and examined the microtubule cytoskeleton closely. Hits were compounds with abnormal cytoskeletons.', 'Justin Yarrow''s screening protocol. Hits not really followed any further--many "weak" microtubule depolymerizers identified.', 'MitoCyoTM', 'MitovisTM', NULL, NULL, 711, 31, 286);
INSERT INTO screen VALUES (48, 41, '2004-06-29 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of the Xenopus kinesin XKCM1.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of the Xenopus kinesin XKCM1. The ATPase activity of purified XKCM1 is assayed in the presence of microtubules using a malachite green assay and read in the plate reader.', '5/30/06 Tim says will not continue this screen in HTS mode at this point. ', '', '', NULL, NULL, 609, 31, 377);
INSERT INTO screen VALUES (49, 41, '2002-03-26 00:00:00', 'Small Molecule', 'Inhibit XKCM1 microtubule depolymerizing activity.', NULL, NULL, 'A screen for compounds that inhibit XKCM1 microtubule depolymerizing activity.  Polymerized microtubules are labeled with fluorescent taxol, compounds are added, followed by purified XKCM1.  The extent of microtubule depolymerization caused by XKCM1 is measured by fluorescence polarization (FP) using the Analyst plate reader.  Inhibitors of XKCM1 activity will stabilize mictotubules under these conditions.   ', NULL, NULL, NULL, NULL, NULL, 609, 31, 178);
INSERT INTO screen VALUES (50, 41, '2003-09-03 00:00:00', 'Small Molecule', 'Affect  cell cycle progression of unsynchronized HeLa cells. ', NULL, NULL, 'A screen for compounds that affect  cell cycle progression of unsynchronized HeLa cells.  Cells are plated and compounds are added ~24 hr later. After ~16 hours, cells are fixed, and stained with DAPI and rhodamine phalloidin to visualize the DNA and actin cytoskeleton.  Cell morphology and cell cycle state are assessed by automated microscopy. NOTE - this screen is being carried out on the CDAM collection to distinguish between compounds that arrest cells in mitosis and compounds that merely slow down the cell cycle.', '', '', '', NULL, NULL, 674, 31, 313);
INSERT INTO screen VALUES (51, 41, '2003-09-03 00:00:00', 'Small Molecule', 'Arrest synchronized HeLa cells in mitosis, without affecting the microtubule cytoskeleton (secondary screen).', NULL, NULL, 'A screen for compounds that arrest synchronized HeLa cells in mitosis, without affecting the microtubule cytoskeleton (secondary screen).  Cells are synchronized in S-phase with a double thymidine block, released and immediately treated with compounds. After ~16 hours, cells are fixed, stained with DAPI and rhodamine phalloidin, and microtubules are examined using immunofluorescence.  Cell morphology and cell cycle state are assessed by automated microscopy. NOTE: this is a secondary screen, designed to eliminate anti-mitotic positives from screen 151 that affect microtubules.', 'Note:  Initially this screen was designed to use Hela cells expressing alpha-tubulin YFP, but he YFP signal was too weak for imaging.', '', '', NULL, NULL, 674, 31, 314);
INSERT INTO screen VALUES (52, 41, '2003-05-30 00:00:00', 'Small Molecule', 'Inhibit the proliferation of EOMA hemangioendothelioma cells.', NULL, NULL, 'A screen for compounds that inhibit the proliferation of EOMA hemangioendothelioma cells.  Cells were exposed to compounds for a short period of time (Zach Perlman recalls that it was for 6-12 hours) and then cell proliferation was measured using a BrdU cytoblot assay.', 'The duplicate data sets from this screen are considered quite good (duplicate wells generally had readings within 0.1 of each other) and the data were used by Zach Perlman and Thomas Mayer to interpret their centrosome reduplicaiton assay screen (Screen # 159). Zach and Thomas said that any FI < 0.75 is a good indication of a compound that inhibits cell proliferation.', 'ANGIOMW', 'ANGIOBrdU', NULL, NULL, 679, 31, 298);
INSERT INTO screen VALUES (53, 41, '2002-01-24 00:00:00', 'Small Molecule', 'Kill p53-/- HCT116 (colon cancer) cells but not isogenic p53+/+ cells.
', NULL, NULL, 'A screen for compounds that kill p53-/- HCT116 (colon cancer) cells but not isogenic p53+/+ cells.  Two cells lines have been created: 1) a p53-/- cell line stably expressing YFP from the CMV promoter and 2) an isogenic "wild-type" cell line stably expressing CFP.  The two lines are mixed and dispensed into assay plates.  After compound addition, the assay plates are imaged using the autoscope.', 'TK Kim left the ICCB.', NULL, NULL, NULL, NULL, 668, 31, 129);
INSERT INTO screen VALUES (54, 41, '2006-06-09 00:00:00', 'RNAi', 'An siRNA screen for enhancers of small molecule inhibitors of the kinesin Eg5 (carried out at low inhibitor concentration).', NULL, NULL, 'An siRNA screen for enhancers of small molecule inhibitors of the kinesin Eg5 (carried out at low inhibitor concentration). For the enhancer screen, I expect to see increased frequency of monopolar spindles at low inhibitor concentration. ', '6/9/06 No application on file yet!
6/9/06 Application received!', '', '', NULL, NULL, 548, 31, 625);
INSERT INTO screen VALUES (55, 41, '2006-07-12 00:00:00', 'RNAi', 'An siRNA screen for suppressors of small molecule inhibitors of the kinesin Eg5 (carried out at high inhibitor concentration).', NULL, NULL, 'An siRNA screen for suppressors of small molecule inhibitors of the kinesin Eg5 (carried out at high inhibitor concentration).  The suppressor screen may see decreased frequency of monopoles at high Eg5 inhibitor concentrations. 
', '', '', '', NULL, NULL, 548, 31, 636);
INSERT INTO screen VALUES (56, 41, '2003-04-22 00:00:00', 'Small Molecule', 'Inhibit the ATPase activity of nonmuscle myosin II.', NULL, NULL, 'A screen for compounds that inhibit the ATPase activity of nonmuscle myosin II. Nonmuscle myosin II purified from human platelets was mixed with actin and ATP. Compounds were added and, after 1.75 hours, the amount of ATP remaining was quantitated using a luciferin/luciferase solution.', 'ChemBridge DiverSet E was screened. All results are published in Straight et al. (2003) Science 299:1743-1747.  Blebbistatin was discovered in this screen.', NULL, NULL, NULL, NULL, 30, 31, 283);
INSERT INTO screen VALUES (57, 41, '2003-04-22 00:00:00', 'Small Molecule', 'Inhibit the actin-stimulated ATPase activity of rabbit muscle myosin  II subfragment 1 (S1).', NULL, NULL, 'A screen for compounds that inhibit the actin-stimulated ATPase activity of rabbit muscle myosin  II subfragment 1 (S1).  S1 was  mixed with polymerized actin and aliquoted into assay plates. Compounds were transferred and the reaction was initiated by adding MgATP. The plates were incubated until >95% of ATP in control wells was hydrolyzed.  The remaining ATP was measured using a solution containing luciferin and luciferase (from Molecular Probes).', 'ChemBridge DiverSet E screened. All results published in Cheung et al. (2002) Nature Cell Biology 4:83-88.', NULL, NULL, NULL, NULL, 30, 31, 281);
INSERT INTO screen VALUES (58, 41, '2003-04-22 00:00:00', 'Small Molecule', 'Inhibit blebbing in filamin -/-  human melanoma cells.', NULL, NULL, 'A screen for known bioactive compounds that inhibit blebbing in filamin -/-  human melanoma cells (M2 cells from the Stoessel lab).  Cells will be plated, incubated for 2 hours, and compounds added.  Ten minutes later, the cells will be fixed and stained with DAPI and NHS-tetramethylrhodamine to visualize the cytoplasm and blebbs.  Positives are compounds that dramatically diminish blebbing. ', 'Known inhibitors of this process (positive controls) are blebbistatin, filopodine (from J. Yarrow), cytochalasin D, Y27632 (Rho kinase, Rock, inhibitor).
5/30/06 Tim says will not continue this screen. ', '', '', NULL, NULL, 445, 31, 282);
INSERT INTO screen VALUES (59, 41, '2006-05-05 00:00:00', 'Small Molecule', 'Inhibit the RanGTPase system, which coordinates several fundamental cellular  processes such as nuclear transport, mitotic spindle formation, and nuclear envelope reassembly after mitosis.  ', NULL, NULL, 'A screen for compounds that inhibit the RanGTPase system, which coordinates several fundamental cellular processes such as nuclear transport, mitotic spindle formation, and nuclear envelope reassembly after mitosis.  The RanGTPase-assay will be set up as a free-running cycle in vitro. The system will contain GTP, Ran, RanGAP, and the Ran nucleotide exchange factor RCC1. The effect of individual compounds on the GTP-turn-over-rate will then be measured using the malachite green reagent. Compounds that either inhibit the cycle or that stimulate the cycle (perhaps by stimulating RanGAP-independent GTPase-activation) will be selected for  further analysis.

', '', '', '', NULL, NULL, 91, 31, 615);
INSERT INTO screen VALUES (300, 2, '2003-09-04 00:00:00', 'Small Molecule', 'Inhibit apoptosis of HeLa cells  that  occurs in response to  adaptation to a mitotic block induced by taxol.', NULL, '2003-11-13 00:00:00', 'A screen for compounds that inhibit apoptosis of HeLa cells  that  occurs in response to  adaptation to a mitotic block induced by taxol.  ', NULL, NULL, NULL, NULL, NULL, 432, 5, 315);
INSERT INTO screen VALUES (298, 2, '2002-01-24 00:00:00', 'Small Molecule', 'Block entry into the nucleus of each of the four mammalian NFAT proteins. 
', NULL, NULL, 'Screen for compoounds that block entry into the nucleus of each of the four mammalian NFAT proteins (NFAT1-4).  Hamster fibroblasts (BHK) cell lines, each expressing one NFAT allele, are incubated with compounds, then fixed and stained with Abs that bind to NFAT.  Nuclear localization of NFAT is monitored by microscopy.', NULL, NULL, NULL, NULL, NULL, 630, 5, 121);
INSERT INTO screen VALUES (107, 33, '2004-01-08 00:00:00', 'Small Molecule', 'Inhibit the activity of the yeast histone deacetylase (HDAC) Hda1.', NULL, NULL, 'A screen for compounds that inhibit the activity of the yeast histone deacetylase (HDAC) Hda1.', NULL, NULL, NULL, NULL, NULL, 557, 35, 336);
INSERT INTO screen VALUES (110, 33, '2004-01-08 00:00:00', 'Small Molecule', 'Inhibit the activity of the yeast histone deacetylase (HDAC) Rpd3.', NULL, NULL, 'A screen for compounds that inhibit the activity of the yeast histone deacetylase (HDAC) Rpd3.', NULL, NULL, NULL, NULL, NULL, 557, 35, 335);
INSERT INTO screen VALUES (119, 33, '2002-02-28 00:00:00', 'Small Molecule', 'Overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor DAPH. ', NULL, NULL, 'A screen for compounds that overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor DAPH. A549 (human lung carcinoma) cells are grown the presence of DAPH and compound for 20 hours.  The ability of the cells to proliferate is then assayed by measuring BrdU incorporation over 3 hours (cells are stained with Abs against BrdU).', NULL, 'null', NULL, NULL, NULL, 282, 35, 174);
INSERT INTO screen VALUES (120, 33, '2002-12-11 00:00:00', 'Small Molecule', 'Suppress the growth-inhibiting effects of rapamycin in the yeast S. cerevisiae (wild-type).', NULL, NULL, 'A screen for compounds that suppress the growth-inhibiting effects of rapamycin in the yeast S. cerevisiae (wild-type).  Compound is added to cells that have been cultured in rapamycin and growth is scored by eye two days later.', NULL, NULL, NULL, NULL, NULL, 681, 35, 252);
INSERT INTO screen VALUES (170, 7, '2004-07-06 00:00:00', 'Small Molecule', 'Increase the number of hematopoetic stem cells in zebrafish embryos.', '2004-07-13 00:00:00', '2004-07-13 00:00:00', 'A screen for compounds that increase the number of hematopoetic stem cells in zebrafish embryos.', '05/19/2006 - Talked with Jill deJong by phone. Out of 2000 compounds screened, 50 appeared to cause the desired phenotype (the mutant embryos had increased numbers of hematopoetic stem cells, by staining).  However, none of these compounds (known bioactives reordered from commercial sources) retested in her secondary assays. Jill therefore has developed a new assay, involving whole mount in situ staining, which will be entered with a new screen number. From this screen (#389) however, Jill did get usable data with regard to library compounds that are toxic or teratogenic to zebrafish, or that cause delays in embryonic development. Jill will provide annotation of those compounds for Screensaver (associated with screen #389). ', '', '', NULL, NULL, 473, 133, 389);
INSERT INTO screen VALUES (169, 7, '2006-05-22 00:00:00', 'Small Molecule', 'Increase gata1 in situ hybridization in cdx4 mutant zebrafish embryos.', NULL, NULL, 'A screen for compounds that increase gata1 in situ hybridization in cdx4 mutant zebrafish embryos.', '', '', '', NULL, NULL, 473, 133, 617);
INSERT INTO screen VALUES (164, 7, '2005-03-04 00:00:00', 'Small Molecule', 'Alleviate anemia and/or porphyria in the zebrafish mutant montalcino.', NULL, '2005-05-25 00:00:00', 'A screen for compounds that alleviate anemia and/or porphyria in the zebrafish mutant montalcino.', '5/25/05 - No official data mtg but Dara communicated with Kim through email about her data and how to annotate it.', NULL, NULL, NULL, NULL, 265, 133, 474);
INSERT INTO screen VALUES (163, 7, '2004-06-02 00:00:00', 'Small Molecule', 'Reactivate fetal globin expression in adult zebrafish.', NULL, NULL, 'A screen for compounds that reactivate fetal globin expression in adult zebrafish.', NULL, NULL, NULL, NULL, NULL, 669, 133, 371);
INSERT INTO screen VALUES (127, 33, '2002-01-24 00:00:00', 'Small Molecule', 'Affect the development of zebrafish embryos.
', NULL, NULL, 'A screen for compounds that affect the development of zebrafish embryos.  After compound addition, the phenotype of zebrafish embryos is monitored using a dissecting scope (not a high throughput screen).

', NULL, NULL, NULL, NULL, NULL, 433, 35, 128);
INSERT INTO screen VALUES (165, 7, '2002-01-24 00:00:00', 'Small Molecule', 'Affect the cell cycle in normal zebrafish embryos.', NULL, NULL, 'Screen for compounds that affect the cell cycle in normal zebrafish embryos.  Zebrafish embryos are grown in the presence of compound, then fixed and stained with an Ab against a cell cycle marker, and examined under the microscope.', 'Two screens carried out simultaneously.', 'FISH-CYC', 'ZebrafishNormal', NULL, NULL, 314, 133, 119);
INSERT INTO screen VALUES (166, 7, '2002-01-24 00:00:00', 'Small Molecule', 'Rescue zebrafish embryos that have a genetic defect in the cell cycle.
', NULL, NULL, 'Screen for compounds that rescue zebrafish embryos that have a genetic defect in the cell cycle.  Mutant zebrafish embryos are grown in the presence of compound, then fixed and stained with an Ab against a cell cycle marker, and examined under the microscope.', 'Two screens carried out simultaneously.', 'FISH-CYC', 'ZebrafishMutant', NULL, NULL, 314, 133, 120);
INSERT INTO screen VALUES (167, 7, '2004-07-06 00:00:00', 'Small Molecule', 'Enhance the function of ferroportin1.', NULL, NULL, 'A screen for compounds that enhance the function of ferroportin1.', NULL, NULL, NULL, NULL, NULL, 132, 133, 397);
INSERT INTO screen VALUES (168, 7, '2004-02-11 00:00:00', 'Small Molecule', 'Affect the process of hematopoietic stem cell development in zebrafish.', NULL, '2004-02-11 00:00:00', ' A screen for compounds that affect the process of hematopoietic stem cell development in zebrafish.', 'Will do assay in 48 well plates. To do this, will transfer into 96-well plates (1ul into 150-200ul) and then reformat', NULL, NULL, NULL, NULL, 453, 133, 338);
INSERT INTO screen VALUES (351, 1, '2004-07-07 00:00:00', 'Small Molecule', 'Inhibit the Wnt  beta-catenin signalling pathway in human colorectal cancer cells.', NULL, NULL, 'A screen for compounds that inhibit the Wnt beta-catenin signalling pathway in human colorectal cancer cells.', NULL, NULL, NULL, NULL, NULL, 513, 513, 403);
INSERT INTO screen VALUES (116, 33, '2002-02-28 00:00:00', 'Small Molecule', 'Overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor Butein.
', NULL, NULL, 'A screen for compounds that overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor Butein. A549 (human lung carcinoma) cells are grown the presence of Butein and compound for 20 hours.  The ability of the cells to proliferate is then assayed by measuring BrdU incorporation over 3 hours (cells are stained with Abs against BrdU).', NULL, 'null', NULL, NULL, NULL, 282, 35, 173);
INSERT INTO screen VALUES (100, 33, '2003-04-01 00:00:00', 'Small Molecule', 'Kill adult C. elegans (worms).', NULL, NULL, 'A screen for compounds that kill adult C. elegans (worms).', 'Protocols and hits in ActivityBase.', 'WORMS', 'WORMLETHALITY', NULL, NULL, 642, 35, 277);
INSERT INTO screen VALUES (101, 33, '2003-04-01 00:00:00', 'Small Molecule', 'Induce production of GFP produced under the control of a heat shock promoter in C. elegans (worms).', NULL, NULL, 'A screen for compounds that induce production of GFP produced under the control of a heat shock promoter in C. elegans (worms).', 'Data in ActivityBase. The only positive compounds were either fluorescent or did not retest.', 'WORMS', 'WORMLETHALITY', NULL, NULL, 642, 35, 279);
INSERT INTO screen VALUES (102, 33, '2003-04-01 00:00:00', 'Small Molecule', 'Kill larval stage L3 C. elegans (worms).', NULL, NULL, 'A screen for compounds that kill larval stage L3 C. elegans (worms)', 'Data in ActivityBase.', 'WORMS', 'WORMLETHALITY', NULL, NULL, 642, 35, 278);
INSERT INTO screen VALUES (103, 33, '2002-01-30 00:00:00', 'Small Molecule', 'Allow survival of Dcna1, Dcmp2 (calcineurin-deficient) yeast grown in 0.8M NaCl.', NULL, NULL, 'Screen for compounds that allow survival of Dcna1, Dcmp2 (calcineurin-deficient) yeast cells grown in 0.8M NaCl.  The extent of growth of the cells in liquid culture is assayed by eye or by absorbance measurement 3-5 days after compound addition.', 'All hits from NCI Open I and therefore data is not in ActivityBase.

Results published in: Butcher, R., Schreiber, S.L. (2003). A small molecule suppressor of FK506 that targets the mitochondria and modulates ionic balance in Saccharomyces cerevisiae. Chem. & Biol. 10, 521-531. ', NULL, NULL, NULL, NULL, 416, 35, 136);
INSERT INTO screen VALUES (104, 33, '2002-06-10 00:00:00', 'Small Molecule', 'Differentially affect histone H3 methylation levels and global acetylation levels in the presence of Trichostatin A (TSA).', NULL, NULL, 'A screen for compounds that differentially affect histone H3 methylation levels and global acetylation levels in the presence of Trichostatin A (TSA). TSA treatment of mammalian cells results in increased levels of both histone H3 methylation and H3 acetylation.  This can be monitored by imaging cells stained with anti-acetylated lysine Abs and anti-H3 methyl-lysine 4 Abs. Cells are pre-treated with compounds from chemical libraries, then treated with TSA.  Cells are fixed and stained and the assay is readout as a cytoblot.  Desirable hits are compounds that allow increased global acetylation but inhibit  H3 methylation. ', 'Carried out in collaboration with Jyoti Kandlikar (undergraduate, starting in SLS lab 6/02).', 'HistoneH3', 'HistoneH3_TSA', NULL, NULL, 416, 35, 210);
INSERT INTO screen VALUES (105, 33, '2003-01-16 00:00:00', 'Small Molecule', 'Differentially affect mammalian histone H3 and H4 acetylation levels.', NULL, NULL, 'A screen for compounds that differentially affect mammalian histone H3 and H4 acetylation levels.  Compounds are added to E549 cells and, after an overnight incubation, histone acetylation levels are monitored via a cytoblot assay using anti- tetra-acetyl H4  and di-acetyl H3  antibodies. ', 'Will be screening only HDAC targeted libraries for this screen.Done in collaboration with Jyoti Kandlikar (undergraduate, starting in SLS lab 6/02).Protocol for Measuring Histone H3 Acetylation Levels and Histone H4 Acetylation Levels Upon Treatment with CompoundsNote: Measurement of H3 modification is done  in parallel with measurement of H4 modification--duplicate sets of plates are processed independently, one set each per primary Ab.1.  Seed white Nunc 384-well plates with A549 cells (40uL per well, 4000 cells per well).  Let attach overnight.2.  Pin in compounds.  Treat for 20-24hrs.3.  Process by cytoblot:  A.  Suck off media.  Fix cells with EtOH and 5% acetic acid (-20degC) at RT for 5''.B.  Wash three times with 80uL antibody dilution buffer (ADB).  Let last ADB wash sit for 25''.C.  Add 20uL ADB containing 1:500 a acetylated histone H3 antibody (rabbit) or 1:500 a acetylated histone H4 antibody (rabbit).  Let sit at RT for 2hrs.  D.  Wash two times with 80uL ADB.E.  Add 20uL ADB containing 1:1000 a rabbit horseradish peroxidase secondary antibody.  Let sit at RT for 1-2hrs.F.  Wash three times with 80uL TBS 1% Triton X-100.  Wash once with 80uL TBS.G.  Add 20uL ECL.  Detect luminescence.ADB1X TBS1% Triton X-1002% BSA', NULL, NULL, NULL, NULL, 416, 35, 260);
INSERT INTO screen VALUES (106, 33, '2003-01-16 00:00:00', 'Small Molecule', 'Differentially affect histone H3 methylation levels and global acetylation levels (no TSA).', NULL, NULL, 'A screen for compounds that differentially affect histone H3 methylation levels and global acetylation levels. Histone H3 methylation and global acetylation can be monitored by staining cells with anti-acetylated lysine Abs and anti-H3 methyl-lysine 4 Abs. Cells are treated with compounds from chemical libraries, fixed and stained and the assay is readout as a cytoblot.  Desirable hits are compounds that cause increased H3 methylation  but  have no effect on global acetylation. ', 'Will screen only HDAC-targeted libraries using this assay.Note: The assay for this screen is carried out using a "dual detection system" (binding of 2 different Abs can be measured in same well) that was developed in the Schreiber Lab.  Method soon to be written up (Jan. 2003).In collaboration with Jyoti Kandlikar (undergraduate, starting in SLS lab 6/02)Protocol for Measuring Histone H3 Lysine 4 Methylation Levels and General Lysine Acetylation Levels Upon Treatment with Compounds1.  Seed white Nunc 384-well plates with A549 cells (40uL per well, 4000 cells per well).  Let attach overnight.2.  Pin in compounds.  Treat for 20-24hrs.3.  Process by cytoblot:  A.  Suck off media.  Fix cells with EtOH and 5% acetic acid (-20degC) at RT for 5''.B.  Wash three times with 80uL antibody dilution buffer (ADB).  Let last ADB wash sit for 25''.C.  Add 20uL ADB containing 1:1000 a histone H3 lysine 4 dimethyl antibody (rabbit) and 1:1000 a acetyl lysine antibody (mouse).  Let sit at RT for 2hrs.  D.  Wash two times with 80uL ADB.E.  Add 20uL ADB containing 1:1000 a rabbit horseradish peroxidase secondary antibody and 1:1000 a mouse alkaline phosphatase secondary antibody.  Let sit at RT for 1-2hrs.F.  Wash three times with 80uL TBS 1% Triton X-100.  Wash once with 80uL TBS.G.  Add 20uL ECL.  Detect luminescence.H.  Wash once with 80uL TBS.  Wash once with 80uL Assay Buffer.I.  Add 20uL Assay Buffer containing 1:200 CDP-Star.  Detect luminescence.      ADB1X TBS1% Triton X-1002% BSAAssay Buffer0.1M diethanolamine (to pH 10)1mM MgCl20.02% sodium azide', NULL, NULL, NULL, NULL, 416, 35, 259);
INSERT INTO screen VALUES (108, 33, '2002-02-22 00:00:00', 'Small Molecule', 'Inhibit deacetylation of tubulin.', NULL, NULL, 'A screen for compounds that inhibit deacetylation of tubulin.  A549  (human lung carcinoma) cells are treated with compounds.  The levels of acetylated tubulin in the cells is assayed with a cytoblot, using a monoclonal antibody specific for acetylated tubulin.', 'Plan to screen a library synthesized by Jason that is biased toward deacetylase inhibitors.', 'null', NULL, NULL, NULL, 557, 35, 166);
INSERT INTO screen VALUES (109, 33, '2002-02-22 00:00:00', 'Small Molecule', 'Inhibit deacetylation of histones.', NULL, NULL, 'A screen for compounds that inhibit deacetylation of histones.  A549  (human lung carcinoma) cells are treated with compounds.  The levels of acetylated histones in the cells is assayed with a cytoblot, using a monoclonal antibody specific for acetylated lysine.', 'Plan to screen a library synthesized by Jason that is biased toward deacetylase inhibitors.', 'null', NULL, NULL, NULL, 557, 35, 167);
INSERT INTO screen VALUES (111, 33, '2002-07-03 00:00:00', 'Small Molecule', 'Suppress dephosphorylation of S6 protein after inhibition of insulin signalling.', NULL, NULL, 'A screen for compounds that suppress dephosphorylation of S6 protein after inhibition of insulin signalling.', '', '', '', NULL, NULL, 568, 35, 241);
INSERT INTO screen VALUES (112, 33, '2002-07-03 00:00:00', 'Small Molecule', 'Suppress dephosphorylation of S6 protein in the presence of rapamycin.', NULL, NULL, 'A screen for compounds that suppress dephosphorylation of S6 protein in the presence of rapamycin.  This assay is carried out using A549 (human lung carcinoma) cells.  The cells are treated with rapamycin. In the absence of additional treatment, this prevents phosphorylation of S6 via the FRAP pathway.  Compounds are then added to the cells and S6 phosphorylation is monitored by cytoblot assay.  Hits are compounds that result in S6 phosphoylation.  ', '', '', '', NULL, NULL, 568, 35, 238);
INSERT INTO screen VALUES (113, 33, '2002-06-07 00:00:00', 'Small Molecule', 'Suppress dephosphorylation of S6 protein in response to amino acid starvation.', NULL, NULL, 'A screen for compounds that suppress dephosphorylation of S6 protein in response to amino acid starvation. This assay is carried out using A549 (human lung carcinoma) cells.  The cells are starved for amino acids. In the absence of additional treatment, this prevents phosphorylation of S6 via the FRAP pathway.  Compounds are added to starved cells and S6 phosphorylation is monitored by cytoblot assay.  Hits are compounds that result in S6 phosphoylation.  ', NULL, 'S6', 'S6AminoAcidStarvation', NULL, NULL, 568, 35, 209);
INSERT INTO screen VALUES (114, 33, '2002-07-03 00:00:00', 'Small Molecule', 'Decrease phosphorylation of S6 protein under normal growth conditions. ', NULL, NULL, 'A screen for compounds that decrease phosphorylation of S6 protein under normal growth conditions. ', '', '', '', NULL, NULL, 568, 35, 240);
INSERT INTO screen VALUES (115, 33, '2002-02-28 00:00:00', 'Small Molecule', 'Are agonists of glucose uptake in serum-starved differentiated 3T3-L1 adipocytes.', NULL, NULL, 'A screen for compounds that are agonists of glucose uptake in serum-starved differentiated 3T3-L1 adipocytes.  Uptake of the the fluorescent glucose analog 6-NBDG is monitored after compound addition using a plate reader.', 'A not-so detailed protocol to be augmented later by Bridget (after publication of her paper):
Using 6-NBDG, a fluorescent glucose analog, I screened for
agonists of glucose uptake in serum-starved differentiated
3T3-L1 adipocytes.  After plating the already differentiated
cells in 384-well clear-bottomed plates, I serum-starved them
overnight.  I then removed the media and replaced it with
low-glucose DMEM supplemented with 275uM 6-NBDG.  I
incubated the cells for one hour at 37C, then washed 4x with
PBS, and read on the Analyst using the fluorescein filter set.', 'null', NULL, NULL, NULL, 282, 35, 176);
INSERT INTO screen VALUES (121, 33, '2003-10-03 00:00:00', 'Small Molecule', 'Differentially affect the growth of  the diploid S. cerevisiae yeast strain S288C at 30 C and 41 C.', NULL, NULL, 'A screen for compounds that differentially affect the growth of  the diploid S. cerevisiae yeast strain S288C at 30 C and 41 C.  Compound is added to cells growing in rich and growth is scored 24-48 hours later.', 'Note: no drug sensitizing mutations will be crossed into the S288C "wt" lab strain.  This screen is one of a group of 3 screens (#''s 319, 320, and 321) to be carried out by Ethan and Steve. The results of which will be compared to each other, to look for different "small molecule signatures" of each of 3 different yeast strains.  The idea for this screen is based on work from Ron Davis''s group: Steinmetz et al., Nature 416:326-330.', NULL, NULL, NULL, NULL, 681, 35, 319);
INSERT INTO screen VALUES (122, 33, '2003-10-03 00:00:00', 'Small Molecule', 'Differentially affect the growth of  the diploid S. cerevisiae yeast strain YJM145/S288C ("clinical strain"/"lab strain" heterozygote) at 30 C and 41 C.', NULL, NULL, 'A screen for compounds that differentially affect the growth of  the S. cerevisiae yeast strain YJM145/S288C ("clinical strain"/"lab strain" heterozygote)  at 30 C and 41 C.  Compound is added to cells growing in rich and growth is scored 24-48 hours later.', 'Note: no drug sensitizing mutations will be crossed into YJM145, however it is believed  (by Steinmetz et al.) that the strain is drug senstitive.  This screen is one of a group of 3 screens (#''s 319, 320, and 321) to be carried out by Ethan and Steve. The results of which will be compared to each other, to look for different "small molecule signatures" of each of 3 different yeast strains.  The idea for this screen is based on work from Ron Davis''s group: Steinmetz et al., Nature 416:326-330.', NULL, NULL, NULL, NULL, 681, 35, 321);
INSERT INTO screen VALUES (123, 33, '2004-06-11 00:00:00', 'Small Molecule', 'Activate expression from the OCT4 promoter in a mouse  fibroblast cell line.', NULL, NULL, 'A screen for compounds that activate expression from the OCT4 promoter in a mouse  fibroblast cell line.', 'Kristen Brennand of the Melton lab is a collaborator on this screen.
9-23-04 Ethan is working with an undergraduate, Sangeetha.', NULL, NULL, NULL, NULL, 681, 35, 372);
INSERT INTO screen VALUES (124, 33, '2003-10-03 00:00:00', 'Small Molecule', 'Differentially affect the growth of  the diploid S. cerevisiae yeast strain YJM145 (a "clinical isolate") at 30 C and 41 C.', NULL, NULL, 'A screen for compounds that differentially affect the growth of  the diploid S. cerevisiae yeast strain YJM145 (a "clinical isolate")  at 30 C and 41 C.  Compound is added to cells growing in rich and growth is scored 24-48 hours later.', 'Note: no drug sensitizing mutations will be crossed into YJM145, however it is believed  (by Steinmetz et al.) that the strain is drug senstitive.  This screen is one of a group of 3 screens (#''s 319, 320, and 321) to be carried out by Ethan and Steve. The results of which will be compared to each other, to look for different "small molecule signatures" of each of 3 different yeast strains.  The idea for this screen is based on work from Ron Davis''s group: Steinmetz et al., Nature 416:326-330.', NULL, NULL, NULL, NULL, 681, 35, 320);
INSERT INTO screen VALUES (125, 33, '2004-09-02 00:00:00', 'Small Molecule', 'Supress or enhance the effects of wortmannin on the growth of the yeast S. cerevisiae.', NULL, NULL, 'A screen for compounds that supress or enhance the effects of wortmannin on the growth of the yeast S. cerevisiae.', NULL, NULL, NULL, NULL, NULL, 111, 35, 416);
INSERT INTO screen VALUES (118, 33, '2002-01-24 00:00:00', 'Small Molecule', 'Overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor Genestein.
', NULL, NULL, 'A screen for compounds that overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor Genestein. A549 (human lung carcinoma) cells are grown the presence of Genestein and compound for 20 hours.  The ability of the cells to proliferate is then assayed by measuring BrdU incorporation over 3 hours (cells are stained with Abs against BrdU).', NULL, NULL, NULL, NULL, NULL, 282, 35, 125);
INSERT INTO screen VALUES (126, 33, '2003-05-08 00:00:00', 'Small Molecule', 'Modulate VCAM-1 expression following TNFalpha stimulation.', NULL, NULL, ' A screen for compounds that modulate VCAM-1 expression following TNFalpha stimulation.  VCAM-1 is expressed in "activated" endothelial cells, and is an important mediator of leukocyte-endothelial cell interactions.  These interactions are thought to contribute to the development of
atherosclerosis. Human umbilical vein endothelial cells (HUVECs) will be seeded into 384 well plates coated with collagen approximately 16 hrs prior to the start of the assay.  The cells will then be stimulated for 4-6 hrs by TNF-alpha at 37C, and compounds will be added during this time. The cells will be fixed with Methanol/Acetone, and VCAM-1 expression will be assayed using an indirect immunoassay (mouse anti-human VCAM-1 antibody, rabbit anti-mouse antibody, avidin-biotin amplication, and alkaline phosphatase).  The alkaline phosphatase substrate para-nitrophenyl phosphate
(pNPP) will be used, and alkaline phosphatase activity assayed via absorbance at 405 nm.
', '5-8-03 from Stan: In discussions at technology subgroup, I have been contemplating screening:
- known bioactives
- some DOS diversity sets (eg Julia''s set J2).  The screening of this set is
a little up in the air right now, with Julia''s move to Kendall Square, etc
so I am still unsure how this will work out (ie screening at ICCB or Kendall
Square).  I will talk further with Julia and Paul on this, and keep you
informed.', NULL, NULL, NULL, NULL, 433, 35, 290);
INSERT INTO screen VALUES (128, 33, '2002-12-19 00:00:00', 'Small Molecule', 'Suppress homozygous lethal zebrafish heart mutations - mixed population format.', NULL, NULL, 'A screen for compounds that suppress a homozygous lethal zebrafish heart mutation - mixed population format.  The phenotype of the mutant is decreased heart contractility and reduced circulation.  Heterozygous zebrafish heart mutants are mated, and the embryos (a mixture of wild-type, heterozygous, and homozygous mutants) are collected immediately after fertilization.  Approximately 20 embryos are arrayed in each well of 48-well plates containing at the 50% epiboly stage.  A   mix of compounds will be added to each well.  The mixed population in each well will be examined visually at 48 hours postfertilization.  The compound will be scored as positive when no mutant phenotypes are detected within a well (restoration of normal heart contractility and circulation will be scored).   ', 'Not for public consumption before Stan enters his data into the database: the heart mutant he is screening here is cloche.', NULL, NULL, NULL, NULL, 433, 35, 256);
INSERT INTO screen VALUES (129, 33, '2002-12-19 00:00:00', 'Small Molecule', 'Supress the sensitivity of the HIF1 zebrafish mutant to hypoxic conditions.', NULL, NULL, 'A screen for compounds that supress the sensitivity of the HIF1 zebrafish mutant to hypoxic conditions. HIF-1alpha (hypoxia inducible factor) is a crucial oxygen sensor in organisms from C. elegans to humans.  HIF-1 alpha activity in the presence of low oxygen levels coordinates many aspects of the cellular and organismic response to hypoxia, including alterations in metabolism, and stimulation of angiogenesis.  Zebrafish with decreased HIF 1alpha activity show decreased survival in the setting of decreased oxygen levels (based on preliminary data) ; suppression of this sensitivity with a small molecule would identify additional pathways important for the response to hypoxia, and may also lead to development of novel therapeutics for conditions such as cardiovascular disease and cancer.   Homozygous HIF1 mutant zebrafish are mated and the embryos are collected immediately after fertilization.  Three embryos are arrayed in each well of 96-well platesat the 50% epiboly stage and compounds are added. The embryos in each well will be examined visually at 24 hours postfertilization, and the compound will be scored as positive when all embryos are alive following the hypoxia treatment.', NULL, NULL, NULL, NULL, NULL, 433, 35, 255);
INSERT INTO screen VALUES (117, 33, '2002-02-28 00:00:00', 'Small Molecule', 'Overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor HNMPA. ', NULL, NULL, 'A screen for compounds that overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor HNMPA. A549 (human lung carcinoma) cells are grown the presence of HNMPA and compound for 20 hours.  The ability of the cells to proliferate is then assayed by measuring BrdU incorporation over 3 hours (cells are stained with Abs against BrdU).', NULL, 'null', NULL, NULL, NULL, 282, 35, 175);
INSERT INTO screen VALUES (130, 33, '2002-01-24 00:00:00', 'Small Molecule', 'Affect mitochondrial function in Sf-1 cells (primary human fibroblasts).
', NULL, NULL, 'A screen for compounds that affect mitochondrial function in Sf-1 cells (primary human fibroblasts).  After compound addition, mitochondrial potential is assayed using a JC-1 based fluorimetric assay.

', '5/9/03 Done screening. No hits recorded.', 'Mito-Activity', 'JC-1-FLUORESCENCE', NULL, NULL, 712, 35, 127);
INSERT INTO screen VALUES (99, 33, '2002-05-14 00:00:00', 'Small Molecule', 'Affect mitochondrial function in Sf-1 cells (primary human fibroblasts).', NULL, NULL, 'A screen for compounds that affect mitochondrial function in Sf-1 cells (primary human fibroblasts).  After compound addition, mitochondrial potential is assayed using a JC-1 based fluorimetric assay.', 'Carrying out the same screen as Bimal Desai, but screening Dave Spring''s biaryl library--Copy A.  He wants to transfer 200-300 nL of compound to each well.', NULL, NULL, NULL, NULL, 371, 35, 194);
INSERT INTO screen VALUES (131, 33, '2002-02-28 00:00:00', 'Small Molecule', 'Overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor DAPH. ', NULL, NULL, 'A screen for compounds that overcome the inhibition of cell proliferation caused by the tyrosine kinase inhibitor DAPH.  A549 (human lung carcinoma) cells are grown the presence of DAPH and compound for 20 hours.  The ability of the cells to proliferate is then assayed by measuring BrdU incorporation over 3 hours (cells are stained with Abs against BrdU).', NULL, 'null', NULL, NULL, NULL, 665, 35, 172);
INSERT INTO screen VALUES (132, 33, '2005-02-16 00:00:00', 'Small Molecule', 'suppress S6 phosphorylation in A549 cells under normal growth conditions', '2005-02-24 00:00:00', '2005-02-24 00:00:00', 'A screen for compounds that suppress S6 phosphorylation in A549 cells under normal growth conditions.  A549 cells will be cultured, small molecules added and S6 phosphorylation detected using a primary antibody to phospho-S6 and an HRP-coupled secondary antibody.  Luminescence will be detected on a plate reader.', 'NT 02/16/05: Jiong is taking over this screen from Ali Shamji (previously listed as screen ID: 240)', NULL, NULL, NULL, NULL, 288, 35, 471);
INSERT INTO screen VALUES (431, 0, '2006-09-15 00:00:00', 'Small Molecule', 'Inhibit the CapD enzyme of Bacillus anthracis.', NULL, '2006-10-23 00:00:00', 'A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis.  CapD is involved in synthesis and surface localization of the poly-gamma-D-glutamate (PDGA) capsule, one of the principal virulence factors during anthrax infection.  CapD mutant strains of B. anthracis lack covalently attached PDGA and are characterized by a significant loss of virulence in animal models.', '', '', '', NULL, NULL, 700, 15, 645);


/* library */

INSERT INTO library VALUES (1, 0, 'ChemDiv1 (Combilab and International)', 'ChemDiv1', 'This ChemDiv collection was jointly purchased with the Lab for Drug Discovery for Neurodegeneration (LDDN) in December 2001. It was part of a total purchase of more than 50,000 new commercial compounds.  These compounds are similar in complexity to the ChemBridge DiverSet E.  However, this collection was compiled so that the molecules have an increased probability of favorable physical-chemical properties and a lack of functional groups that might cause toxicity or reduce stability.', NULL, 'Small Molecule', 'Commercial', 587, 668, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (2, 0, 'Mitchison Kinase 1', 'Mitchison1', NULL, NULL, 'RNAi', 'siRNA', 50091, 50092, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (3, 0, 'Mixed Commercial Plate I2', 'MixCom3', 'This plate contains compounds purchased from Bionet, Maybridge, Peakdale, and ChemDiv jointly with the Lab for Drug Discovery for Neurodegeneration (LDDN) during the winter of 2001-2002.', NULL, 'Small Molecule', 'Commercial', 669, 669, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (4, 0, 'Dyhydropyrancarboxamide 3', 'DHPC3', NULL, NULL, 'Small Molecule', 'DOS', 1318, 1336, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (5, 0, 'Mouse1: Kinases-Phosphatases', 'Mouse1', NULL, NULL, 'RNAi', 'siRNA', 50025, 50027, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (6, 0, 'ICCB Bioactives 1', 'ICCBBio1', 'The collection was assembled by ICCB investigators and collaborators, who chose compounds that affect a wide variety of biological pathways relevant to research projects carried out at the Institute. Most of the compounds are commercially available and include an Ion Channel Ligand library (70 compounds) and a Bioactive Lipids library (200 compounds), both purchased from Biomol, as well as other well-characterized compounds that perturb cell pathways. We hope that this collection will help both in assay development and in target identification.

Because the compounds are biologically active at a variety of concentrations and because active concentrations differ among cell types, each compound in the collection is plated at three stock concentrations on three different plates. Thus there are High, Medium, and Low concentration copies for each plate (see below). We recommend that you screen the plates at all 3 concentrations to get the most information from your assay: 

Copies N.O: High concentration plates (approximately 5 mg/ml (~13mM) for most compounds; the high concentration of "potent" compounds is ~0.5 mg/ml (~1.3mM)). All cherry picks will be provided from a high concentration plate. 
Copies P.Q: Medium concentration plates (~1.1 mg/ml (~3mM); ~0.11 mg/ml (~0.3mM) for "potent" compounds). 
Copies R.S: Low concentration plates (~0.25 mg/ml (~0.65mM); ~0.025 (~655M)mg/ml for "potent" compounds).

', NULL, 'Small Molecule', 'Known Bioactives', 684, 685, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (7, 0, 'NCI Marine Extracts', 'NCIMarEx', NULL, NULL, 'Small Molecule', 'Natural Products', 671, 671, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (8, 0, 'Dihydropyrancarboxamide 1', 'DHPC1', NULL, NULL, 'Small Molecule', 'DOS', 351, 368, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (9, 0, 'Mouse2: GPCRs', 'Mouse2', NULL, NULL, 'RNAi', 'siRNA', 50028, 50029, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (10, 0, 'Peakdale2', 'Peakdale2', 'The Maybridge2 collecon was jointly purchased with the Lab for Drug Discovery for Neurodegenerations (LDDN) in November 2002.', NULL, 'Small Molecule', 'Commercial', 1305, 1305, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (11, 0, 'Bionet1', 'Bionet1', 'The Bionet collection was purchased jointly with the Lab for Drug Discovery for Neurodegeneration (LDDN) in January 2002.  It was part of a total purchase of more than 50,000 new commercial compounds.  These compounds are similar in complexity to the ChemBridge DiverSet E.  However, this collection was compiled so that the molecules have an increased probability of favorable physical-chemical properties and a lack of functional groups that might cause toxicity or reduce stability.', NULL, 'Small Molecule', 'Commercial', 568, 582, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (12, 0, 'Human4: Remaining Genome', 'Human4', NULL, NULL, 'RNAi', 'siRNA', 50047, 50090, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (13, 0, 'Dyhydropyrancarboxamide 5', 'DHPC5', NULL, NULL, 'Small Molecule', 'DOS', 1337, 1337, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (14, 0, 'ChemDiv3', 'ChemDiv3', NULL, NULL, 'Small Molecule', 'Commercial', 1473, 1519, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (15, 0, 'Mixed Commercial4', 'MixCom4', 'The Maybridge2 collecon was jointly purchased with the Lab for Drug Discovery for Neurodegenerations (LDDN) in November 2002.', NULL, 'Small Molecule', 'Commercial', 1306, 1306, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (16, 0, 'Commercial Diversity Set 1', 'CDS1', 'This set of compounds was selected from existing ICCB commercial libraries to provide a small diverse collection that can be used in pilot screens.', NULL, 'Small Molecule', 'Commercial', 1231, 1245, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (17, 0, 'ICCB6', 'ICCB6', NULL, NULL, 'Small Molecule', 'Discrete', 1463, 1463, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (18, 0, 'ICCB1', 'ICCB1', 'These are synthetic intermediates generated by ICCB chemists. To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'Discrete', 52, 52, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (19, 0, 'ICBG Fungal Extracts 1', 'ICBGExtracts1', NULL, NULL, 'Small Molecule', 'Natural Products', 1453, 1455, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (20, 0, 'Maybridge1', 'Maybridge1', 'The Maybridge collection was jointly purchased with the Lab for Drug Discovery for Neurodegeneration (LDDN) in January 2002. It was part of a total purchase of more than 50,000 new commercial compounds.  These compounds are similar in complexity to the ChemBridge DiverSet E.  However, this collection was compiled so that the molecules have an increased probability of favorable physical-chemical properties and a lack of functional groups that might cause toxicity or reduce stability.', NULL, 'Small Molecule', 'Commercial', 542, 566, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (21, 0, 'ChemDiv5', 'ChemDiv5', NULL, NULL, 'Small Molecule', 'Commercial', 1709, 1712, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (22, 0, 'ChemBridge DiverSet E', 'CBDivE', 'This compound collection was imported by ChemBridge Corporation from the Ukraine and Russia.  It was obtained by the ICCB in 1998 and is a reasonably diverse set of compounds selected from approximately 100 different combinatorial libraries. Although the majority of the compounds still appear stable by LC/MS analysis, several compounds have been found to be modified (e.g. oxidized or hydrolyzed) during the many years of storage. Because of the age of the library, as of May 2002, only about 75% of these compounds were available for re-supply from current ChemBridge stocks.  Some of these out-of-stock compounds may be available from ChemBridge by custom re-synthesis.', NULL, 'Small Molecule', 'Commercial', 1, 51, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (23, 0, 'Conformationally-diverse heterocycles 2', 'CDH2', 'Part of DiversitySet J2, plate 10J2', NULL, 'Small Molecule', 'DOS', 847, 847, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (24, 0, 'Mixed Commercial Plate 2', 'MixCom2', 'This plate contains compounds purchased from Bionet (25% of the plate) and CEREP (75%of the plate) jointly with the Lab for Drug Discovery for Neurodegeneration (LDDN) during the winter of 2001-2002.', NULL, 'Small Molecule', 'Commercial', 567, 567, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (25, 0, 'Dyhydropyrancarboxamide 4 ', 'DHPC4', NULL, NULL, 'Small Molecule', 'DOS', 1317, 1317, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (26, 0, 'DOS Diversity Set 1', 'DDS1', 'This set of compounds was selected from nine ICCB DOS libraries to provide a diverse collection that can be used in pilot screens.', NULL, 'Small Molecule', 'DOS', 1201, 1228, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (27, 0, 'Furan Oxidation Library1', 'FOLD 1', NULL, NULL, 'Small Molecule', 'DOS', 1307, 1316, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (28, 0, 'ChemBridge3', 'ChemBridge3', NULL, NULL, 'Small Molecule', 'Commercial', 1577, 1606, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (29, 0, 'Serine Derived Peptidomimetic 2', 'SDP1-2', NULL, NULL, 'Small Molecule', 'DOS', 1029, 1068, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (30, 0, 'IFLab1', 'IFLab1', NULL, NULL, 'Small Molecule', 'Commercial', 1412, 1430, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (31, 0, 'BIOMOL ICCB Known Bioactives 2', 'BiomolICCB2', NULL, NULL, 'Small Molecule', 'Known Bioactives', 1791, 1792, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (32, 0, 'Cyclic peptides, 3- and 4-mer parallel synthesis', 'CycPep2', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 504, 517, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (33, 0, 'ICBG Fungal Extracts 2', 'ICBGExtracts2', NULL, NULL, 'Small Molecule', 'Natural Products', 1559, 1560, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (34, 0, 'ChemBridge Microformats', 'CBMicro', E'This collection was purchased by the Cystic Fibrosis Foundation and given to the ICCB by Dr. Stephen Lory (Department of Microbiology and Molecular Genetics, Harvard Medical School) in the summer of 2002.

The compounds were selected by scientists at ChemBridge using computational methods from the larger ChemBridge collection of \034handcrafted\035 compounds, obtained from chemists around the world. Their selection methods assure \034diversity and drug-likeness\035 of the compounds. These compounds are similar in complexity to our other commercial collections and do not overlap at all with the compounds in the ChemBridge DiverSet E collection.', NULL, 'Small Molecule', 'Commercial', 686, 842, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (35, 0, 'Dihydropyrancarboxamide DOS library', 'DHPC0', 'This plate should be screened with the DHPC2 library. To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 350, 350, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (36, 0, 'Ansa-seco-steroid', 'SES1', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 1130, 1156, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (37, 0, 'ActiMolTimTec1', 'ActiMolTimTec1', NULL, NULL, 'Small Molecule', 'Commercial', 1534, 1558, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (38, 0, 'Mouse3: Remaining Druggable Genome', 'Mouse3', NULL, NULL, 'RNAi', 'siRNA', 50030, 50046, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (39, 0, 'Shikimic acid-derived, reactivity-biased (electrophilic) 1', 'SAD-E 1', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 672, 683, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (40, 0, 'Bi- and di-aryl DOS library', 'BDA1', 'Synthesis of this library is described in Spring, et al. (2002) Diversity-oriented synthesis of biaryl-containing medium rings using a one bead/one stock solution platform. J. Am. Chem. Soc. 124, 1354-13.

To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 344, 349, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (41, 0, 'Maybridge2', 'Maybridge2', 'The Maybridge2 collecon was jointly purchased with the Lab for Drug Discovery for Neurodegenerations (LDDN) in November 2002.', NULL, 'Small Molecule', 'Commercial', 1303, 1304, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (42, 0, 'Ferrier/Pauson-Khand DOS library; (S) configuration 1', 'FPK2-1', 'Synthesis of this library was published in Kubota et al. (2002) Pathway Development and Pilot Library Realization in Diversity-Oriented Synthesis; Exploring Ferrier and Pauson-Khand Reactions on a Glycal Template. Chemistry & Biology, 9, 265-276.

To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 583, 586, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (43, 0, 'Shikimic acid-derived, reactivity-biased (electrophilic) 2', 'SAD-E 2', NULL, NULL, 'Small Molecule', 'DOS', 1079, 1079, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (44, 0, 'Peakdale1', 'Peakdale1', 'The Peakdale collection was jointly purchased with the Lab for Drug Discovery for Neurodegeneration (LDDN) in December 2001. It was part of a total purchase of more than 50,000 new commercial compounds.  These compounds are similar in complexity to the ChemBridge DiverSet E.  However, this collection was compiled so that the molecules have an increased probability of favorable physical-chemical properties and a lack of functional groups that might cause toxicity or reduce stability.', NULL, 'Small Molecule', 'Commercial', 518, 525, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (45, 0, 'Diversity Set J2', 'DIVJ2', NULL, NULL, 'Small Molecule', 'Annotation', 1264, 1275, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (46, 0, 'NCI Structural Diversity Set, version 1', 'NCIStruc1', 'This library contains approximately 2000 compounds from the Developmental Therapeutics Program at the National Cancer Institute.  All of these compounds been tested in the NCI 60 cell line screen.  These compounds have been sent to a large number of academic labs.  The NCI has large quantities of most these compounds available for follow-up.', NULL, 'Small Molecule', 'NCI', 53, 59, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (47, 0, 'Dihydropyrancarboxamide diversity set 2', 'DHPC-J2', 'Part of DiversitySet J2, plates 06J2, 07J2, 08J2', NULL, 'Small Molecule', 'DOS', 843, 845, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (48, 0, 'ChemDiv Anti-Mitotic Set', 'ChemDivAM', NULL, NULL, 'Small Molecule', 'Commercial', 1157, 1160, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (49, 0, 'Mixed Commercial Plate 1', 'MixCom1', 'This plate contains compounds purchased from Peakdale (50% of the plate) and Maybridge (50%of the plate) jointly with the Lab for Drug Discovery for Neurodegeneration (LDDN) during the winter of 2001-2002.', NULL, 'Small Molecule', 'Commercial', 541, 541, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (50, 0, 'Human1: Kinases-Phosphatases', 'Human1', NULL, NULL, 'RNAi', 'siRNA', 50001, 50003, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (51, 0, 'DOS Diversity Set 2', 'DDS2', NULL, NULL, 'Small Molecule', 'DOS', 1343, 1360, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (52, 0, 'NCDDG1', 'NCDDG1', NULL, NULL, 'Small Molecule', 'Natural Products', 1707, 1708, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (53, 0, 'Aqueous NCI Plant and Fungal Extracts', 'AqNCIPlantEx', NULL, NULL, 'Small Molecule', 'Natural Products', 1069, 1074, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (54, 0, 'BIOMOL ICCB Known Bioactives 1', 'BiomolICCB1', NULL, NULL, 'Small Molecule', 'Known Bioactives', 1361, 1362, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (55, 0, 'ChemDiv4', 'ChemDiv4', NULL, NULL, 'Small Molecule', 'Commercial', 1607, 1648, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (56, 0, 'Organic NCI Plant and Fungal Extracts', 'OrgNCIPlantEx', NULL, NULL, 'Small Molecule', 'Natural Products', 1075, 1078, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (57, 0, 'CEREP', 'CEREP', 'The CEREP collection was jointly purchased with the Lab for Drug Discovery for Neurodegeneration (LDDN) in December 2001. It was part of a total purchase of more than 50,000 new commercial compounds.  These compounds are similar in complexity to the ChemBridge DiverSet E.  However, this collection was compiled so that the molecules have an increased probability of favorable physical-chemical properties and a lack of functional groups that might cause toxicity or reduce stability.', NULL, 'Small Molecule', 'Commercial', 526, 540, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (58, 0, 'Sergey Kozmin Collection 1', 'SKC1', NULL, NULL, 'Small Molecule', 'DOS', 1161, 1163, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (59, 0, 'Prestwick1 Collection', 'Prestwick1', NULL, NULL, 'Small Molecule', 'Known Bioactives', 1568, 1571, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (60, 0, 'NCI Open Collection 1', 'NCIOpen1', 'This library contains approximately 90,000 compounds from the National Cancer Institute.  Although this collection is much larger than the Structural Diversity set, it contains significant structural redundancy and 10-20% of compounds (metal complexes, simple aliphatic compounds) are unlikely to be biologically interesting.  Approximately 20% of these compounds have been tested in the NCI 60 cell line screen.', NULL, 'Small Molecule', 'NCI', 60, 343, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (61, 0, 'Galanthamine-like DOS library', 'GLL1', 'Synthesis of this library is described in Pelish HE, Westwood NJ, Feng Y, Kirchhausen T, and Shair MD (2001) Use of Biomimetic Diversity-Oriented Synthesis to Discover Galanthamine-Like Molecules with Biological Properties beyond Those of the Natural Product. J. Am. Chem. Soc., 123, 6740-6741.

To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 386, 404, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (62, 0, 'Carpanone-like-library', 'CLL1', NULL, NULL, 'Small Molecule', 'DOS', 974, 1028, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (63, 0, 'IFLab2', 'IFLab2', NULL, NULL, 'Small Molecule', 'Commercial', 1459, 1459, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (64, 0, '1,3-Dioxane DOS library, structurally-biased (HDAC)', 'DIOX-H', 'Synthesis of this library is described in Sternson, S. M. et al. (2001) Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. 3, 4239-4242.

To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 405, 425, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (65, 0, 'Philippines Plant Extracts 1', 'PhilPlantEx1', 'From Christine Hernandez of the Philippines via a collabroation with Jon Clardy. Plated March 2003.', NULL, 'Small Molecule', 'Natural Products', 1080, 1080, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (66, 0, 'Chemical Methodology Library Development 1', 'CMLD1', 'Chemical Methodology Library Development 1', NULL, 'Small Molecule', 'Discrete', 1462, 1462, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (67, 0, 'SpOx1', 'SpOx1', NULL, NULL, 'Small Molecule', 'DOS', 1276, 1302, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (68, 0, '1,3-dioxane library', 'DIOX2', NULL, NULL, 'Small Molecule', 'DOS', 858, 941, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (69, 0, 'Cyclic peptides, 6- and 7-mer parallel synthesis', 'CycPep1', NULL, NULL, 'Small Molecule', 'DOS', 385, 385, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (70, 0, 'Philippines Plant Extracts 2', 'PhilPlantEx2', 'These extracts were collected by Christine in the Clardy lab and given to the screening room to plate and screen.', NULL, 'Small Molecule', 'Natural Products', 1341, 1342, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (71, 0, 'ICCB3', 'ICCB3', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'Discrete', 438, 438, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (72, 0, 'ICBG Fungal Extracts 3', 'ICBGExtracts3', NULL, NULL, 'Small Molecule', 'Natural Products', 1572, 1576, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (73, 0, 'Starr Foundation Extracts 1', 'Starr Foundn1', 'Extracts are part of a collaboration of Jon Clardy and the Starr foundation to research the biological function of Chinese herbal medicines. Extracts came in 4 shipments from a company in Costa Rica.', NULL, 'Small Molecule', 'Natural Products', 1338, 1340, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (74, 0, 'Human2: GPCRs', 'Human2', NULL, NULL, 'RNAi', 'siRNA', 50004, 50005, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (75, 0, 'ICCB2', 'ICCB2', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'Discrete', 383, 383, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (76, 0, 'Serine Derived Peptidomimetic 1', 'SDP1-1', NULL, NULL, 'Small Molecule', 'DOS', 1126, 1129, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (77, 0, 'Shikimic acid-derived DOS library 2', 'SAD2', NULL, NULL, 'Small Molecule', 'DOS', 426, 437, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (78, 0, 'Tetrahydrooxapine parallel synthesis', 'THOX1', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 384, 384, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (79, 0, 'Human3: Remaining Druggable Genome', 'Human3', NULL, NULL, 'RNAi', 'siRNA', 50006, 50024, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (80, 0, 'Appendino Plate 1', 'Appendino1', NULL, NULL, 'Small Molecule', 'Natural Products', 1460, 1460, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (81, 0, 'Maybridge5', 'Maybridge5', NULL, NULL, 'Small Molecule', 'Commercial', 1661, 1670, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (82, 0, 'DAP2', 'DAP2', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 1246, 1257, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (83, 0, 'Conformationally-diverse heterocycles 1', 'CDH1', 'Part of DiversitySet J2, plate 09J2', NULL, 'Small Molecule', 'DOS', 846, 846, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (84, 0, 'Shikimic acid-derived, Heck chemistry', 'SAH1', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 1104, 1121, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (85, 0, 'Starr Foundation Extracts 2', 'StarrFoundn2', NULL, NULL, 'Small Molecule', 'Natural Products', 1561, 1563, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (86, 0, 'NCI Structural Diversity Set, version 2', 'NCIStruc2', 'This library contains mostly the same compounds as the NCI structural Diversity set, version I. However, the plate layout is different and the concentration is now 1mM instead of 10mM. This library contains approximately 2000 compounds from the Developmental Therapeutics Program at the National Cancer Institute.  All of these compounds been tested in the NCI 60 cell line screen.  These compounds have been sent to a large number of academic labs.  The NCI has large quantities of most these compounds available for follow-up.', NULL, 'Small Molecule', 'NCI', 851, 857, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (87, 0, 'Enamine 1', 'Enamine1', NULL, NULL, 'Small Molecule', 'Commercial', 1394, 1411, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (106, 0, 'Enamine 2', 'Enamine2', NULL, NULL, 'Small Molecule', 'Commercial', 1715, 1790, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (88, 0, 'Specplus', 'Specplus', 'This collection of characterized bioactive compounds was compiled by MicroSource Discovery Systems. It was purchased in February, 2003 by the ALS Association via ICCB-ICG post-doctoral fellow Qing Liu. Most of the compounds are pure natural products and their derivatives, and include simple and complex oxygen heterocycles, alkaloids, sequiterpenes, diterpenes, pentercyclic triterpenes, and sterols. The SpecPlus and NINDS collections combined are sold by MicroSource as the Spectrum Collection.', NULL, 'Small Molecule', 'Known Bioactives', 1081, 1083, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (89, 0, 'NINDS Custom Collection', 'NINDS', E'This collection of characterized bioactive compounds was compiled by MicroSource Discovery Systems for the National Institute of Neurological Disorders and Stroke (NINDS), the Huntington\031s Disease Society of America (HDSA), the Amyotrophic Lateral Sclerosis (ALS) Association, and the Hereditary Disease Foundation (HDF).  It was purchased in December, 2001 by the ALS Association via ICCB-MTL post-doctoral fellow Qing Liu.  Three quarters of the compounds in the collection are FDA-approved and the rest - which include some controlled substances such as cannabinoids - are known to influence brain activity.', NULL, 'Small Molecule', 'Known Bioactives', 500, 503, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (90, 0, 'Chemical Diversity 2', 'ChemDiv2', NULL, NULL, 'Small Molecule', 'Commercial', 1369, 1393, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (91, 0, 'Maybridge3', 'Maybridge3', NULL, NULL, 'Small Molecule', 'Commercial', 1431, 1452, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (92, 0, 'Diels-Alder polycyclic adducts', 'DAP1', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 440, 499, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (93, 0, 'Mixed Commercial Plate 5', 'MixCom5', NULL, NULL, 'Small Molecule', 'Commercial', 1520, 1520, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (94, 0, 'Prestwick_MMRF Collection', 'Prestwick_MMRF', NULL, NULL, 'Small Molecule', 'Known Bioactives', 1564, 1567, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (95, 0, 'Dihydropyrancarboxamide 2', 'DHPC2', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 1122, 1125, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (96, 0, 'NCI Open Collection 2', 'NCIOpen2', NULL, NULL, 'Small Molecule', 'NCI', 942, 973, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (97, 0, 'ICCB4', 'ICCB4', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'Discrete', 439, 439, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (98, 0, 'ICCB5', 'ICCB5', NULL, NULL, 'Small Molecule', 'Discrete', 1363, 1363, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (99, 0, 'Ferrier/Pauson-Khand DOS library; (S) configuration 2', 'FPK2-2', 'Synthesis of this library was published in Kubota et al. (2002) Pathway Development and Pilot Library Realization in Diversity-Oriented Synthesis; Exploring Ferrier and Pauson-Khand Reactions on a Glycal Template. Chemistry & Biology, 9, 265-276.

To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 379, 382, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (100, 0, 'Acyclic and macrocyclic lactone', 'AML1', 'To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 1084, 1103, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (101, 0, 'NCI Mechanistic Diversity', 'NCIMech1', 'This library contains 879 compounds from the Developmental Therapeutics Program at the National Cancer Institute. In contrast to the Structural Diversity Set (in which compounds were chosen on the basis of structural diversity), compounds in the Mechanistic Diversity Set were chosen to represent a broad range of growth inhibition patterns in the NCI human tumor 60 cell line screen. The NCI has large quantities of most these compounds available for follow-up.', NULL, 'Small Molecule', 'NCI', 848, 850, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (102, 0, 'Maybridge4', 'Maybridge4', NULL, NULL, 'Small Molecule', 'Commercial', 1521, 1533, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (103, 0, 'Diversity Set J1', 'DIVJ1', NULL, NULL, 'Small Molecule', 'Annotation', 1258, 1263, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (104, 0, 'Bionet (Ryan Scientific) 2', 'Bionet2', NULL, NULL, 'Small Molecule', 'Commercial', 1364, 1368, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);
INSERT INTO library VALUES (105, 0, 'Ferrier/Pauson-Khand DOS library; (R) configuration', 'FPK1', 'Synthesis of this library was published in Kubota et al. (2002) Pathway Development and Pilot Library Realization in Diversity-Oriented Synthesis; Exploring Ferrier and Pauson-Khand Reactions on a Glycal Template. Chemistry & Biology, 9, 265-276.

To obtain more information regarding these compounds, see the Head of Chemical Technology, John Tallarico.', NULL, 'Small Molecule', 'DOS', 369, 378, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);


/* up the sequences to distinguish pre-loaded data from later data */

SELECT pg_catalog.setval('screensaver_user_id_seq', 1000, true);
SELECT pg_catalog.setval('screen_id_seq', 1000, true);
SELECT pg_catalog.setval('library_id_seq', 1000, true);
